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Abstract 
 
Toll-like receptors (TLRs)-7/-8 are among pathogen recognition receptors (PRRs) present in the 
endosomal compartment that are activated by viral single-stranded RNA (ssRNA) as well as 
synthetic small molecules. TLR7/8 agonists hold promise as potential vaccine adjuvants, since 
they directly activate antigen-presenting cells and enhance T helper 1-driven immune 
responses.  
 
A general introduction to TLRs, with an emphasis on the role of TLR7/8 activation in innate and 
adaptive immune responses is presented in Chapter 1.  
 
Structure-activity relationship (SAR) studies in small molecule TLR8/7-agonistic ligands showed 
that thiazolo[4,5-c]quinolines display mixed TLR8/7 agonistic activities with the optimal C2-alkyl 
chain length being butyl (Chapter 2).  
 
In an ongoing search toward exploring alternative chemotypes, furo[2,3-c]pyridines with 
pyridoxal as the aldehyde component in a one-pot multicomponent Groebke−Blackburn− 
Bienaymé reaction were obtained and found to exhibit TLR8-dependent NF-B activation and 
strong adjuvanticity without proinflammatory cytokine induction (Chapter 3).  
 
Combinatorial libraries using the Groebke–Blackburn–Bienaymé reaction have also yielded 
TLR7/8-inactive, but antibacterial imidazo[1,2-a]pyridines (Chapter 4).  
 
Based on the previously reported SARs on imidazoquinolines, the syntheses and biological 
evaluation of novel imidazo[4,5-c]pyridine analogues were undertaken, with modifications at the 
N4- and C6 positions, which afforded strong Type I IFN inducers in conjunction with attenuated 
proinflammatory profiles (Chapter 5).  
 
 iv  
With the goal of defining structural requisites governing activity and selectivity at TLR7 and/or 
TLR8, we undertook scaffold-hopping approach, quantum chemical calculations followed by 
linear discriminant analyses that permitted the classification of inactive, TLR8-active, and 
TLR7/8 dual-active compounds, confirming the critical role of partial charges in determining 
biological activity (Chapter 6).  
 
Molecular conjugation of TLR7/8 agonists to hyaluronic acid (HA) was evaluated to enhance 
selective and targeted delivery of vaccine construct to draining lymph nodes while limiting 
systemic exposure. The superior adjuvanticity evoking affinity-matured high-avidity 
immunoglobulins after a single boost was observed with HA conjugate bearing dual TLR7/8 
agonist (Chapter 7).   
 
Extensive SAR investigations in several TLR7/8 agonistic scaffolds and exploration as vaccine 
adjuvant candidates have incrementally improved our understanding of how these molecules 
activate innate and adaptive immune responses and also catalyzed novel approaches to 
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Abbreviations 
AIBN azobisisobutyronitrile 
APC antigen-presenting cell 
Be-1 B-effector-1-cells 
CCR chemokine receptor 
cDC conventional dendritic cell 
CDMT 2-chloro-4,6-dimethoxy-1,3,5-triazine  
CIK cytokine-induced killer 
CLR C-type lectin receptor 
CRP C-reactive protein 
CXCL chemokine ligand  
DC dendritic cell 




DS degree of substitution  
dsRNA double stranded RNA 
EC50 half maximal effective concentration 
ECM extracellular matrix 
EDC N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide  
ELISA enzyme-linked immunosorbent assay  
ESI electrospray ionization 
GlcNAc N-acetyl glucosamine 
GlcUA glucuronic acid 
HA hyaluronic acid 
HAase hyaluronidase 
HBTU N,N,N′,N′-Tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate 
HCV hepatitis C virus 
HEK human embryonic kidney 
HIV human immunodeficiency virus  
hPBMC human peripheral blood mononuclear cell  




IP interferon gamma-induced protein  
IRF IFN regulatory factor 
ITAM immunoreceptor tyrosine-based activation motif 
LC liquid chromatography 
LDH lactate dehydrogenase 
LPS lipopolysaccharides 
LRR leucine-rich repeats  
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LYVE-1 lymphatic vessel endothelial hyaluronan receptor-1  
MBC minimum bactericidal concentration 
MCP monocyte chemoattractant protein 
mCPBA m-chloroperoxybenzoic acid  
MDA melanoma differentiation-associated protein 
MES 2-(N-morpholino)ethanesulfonic acid 
MESP molecular electrostatic potential  
MHC major histocompatibility complex 
MIC minimum inhibitory concentration 
MIP macrophage inflammatory protein 
MPL monophosphoryl lipid A 
MRSA methicillin-resistant Staphylococcus aureus 
MS mass spectroscopy 
MyD88 myeloid differentiation primary response gene 88 
NALP NACHT, LRR and PYD domains-containing protein 
NBS N-bromosuccinimide  
NF-B nuclear factor B 
NK natural killer 
NLR NOD-like receptor 
NMM N-methylmorpholine  
NMP N-methyl-2-pyrrolidone  
NMR nuclear magnetic resonance 
NOD nucleotide oligomerization domain 
ORTEP oak ridge thermal ellipsoid plot 
PAMP pathogen-associated molecular pattern 
PBS phosphate buffer saline 
pDC plasmacytoid dendritic cell  
PLVAP plasmalemma vesicle-associated protein 
PRR pattern recognition receptor 
QSAR quantitative structure-activity relationship 
RIG retinoic acid inducible gene 
RLR RIG-I-like receptor 
sAP secreted alkaline phosphatase  
SAR structure-activity relationship 
SEC size exclusion chromatography  
ssRNA single stranded RNA 
TB tuberculosis 
TBAF tetra-n-butylammonium fluoride 
TFA trifluoroacetic acid 
Th1 T helper 1  
Th2 T helper 2  
THF tetrahydrofuran 
TIR toll/IL-1 receptor  
TLR toll-like receptor 
TNF tumor nectosis factor 
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1.1. Vaccine Adjuvants 
 
There can be no greater substantiation of Benjamin Franklin’s adage, ‘An ounce of prevention is 
worth a pound of cure’ than the resounding impact that vaccines have had in preventing 
morbidity and mortality due to infectious diseases.1 Vaccines have resulted in the eradication or 
dramatic reduction in number of cases such as smallpox, polio, and tetanus. Nevertheless, 
there is still a pressing need for new vaccines for diseases for which sufficiently effective 
vaccines do not exist, but also to replace reactogenic vaccines with safer alternatives.2  
 
In order to achieve a high level of efficacy and safety, many newer vaccines with more defined 
composition that is often linked to lower immunogenicity rely on potent immunostimulants 
(vaccine adjuvants).3 The Food and Drug Administration (FDA) considers an adjuvant to a 
substance added to vaccines to enhance the immune response in vaccinated individuals. 
Adjuvants also serve to reduce the amount of antigen needed for the induction of a robust 
immune response (‘dose-sparing effect’) or the number of immunizations needed for protective 
immunity. The ability of adjuvants to broaden antibody responses could be crucial for the 
success of vaccines against many pathogens that display substantial antigenic drift and/or strain 
variations including influenza viruses, human immunodeficiency virus (HIV), human papilloma 
virus (HPV), and the malaria parasite.4 Adjuvants also help improve the efficacy of vaccines in 
newborns, the elderly or immunocompromised persons, or can be used as antigen delivery 
systems for the uptake of antigens.5  
 
Several hundred natural and synthetic compounds have been identified to have adjuvantic 
activity (Table 1).5-6 Alum, principally aluminum phosphate or hydroxide, was originally identified 
in the 1920s and has been the most widely used human adjuvants.7 Studies have shown that 
alum enhances antigen uptake by dendritic cells (DCs), recruitment of immune-competent cells 
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to the injection site, and stimulation of immune cells via the inflammasome pathway,8 although 
further details and precise mechanisms need to be elucidated.9 A second adjuvant that could be 
considered a success is the MF59 squalene oil in water emulsion (O/W). MF59 is licensed in 
most of Europe for use with seasonal flu vaccines in the elderly. MF59 induces the recruitment 
of neutrophils and monocytes to the site of immunization and potentiates both cellular and 
humoral immune responses.10 Virosomes are liposomes that contain fusogenic viral proteins 
and have been licensed as a component of an influenza vaccine.11 They can be classified more 
as delivery systems since their main function is to promote more effective delivery of vaccine 
antigens and immunostimulants. The most advanced of adjuvants, termed the AS series, are 
generally combinations of alum (or emulsions or liposomes) with immune potentiators.12 The 
immune potentiator component(s) is added to increase antibody titers or to induce more potent 
and focused T cell responses. The more complex formulations, comprising of three or more 
adjuvant components, are particularly designed to induce more potent T helper 1 (Th1) cellular 
immune responses.13 
 
Despite the impressive success of currently approved adjuvants for generating immunity to viral 
and bacterial infections, an understanding of the mechanism of action of vaccine adjuvants has 
remained rudimentary until recently, and there is a compelling need for the rational development 
of adjuvants that not only provide protective antibody responses, but also generate strong T cell 
immunity, especially in subunit vaccine constructs incorporating highly purified, recombinantly 
expressed proteins as immunogens.14 Adjuvants that stimulate cellular immunity (antigen-
specific CD4 and CD8 responses) have been particularly important in protective immunity 
against intracellular pathogens, and it is worth noting that none of the currently approved 
adjuvants uniformly and/or sufficiently enhance cell-mediated immune responses. The 
availability of adjuvants with defined mechanisms of action would not only permit a greater 
insight into the interface between innate and adaptive immunity, but could perhaps also help 
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circumvent some of the potential deficiencies associated with current vaccines and catalyze the 
development of highly efficacious, yet safe vaccines for infectious diseases.  
 
Table 1. Major adjuvant formulations tested in humans.  
Name Class Receptors or Pathway Indications 
Licensed Adjuvants 




MF59 Oil/water emulsion 
Immune cell recruitment, 
Ag uptake 
Influenza (Fraud),  
Pandemic flu 
Liposome Lipid vesicle Ag delivery HAV, Flu 
AS03 Oil/water emulsion + -tocopherol  Pandemic flu (Pandemic) 
AS04 Monophosphoryl Lipid A (MPL) + Alum TLR4  HBV (Fendrix), HPV (Cevarix) 
Widespread Experimental Use or in Late Stage Clinical Development 
Montanide Water/oil emulsion  Malaria, cancer 
PLG Polymeric microparticle  DNA vaccine (HIV) 
Flagellin Flagellin from S. typhimurium TLR5 Flu 
QS21 Saponin  Various 
AS01 MPL + liposomes + QS21 TLR4 Malaria, TB 
AS02 MPL + Oil/water emulsion + QS21 TLR4 Malaria 
RC-529 Synthetic MPL + Alum TLR4 HBV 
ISCOMs Saponins + cholesterol + phospholipids  Various 
Poly(I:C) Synthetic derivative of dsRNA TLR3, MDA5  
IC31 Peptide + oligonucleotide TLR9 TB 
CpG 7909 Oligonucleotide + Alum or MF59 TLR9 HBV, malaria, HCV 
ISS Oligonucleotide Alum TLR9 HBV 
MF59 + 
MTP-PE 
Lipidated MDP + Oil/water emulsion  HIV, Flu 
Imiquimod Imidazoquinoline derivatives TLR7/8  
CAF01 Trehalose dimycolate Mincle  
 
 
1.2. Innate Immunity and Toll-like Receptors (TLRs) 
 
The human immune system can be conceived of as comprising of two mutually non-exclusive 
subsystems: the innate and the adaptive components; these two limbs work cooperatively to 
afford protection from numerous pathogenic microorganisms and toxins.15 Until recently, innate 
immunity was thought of as rather crude and unsophisticated first line of defense, providing non-
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specific microbicidal activity and early inflammatory signals and merely allowing downstream 
adaptive immune responses more time to develop. However, it is now clear that the adaptive 
immune responses are largely predicated upon the level and specificity of the initial signals 
perceived by innate immune cells following infection and/or vaccination, determining whether or 
not specific and sustained response and protection will ensue.6b, 15a, 16 
 
Vaccine adjuvant research has expanded rapidly in the past decade and has directly benefited 
from our evolving understanding of immunology, beginning with the recognition of the cellular 
elements involved in innate immunity, and growing to encompass the elucidation of the 
mechanisms of recruitment of adaptive immune effector pathways. Knowledge of the molecular 
mechanism of innate immune activation has also afforded a large number of potential new 
targets for immune stimulators.17 Numerous receptors and signaling pathways in the innate 
immune system have been defined. Unlike adaptive immunity, the initial innate immune 
responses rely on a limited number of germline-encoded pattern recognition receptors (PRRs), 
which recognize specific molecular patterns present in molecules that are broadly shared by 
pathogens but are sufficiently different so as to be distinguishable from host molecules, and are 
collectively referred to as pathogen-associated molecular patterns (PAMPs).18 PRRs are 
classified according to their structural homology: Toll-like receptors (TLRs), RIG-I-like receptors 
(RLRs),19 NOD-like receptors (NLRs),20 and C-type lectin receptors (CLRs).21  
 
The TLR family is one of the well studied targets in terms of ligands, downstream signaling 
pathways, and functional relevance.22 There are 10 TLRs in the human genome; these are 
transmembrane proteins with an extracellular domain having leucine-rich repeats (LRR) and a 
cytosolic domain called the Toll/IL-1 receptor (TIR) domain.18b The ligands for these receptors 
are highly conserved microbial molecules such as lipopolysaccharides (LPS) (recognized by 
TLR4), lipopeptides (TLR2 in combination with TLR1 or TLR6), flagellin (TLR5), single stranded 
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RNA (TLR7 and TLR8), double stranded RNA (TLR3), CpG motif-containing DNA (recognized 
by TLR9), and profilin present on uropathogenic bacteria (TLR11).23 TLR1, -2, -4, -5, and -6 
recognize extracellular stimuli, while TLR3, -7, -8 and -9 function within the endolysosomal 
compartment.18b The activation of TLRs by their cognate ligands leads to production of 
inflammatory cytokines, and up-regulation of major histocompatibility complex (MHC) molecules 
and co-stimulatory signals in antigen-presenting cells as well as activating natural killer (NK) 
cells (innate immune response), in addition to priming and amplifying T-, and B-cell effector 
functions (adaptive immune responses).24 TLR stimuli serve to link innate and adaptive 
immunity and therefore there is considerable interest in utilizing TLR agonists as vaccine 
adjuvants.25  
 
The discovery of TLRs and identification of natural TLR ligands have intensified the search for 
synthetic agonists that can target TLRs with greater specificity and selectivity than pathogen-
derived ligands.24c, 26 Interestingly, many immunostimulants that had been identified previously 
were later found to be TLR agonists such as imidazoquinolines for TLR7/8 (vide infra).24c 
Indeed, the only TLR agonist approved by the FDA as an adjuvant (3-O-desacyl-4′-
monophosphoryl lipid A, derived from hydrolytic treatment of lipopolysaccharide isolated from 
Salmonella Minnesota Re595;27 MPL) was indentified to be a TLR4 agonist28 long after its 
adjuvantic properties had been established.29 
 
A detailed understanding of the structural and mechanistic bases of adjuvanticity and toxicity is 
pivotal in rationally developing novel adjuvants. In an effort to explore and develop strategies for 
the rapid and simultaneous evaluation of both adjuvantic potency and proinflammatory activities 
of relatively large focused libraries of compounds being generated by our group, we have 
examined representative members of virtually the entire compendium of known TLR agonists in 
a series of hierarchical assays. Of all the innate immune stimuli examined, we found that TLR2 
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(thioacylglycerol lipopeptide chemotype), TLR4 (LPS and MPL), TLR5 (flagellin), and TLR7 
(imidazoquinoline chemotype) were immunostimulatory; the imidazoquinoline class of TLR7 
agonists was found to be extraordinarily immunostimulatory, stimulating virtually all subsets of 
lymphocytes, and yet without inducing dominant proinflammatory cytokine responses.30 
 
 
1.3. Intracellular TLR Activation – TLR7/8 
 
The prototypical intracellular TLRs (TLR3 and TLR7-9) are generally associated with sensing 
nucleic acids released within endosomal compartments. Their activation leads to the production 
of a variety of nuclear factor (NF)-B-mediated cytokines and Type I interferons (IFNs). TLR7 
and TLR8 are phylogenetically and structurally related. TLR7 is expressed in plasmacytoid 
dendritic cells (pDC) and B cells, whereas TLR8 is mainly expressed in conventional/myeloid 
dendritic cells (cDCs), monocytes, macrophages, and neutrophils. Single stranded RNA 
(ssRNA) molecules of viral as well as nonviral origin (poly(dT); double-stranded thymidine 
homopolymer) induce the production of inflammatory cytokines, mediated by the recognition in 
the endosomal compartment by TLR7 and TLR8.31 TLR7 preferentially recognizes GU-rich RNA 
sequences and TLR8 has more affinity for AU-rich sequences.32 The activation by ssRNA 
induces the recruitment of the adapter protein	Myeloid Differentiation primary response gene 88 
(MyD88) via its TIR domain. TIR domains initiate the signaling cascade through TIR adapters, 
leading to downstream responses to specific pathogens. This results in the activation of NF-B 
and IFN regulatory factors (IRFs) 3 and 7, which in turn induce the production of 
proinflammatory cytokines such as tumor necrosis factor (TNF)-, interleukin (IL)-1 and IL-6 and 
Type I IFNs, respectively.33 TLR7 and TLR8 can also detect a variety of synthetic chemical 
agonists. Small molecule, non-polymeric, synthetic agonists include the imidazoquinolines 
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(imiquimod, resiquimod [R-848], and gardiquimod),34 as well as guanosine analogues such as 
loxoribine35 (Fig. 1).  
 
Long before endosomal TLR7 was discovered to serve as the primary sensor for short, single-
stranded, GU-rich RNA sequences (ssRNA), mainly of viral origin,31a-c a number of small 
molecules were synthesized and evaluated in the 1970s and '80s for antiviral activities owing to 
their pronounced Type I interferon (IFN- and -) inducing properties.36 Members of the 1H-
imidazo[4,5-c]quinolines were found to be good Type I IFN inducers in human cell-derived 
assays,37 and FDA approval was obtained in 1997 for Imiquimod (commercialized under the 
brand name Aldara™) for the treatment of basal cell carcinoma and actinic keratosis.38 The drug 
was later discovered to be a TLR7 agonist. The induction of IFN-, IL-6 and TNF- by 
imiquimod has been observed in vitro and in both human and animal studies. Imiquimod also 
activates NK lymphocytes and cells of the monocyte/macrophage lineage, and induces B 
lymphocytes to proliferate and differentiate.39 Resiquimod (R-848), another structurally similar 
compound, stimulates immune responses via TLR7 in mice and via TLR7 and TLR8 in 
humans.40 Resiquimod also triggers significant cytokine secretion, macrophage activation, and 
enhancement of cellular immunity.41 Resiquimod reached Phase III clinical trials for the topical 
treatment of genital herpes; however, development was suspended due to lack of adequate 
efficacy.42 CL097 and 3M-003 are derivatives of resiquimod that activate both TLR7 and 
TLR8.43 3M-001, selective TLR7 agonist, stimulates plasmacytoid dendritic cells to produce 
cytokines such as IFN- and IFN- inducible protein (IP)-10.44 Gardiquimod is another agonist of 
human and mouse TLR7 and more potent than imiquimod. At higher concentration, it is also 
known to activate TLR8.43b CL075 (3M-002) is a thiazoquinoline derivative that triggers TLR8 in 
human peripheral blood mononuclear cells (PBMCs). Agonistic activity of CL075 at TLR8 is 
known to activate NF-B and trigger secretion of TNF- and IL-12. This compound also 
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activates TLR7, however, to a lesser extent.45 Loxoribine is a guanosine ribonucleoside 
analogue that activates human and mouse TLR7. This compound enhances anti-tetanus-
specific IgG antibody anamnestic responses in a dose-dependent manner in human PBMCs, as 
well as strongly activating NK cells in IL-12-dependent manner.35c Isatoribine (ANA245) and 
ANA975 (an oral prodrug of isatoribine) are other examples of guanosine nucleoside analogues. 
Isatoribine, like imiquimod, was also identified as an immune potentiator before its mechanism 
of action was elucidated to be through activation of TLR7. These agents were developed for 
treatment of HCV infection;46 however, ANA975 has been discontinued due to unacceptable 
toxicity.47 Bropirimine is an aryl pyrimidinone analogue, an antineoplastic compound that 
induces IFN- and is used for treatment of carcinoma.48 The mechanism of action of bropirimine 
is likely associated with direct anti-tumor effect rather than cytokine mediated anti-tumor 
activity.49  
 
Fig. 1. Chemical structures of representative synthetic TLR7/8 agonists. 
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Much of what is known about the vaccine adjuvant potential of TLR7 and/or TLR8 agonists has 
been derived from preclinical studies in animal models using the imidazoquinolines. These 
compounds, as mentioned earlier, have shown to directly activate antigen-presenting cells 
resulting in the induction of costimulatory molecules and numerous cytokines that modulate 
adaptive immunity.50 In terms of differences between human TLR7 and TLR8, TLR7-selective 
agonists were known to be more effective at inducing IFN- and IFN-regulated cytokines than 
TLR8-selective agonists. On the other hand, TLR8 is functional in monocytes and myeloid DC, 
and its engagement results in the production of dominant proinflammatory cytokines such as 
TNF-, IL-12, and MIP-1.45 Together with IL-12, Type I IFNs appear to be required for optimal 
Th1 and CD8+ T cell responses following the administration of TLR7 and TLR8 agonists.51 Thus, 
TLR7 and TLR8 agonists, as well as TLR7/8 dual agonists could hold potential applications as 
vaccine adjuvants, especially in regard to their propensity for promoting Th1-type immune 
responses. 
 
Fig. 2. A. Target receptors on APCs for adjuvants and their downstream signaling (adapted from Reed, 
S. G. et al, Nature medicine 2013, 19 (12), 1597). B. Expression of TLRs in human DCs and their ability 
to produce cytokines. 
Plasmacytoid DC Myeloid DC
Type I IFN (IFN-/) 
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Desirous of specifically identifying chemotypes with strong Th1-biased immunostimulatory 
signatures, we implemented screens examining the induction of Type I and Type II IFNs (IFN-
/ and IFN-, respectively),52 IL-12,53 and IL-1854 using human PBMCs, all of which are 
strongly associated with dominant Th1 outcomes. These studies enabled us to determine that of 
all of the diverse chemotypes of our rapidly expanding libraries and identify N1-(4-aminomethyl) 
benzyl-substituted TLR7/8 dual-agonistic imidazoquinoline (Fig. 3) that displayed a prominent 
Th1 bias, orders of magnitude higher than that of even lipopolysaccharide. This lead compound 
has been pivotal in exploring a variety of concepts such as TLR7/8 modulators and 
antagonists,55 model self-adjuvanting subunit vaccine constructs,56 a dendrimeric adjuvant,57 
and cell-permeable, endosome-localizing, fluorescent analogues that retain agonistic activity58 
(Fig. 3). The covalently coupled TLR7/TLR8 dual-agonistic imidazoquinoline to antigens using 
mild, nondenaturing conditions induced high antibody titers indicative of Th1 immunity.56 The 
dendrimeric adjuvant consisting of six linked TLR7/8 agonists (hexamer) lost TLR8 activity but 
retained the TLR7 agonistic effects, and it was found to be superior to the imidazoquinoline 
monomer in inducing high titers of high-affinity antibodies to bovine -lactalbumin in rabbits. 
Additionally, epitope mapping experiments showed that the dendrimer induced immunoreactivity 
to more contiguous peptide epitopes along the amino acid sequence of the model antigen.57 
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Excessive or uncontrolled innate immune responses could potentially result in reactogenicity, 
and even undermine subsequent adaptive immune responses, and it is of particular importance 
to simultaneously take into consideration aspects of immune potentiation alongside safety 
issues associated with local or systemic immune activation and inflammation.  
 
The premise of this thesis is that a careful and systematic exploration of chemical space around 
TLR7/8 chemotypes, as well as the development of standardized panels of bioassays that 
permit a detailed insight into the immunopharmacology of such molecules would not only allow 
the determination of the structural correlates governing adjuvantic activity (Chapters 2-6), but 
also allow the rational exploration of novel strategies to dissociate adjuvanticity from 
reactogenicity (Chapter 7).  
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2.1. Introduction  
 
We decided to extend our investigations toward delineating structure-activity relationships 
(SAR) in small-molecule agonistic ligands of TLR8 (thiazolo[4,5-c]quinolines) for the following 
reasons: First, the thiazoloquinolines are of interest because like the imidazoquinolines, these 
compounds were identified in antiviral assays long before the discovery of the endosomal TLR7 
and TLR8 receptors,36, 59 and other than the original landmark studies performed by 
investigators at 3M Pharmaceuticals,60 SAR of the thiazoloquinoline chemotype remains poorly 
explored; qualitative assays for TNF- and IFN- induction in human blood were performed in 
these initial studies as surrogate biomarkers of immunostimulation, and no data on TLR-7 and -
8 specific agonistic activities existed in the literature. Second, TLR8 agonists, both single-
stranded RNA as well as small molecule imidazoquinoline ligands such as R-848 (resiquimod, 
Chapter 1)61 and thiazoloquinolines such as 3M-002 (CL075, Chapter 1)45, 62 appear uniquely 
potent in activating costimulatory responses in neonatal antigen-presenting cells (APCs), 
inducing robust production of the Th1-polarizing cytokines TNF- and IL-12, which are not 
observed upon stimulation by TLR-2, -4, or -7 agonists. Such Th1-biasing compounds are of 
particular interest as candidate vaccine adjuvants in the newborn.63 During the first few weeks of 
life, newborns rely almost entirely on maternal IgG antibodies acquired by passive 
transplacental passage,64 and remain susceptible to a wide range of pathogens until early 
infancy.65 Neonates and infants, in whom vaccines could — and perhaps should — have the 
greatest impact, do not mount adequate adaptive immune responses, and therefore are most 
vulnerable; consequently, even the most efficacious vaccines that confer excellent protection in 
adults may fail to elicit strong immune responses in them.66 There is mounting evidence pointing 
to significant differences between adult and infant innate immune responses.67 The neonatal 
immunophenotype is characterized by decreased production of both Type I and Type II IFNs, IL-
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12, IL-18, IL-23 and other proinflammatory cytokines such as TNF-, the preferential induction 
of memory B lymphocytes rather than immunoglobulin-secreting plasma cells, as well as a 
pronounced Th2 skewing of T-cell responses.65-66, 68 TLR8 agonists induce the production of IL-
12, IL-18 and IFN-, and may therefore be of value in developing vaccines for the neonate. We 
therefore sought to explore SAR in the thiazoloquinolines (typified by CL075, 8c in Scheme 1).  
 
Our studies began with examining the optimal alkyl chain length at the C2 position. We found, 
as expected, that the C2-alkyl thiazoloquinolines exhibit mixed TLR8/7 agonistic activities in 
primary reporter gene assays with the optimal chain length being butyl. We observed 
unexpectedly strict length dependence with only the C2-butyl, but none of the other analogues, 
inducing IFN- in human PBMCs. Examination of analogues with branched alkyl groups at C2 
suggested poor tolerance of terminal steric bulk. We noted, however, that certain C2-branched 
analogues were substantially more TLR8-selective than their corresponding straight-chain 
analogues. Virtually all modifications at C8 led to abrogation of agonistic activity. Alkylation on 
the C4-amine was not tolerated, whereas N-acyl analogues with short acyl groups (other than 
acetyl) retained activity. 
 
 
2.2. Results and Discussion 
 
In our previous work on the TLR7-active imidazoquinolines, we had observed a distinct 
relationship between C2-alkyl chain length and TLR7-agonistic potency,69 and we therefore 
thought it logical to begin our SAR studies on the thiazoloquinolines by examining analogues 
with C2-alkyl groups of varying chain lengths. These analogues (8a-h, Scheme 1) were 
synthesized in parallel from the 3-aminoquinolin-4-ol precursor 4.69  
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Fig. 1. TLR7 and TLR8 agonistic potencies of the C2-alkyl thiazoloquinoline homologues. Data points 
represent means and standard deviations of EC50 values derived from dose-response profiles and are 
computed on quadruplicates. 
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In primary screens using human TLR7 and TLR8-specific reporter gene assays, these 
analogues exhibited, as anticipated, mixed TLR8/TLR7 agonism; the EC50 values of 8c (CL075) 
were found to be 1.32 M and 5.48 M, respectively (Fig. 1, Table 1). As in our earlier SAR 
studies on the imidazoquinolines,69 we observed a clear dependence of agonistic potency on 
the C2-alkyl chain length. The C2-methyl, -ethyl, and -propyl analogues (8a-c) displayed 
comparable potencies in the hTLR8 and hTLR7 reporter gene assays (Fig. 1). Maximal TLR8-
agonistic potency was observed in the butyl analogue (8d). Increasing the chain length to pentyl 
(8e) led to attenuation of potency, and higher homologues (8f-h) showed abrogation of activity 
(Fig. 1, Table 1). The C2-butyl analogue 8d appeared to exhibit substantially higher TLR7-
agonistic potency than 8c (Figs. 1 and 3), suggesting that subtle variations at C2 could 
modulate TLR8 versus TLR7 specificity. 
 
We therefore synthesized several additional analogues of both 8c (C2-n-propyl) and 8d (C2-n-
butyl) with branched alkyl groups at C2 (8i-o, Scheme 1) and examined their activities (Fig. 2). 
The introduction of an isopropyl group at C2 (8i) led to an approximately ten-fold reduction in 
TLR8-agonistic potency (Table 1), while the attenuation of its activity in TLR7-specific reporter 
gene assays was more modest (about two-fold). Rather dramatic differences were noted 
between 8j (C2-isobutyl)/8k (C2-neopentyl) and 8l (C2-isopentyl)/8m (C2-neohexyl) congeneric 
pairs. Whereas 8j was as potent as 8c in TLR8 agonism assays, 8k was inactive (Fig. 2), which 
suggested poor tolerance of terminal steric bulk. However, 8l and 8m were both inactive, 
pointing to additional length requirements in C2-branched alkyl substituents. These results led 
us to evaluate analogues 8n (2-methylpropyl substituent at C2) and 8o (2-methylbutyl 
substituent). Both these compounds retained TLR8 agonistic properties readily comparable to 
their parent compounds 8c and 8d, respectively, lending support to the premise that steric bulk 
at the -position of the C2-alkyl group was not tolerated. We also evaluated bioisosteric 
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analogues 8p and 8q (Scheme 1) with terminal trifluoromethyl groups. A decrease in potency at 
TLR8 was observed in the longer homologue (8q). We noted that, in general, analogues with 
branched C2-alkyl groups of optimal chain length and bulk (such as 8j, 8n, and 8o) are 
substantially more TLR8-selective than their corresponding straight-chain analogues (Fig. 2).  
 
 Fig. 2. TLR8- and TLR7-specific NF-B induction profiles of branched-chain and trifluoromethyl 
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However, in secondary cytokine induction screens using human PBMCs, the branched-chain 
analogues behave differently in that they were neither as potent as their straight-chain parent 
compounds (Fig. 3), nor did they show enhanced IL-12, IL-18, and IFN- production (data not 
shown) as would be expected for TLR8-selective compounds. We do not yet understand the 
basis of attenuated activity of the C2-branched analogues, and we are currently exploring 
whether differential plasma protein binding behavior of these compounds could be 
contributory.70 
 
Fig. 3. EC50 values of proinflammatory cytokine induction in human PBMCs by analogues of 8c and 8d. 
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Noting that previous studies in the patent literature60, 71 had been performed largely on the C7 
position, and C8 and C4 analogues remain unexplored. We therefore first examined 
substituents on the quinoline at the C8 position of 8c (CL075). Electrophilic substitution on the 
quinoline ring selectively afforded the 8-nitro analogue 9 (Scheme 2), and the 8-bromo analogue 
14 (Scheme 4), both of which were inactive. The 8-amino (10) and 8-azido (11) analogues were 
obtained from 9 (Scheme 2). Compound 10 showed attenuated activity relative to 8c, and 11 
was inactive. The triazole derivatives 12a-g were synthesized from 11 (Scheme 2) using 
conventional copper-catalyzed ‘click’ chemistry; of these analogues, the triazolo analogue 12e 
displayed feeble, but selective TLR8 agonism (Table 1). Selective C8 N-alkylation and N-
acylation of the 8-amino analogue 10 provided analogues 13a and 13b (Scheme 3), both of 
which were inactive (Table 1). 
 
Scheme 2. Modification at the C8 position. 
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Scheme 3. Synthesis of C8 N-alkyl and N-acyl analogues. 
 
 
Scheme 4. Synthesis of 8-bromothiazoloquinoline. 
 
 
Next, the C4-amine of 8c was alkylated or acylated, yielding analogues 15a-l (Scheme 5). The 
C4-N-alkylated compounds 15a and 15b were devoid of any agonistic activity, while some, but 
not all of the C4-N-acylated derivatives with short acyl groups were found to be active. 
Specifically, the formyl (15d), and butyryl (15f) analogues, but not the acetyl (15e) compound, 
were active. Cytokine induction profiles in hPBMCs mirrored these findings with a near-
complete loss of activity for the acetyl compound 15e (Fig. 5A). Our provisional interpretation 
that a stringent length requirement exists for the acyl substituents on the C4-amine was borne 
out in compounds 15j-l (azidoacetamide, azidopropionamide and pentynamide analogues, 
respectively), which displayed weak, TLR8-selective agonistic activity (Table 1). Aromatic 
amides at this position appear not to be tolerated, since the benzamide analogue 15i was 
entirely inactive. A series of carbamates (15m-p) and sulfonamides (15r-v) were also 
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synthesized (Scheme 5). The carbamate derivatives showed feeble activity with very low area-
under-curves in primary TLR8 screens, while the sulfonamide analogues were completely 
inactive (Table 1). Several other analogs including urea (15q; Scheme 5), phosphoramidate 
(15w; Scheme 5) and guanidine (17; Scheme 6) functional groups at C4 were also examined, 
but were found to be inactive. 
 
Scheme 5. Synthesis of C4 N-alkyl and N-acyl analogues.   
 
 
Scheme 6. Synthesis of C4 guanidino analogues. 
 
 
The peculiar SAR, with only the acetamide analogue (15e) showing loss of activity was 
unexpected and, desiring to confirm this pattern, we also synthesized selected amide analogues 
of 8d (18a-c, formamide, acetamide, and butyramide derivatives, respectively; Scheme 7).  As 
the 8c derivatives, a virtually identical pattern was observed, with a selective loss of activity for 
the acetamide analogue 18b (Figs. 4B and 5B, Table 1).  
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Fig. 4. TLR8 induction by C4-amides of 8c (Panel A) and 8d (Panel B). Data points represent means and 
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Fig. 5. Dose-response profiles of proinflammatory cytokine induction in hPBMCs by C4-amides of 8c 
(Panel A) and 8d (Panel B). Representative data from three independent experiments are presented. 






















Our studies aimed at understanding structure-activity relationships in the thiazoloquinolines 
have yielded two compounds of interest: 8c and 8d, possessing differential TLR8/TLR7-
agonistic properties. All of the other analogues were either of lower potency, or exhibited very 
poor aqueous solubility (such as the amide analogues 15d and 18a, for instance). We therefore 
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TLR8 was thought to be functionally inactive,72 we chose to examine the adjuvantic activities of 
8c, 8d directly in a rabbit model using bovine -lactalbumin as a model subunit vaccine antigen, 
which is a small (14 kDa), soluble protein which we have adopted as our test-antigen in ongoing 
humoral and cellular immune response assays.56  
 
We were gratified to find that both 8c and 8d were highly adjuvantic in evoking high antigen-
specific IgG titers (Fig. 6). Importantly, no evidence of local or systemic toxicity was apparent in 
any of the cohorts. The data suggest that 8d, with its dual TLR7/TLR8-agonistic properties, 
elicits adjuvanticity with greater consistency and uniformity, as evidenced by narrower 
confidence intervals of antibody titers (Fig. 6).  
 
Fig. 6. Box-plots of anti-bovine -lactalbumin IgG titers in cohorts of three rabbits immunized with -
lactalbumin adjuvanted with either 8c or 8d. Means and medians of titers are represented by □ and ─ 
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8a CH3 H H 2.06 10.24 
8b C2H5 H H 0.81 5.12 
8c C3H7 H H 1.32 5.48 
8d C4H9 H H 0.41 0.86 
8e C5H11 H H 1.94 4.14 
8f C6H13 H H Inactive Inactive 
8g C7H15 H H Inactive Inactive 
8h C9H19 H H Inactive Inactive 
8i CH(CH3)2 H H 10.85 9.67 
8j CH2CH(CH3)2 H H 1.55 6.96 
8k CH2C(CH3)3 H H Inactive Inactive 
8l C2H5CH(CH3)2 H H Inactive Inactive 
8m C2H5C(CH3)3 H H Inactive Inactive 
8n (S)-2-(sec-butyl) H H 2.77 8.11 
8o (S)-2-(2-methylbutyl) H H 2.51 4.74 
8p C2H5CF3 H H 1.61 3.63 
8q C3H7CF3 H H 6.29 2.25 
9 C3H7 H NO2 Inactive Inactive 
10 C3H7 H NH2 3.88 8.19 
11 C3H7 H N3 Inactive Inactive 
12a C3H7 H 
 
Inactive Inactive 
12b C3H7 H 
 
Inactive Inactive 
12c C3H7 H 
 
Inactive Inactive 
12d C3H7 H 
 
Inactive Inactive 
12e C3H7 H 
 
Inactive Inactive 
12f C3H7 H 
 
9.84 Inactive 
12g C3H7 H 
 
Inactive Inactive 
13a C3H7 H NHC6H13 Inactive Inactive 
13b C3H7 H NHCOC3H7 Inactive Inactive 
14 C3H7 H Br Inactive Inactive 
15a C3H7 C4H9 H Inactive Inactive 
15b C3H7 C6H13 H Inactive Inactive 
15c C3H7 C16H33 H Inactive Inactive 
15d C3H7 CHO H 0.88 Inactive 
15e C3H7 COCH3 H Inactive Inactive 
15f C3H7 COC3H7 H 1.14 Inactive 
15g C3H7 COC7H15 H Inactive Inactive 
15h C3H7 COC15H31 H Inactive Inactive 
15i C3H7 COC5H5 H Inactive Inactive 
15j C3H7 COCH2N3 H 1.20 3.53 
15k C3H7 COC2H4N3 H 2.23 Inactive 
15l C3H7 COC2H4C≡C H 1.20 Inactive 
15m C3H7 CO2CH3 H Weak Inactive 
15n C3H7 CO2C2H5 H Inactive Inactive 
15o C3H7 CO2C4H9 H Inactive Inactive 
15p C3H7 CO2C8H17 H Inactive Inactive 
15q C3H7 CONH2 H Inactive Inactive 
15r C3H7 SO2CH3 H 10.56 Inactive 
15s C3H7 SO2C2H5 H Inactive Inactive 
15t C3H7 SO2C3H7 H Inactive Inactive 
15u C3H7 SO2C4H9 H Inactive Inactive 
15v C3H7 SO2C6H4CH3 H Inactive Inactive 
15w C3H7 PO(OEt)2 H Inactive Inactive 
17 C3H7 CNHNH2 H Inactive Inactive 
18a C4H9 CHO H 2.31 2.54 
18b C4H9 COCH3 H Inactive Inactive 
18c C4H9 COC3H7 H 0.42 0.49 
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2.3. Conclusion 
 
TLR8 agonists are thought to be uniquely potent in activating adaptive immune responses by 
inducing robust production of T helper 1-polarizing cytokines, and may be promising candidate 
vaccine adjuvants, especially for neonatal vaccines. Thiazoloquinoline analogues with methyl, 
ethyl, propyl and butyl groups at C2 displayed comparable TLR8-agonistic potencies; however, 
the C2-butyl compound 8d was unique in possessing substantial TLR7-agonistic activity. 
Analogues with branched alkyl groups at C2 displayed poor tolerance of terminal steric bulk. 
C4-N-acyl analogues with short acyl groups (other than acetyl) retained TLR8 agonistic activity, 
but were substantially less water-soluble. Immunization in rabbits with a model subunit antigen 
adjuvanted with the most potent TLR8 agonist showed dramatic enhancements of antigen-





Chemistry. All of the solvents and reagents used were obtained commercially and used as 
such unless noted otherwise. Moisture- or air-sensitive reactions were conducted under nitrogen 
atmosphere in oven-dried (120 °C) glass apparatus. The solvents were removed under reduced 
pressure using standard rotary evaporators. Flash column chromatography was carried out 
using RediSep Rf ‘Gold’ high performance silica columns on CombiFlash Rf instrument unless 
otherwise mentioned, while thin-layer chromatography was carried out on silica gel (200 m) 
CCM pre-coated aluminum sheets. Purity for all final compounds was confirmed to be greater 
than 98% by LC-MS using a Zorbax Eclipse Plus 4.6 mm × 150 mm, 5 m analytical reverse 
phase C18 column with H2O–isopropanol or H2O–CH3CN gradients and either an Agilent ESI-
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TOF mass spectrometer (mass accuracy of 20 ppm) or an Agilent 6520 ESI-QTOF mass 
spectrometer (mass accuracy of <10 ppm) operating in the positive ion (or negative ion, as 
appropriate) acquisition mode. 
 
Synthesis of compound 2: 2-(2-Nitroethylideneamino)benzoic acid. Nitromethane (4.32 mL, 
80 mmol) was added dropwise to a solution of NaOH (9.6 g, 250 mmol) in water (10 mL) at 0 
C. The mixture was then warmed to 40 ºC and nitromethane (4.32 mL, 80 mmol) was again 
added slowly at 40-45 ºC. The temperature was maintained until a clear solution was obtained. 
The reaction mixture was then heated to 55 ºC for 2-5 minutes, cooled to 30 ºC, poured onto 
crushed ice and acidified with conc. HCl (11 mL). The resultant solution of methazoic acid was 
added immediately to a filtered solution of anthranilic acid 1 (10 g, 73 mmol) and conc. HCl (3.3 
mL) in water (75 mL). The reaction mixture was allowed to stand at room temperature for 12 h. 
After filtration, the residue obtained was washed with water, and dried to yield compound 2 
(12.94 g, 85%). 1H NMR (400 MHz, MeOD)  8.14 (d, J = 7.7 Hz, 1H), 7.83 (d, J = 6.1 Hz, 1H), 
7.68 – 7.59 (m, 2H), 7.22 (t, J = 7.4 Hz, 1H), 6.73 (d, J = 6.3 Hz, 1H). 13C NMR (101 MHz, 
MeOD)  168.6, 141.2, 136.6, 134.3, 132.0, 123.2, 116.7, 114.5, 100.0. MS (ESI) calculated for 
C9H8N2O4, m/z 208.05, found 209.06 [M+H]
+. 
 
Synthesis of compound 3: 3-Nitroquinolin-4-ol. A solution of compound 2 (12.94 g, 62.2 
mmol) in acetic anhydride (50 mL) was placed in a 2-neck flask fitted with a reflux condenser. It 
was stirred and heated to 105 ºC until a clear solution was obtained. Heating was then 
discontinued and potassium acetate (6.22 g, 63.5 mmol) was added. The mixture was then 
refluxed for 15 min with vigorous stirring, until a solid started to precipitate. The reaction mixture 
was then slowly cooled to room temperature. The residue was filtered, washed with glacial 
acetic acid until the washings were colorless, then suspended in water, filtered, washed with 
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water and dried at 110 ºC to get 3-nitroquinolin-4-ol 3 (4.68 g, 40%). 1H NMR (500 MHz, DMSO) 
 13.04 (s, 1H), 9.21 (s, 1H), 8.25 (dd, J = 8.1, 1.1 Hz, 1H), 7.83 – 7.77 (m, 1H), 7.74 – 7.70 (m, 
1H), 7.52 (ddd, J = 8.1, 7.1, 1.1 Hz, 1H). 13C NMR (126 MHz, DMSO)  167.6, 142.5, 138.3, 
133.2, 130.9, 128.1, 125.9, 125.8, 119.5. MS (ESI) calculated for C9H6N2O3, m/z 190.04, found 
191.05 [M+H]+. 
 
Synthesis of compound 4: 3-Aminoquinolin-4-ol. To a solution of compound 3 (1.89 g, 9.93 
mmol) in DMF (25 mL), was added 5% Pt on carbon (20%, 0.38 g). The reaction mixture was 
allowed to react in a Parr hydrogenation apparatus at 60 psi H2 pressure for 3.5 h with vigorous 
shaking. The reaction mixture was filtered through celite with several washes of methanol. The 
filtrate was concentrated by evaporation to get compound 4 (1.5 g, 94%). 1H NMR (500 MHz, 
MeOD)  8.90 (d, J = 8.1 Hz, 1H), 8.33 (d, J = 5.8 Hz, 1H), 8.30 – 8.23 (m, 2H), 7.97 (ddd, J = 
8.1, 6.0, 1.9 Hz, 1H). 13C NMR (126 MHz, MeOD)  146.9, 140.8, 138.9, 134.2, 131.2, 130.6, 
128.7, 127.5. MS (ESI) calculated for C9H8N2O, m/z 160.06, found 161.07 [M+H]
+. 
 
Synthesis of compound 5a: N-(4-hydroxyquinolin-3-yl)acetamide. Compound 4 (200 mg, 
1.25 mmol) was dissolved in a mixture of CH2Cl2 (20 mL) and DMF (2 mL) and stirred at room 
temperature for 5 min. Acetyl chloride (133 L, 1.875 mmol) was added to the stirring reaction 
mixture at 0 ºC and the solution was allowed to react for 1.5 h. Solvents were removed and the 
crude residue was purified using silica gel column chromatography (0-10% MeOH in CH2Cl2) to 
obtain the compound 5a (106 mg, 42%).  1H NMR (500 MHz, CDCl3)  9.20 (d, J = 5.5 Hz, 1H), 
8.86 (s, 1H), 8.46 (s, 1H), 8.41 (dd, J = 8.3, 1.0 Hz, 1H), 7.62 (ddd, J = 8.3, 7.1, 1.3 Hz, 1H), 
7.41 – 7.32 (m, 2H), 2.26 (s, 3H). 13C NMR (126 MHz, CDCl3)  169.1, 137.9, 132.1, 126.6, 
126.3, 123.6, 123.3, 122.9, 117.6, 24.6. MS (ESI) calculated for C11H10N2O2, m/z 202.07, found 
203.08 [M+H]+. 
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Compounds 5b-5q were synthesized similarly as compound 5a. 
 
5b: N-(4-hydroxyquinolin-3-yl)propionamide. 132 mg, 43%. 1H NMR (500 MHz, CDCl3)  
9.29 (s, 1H), 8.71 (s, 1H), 8.42 (d, J = 7.7 Hz, 1H), 7.64 (t, J = 7.4 Hz, 1H), 7.49 (s, 1H), 7.38 (s, 
1H), 2.56 (dd, J = 14.2, 7.0 Hz, 2H), 1.31 (t, J = 7.5 Hz, 3H). 13C NMR (126 MHz, CDCl3)  
137.9, 132.2, 126.1, 126.1, 124.5, 124.1, 124.0, 123.9, 118.0, 30.6, 9.9. MS (ESI) calculated for 
C12H12N2O2, m/z 216.09, found 217.10 [M+H]
+. 
 
5c: N-(4-hydroxyquinolin-3-yl)butyramide. 1H NMR (500 MHz, MeOD)  9.02 (s, 1H), 8.28 
(dd, J = 8.3, 1.3 Hz, 1H), 7.68 (ddd, J = 8.4, 7.0, 1.4 Hz, 1H), 7.57 (d, J = 8.4 Hz, 1H), 7.42 – 
7.35 (m, 1H), 2.46 (t, J = 7.5 Hz, 2H), 1.74 (dd, J = 14.9, 7.4 Hz, 2H), 1.01 (t, J = 7.4 Hz, 3H). 
13C NMR (126 MHz, MeOD)  174.6, 172.2, 139.7, 133.1, 131.3, 126.2, 124.8, 124.7, 122.8, 
119.4, 39.6, 20.3, 14.0. MS (ESI) calculated for C13H14N2O2, m/z 230.11, found 231.11 [M+H]
+. 
 
5d: N-(4-hydroxyquinolin-3-yl)pentanamide. 155 mg, 52%. 1H NMR (500 MHz, CDCl3)  
10.61 (s, 1H), 9.18 (s, 1H), 8.98 (s, 1H), 8.19 (d, J = 8.0 Hz, 1H), 7.72 – 7.62 (m, 2H), 7.37 – 
7.30 (m, 1H), 2.44 (t, J = 7.4 Hz, 2H), 1.60 – 1.52 (m, 2H), 1.32 (dq, J = 14.7, 7.4 Hz, 2H), 0.89 
(dd, J = 12.5, 5.1 Hz, 3H). 13C NMR (126 MHz, CDCl3)  171.6, 168.9, 138.0, 131.4, 129.1, 
124.0, 123.0, 122.9, 121.4, 118.5, 27.4, 21.9, 13.8. MS (ESI) calculated for C14H16N2O2, m/z 
244.12, found 245.13 [M+H]+. 
 
5e: N-(4-hydroxyquinolin-3-yl)hexanamide. 141 mg, 44%. 1H NMR (500 MHz, CDCl3)  9.65 
(s, 1H), 8.44 (d, J = 8.2 Hz, 1H), 8.31 (d, J = 7.2 Hz, 1H), 7.88 (t, J = 7.4 Hz, 1H), 7.68 (t, J = 7.3 
Hz, 1H), 2.82 (t, J = 6.5 Hz, 2H), 1.88 – 1.76 (m, 2H), 1.48 – 1.35 (m, 4H), 0.92 (t, J = 7.0 Hz, 
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3H). 13C NMR (126 MHz, CDCl3)  177.9, 137.1, 133.7, 128.0, 124.8, 122.0, 120.7, 120.1, 36.1, 
31.3, 25.6, 22.5, 14.1. MS (ESI) calculated for C15H18N2O2, m/z 258.14, found 259.15 [M+H]
+. 
 
5f: N-(4-hydroxyquinolin-3-yl)heptanamide. 105 mg, 31%. 1H NMR (500 MHz, CDCl3)  9.24 
(d, J = 6.3 Hz, 1H), 8.88 (d, J = 1.6 Hz, 1H), 8.46 (s, 1H), 8.43 – 8.40 (m, 1H), 7.62 (ddd, J = 
8.4, 7.1, 1.4 Hz, 1H), 7.40 – 7.33 (m, 2H), 2.49 – 2.44 (m, 2H), 1.80 – 1.72 (m, 2H), 1.44 – 1.36 
(m, 2H), 1.32 (td, J = 7.1, 3.5 Hz, 4H), 0.89 (dd, J = 9.7, 4.3 Hz, 3H). 13C NMR (126 MHz, 
CDCl3)  172.3, 170.7, 138.0, 132.0, 126.5, 126.3, 123.5, 123.3, 122.8, 117.6, 37.7, 31.7, 29.1, 
25.8, 22.6, 14.2. MS (ESI) calculated for C16H20N2O2, m/z 272.15, found 273.16 [M+H]
+. 
 
5g: N-(4-hydroxyquinolin-3-yl)octanamide. 263 mg, 73%. 1H NMR (500 MHz, CDCl3)  9.25 
(d, J = 6.4 Hz, 1H), 8.99 (s, 1H), 8.46 (s, 1H), 8.43 – 8.40 (m, 1H), 7.62 (ddd, J = 8.4, 7.0, 1.4 
Hz, 1H), 7.40 – 7.33 (m, 2H), 2.49 – 2.44 (m, 2H), 1.81 – 1.73 (m, 2H), 1.41 – 1.24 (m, 8H), 
0.88 (t, J = 6.9 Hz, 3H). 13C NMR (126 MHz, CDCl3)  172.3, 170.8, 138.0, 132.0, 126.6, 126.3, 
123.5, 123.3, 122.8, 117.6, 37.7, 31.9, 29.4, 29.2, 25.9, 22.8, 14.2. MS (ESI) calculated for 
C17H22N2O2, m/z 286.17, found 287.18 [M+H]
+. 
 
5h: N-(4-hydroxyquinolin-3-yl)decanamide. 231 mg, 59%. 1H NMR (500 MHz, CDCl3)  9.24 
(s, 1H), 8.47 (s, 1H), 8.41 (dd, J = 8.2, 1.0 Hz, 1H), 7.63 – 7.58 (m, 1H), 7.40 (d, J = 8.4 Hz, 
1H), 7.37 – 7.32 (m, 1H), 2.50 – 2.43 (m, 2H), 1.80 – 1.72 (m, 2H), 1.43 – 1.20 (m, 12H), 0.87 (t, 
J = 7.0 Hz, 3H). 13C NMR (126 MHz, CDCl3)  172.4, 170.8, 138.0, 132.0, 126.8, 126.2, 123.5, 
123.3, 122.7, 117.7, 37.7, 32.0, 29.6, 29.5, 29.4, 29.4, 25.9, 22.8, 14.3. MS (ESI) calculated for 
C19H26N2O2, m/z 314.20, found 315.21 [M+H]
+. 
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Synthesis of compound 6a: 2-Methylthiazolo[4,5-c]quinoline. To a solution of compound 5a 
(100 mg, 0.49 mmol) in pyridine (10 mL), was added phosphorous pentasulfide (109 mg, 0.49 
mmol) and reaction mixture was refluxed for 2 h. The resulting solution was cooled to room 
temperature and pyridine was removed under reduced pressure. The residue was dissolved in 
water and pH was adjusted to 8 with saturated sodium bicarbonate solution and extracted in 
ethyl acetate. The organic layer was dried over sodium sulfate and concentrated to afford 
compound 6a (64 mg, 65%). 1H NMR (500 MHz, CDCl3)  9.42 (s, 1H), 8.23 (d, J = 8.3 Hz, 1H), 
7.94 (dd, J = 8.1, 0.9 Hz, 1H), 7.73 (ddd, J = 8.4, 7.0, 1.4 Hz, 1H), 7.62 (ddd, J = 8.1, 7.1, 1.1 
Hz, 1H), 2.94 (s, 3H). 13C NMR (126 MHz, CDCl3)  167.5, 148.0, 145.6, 144.3, 141.1, 130.6, 
128.8, 127.6, 125.0, 123.5, 20.3. MS (ESI) calculated for C11H8N2S, m/z 200.04, found 201.05 
[M+H]+. 
 
Compounds 6b-6q were synthesized similarly as compound 6a. 
 
6b: 2-Ethylthiazolo[4,5-c]quinoline. 90 mg, 70%. 1H NMR (500 MHz, CDCl3)  9.45 (s, 1H), 
8.24 (d, J = 8.3 Hz, 1H), 7.99 – 7.94 (m, 1H), 7.73 (ddd, J = 8.4, 7.0, 1.4 Hz, 1H), 7.64 (ddd, J = 
8.1, 7.1, 1.1 Hz, 1H), 3.26 (q, J = 7.6 Hz, 2H), 1.54 (dd, J = 10.6, 4.5 Hz, 3H). 13C NMR (126 
MHz, CDCl3)  174.2, 147.9, 145.8, 144.2, 140.6, 130.6, 128.8, 127.6, 125.0, 123.6, 28.0, 14.0. 
MS (ESI) calculated for C12H10N2S, m/z 214.06, found 215.08 [M+H]
+. 
 
6c: 2-Propylthiazolo[4,5-c]quinoline. 950 mg, 95%. 1H NMR (400 MHz, CDCl3)  9.45 (s, 1H), 
8.24 (d, J = 8.3 Hz, 1H), 7.97 (dd, J = 8.1, 0.9 Hz, 1H), 7.74 (ddd, J = 8.4, 7.0, 1.4 Hz, 1H), 7.69 
– 7.59 (m, 1H), 3.26 – 3.11 (m, 2H), 2.04 – 1.92 (m, 2H), 1.10 (t, J = 7.4 Hz, 3H). 13C NMR (126 
MHz, CDCl3)  172.8, 147.9, 145.8, 144.3, 140.7, 130.6, 128.8, 127.6, 125.0, 123.6, 36.4, 23.3, 
13.8. MS (ESI) calculated for C13H12N2S, m/z 228.07, found 229.08 [M+H]
+. 
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6d: 2-Butylthiazolo[4,5-c]quinoline. 108 mg, 73%. 1H NMR (500 MHz, CDCl3)  9.44 (s, 1H), 
8.24 (d, J = 8.4 Hz, 1H), 7.96 (dd, J = 8.1, 0.9 Hz, 1H), 7.73 (ddd, J = 8.4, 5.4, 1.4 Hz, 1H), 7.63 
(ddd, J = 8.1, 7.1, 1.1 Hz, 1H), 3.25 – 3.19 (m, 2H), 1.97 – 1.89 (m, 2H), 1.55 – 1.46 (m, 2H), 
1.00 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3)  173.0, 147.9, 145.8, 144.2, 140.6, 130.6, 
128.8, 128.8, 127.6, 125.0, 123.6, 34.2, 32.0, 22.4, 13.9. MS (ESI) calculated for C14H14N2S, 
m/z 242.09, found 243.10 [M+H]+. 
 
6e: 2-Pentylthiazolo[4,5-c]quinoline. 104 mg, 76%. 1H NMR (500 MHz, CDCl3)  9.45 (s, 1H), 
8.24 (d, J = 8.3 Hz, 1H), 7.96 (dd, J = 8.1, 0.9 Hz, 1H), 7.73 (ddd, J = 8.4, 7.0, 1.4 Hz, 1H), 7.63 
(ddd, J = 8.1, 7.1, 1.1 Hz, 1H), 3.24 – 3.17 (m, 2H), 1.95 (dt, J = 15.3, 7.7 Hz, 2H), 1.50 – 1.36 
(m, 4H), 0.93 (t, J = 7.2 Hz, 3H). 13C NMR (126 MHz, CDCl3)  173.1, 147.9, 145.8, 144.2, 
140.7, 130.6, 128.8, 127.6, 125.0, 123.6, 34.4, 31.4, 29.6, 22.5, 14.1. MS (ESI) calculated for 
C15H16N2S, m/z 256.10, found 257.14 [M+H]
+. 
 
6f: 2-Hexylthiazolo[4,5-c]quinoline. 93 mg, 96%. 1H NMR (500 MHz, CDCl3)  9.45 (s, 1H), 
8.24 (d, J = 8.4 Hz, 1H), 7.97 (dd, J = 8.1, 0.9 Hz, 1H), 7.74 (ddd, J = 8.4, 7.0, 1.4 Hz, 1H), 7.66 
– 7.62 (m, 1H), 3.25 – 3.19 (m, 2H), 1.98 – 1.90 (m, 2H), 1.48 (dd, J = 10.5, 4.5 Hz, 2H), 1.36 
(ddd, J = 16.3, 7.0, 4.9 Hz, 4H), 0.90 (dd, J = 9.4, 4.7 Hz, 3H). 13C NMR (126 MHz, CDCl3)  
173.1, 147.9, 145.8, 144.3, 140.7, 130.6, 128.8, 127.6, 125.0, 123.6, 34.5, 31.6, 29.9, 28.9, 
22.6, 14.2. MS (ESI) calculated for C16H18N2S, m/z 270.12, found 271.14 [M+H]
+. 
 
6g: 2-Heptylthiazolo[4,5-c]quinoline. 108 mg, 42%. 1H NMR (500 MHz, CDCl3)  9.44 (s, 1H), 
8.23 (d, J = 8.4 Hz, 1H), 7.96 (dd, J = 8.1, 0.9 Hz, 1H), 7.73 (ddd, J = 8.4, 7.0, 1.4 Hz, 1H), 7.65 
– 7.60 (m, 1H), 3.22 – 3.17 (m, 2H), 1.94 (dt, J = 15.3, 7.6 Hz, 3H), 1.50 – 1.43 (m, 3H), 1.40 – 
1.35 (m, 2H), 1.31 – 1.27 (m, 4H), 0.88 (t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, CDCl3)  173.1, 
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147.9, 145.8, 144.2, 140.6, 130.6, 128.8, 127.6, 125.0, 123.6, 34.5, 31.8, 29.9, 29.2, 29.1, 22.7, 
14.2. MS (ESI) calculated for C17H20N2S, m/z 284.13, found 285.17 [M+H]
+. 
 
6h: 2-Nonylthiazolo[4,5-c]quinoline. 157 mg, 52%. 1H NMR (500 MHz, CDCl3)  9.45 (s, 1H), 
8.24 (d, J = 8.4 Hz, 1H), 7.96 (d, J = 8.1 Hz, 1H), 7.73 (ddd, J = 8.4, 5.3, 1.4 Hz, 1H), 7.63 (t, J = 
7.5 Hz, 1H), 3.23 – 3.18 (m, 2H), 1.94 (dt, J = 15.4, 7.7 Hz, 2H), 1.51 – 1.43 (m, 2H), 1.40 – 
1.34 (m, 2H), 1.31 – 1.24 (m, 8H), 0.87 (t, J = 6.9 Hz, 3H). 13C NMR (126 MHz, CDCl3)  173.1, 
147.9, 145.8, 144.2, 130.6, 128.8, 128.7, 127.6, 125.0, 123.6, 120.3, 34.5, 32.0, 29.9, 29.5, 
29.4, 29.4, 29.2, 22.8, 14.2. MS (ESI) calculated for C19H24N2S, m/z 312.17, found 313.19 
[M+H]+. 
 
6i: 2-Isopropylthiazolo[4,5-c]quinoline. 164 mg, 83%. 1H NMR (500 MHz, CDCl3)  9.46 (s, 
1H), 8.24 (d, J = 8.2 Hz, 1H), 8.01 – 7.96 (m, 1H), 7.73 (ddd, J = 8.4, 7.0, 1.4 Hz, 1H), 7.64 
(ddd, J = 8.1, 7.0, 1.2 Hz, 1H), 3.58 – 3.48 (m, 1H), 1.56 (d, J = 6.9 Hz, 6H). 13C NMR (126 
MHz, CDCl3)  179.3, 147.8, 145.9, 144.2, 140.2, 130.6, 128.8, 127.6, 125.0, 123.7, 34.3, 23.1. 
MS (ESI) calculated for C13H12N2S, m/z 228.10, found 229.08 [M+H]
+. 
 
6j: 2-Isobutylthiazolo[4,5-c]quinoline. 150 mg, 72%. 1H NMR (500 MHz, MeOD)  9.31 (s, 
1H), 8.18 (d, J = 8.3 Hz, 1H), 8.11 (dd, J = 8.1, 0.9 Hz, 1H), 7.81 (ddd, J = 8.4, 7.0, 1.4 Hz, 1H), 
7.73 (ddd, J = 8.1, 7.1, 1.2 Hz, 1H), 2.30 (m, J = 13.7, 6.8 Hz, 1H), 1.08 (d, J = 6.6 Hz, 6H). 13C 
NMR (126 MHz, MeOD)  174.5, 148.7, 146.0, 144.7, 142.6, 130.5, 130.4, 129.3, 126.2, 124.7, 
43.7, 31.1, 22.6. MS (ESI) calculated for C14H14N2S, m/z 242.09, found 243.09 [M+H]
+. 
 
6l: 2-Isopentylthiazolo[4,5-c]quinoline. 165 mg, 75%. 1H NMR (500 MHz, CDCl3)  9.44 (s, 
1H), 8.26 – 8.22 (m, 1H), 7.98 – 7.95 (m, 1H), 7.73 (ddd, J = 8.4, 7.0, 1.4 Hz, 1H), 7.64 (ddd, J 
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= 8.1, 7.0, 1.2 Hz, 1H), 3.26 – 3.20 (m, 2H), 1.88 – 1.82 (m, 2H), 1.75 (dd, J = 13.3, 6.7 Hz, 1H), 
1.01 (d, J = 6.6 Hz, 6H). 13C NMR (126 MHz, CDCl3)  173.2, 147.9, 145.8, 144.3, 140.6, 130.6, 
128.8, 127.6, 125.0, 123.6, 38.8, 32.5, 27.9, 22.5. MS (ESI) calculated for C15H16N2S, m/z 
256.10.10, found 257.10 [M+H]+. 
 
6o: (S)-2-(2-methylbutyl)thiazolo[4,5-c]quinoline. 170 mg, 77%. 1H NMR (500 MHz, CDCl3)  
9.45 (s, 1H), 8.24 (d, J = 8.3 Hz, 1H), 7.96 (dd, J = 8.1, 0.9 Hz, 1H), 7.73 (ddd, J = 8.4, 7.0, 1.4 
Hz, 1H), 7.63 (ddd, J = 8.1, 7.1, 1.1 Hz, 1H), 3.21 (dd, J = 14.6, 6.2 Hz, 1H), 3.01 (dd, J = 14.6, 
8.2 Hz, 1H), 2.12 – 2.02 (m, 1H), 1.58 – 1.48 (m, 1H), 1.40 – 1.30 (m, 1H), 1.03 (d, J = 6.7 Hz, 
3H), 0.98 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3)  172.1, 147.9, 145.8, 144.2, 140.8, 
130.6, 128.8, 127.6, 125.0, 123.6, 41.4, 36.3, 29.4, 19.2, 11.5. MS (ESI) calculated for 
C15H16N2S, m/z 256.10, found 257.10 [M+H]
+. 
 
6p: 2-(3,3,3-Trifluoropropyl)thiazolo[4,5-c]quinoline. 180 mg, 74%. 1H NMR (500 MHz, 
CDCl3)  9.45 (s, 1H), 8.26 (d, J = 8.4 Hz, 1H), 7.99 – 7.95 (m, 1H), 7.76 (ddd, J = 8.4, 7.0, 1.4 
Hz, 1H), 7.66 (ddd, J = 8.1, 7.0, 1.2 Hz, 1H), 3.51 – 3.45 (m, 2H), 2.91 – 2.80 (m, 2H). 13C NMR 
(126 MHz, CDCl3)  168.0, 147.7, 145.8, 144.4, 140.8, 130.7, 129.2, 127.8, 126.4 (q, 1JCF = 
276.5 Hz), 125.0, 123.4, 33.0 (q, 2JCF = 29.8 Hz), 27.0 (q, 3JCF = 3.5 Hz). MS (ESI) calculated 
for C13H9F3N2S, m/z 282.04, found 283.04 [M+H]
+. 
 
6q: 2-(4,4,4-Trifluorobutyl)thiazolo[4,5-c]quinoline. 190 mg, 75%. 1H NMR (500 MHz, CDCl3) 
 9.46 (s, 1H), 8.26 (d, J = 8.2 Hz, 1H), 8.00 – 7.95 (m, 1H), 7.76 (ddd, J = 8.4, 7.0, 1.4 Hz, 1H), 
7.66 (ddd, J = 8.1, 7.0, 1.2 Hz, 1H), 3.32 (t, J = 7.2 Hz, 2H), 2.37 – 2.22 (m, 4H). 13C NMR (126 
MHz, CDCl3)  170.4, 147.9, 145.8, 144.4, 140.7, 130.7, 129.1, 127.8, 127.0 (q, 1JCF = 276.4 
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Hz), 125.0, 123.5, 33.9 (q, 2JCF = 28.9 Hz), 33.0, 21.1 (q, 3JCF = 3.0 Hz). MS (ESI) calculated 
for C14H11F3N2S, m/z 296.05, found 297.06 [M+H]
+. 
 
Synthesis of compound 7a: 2-Methylthiazolo[4,5-c]quinoline 5-oxide. To a solution of 
compound 6a (57 mg, 0.28 mmol) in CHCl3 (10 mL), was added m-chloroperoxybenzoic acid 
(95 mg, 0.43 mmol) and the reaction mixture was stirred at room temperature for 18 h. The 
solvent was then removed under reduced pressure and the crude residue was purified using 
silica gel column chromatography (5% MeOH/CH2Cl2) to obtain compound 7a (57 mg, 94%). 
1H 
NMR (500 MHz, CDCl3)  9.13 (s, 1H), 8.89 (d, J = 8.9 Hz, 1H), 7.94 (dd, J = 7.9, 1.1 Hz, 1H), 
7.81 – 7.72 (m, 2H), 2.93 (s, 3H). 13C NMR (126 MHz, CDCl3)  169.7, 147.2, 139.0, 131.5, 
131.1, 129.9, 129.7, 125.6, 123.8, 121.6, 20.4. MS (ESI) calculated for C11H8N2OS, m/z 216.04, 
found 217.05 [M+H]+. 
 
Compounds 7b-7q were synthesized similarly as compound 7a. 
7b: 2-Ethylthiazolo[4,5-c]quinoline 5-oxide. 81 mg, 88%. 1H NMR (500 MHz, CDCl3)  9.15 
(s, 1H), 8.90 (dd, J = 8.6, 0.8 Hz, 1H), 7.95 (dd, J = 8.0, 1.0 Hz, 1H), 7.82 – 7.72 (m, 2H), 3.23 
(q, J = 7.6 Hz, 2H), 1.53 (d, J = 15.1 Hz, 3H). 13C NMR (126 MHz, CDCl3)  176.4, 147.1, 139.0, 
131.6, 130.7, 129.9, 129.6, 125.6, 123.9, 121.6, 28.0, 13.9. MS (ESI) calculated for 
C12H10N2OS, m/z 230.05, found 231.06 [M+H]
+. 
 
7c: 2-Propylthiazolo[4,5-c]quinoline 5-oxide. 950 mg, 88%. 1H NMR (400 MHz, CDCl3)  9.14 
(s, 1H), 8.90 (d, J = 8.7 Hz, 1H), 7.95 (dd, J = 7.9, 1.1 Hz, 1H), 7.82 – 7.71 (m, 2H), 3.17 (t, J = 
7.6 Hz, 2H), 1.95 (dt, J = 14.9, 7.4 Hz, 2H), 1.09 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) 
 175.0, 147.1, 139.0, 131.6, 130.7, 129.9, 129.6, 123.9, 121.6, 36.4, 23.2, 13.8. MS (ESI) 
calculated for C13H12N2OS, m/z 244.07, found 245.07 [M+H]
+. 
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7d: 2-Butylthiazolo[4,5-c]quinoline 5-oxide. 82 mg, 75%. 1H NMR (500 MHz, CDCl3)  9.13 
(s, 1H), 8.90 – 8.86 (m, 1H), 7.94 (dd, J = 7.9, 1.1 Hz, 1H), 7.80 – 7.71 (m, 2H), 3.21 – 3.16 (m, 
2H), 1.94 – 1.86 (m, 2H), 1.53 – 1.45 (m, 2H), 0.99 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, 
CDCl3)  175.2, 147.1, 139.0, 131.6, 130.6, 129.9, 129.6, 125.6, 123.9, 121.6, 34.2, 31.8, 22.4, 
13.9. MS (ESI) calculated for C14H14N2OS, m/z 258.08, found 259.09 [M+H]
+. 
 
7e: 2-Pentylthiazolo[4,5-c]quinoline 5-oxide. 90 mg, 87%. 1H NMR (500 MHz, CDCl3)  9.13 
(s, 1H), 8.88 (d, J = 8.1 Hz, 1H), 7.94 (dd, J = 8.0, 1.2 Hz, 1H), 7.81 – 7.70 (m, 2H), 3.22 – 3.13 
(m, 2H), 1.92 (dt, J = 15.4, 7.7 Hz, 2H), 1.48 – 1.36 (m, 4H), 0.92 (t, J = 7.1 Hz, 3H). 13C NMR 
(126 MHz, CDCl3)  175.3, 147.0, 138.9, 131.6, 130.7, 129.9, 129.6, 125.6, 123.9, 121.6, 34.5, 
31.3, 29.5, 22.4, 14.0. MS (ESI) calculated for C15H16N2OS, m/z 272.10, found 273.11 [M+H]
+. 
 
7f: 2-Hexylthiazolo[4,5-c]quinoline 5-oxide. 65 mg, 76%. 1H NMR (500 MHz, CDCl3)  9.15 
(s, 1H), 8.90 (d, J = 8.5 Hz, 1H), 7.96 (dd, J = 8.0, 1.0 Hz, 1H), 7.82 – 7.72 (m, 2H), 3.22 – 3.17 
(m, 2H), 1.92 (dd, J = 15.3, 7.7 Hz, 2H), 1.51 – 1.44 (m, 2H), 1.40 – 1.30 (m, 4H), 0.90 (t, J = 
7.1 Hz, 3H). 13C NMR (126 MHz, CDCl3)  175.3, 147.1, 139.0, 131.7, 130.8, 129.9, 129.6, 
125.6, 123.9, 121.6, 34.5, 31.6, 29.8, 28.9, 22.6, 14.2. MS (ESI) calculated for C16H18N2OS, m/z 
286.11, found 287.12 [M+H]+. 
 
7g: 2-Heptylthiazolo[4,5-c]quinoline 5-oxide. 81 mg, 75%. 1H NMR (500 MHz, CDCl3)  9.13 
(s, 1H), 8.88 (dd, J = 8.7, 0.8 Hz, 1H), 7.94 (dd, J = 7.9, 1.1 Hz, 1H), 7.80 – 7.71 (m, 2H), 3.21 – 
3.15 (m, 2H), 1.91 (dt, J = 15.3, 7.6 Hz, 2H), 1.49 – 1.42 (m, 2H), 1.41 – 1.35 (m, 2H), 1.32 – 
1.26 (m, 4H), 0.88 (t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, CDCl3)  175.3, 147.0, 138.9, 131.6, 
130.7, 129.9, 129.6, 125.6, 123.9, 121.6, 34.5, 31.7, 29.8, 29.2, 29.0, 22.7, 14.2. MS (ESI) 
calculated for C17H20N2OS, m/z 300.13, found 301.14 [M+H]
+. 
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7h: 2-Nonylthiazolo[4,5-c]quinoline 5-oxide. 105 mg, 66%. 1H NMR (500 MHz, CDCl3)  9.13 
(s, 1H), 8.88 (d, J = 8.5 Hz, 1H), 7.93 (dd, J = 7.9, 1.1 Hz, 1H), 7.81 – 7.69 (m, 2H), 3.19 – 3.14 
(m, 2H), 1.91 (dt, J = 15.3, 7.6 Hz, 2H), 1.45 (dt, J = 14.9, 7.0 Hz, 2H), 1.35 (dd, J = 14.2, 6.9 
Hz, 2H), 1.29 – 1.21 (m, 8H), 0.86 (t, J = 6.9 Hz, 3H). 13C NMR (126 MHz, CDCl3)  175.3, 
147.0, 138.9, 131.6, 130.7, 129.8, 129.6, 125.6, 123.9, 121.5, 34.5, 31.9, 29.8, 29.5, 29.3, 29.2, 
22.8, 14.2. MS (ESI) calculated for C19H24N2OS, m/z 328.16, found 329.17 [M+H]
+. 
 
7i: 2-Isopropylthiazolo[4,5-c]quinoline 5-oxide. 150 mg, 62%. 1H NMR (500 MHz, CDCl3)  
9.15 (s, 1H), 8.90 (dd, J = 8.7, 1.0 Hz, 1H), 7.99 – 7.95 (m, 1H), 7.79 (ddd, J = 8.6, 7.0, 1.5 Hz, 
1H), 7.77 – 7.72 (m, 1H), 3.54 – 3.45 (m, 1H), 1.54 (d, J = 6.9 Hz, 6H). 13C NMR (126 MHz, 
CDCl3)  181.5, 147.0, 138.9, 131.7, 130.3, 129.9, 129.6, 125.6, 124.0, 121.6, 34.4, 23.0. MS 
(ESI) calculated for C13H12N2OS, m/z 244.07.10, found 245.07 [M+H]
+. 
 
7j: 2-Isobutylthiazolo[4,5-c]quinoline 5-oxide. 80 mg, 75%. 1H NMR (500 MHz, MeOD)  
9.26 (s, 1H), 8.79 (dd, J = 8.6, 0.9 Hz, 1H), 8.25 – 8.21 (m, 1H), 7.95 (ddd, J = 8.7, 7.1, 1.5 Hz, 
1H), 7.90 (ddd, J = 8.2, 7.1, 1.4 Hz, 1H), 3.14 (d, J = 7.2 Hz, 2H), 2.35 – 2.25 (m, 1H), 1.09 (d, J 
= 6.6 Hz, 6H). 13C NMR (126 MHz, MeOD)  176.8, 147.8, 139.0, 135.3, 133.5, 131.7, 131.6, 
127.2, 125.2, 121.5, 43.7, 31.0, 22.6. MS (ESI) calculated for C14H14N2OS, m/z 258.08.10, 
found 259.08 [M+H]+. 
 
7k: 2-Neopentylthiazolo[4,5-c]quinoline 5-oxide. 80 mg, 75%. 1H NMR (500 MHz, MeOD)  
9.31 (s, 1H), 8.79 (dd, J = 8.7, 0.9 Hz, 1H), 8.26 – 8.22 (m, 1H), 7.99 – 7.88 (m, 2H), 3.16 (s, 
2H), 1.13 (s, 9H). 13C NMR (126 MHz, MeOD)  174.7, 147.8, 138.8, 135.9, 133.8, 131.8, 131.7, 
127.3, 125.1, 121.4, 48.3, 33.2, 29.9. MS (ESI) calculated for C14H16N2OS, m/z 272.10, found 
273.10 [M+H]+. 
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7l: 2-Isopentylthiazolo[4,5-c]quinoline 5-oxide. 110 mg, 69%. 1H NMR (500 MHz, MeOD)  
9.23 (s, 1H), 8.77 (dd, J = 8.6, 0.9 Hz, 1H), 8.21 – 8.18 (m, 1H), 7.93 (ddd, J = 8.7, 7.0, 1.5 Hz, 
1H), 7.89 (ddd, J = 8.2, 7.1, 1.3 Hz, 1H), 3.27 (dd, J = 8.4, 7.4 Hz, 2H), 1.88 – 1.82 (m, 2H), 
1.78 – 1.69 (m, 1H), 1.02 (d, J = 6.6 Hz, 6H). 13C NMR (126 MHz, MeOD)  178.1, 147.7, 138.9, 
135.1, 133.5, 131.6, 131.6, 127.1, 125.1, 121.5, 39.6, 33.1, 28.8, 22.6. MS (ESI) calculated for 
C15H16N2OS, m/z 272.10, found 273.10 [M+H]
+. 
 
7m: 2-(3,3-Dimethylbutyl)thiazolo[4,5-c]quinoline 5-oxide. 80 mg, 76%. 1H NMR (500 MHz, 
MeOD)  9.22 (s, 1H), 8.77 (dd, J = 8.7, 0.9 Hz, 1H), 8.21 – 8.18 (m, 1H), 7.93 (ddd, J = 8.7, 
7.1, 1.5 Hz, 1H), 7.89 (ddd, J = 8.2, 7.1, 1.3 Hz, 1H), 3.27 – 3.22 (m, 2H), 1.89 – 1.84 (m, 2H), 
1.04 (s, 9H). 13C NMR (126 MHz, MeOD)  178.7, 147.7, 138.9, 135.1, 133.4, 131.6, 131.6, 
127.1, 125.1, 121.4, 44.7, 31.5, 30.9, 29.5. MS (ESI) calculated for C16H18N2OS, m/z 286.11, 
found 287.11 [M+H]+. 
 
7n: (S)-2-(sec-butyl)thiazolo[4,5-c]quinoline 5-oxide. 117 mg, 78%. 1H NMR (500 MHz, 
MeOD)  9.23 (s, 1H), 8.77 (dd, J = 8.6, 1.0 Hz, 1H), 8.22 – 8.18 (m, 1H), 7.93 (ddd, J = 8.7, 
7.1, 1.5 Hz, 1H), 7.88 (ddd, J = 8.2, 7.1, 1.4 Hz, 1H), 3.35 (dd, J = 13.9, 6.9 Hz, 1H), 2.04 – 1.94 
(m, 1H), 1.92 – 1.82 (m, 1H), 1.52 (d, J = 6.9 Hz, 3H), 1.02 (t, J = 7.4 Hz, 3H). 13C NMR (126 
MHz, MeOD)  183.1, 147.7, 138.9, 134.7, 133.5, 131.6, 131.6, 127.1, 125.2, 121.5, 42.3, 31.6, 
20.9, 12.0. MS (ESI) calculated for C14H14N2OS, m/z 258.09, found 259.08 [M+H]
+. 
 
7o: (S)-2-(2-methylbutyl)thiazolo[4,5-c]quinoline 5-oxide. 103 mg, 74%. 1H NMR (500 MHz, 
MeOD)  9.24 (s, 1H), 8.78 (dd, J = 8.7, 0.8 Hz, 1H), 8.23 – 8.19 (m, 1H), 7.94 (ddd, J = 8.7, 
7.1, 1.5 Hz, 1H), 7.89 (dd, 1H), 3.26 (dd, J = 14.7, 6.2 Hz, 1H), 3.06 (dd, J = 14.7, 8.0 Hz, 1H), 
2.14 – 2.03 (m, 1H), 1.60 – 1.50 (m, 1H), 1.44 – 1.30 (m, 1H), 1.04 (d, J = 6.7 Hz, 3H), 1.00 (t, J 
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= 7.4 Hz, 3H). 13C NMR (126 MHz, MeOD)  177.0, 147.8, 139.0, 135.3, 133.5, 131.7, 131.6, 
127.1, 125.1, 121.5, 41.8, 37.4, 30.2, 19.4, 11.6. MS (ESI) calculated for C15H16N2OS, m/z 
272.10, found 273.10 [M+H]+. 
 
7p: 2-(3,3,3-Trifluoropropyl)thiazolo[4,5-c]quinoline 5-oxide. 120 mg, 75%. 1H NMR (500 
MHz, MeOD)  9.24 (s, 1H), 8.76 (dd, J = 8.8, 0.7 Hz, 1H), 8.17 (dd, 1H), 7.93 (ddd, J = 8.6, 7.0, 
1.4 Hz, 1H), 7.88 (ddd, J = 8.2, 7.1, 1.3 Hz, 1H), 3.54 (t, 2H), 2.99 – 2.87 (m, 2H).13C NMR (126 
MHz, MeOD)  173.8, 147.6, 139.1, 135.2, 133.6, 131.8, 131.6, 128.1 (q, 1JCF = 275.6 Hz), 
127.1, 125.0, 121.5, 33.2 (q, 2JCF = 29.7 Hz), 27.7 (q, 3JCF = 3.5 Hz). MS (ESI) calculated for 
C13H9F3N2OS, m/z 298.04, found 299.04 [M+H]
+. 
 
7q: 2-(4,4,4-Trifluorobutyl)thiazolo[4,5-c]quinoline 5-oxide. 128 mg, 81%. 1H NMR (500 
MHz, MeOD)  9.26 (s, 1H), 8.80 – 8.74 (m, 1H), 8.22 – 8.18 (m, 1H), 7.94 (ddd, J = 8.6, 7.1, 
1.5 Hz, 1H), 7.89 (ddd, J = 8.2, 7.1, 1.3 Hz, 1H), 3.36 (t, J = 7.5 Hz, 2H), 2.48 – 2.34 (m, 2H), 
2.27 – 2.17 (m, 2H). 13C NMR (126 MHz, MeOD)  176.0, 147.8, 139.0, 135.2, 133.6, 131.7, 
131.6, 128.6 (q, 1JCF = 275.4 Hz), 127.1, 125.1, 121.5, 33.6 (q, 2JCF = 29.0 Hz), 33.5, 22.6 (q, 
3JCF = 3.2 Hz). MS (ESI) calculated for C14H11F3N2OS, m/z 312.05, found 313.05 [M+H]
+. 
 
Synthesis of compound 8a: 2-Methylthiazolo[4,5-c]quinolin-4-amine. Compound 7a (50 
mg, 0.23 mmol) was dissolved in anhydrous CH2Cl2 (5 mL). Benzoyl isocyanate (68 mg, 0.46 
mmol) was added to the reaction mixture and refluxed for 30 min. The solvent was then 
removed under vacuum and the residue was dissolved in anhydrous methanol (5 mL). Excess 
of sodium methoxide was added and the reaction mixture was refluxed for 2 h. After evaporating 
solvents under reduced pressure, the crude residue was purified using silica gel column 
chromatography (0-7% MeOH in CH2Cl2) to obtain compound 8a as a white solid (41 mg, 82%). 
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1H NMR (400 MHz, CDCl3)  7.77 (dd, J = 8.4, 0.5 Hz, 1H), 7.72 (dd, J = 8.0, 1.0 Hz, 1H), 7.55 
(ddd, J = 8.4, 7.1, 1.5 Hz, 1H), 7.31 (ddd, J = 8.1, 7.1, 1.2 Hz, 1H), 5.61 (s, 2H), 2.89 (s, 3H). 
13C NMR (126 MHz, CDCl3)  165.9, 151.5, 144.8, 141.0, 138.1, 129.1, 126.8, 124.8, 123.2, 
120.1, 20.1. MS (ESI) calculated for C11H9N3S, m/z 215.05, found 216.06 [M+H]
+. 
 
Compounds 8b-8q were synthesized similarly as compound 8a. 
 
8b: 2-Ethylthiazolo[4,5-c]quinolin-4-amine. White solid (36 mg, 47%). 1H NMR (400 MHz, 
CDCl3)  7.77 (dd, J = 8.4, 0.5 Hz, 1H), 7.74 (dd, J = 8.0, 1.1 Hz, 1H), 7.56 (ddd, J = 8.4, 7.1, 
1.5 Hz, 1H), 7.31 (ddd, J = 8.1, 7.1, 1.1 Hz, 1H), 5.58 (s, 2H), 3.20 (q, J = 7.6 Hz, 2H), 1.51 (t, J 
= 7.6 Hz, 3H). 13C NMR (126 MHz, CDCl3)  172.6, 151.6, 144.8, 140.4, 138.0, 129.0, 126.8, 
124.8, 123.2, 120.2, 27.8, 14.1. MS (ESI) calculated for C12H11N3S, m/z 229.07, found 230.08 
[M+H]+. 
 
8c: 2-Propylthiazolo[4,5-c]quinolin-4-amine. White solid (450 mg, 90%). 1H NMR (400 MHz, 
CDCl3)  7.77 (d, J = 8.4 Hz, 1H), 7.73 (dd, J = 8.0, 1.3 Hz, 1H), 7.55 (ddd, J = 8.4, 7.1, 1.4 Hz, 
1H), 7.34 – 7.27 (m, 1H), 5.67 (s, 2H), 3.13 (t, J = 7.6 Hz, 2H), 1.94 (dd, J = 15.0, 7.4 Hz, 2H), 
1.09 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3)  171.2, 151.7, 144.7, 140.5, 138.0, 129.0, 
126.8, 124.8, 123.1, 120.2, 36.2, 23.4, 13.8. MS (ESI) calculated for C13H13N3S, m/z 243.08, 
found 244.09 [M+H]+. 
 
8d: 2-Butylthiazolo[4,5-c]quinolin-4-amine. White solid (25 mg, 32%). 1H NMR (400 MHz, 
CDCl3)  7.77 (dd, J = 8.4, 0.6 Hz, 1H), 7.73 (dd, J = 8.0, 1.0 Hz, 1H), 7.56 (ddd, J = 8.5, 7.1, 
1.5 Hz, 1H), 7.31 (ddd, J = 8.1, 7.1, 1.2 Hz, 1H), 5.56 (s, 2H), 3.20 – 3.13 (m, 2H), 1.90 (dt, J = 
15.3, 7.6 Hz, 2H), 1.50 (dq, J = 14.7, 7.4 Hz, 2H), 1.00 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, 
 51  
CDCl3)  171.5, 151.6, 144.7, 140.5, 138.0, 129.0, 126.8, 124.8, 123.2, 120.2, 34.0, 32.0, 22.4, 
13.9. MS (ESI) calculated for C14H15N3S, m/z 257.10, found 258.11 [M+H]
+. 
 
8e: 2-Pentylthiazolo[4,5-c]quinolin-4-amine. White solid (38 mg, 45%). 1H NMR (400 MHz, 
CDCl3)  7.77 (d, J = 8.1 Hz, 1H), 7.73 (dd, J = 8.0, 1.1 Hz, 1H), 7.55 (ddd, J = 8.4, 7.1, 1.4 Hz, 
1H), 7.34 – 7.29 (m, 1H), 5.59 (s, 2H), 3.18 – 3.12 (m, 2H), 1.96 – 1.86 (m, 2H), 1.50 – 1.35 (m, 
4H), 0.94 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, CDCl3)  171.5, 151.6, 144.7, 140.5, 138.0, 
129.0, 126.8, 124.8, 123.2, 120.2,  34.3, 31.4, 29.7, 22.5, 14.1 MS (ESI) calculated for 
C15H17N3S, m/z 271.11, found 272.12 [M+H]
+. 
 
8f: 2-Hexylthiazolo[4,5-c]quinolin-4-amine. White solid (25 mg, 44%). 1H NMR (400 MHz, 
CDCl3)  7.77 (dd, J = 8.4, 0.5 Hz, 1H), 7.73 (dd, J = 8.0, 1.0 Hz, 1H), 7.55 (ddd, J = 8.4, 7.1, 
1.5 Hz, 1H), 7.31 (ddd, J = 8.1, 7.1, 1.1 Hz, 1H), 5.56 (s, 2H), 3.21 – 3.11 (m, 2H), 1.91 (dt, J = 
15.3, 7.5 Hz, 2H), 1.46 (dt, J = 9.2, 7.0 Hz, 2H), 1.39 – 1.30 (m, 4H), 0.91 (t, J = 7.1 Hz, 3H). 13C 
NMR (126 MHz, CDCl3)  171.6, 151.6, 144.7, 140.51, 138.0, 129.1, 126.8, 124.8, 123.2, 120.2, 
34.3, 31.6, 30.0, 29.0, 22.6, 14.2. MS (ESI) calculated for C16H19N3S, m/z 285.13, found 286.14 
[M+H]+. 
 
8g: 2-Heptylthiazolo[4,5-c]quinolin-4-amine. White solid (34 mg, 42%). 1H NMR (400 MHz, 
CDCl3)  7.77 (dd, J = 8.4, 0.5 Hz, 1H), 7.73 (dd, J = 8.0, 1.0 Hz, 1H), 7.55 (ddd, J = 8.4, 7.1, 
1.5 Hz, 1H), 7.31 (ddd, J = 8.1, 7.1, 1.2 Hz, 1H), 5.56 (s, 2H), 3.20 – 3.08 (m, 2H), 1.91 (dt, J = 
15.3, 7.6 Hz, 2H), 1.50 – 1.42 (m, 2H), 1.38 (ddd, J = 14.0, 8.2, 5.2 Hz, 2H), 1.30 (dt, J = 11.5, 
3.9 Hz, 4H), 0.89 (t, J = 6.9 Hz, 3H). 13C NMR (126 MHz, CDCl3)  171.6, 151.6, 144.7, 140.5, 
138.0, 129.0, 126.8, 124.8, 123.2, 120.2, 34.3, 31.8, 30.0, 29.2, 29.1, 22.8, 14.2. MS (ESI) 
calculated for C17H21N3S, m/z 299.15, found 300.16 [M+H]
+. 
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8h: 2-Nonylthiazolo[4,5-c]quinolin-4-amine. White solid (26 mg, 26%). 1H NMR (400 MHz, 
CDCl3)  7.77 (dd, J = 8.4, 0.5 Hz, 1H), 7.73 (dd, J = 8.0, 1.0 Hz, 1H), 7.55 (ddd, J = 8.5, 7.1, 
1.5 Hz, 1H), 7.31 (ddd, J = 8.1, 7.1, 1.2 Hz, 1H), 5.57 (s, 2H), 3.21 – 3.09 (m, 2H), 1.91 (dt, J = 
15.3, 7.6 Hz, 2H), 1.46 (ddd, J = 14.9, 8.7, 6.5 Hz, 2H), 1.36 (dd, J = 13.7, 6.7 Hz, 2H), 1.28 (s, 
8H), 0.88 (t, J = 6.9 Hz, 3H). 13C NMR (126 MHz, CDCl3)  171.6, 151.6, 144.7, 140.5, 138.0, 
129.0, 126.8, 124.8, 123.2, 120.2, 34.3, 32.0, 30.0, 29.6, 29.4, 29.4, 29.2, 22.8, 14.3. MS (ESI) 
calculated for C19H25N3S, m/z 327.18, found 328.19 [M+H]
+. 
 
8i: 2-Isopropylthiazolo[4,5-c]quinolin-4-amine. White solid (40 mg, 67%). 1H NMR (500 MHz, 
CDCl3)  7.77 (dd, J = 8.4, 0.5 Hz, 1H), 7.75 – 7.71 (m, 1H), 7.55 (ddd, J = 8.4, 7.0, 1.5 Hz, 1H), 
7.31 (ddd, J = 8.1, 7.1, 1.2 Hz, 1H), 5.66 (s, 2H), 3.51 – 3.41 (m, 1H), 1.52 (d, J = 6.9 Hz, 6H). 
13C NMR (126 MHz, CDCl3)  177.7, 151.8, 144.7, 140.0, 137.9, 129.0, 126.8, 124.8, 123.1, 
120.3, 34.2, 23.2. MS (ESI) calculated for C13H13N3S, m/z 243.09.10, found 244.09 [M+H]
+. 
 
8j: 2-Isobutylthiazolo[4,5-c]quinolin-4-amine. White solid (38 mg, 77%). 1H NMR (500 MHz, 
CDCl3)  7.77 (dd, J = 8.4, 0.5 Hz, 1H), 7.73 (dd, J = 8.0, 1.0 Hz, 1H), 7.55 (ddd, J = 8.4, 7.1, 
1.5 Hz, 1H), 7.31 (ddd, J = 8.1, 7.1, 1.1 Hz, 1H), 5.63 (s, 2H), 3.02 (d, J = 7.2 Hz, 2H), 2.30 – 
2.20 (m, 1H), 1.06 (d, J = 6.6 Hz, 6H). 13C NMR (126 MHz, CDCl3)  170.3, 151.7, 144.8, 140.6, 
138.1, 129.1, 126.8, 124.9, 123.1, 120.2, 43.1, 30.0, 22.5. MS (ESI) calculated for C14H15N3S, 
m/z 257.10, found 258.10 [M+H]+. 
 
8k: 2-Neopentylthiazolo[4,5-c]quinolin-4-amine. White solid (45 mg, 76%). 1H NMR (500 
MHz, CDCl3)  7.77 (dd, J = 8.4, 0.5 Hz, 1H), 7.74 (dd, J = 8.0, 1.0 Hz, 1H), 7.55 (ddd, J = 8.4, 
5.5, 1.5 Hz, 1H), 7.31 (ddd, J = 8.1, 7.1, 1.1 Hz, 1H), 5.60 (s, 2H), 3.04 (s, 2H), 1.10 (s, 9H). 13C 
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NMR (126 MHz, CDCl3)  168.1, 151.7, 144.8, 140.7, 138.2, 129.1, 126.8, 124.9, 123.2, 120.1, 
47.8, 32.3, 29.7. MS (ESI) calculated for C14H17N3S, m/z 271.11, found 272.11 [M+H]
+. 
 
8l: 2-Isopentylthiazolo[4,5-c]quinolin-4-amine. White solid (40 mg, 68%). 1H NMR (500 MHz, 
CDCl3)  7.77 (dd, J = 8.4, 0.5 Hz, 1H), 7.73 (dd, J = 8.0, 1.0 Hz, 1H), 7.55 (ddd, J = 8.4, 7.1, 
1.5 Hz, 1H), 7.31 (ddd, J = 8.1, 7.1, 1.1 Hz, 1H), 5.61 (s, 2H), 3.20 – 3.13 (m, 2H), 1.84 – 1.78 
(m, 2H), 1.77 – 1.69 (m, 1H), 1.00 (d, J = 6.5 Hz, 6H). 13C NMR (126 MHz, CDCl3)  171.7, 
151.6, 144.7, 140.5, 138.0, 129.0, 126.8, 124.8, 123.2, 120.2, 38.9, 32.3, 27.9, 22.5. MS (ESI) 
calculated for C15H16N2OS, m/z 271.11, found 272.11 [M+H]
+. 
 
8m: 2-(3,3-Dimethylbutyl)thiazolo[4,5-c]quinolin-4-amine. White solid (45 mg, 65%). 1H 
NMR (500 MHz, CDCl3)  7.77 (dd, J = 8.4, 0.5 Hz, 1H), 7.74 – 7.70 (m, 1H), 7.55 (ddd, J = 8.4, 
7.0, 1.5 Hz, 1H), 7.31 (ddd, J = 8.1, 7.1, 1.1 Hz, 1H), 5.64 (s, 2H), 3.17 – 3.09 (m, 2H), 1.86 – 
1.79 (m, 2H), 1.02 (s, 9H). 13C NMR (126 MHz, CDCl3)  172.2, 151.6, 144.7, 140.4, 138.0, 
129.0, 126.8, 124.8, 123.1, 121.0, 44.1, 30.8, 30.1, 29.3. MS (ESI) calculated for C16H19N3S, 
m/z 285.13, found 286.14 [M+H]+. 
 
8n: (S)-2-(sec-butyl)thiazolo[4,5-c]quinolin-4-amine. White solid (45 mg, 76%). 1H NMR (500 
MHz, CDCl3)  7.79 – 7.75 (m, 1H), 7.75 – 7.72 (m, 1H), 7.55 (ddd, J = 8.4, 7.0, 1.5 Hz, 1H), 
7.31 (ddd, J = 8.1, 7.1, 1.2 Hz, 1H), 5.63 (s, 2H), 3.30 – 3.21 (m, 1H), 2.00 – 1.90 (m, 1H), 1.88 
– 1.76 (m, 1H), 1.49 (d, J = 6.9 Hz, 3H), 1.00 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3)  
177.0, 151.7, 144.7, 140.0, 137.9, 129.0, 126.8, 124.8, 123.1, 120.3, 41.0, 30.9, 21.0, 11.9. MS 
(ESI) calculated for C14H15N3S, m/z 257.10, found 258.10 [M+H]
+. 
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8o: (S)-2-(2-methylbutyl)thiazolo[4,5-c]quinolin-4-amine. White solid (46 mg, 77%). 1H NMR 
(500 MHz, CDCl3)  7.77 (dd, J = 8.4, 0.5 Hz, 1H), 7.73 (dd, J = 8.0, 1.0 Hz, 1H), 7.55 (ddd, J = 
8.4, 7.1, 1.5 Hz, 1H), 7.31 (ddd, J = 8.1, 7.1, 1.1 Hz, 1H), 5.66 (s, 2H), 3.14 (dd, J = 14.6, 6.2 
Hz, 1H), 2.96 (dd, J = 14.6, 8.1 Hz, 1H), 2.08 – 1.97 (m, 1H), 1.57 – 1.47 (m, 1H), 1.38 – 1.28 
(m, 1H), 1.02 (d, J = 6.7 Hz, 3H), 0.97 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3)  170.5, 
151.7, 144.7, 140.6, 138.1, 129.0, 126.8, 124.8, 123.1, 120.2, 41.2, 36.3, 29.3, 19.2, 11.5. MS 
(ESI) calculated for C15H17N3S, m/z 271.11, found 272.11 [M+H]
+. 
 
8p: 2-(3,3,3-Trifluoropropyl)thiazolo[4,5-c]quinolin-4-amine. White solid (70 mg, 78%).  1H 
NMR (500 MHz, CDCl3)  7.80 – 7.76 (m, 1H), 7.73 (dd, J = 8.0, 1.0 Hz, 1H), 7.58 (ddd, J = 8.4, 
7.1, 1.4 Hz, 1H), 7.35 – 7.30 (m, 1H), 5.63 (s, 2H), 3.45 – 3.39 (m, 2H), 2.87 – 2.76 (m, 2H). 13C 
NMR (126 MHz, CDCl3)  166.5, 151.6, 145.0, 140.8, 137.9, 129.4, 126.9, 126.4 (q, 1JCF = 
276.5 Hz), 124.9, 123.4, 119.9, 33.1 (q, 2JCF = 29.8 Hz), 26.8 (q, 3JCF = 3.4 Hz). MS (ESI) 
calculated for C13H10F3N3S, m/z 297.05, found 298.05 [M+H]
+. 
 
8q: 2-(4,4,4-Trifluorobutyl)thiazolo[4,5-c]quinolin-4-amine. White solid (50 mg, 72%). 1H 
NMR (500 MHz, CDCl3)  7.77 (dd, J = 8.4, 0.4 Hz, 1H), 7.73 (dd, J = 8.0, 1.1 Hz, 1H), 7.57 
(ddd, J = 8.4, 7.1, 1.4 Hz, 1H), 7.32 (ddd, J = 8.1, 7.1, 1.1 Hz, 1H), 5.62 (s, 2H), 3.25 (t, J = 7.2 
Hz, 2H), 2.36 – 2.26 (m, 2H), 2.26 – 2.18 (m, 2H). 13C NMR (126 MHz, CDCl3)  168.8, 151.6, 
144.9, 140.6, 138.1, 129.3, 127.0 (q, 1JCF = 276.4 Hz), 126.9, 124.9, 123.3, 120.0, 33.1 (q, 
2JCF = 29.7 Hz), 32.7, 21.9 (q, 3JCF = 3.0 Hz). MS (ESI) calculated for C14H12F3N3S, m/z 
311.07, found 312.07 [M+H]+. 
 
Synthesis of compound 9: 8-Nitro-2-propylthiazolo[4,5-c]quinolin-4-amine. To a stirred 
solution of compound 8c (200 mg, 0.82 mmol) in H2SO4 (0.5 mL), was added HNO3 (0.5 mL) 
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and the reaction mixture was stirred at room temperature for 1 h.  The reaction mixture was 
neutralized with 1N NaOH and extracted with EtOAc (3 × 15 mL). The combined organic layer 
was dried over Na2SO4, concentrated under reduced pressure, and the crude residue was 
purified using silica gel column chromatography (0-5% MeOH in CH2Cl2) to obtain compound 9 
as a yellow solid (171 mg, 72%). 1H NMR (400 MHz, CDCl3)  8.68 (d, J = 2.5 Hz, 1H), 8.35 (dd, 
J = 9.2, 2.6 Hz, 1H), 7.80 (d, J = 9.2 Hz, 1H), 6.09 (s, 2H), 3.17 (dd, J = 8.7, 6.4 Hz, 2H), 1.97 
(dd, J = 15.0, 7.5 Hz, 2H), 1.11 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3)  173.3, 153.6, 
148.3, 142.5, 141.2, 138.7, 127.3, 123.2, 121.5, 119.1, 36.2, 23.3, 13.8. MS (ESI) calculated for 
C13H12N4O2S, m/z 288.07, found 289.08 [M+H]
+. 
 
Synthesis of compound 10: 2-Propylthiazolo[4,5-c]quinoline-4,8-diamine. To a stirred 
solution of compound 9 (200 mg, 0.69 mmol) in methanol (5 mL), were added zinc dust (453 
mg, 6.94 mmol) and ammonium formate (437 mg, 6.94 mmol), and the reaction mixture was 
stirred at room temperature for 30 min. The reaction mixture was then filtered through celite, the 
filtrate concentrated under reduced pressure, and purified over silica gel column 
chromatography (0-10% MeOH in CH2Cl2) to afford compound 10 as a yellow solid (185 mg, 
88%). 1H NMR (400 MHz, CDCl3)  8.71 (s, 1H), 8.46 (s, 2H), 7.70 (d, J = 8.9 Hz, 1H), 7.00 (dd, 
J = 8.9, 2.5 Hz, 1H), 6.87 (d, J = 2.4 Hz, 1H), 3.17 – 3.09 (m, 2H), 1.99 – 1.88 (m, 2H), 1.08 (t, J 
= 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3)  173.1, 170.3, 149.2, 143.9, 142.1, 137.1, 129.5, 
121.9, 120.7, 118.7, 107.4, 36.1, 23.2, 13.8. MS (ESI) calculated for C13H14N4S, m/z 258.09, 
found 259.10 [M+H]+. 
 
Synthesis of compound 11: 8-Azido-2-propylthiazolo[4,5-c]quinolin-4-amine. To a stirred 
solution of compound 10 (25 mg, 0.096 mmol) in a 1:1 mixture of acetic acid and water (2 mL), 
was added sodium nitrite (20 mg, 0.29 mmol) and the reaction mixture was stirred at room 
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temperature for 1 h. Sodium azide (18.8 mg, 0.29 mmol) was then added to the reaction mixture 
and stirred for additional 1 h. The reaction mixture was neutralized with 1N NaOH and extracted 
with EtOAc (3 × 10 mL). The combined organic layer was dried over Na2SO4, concentrated 
under reduced pressure, and the crude compound was purified on silica gel column 
chromatography (0-5% MeOH in CH2Cl2) to obtain compound 11 as a brown solid (18 mg, 
67%). 1H NMR (400 MHz, CDCl3)  7.76 (d, J = 8.9 Hz, 1H), 7.31 (d, J = 2.5 Hz, 1H), 7.26 – 
7.23 (m, 1H), 5.60 (s, 2H), 3.17 – 3.12 (m, 2H), 2.01 – 1.90 (m, 2H), 1.09 (t, J = 7.4 Hz, 3H). 13C 
NMR (126 MHz, CDCl3)  172.0, 151.3, 139.5, 138.5, 134.8, 128.4, 121.0, 120.8, 113.5, 36.2, 
23.4, 13.8.  MS (ESI) calculated for C13H12N6S, m/z 284.08, found 285.09 [M+H]
+. 
 
Synthesis of compound 12a: 2-(1-(4-Amino-2-propylthiazolo[4,5-c]quinolin-8-yl)-1H-1,2,3-
triazol-4-yl)propan-2-ol. To a stirred solution of compound 11 (12 mg, 0.042 mmol) in THF (1 
mL), were added CuSO4.5H2O (1.3 mg, 0.005 mmol, in 0.5 mL water), sodium ascorbate (2.1 
mg, 0.010 mmol, in 0.5 mL water), 2-methylbut-3-yn-2-ol (8.4 L, 0.084 mmol) and the reaction 
mixture stirred at room temperature for 1 h.  The reaction mixture was diluted with water and 
extracted with EtOAc (3 × 10 mL). The combined organic layer was dried over Na2SO4, 
concentrated under reduced pressure, and the crude residue was purified using silica gel 
column chromatography (0-10% MeOH in CH2Cl2) to obtain compound 12a as a white solid (14 
mg, 92%). 1H NMR (400 MHz, CDCl3)  8.12 (d, J = 2.0 Hz, 1H), 7.97 (s, 1H), 7.91 – 7.81 (m, 
2H), 5.74 (s, 2H), 3.49 (s, 1H), 3.19 – 3.13 (m, 2H), 1.96 (dd, J = 15.0, 7.5 Hz, 2H), 1.74 (s, 6H), 
1.10 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3)  172.5, 156.5, 152.2, 144.5, 140.2, 138.7, 
132.0, 128.3, 121.5, 120.3, 117.8, 116.4, 68.9, 36.2, 30.7, 23.4, 13.8. MS (ESI) calculated for 
C18H20N6OS, m/z 368.14, found 369.15 [M+H]
+. 
 
Compounds 12b-12f were synthesized similarly as compound 12a. 
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12b: (1-(4-Amino-2-propylthiazolo[4,5-c]quinolin-8-yl)-1H-1,2,3-triazol-4-yl)methanol. 
White solid (15 mg, 83%). 1H NMR (500 MHz, DMSO)  8.84 (s, 1H), 8.33 (d, J = 2.5 Hz, 1H), 
8.06 (dd, J = 9.0, 2.5 Hz, 1H), 7.76 (d, J = 9.0 Hz, 1H), 7.13 (s, 2H), 5.37 (t, J = 5.6 Hz, 1H), 
4.64 (d, J = 5.9 Hz, 2H), 3.19 (t, J = 7.5 Hz, 2H), 1.88 (dt, J = 14.8, 7.4 Hz, 2H), 1.04 (t, J = 7.4 
Hz, 3H). 13C NMR (126 MHz, DMSO)  171.8, 152.7, 149.2, 144.5, 139.1, 138.2, 130.8, 127.3, 
121.2, 120.9, 118.9, 115.2, 55.1, 35.2, 22.8, 13.5.  MS (ESI) calculated for C16H16N6OS, m/z 
340.11, found 341.11 [M+H]+. 
 
12c: 8-(4-Phenyl-1H-1,2,3-triazol-1-yl)-2-propylthiazolo[4,5-c]quinolin-4-amine. Solid (19 
mg, 93%). 1H NMR (500 MHz, DMSO)  9.44 (s, 1H), 8.36 (d, J = 2.5 Hz, 1H), 8.12 (dd, J = 9.0, 
2.5 Hz, 1H), 7.97 (dd, J = 8.2, 1.1 Hz, 2H), 7.80 (d, J = 9.0 Hz, 1H), 7.53 (dd, J = 10.6, 4.8 Hz, 
2H), 7.44 – 7.37 (m, 1H), 7.17 (s, 2H), 3.21 (t, J = 7.5 Hz, 2H), 1.90 (dd, J = 14.9, 7.4 Hz, 2H), 
1.04 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, DMSO)  171.8, 152.8, 147.3, 144.7, 139.0, 138.2, 
130.6, 130.4, 129.1, 128.3, 127.4, 125.3, 120.9, 119.8, 118.9, 115.3, 35.2, 22.8, 13.5. MS (ESI) 
calculated for C21H18N6S, m/z 386.13, found 387.14 [M+H]
+. 
 
12d: 2-Propyl-8-(4-propyl-1H-1,2,3-triazol-1-yl)thiazolo[4,5-c]quinolin-4-amine. Yellow solid 
(16 mg, 86%). 1H NMR (500 MHz, DMSO)  8.72 (s, 1H), 8.28 (d, J = 2.4 Hz, 1H), 8.04 (dd, J = 
9.0, 2.5 Hz, 1H), 7.75 (d, J = 9.0 Hz, 1H), 7.12 (s, 2H), 3.19 (t, J = 7.5 Hz, 2H), 2.71 (t, J = 7.5 
Hz, 2H), 1.89 (dd, J = 14.9, 7.4 Hz, 2H), 1.72 (dd, J = 14.9, 7.4 Hz, 2H), 1.04 (t, J = 7.4 Hz, 3H), 
0.98 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, DMSO)  171.8, 152.7, 148.0, 144.4, 139.0, 138.2, 
130.9, 127.3, 120.8, 120.3, 118.9, 115.0, 35.2, 27.1, 22.8, 22.1, 13.7, 13.5. MS (ESI) calculated 
for C18H20N6S, m/z 352.15, found 353.15 [M+H]
+. 
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12e: 8-(4-Pentyl-1H-1,2,3-triazol-1-yl)-2-propylthiazolo[4,5-c]quinolin-4-amine. Solid (19 
mg, 91%). 1H NMR (500 MHz, DMSO)  8.71 (s, 1H), 8.27 (d, J = 2.5 Hz, 1H), 8.04 (dd, J = 9.0, 
2.5 Hz, 1H), 7.75 (d, J = 9.0 Hz, 1H), 7.12 (s, 2H), 3.19 (t, J = 7.5 Hz, 2H), 2.72 (t, J = 7.6 Hz, 
2H), 1.89 (dd, J = 14.9, 7.4 Hz, 2H), 1.69 (dt, J = 15.3, 7.6 Hz, 2H), 1.42 – 1.26 (m, 6H), 1.04 (t, 
J = 7.4 Hz, 3H), 0.87 (dd, J = 9.2, 4.9 Hz, 3H). 13C NMR (126 MHz, DMSO)  171.8, 152.7, 
148.2, 144.4, 139.0, 138.2, 130.9, 127.3, 120.8, 120.2, 118.9, 114.9, 35.2, 31.1, 28.8, 28.3, 




White solid (18 mg, 90%). 1H NMR (500 MHz, DMSO)  8.98 (s, 1H), 8.31 (d, J = 2.4 Hz, 1H), 
8.07 (dd, J = 9.0, 2.5 Hz, 1H), 7.76 (d, J = 9.0 Hz, 1H), 7.13 (s, 2H), 3.19 (t, J = 7.5 Hz, 2H), 
1.89 (dd, J = 14.8, 7.4 Hz, 2H), 1.04 (t, J = 7.4 Hz, 3H), 0.36 – 0.33 (m, 9H). 13C NMR (126 
MHz, DMSO)  171.8, 152.7, 146.1, 144.4, 139.1, 138.2, 130.7, 128.9, 127.3, 121.3, 118.9, 
115.3, 35.2, 22.8, 13.5, -0.9. MS (ESI) calculated for C18H22N6SSi, m/z 382.14, found 383.14 
[M+H]+. 
 
Synthesis of compound 12g: 2-Propyl-8-(1H-1,2,3-triazol-1-yl)thiazolo[4,5-c]quinolin-4-
amine. To a stirred solution of compound 12f (20 mg, 0.0.52 mmol) in THF (1 mL) was added 
TBAF (20 mg, 0.078 mmol), and the reaction mixture was stirred at room temperature for 10 h. 
The reaction mixture was then diluted with water and extracted with EtOAc (3 × 10 mL). The 
organic layer was dried over Na2SO4, concentrated under reduced pressure, and the crude 
material purified using silica gel column chromatography (0-5% MeOH in CH2Cl2) to obtain 
compound 12g as a white solid (14 mg, 87%). 1H NMR (500 MHz, DMSO)  8.94 (d, J = 1.1 Hz, 
1H), 8.29 (d, J = 2.4 Hz, 1H), 8.04 (dd, J = 9.0, 2.5 Hz, 1H), 7.98 (d, J = 1.1 Hz, 1H), 7.75 (d, J = 
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9.0 Hz, 1H), 7.12 (s, 2H), 3.17 (t, J = 7.5 Hz, 2H), 1.91 – 1.83 (m, 2H), 1.02 (t, J = 7.4 Hz, 3H). 
13C NMR (126 MHz, DMSO)  171.7, 152.8, 144.6, 139.1, 138.2, 134.4, 130.7, 127.4, 123.4, 
121.2, 118.9, 115.5, 35.23 22.8, 13.5. MS (ESI) calculated for C15H14N6S, m/z 310.10, found 
311.10 [M+H]+. 
 
Synthesis of compound 13a: N8-hexyl-2-propylthiazolo[4,5-c]quinoline-4,8-diamine. To a 
stirred solution of compound 10 (25 mg, 0.096 mmol) in DMF (2 mL) were added 1-iodohexane 
(20.5 mg, 0.096mmol) and potassium carbonate (26.7 mg, 0.19 mmol), and the reaction mixture 
was stirred at room temperature for 4 h. The reaction mixture was diluted with water and 
extracted with EtOAc (3 × 10 mL). The organic layer was dried over Na2SO4, concentrated 
under reduced pressure, and the crude compound was purified using silica gel column 
chromatography (0-5% MeOH in CH2Cl2) to obtain 13a as a solid (16 mg, 61%). 
1H NMR (500 
MHz, CDCl3)  7.69 (d, J = 8.9 Hz, 1H), 6.96 (dd, J = 8.9, 2.6 Hz, 1H), 6.67 (d, J = 2.5 Hz, 1H), 
6.15 (s, 2H), 3.87 (s, 1H), 3.18 (t, J = 7.1 Hz, 2H), 3.15 – 3.11 (m, 2H), 1.99 – 1.89 (m, 2H), 1.68 
(dt, J = 14.7, 7.2 Hz, 2H), 1.49 – 1.41 (m, 2H), 1.35 (td, J = 7.2, 3.7 Hz, 4H), 1.09 (t, J = 7.4 Hz, 
3H), 0.92 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, CDCl3)  172.1, 148.2, 145.5, 141.2, 137.4, 
124.8, 120.3, 119.8, 102.9, 44.3, 36.2, 31.8, 29.4, 27.0, 23.3, 22.8, 14.2, 13.8. MS (ESI) 
calculated for C19H26N4S, m/z 342.19, found 343.20 [M+H]
+. 
 
Synthesis of compound 13b: N-(4-amino-2-propylthiazolo[4,5-c]quinolin-8-yl)butyramide. 
To a stirred solution of compound 10 (20 mg, 0.077 mmol) in CH2Cl2 (2 mL) were added 
triethylamine (30 L, 0.164 mmol) and butyryl chloride (8.7 L, 0.082); the reaction mixture was 
stirred at room temperature for 1 h. The reaction mixture was then diluted with water and 
extracted with EtOAc (3 × 10 mL). The combined organic layer was dried over Na2SO4, 
concentrated under reduced pressure, and the crude compound was purified using silica gel 
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column chromatography (0-10% MeOH in CH2Cl2) to furnish compound 13b as a white solid (22 
mg, 87%). 1H NMR (400 MHz, CDCl3)  8.34 (d, J = 2.2 Hz, 1H), 7.71 (d, J = 8.9 Hz, 1H), 7.37 
(dd, J = 8.9, 2.4 Hz, 2H), 5.67 (d, J = 1.2 Hz, 2H), 3.13 (t, J = 7.4 Hz, 2H), 2.41 (t, J = 7.4 Hz, 
2H), 1.94 (dd, J = 15.0, 7.5 Hz, 2H), 1.85 – 1.74 (m, 2H), 1.11 – 1.02 (m, 6H). 13C NMR (126 
MHz, CDCl3)  172.0, 171.5, 150.9, 140.6, 138.2, 133.4, 126.8, 122.1, 120.2, 114.6, 39.8, 36.2, 
23.3, 19.2, 13.9, 13.8. MS (ESI) calculated for C17H20N4OS, m/z 328.14, found 329.15 [M+H]
+. 
 
Synthesis of compound 14: 8-Bromo-2-propylthiazolo[4,5-c]quinolin-4-amine. To a stirred 
solution of compound 8c (50 mg, 0.205 mmol) in CH3CN (1 mL) were added N-
bromosuccinimide (44 mg, 0.246 mmol), ammonium acetate (1.6 mg, 0.02 mmol) and the 
reaction mixture was stirred at room temperature for 12 h.  The reaction mixture was then 
diluted with water and extracted with EtOAc (3 × 10 mL). The combined organic layer was dried 
over Na2SO4, concentrated under reduced pressure, and the crude material was purified using 
silica gel column chromatography (0-5% MeOH in CH2Cl2) to obtain compound 14 as a white 
solid (40 mg, 67%).  1H NMR (500 MHz, CDCl3)  7.86 (dd, J = 2.0, 0.6 Hz, 1H), 7.61 (dd, J = 
3.9, 1.3 Hz, 2H), 5.68 (s, 2H), 3.16 – 3.11 (m, 2H), 1.95 (dt, J = 15.0, 7.4 Hz, 2H), 1.09 (t, J = 
7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3)  172.1, 151.8, 143.4, 139.3, 138.4, 132.1, 128.4, 
126.9, 121.5, 115.9, 36.2, 23.4, 13.8. MS (ESI) calculated for C13H12BrN3S, m/z 320.99, found 
322.00 [M+H]+. 
 
Synthesis of compound 15a: N-butyl-2-propylthiazolo[4,5-c]quinolin-4-amine. To a stirred 
solution of compound 8c (50 mg, 0.205 mmol) in THF (1 mL) were added sodium hydride (10 
mg, 0.41 mmol) and 1-iodobutane (35 L, 0.308 mmol), the resulting mixture was stirred at 
room temperature for 6 h. The reaction mixture was then diluted with water and extracted with 
CH2Cl2 (3 × 10 mL). The organic layer was dried over Na2SO4, concentrated under reduced 
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pressure, and the crude compound was purified using silica gel column chromatography (0-5% 
MeOH in CH2Cl2) to obtain compound 15a (45 mg, 70%). 
1H NMR (500 MHz, CDCl3)  7.81 (dd, 
J = 8.3, 0.5 Hz, 1H), 7.70 – 7.66 (m, 1H), 7.51 (ddd, J = 8.4, 7.1, 1.5 Hz, 1H), 7.23 (ddd, J = 8.0, 
7.1, 1.1 Hz, 1H), 5.96 (t, J = 4.8 Hz, 1H), 3.77 – 3.69 (m, 2H), 3.15 – 3.08 (m, 2H), 1.99 – 1.89 
(m, 2H), 1.75 (ddd, J = 14.9, 11.1, 7.5 Hz, 2H), 1.52 (dq, J = 14.7, 7.4 Hz, 2H), 1.08 (t, J = 7.4 
Hz, 3H), 1.00 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3)  170.7, 151.2, 145.3, 138.9, 
138.3, 128.6, 126.9, 124.5, 122.1, 119.3, 40.6, 36.0, 31.9, 23.3, 20.3, 14.0, 13.7. MS (ESI) 
calculated for C17H21N3S, m/z 299.15, found 300.14 [M+H]
+. 
 
Compounds 15b and 15c were synthesized similarly as compound 15a. 
 
15b: N-hexyl-2-propylthiazolo[4,5-c]quinolin-4-amine. White solid (9.9 mg, 72%, based on 
starting material recovery). 1H NMR (400 MHz, CDCl3)  7.81 (d, J = 8.3 Hz, 1H), 7.68 (dd, J = 
7.9, 1.1 Hz, 1H), 7.51 (ddd, J = 8.5, 7.1, 1.5 Hz, 1H), 7.23 (ddd, J = 8.1, 7.2, 1.1 Hz, 1H), 5.96 (t, 
J = 4.6 Hz, 1H), 3.71 (dt, J = 7.2, 5.8 Hz, 2H), 3.11 (dd, J = 8.7, 6.5 Hz, 2H), 1.94 (dd, J = 15.0, 
7.5 Hz, 2H), 1.76 (t, J = 7.3 Hz, 2H), 1.53 – 1.44 (m, 2H), 1.36 (ddd, J = 6.9, 6.2, 3.3 Hz, 4H), 
1.08 (t, J = 7.4 Hz, 3H), 0.91 (dd, J = 9.1, 5.1 Hz, 3H). 13C NMR (101 MHz, CDCl3)  170.9, 
151.3, 145.5, 139.1, 138.5, 128.8, 127.1, 124.6, 122.3, 119.5, 41.1, 36.2, 31.8, 29.9, 27.1, 23.5, 
22.8, 14.2, 13.8. MS (ESI) calculated for C19H25N3S, m/z 327.18, found 328.18 [M+H]
+. 
 
15c: N-hexadecyl-2-propylthiazolo[4,5-c]quinolin-4-amine. White solid (26 mg, 68%). 1H 
NMR (400 MHz, CDCl3)  7.81 (d, J = 7.9 Hz, 1H), 7.68 (dd, J = 7.9, 1.1 Hz, 1H), 7.51 (ddd, J = 
8.5, 7.1, 1.5 Hz, 1H), 7.23 (td, J = 7.1, 3.6 Hz, 1H), 5.96 (s, 1H), 3.71 (dd, J = 12.9, 7.1 Hz, 2H), 
3.11 (dd, J = 8.7, 6.5 Hz, 2H), 1.98 – 1.88 (m, 2H), 1.76 (dt, J = 14.8, 7.4 Hz, 2H), 1.51 – 1.43 
(m, 2H), 1.30 – 1.21 (m, 24H), 1.08 (t, J = 7.4 Hz, 3H), 0.88 (t, J = 6.8 Hz, 3H). 13C NMR (126 
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MHz, CDCl3)  170.9, 151.4, 145.5, 139.1, 138.5, 128.7, 127.1, 124.6, 122.3, 119.5, 41.1, 36.8, 
36.1, 32.1, 29.9, 29.8, 29.8, 29.8, 29.8, 29.8, 29.7, 29.6, 29.5, 27.3, 24.8, 23.5, 22.8, 14.3, 13.9. 
MS (ESI) calculated for C29H45N3S, m/z 467.33, found 468.35 [M+H]
+. 
 
Synthesis of compound 15d: N-(2-propylthiazolo[4,5-c]quinolin-4-yl)formamide. To a 
stirred solution of compound 8c (50 mg, 0.205 mmol) in 1,4-dioxane (1 mL) were added 2,2,2-
trifluoroethylformate (60 L, 0.616 mmol) and triethylamine (86 L, 0.616 mmol). The resulting 
mixture was stirred at 80 °C for 12 h. The reaction mixture was then diluted with water and 
extracted with CH2Cl2 (3 × 10 mL). The combined organic layer was dried over Na2SO4, 
concentrated under reduced pressure, and the crude compound was purified using silica gel 
column chromatography (0-3% MeOH in CH2Cl2) to furnish compound 15d as a white solid (26 
mg, 46%). 1H NMR (500 MHz, CDCl3)  9.84 (d, J = 10.8 Hz, 1H), 8.86 (d, J = 10.3 Hz, 1H), 
8.03 – 7.94 (m, 1H), 7.84 (ddd, J = 8.0, 1.4, 0.5 Hz, 1H), 7.67 (ddd, J = 8.5, 7.0, 1.4 Hz, 1H), 
7.50 (ddd, J = 8.1, 7.1, 1.2 Hz, 1H), 3.24 – 3.08 (m, 2H), 2.05 – 1.87 (m, 2H), 1.09 (t, J = 7.4 Hz, 
3H). 13C NMR (126 MHz, CDCl3)  172.7, 162.0, 143.8, 143.2, 141.7, 137.5, 129.5, 128.8, 
125.8, 124.8, 121.9, 36.2, 23.1, 13.8. MS (ESI) calculated for C14H13N3OS, m/z 271.08, found 
272.09 [M+H]+. 
 
Synthesis of compound 15e: N-(2-propylthiazolo[4,5-c]quinolin-4-yl)acetamide. To a 
stirred solution of compound 8c (20 mg, 0.082 mmol) in pyridine (1 mL) was added acetyl 
chloride (5.8 L, 0.082 mmol), the resulting mixture was stirred at room temperature for 1 h. The 
solvent was evaporated under reduced pressure and extracted with CH2Cl2 (3 × 10 mL). The 
combined organic layer was dried over Na2SO4, concentrated under reduced pressure, and the 
crude compound was purified using silica gel column chromatography (0-5% MeOH in CH2Cl2) 
to furnish compound 15e as a white solid (18 mg, 78%). 1H NMR (500 MHz, CDCl3)  8.03 (d, J 
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= 8.3 Hz, 1H), 7.88 (dd, J = 8.1, 0.9 Hz, 1H), 7.72 (ddd, J = 8.4, 7.2, 1.3 Hz, 1H), 7.59 – 7.54 
(m, 1H), 3.17 (td, J = 7.6, 2.3 Hz, 2H), 2.77 (s, 3H), 1.96 (dd, J = 15.0, 7.5 Hz, 2H), 1.09 (t, J = 
7.3 Hz, 3H). 13C NMR (126 MHz, CDCl3)  173.0, 144.7, 138.3, 131.6, 130.0, 127.2, 126.5, 
125.9, 125.3, 125.0, 121.2, 36.2, 25.7, 23.2, 13.8. MS (ESI) calculated for C15H15N3OS, m/z 
285.09, found 286.11 [M+H]+. 
 
Compounds 15f-15i were synthesized similarly as compound 15e. 
 
15f: N-(2-propylthiazolo[4,5-c]quinolin-4-yl)butyramide. White solid (20 mg, 78%). 1H NMR 
(500 MHz, CDCl3)  8.96 (s, 1H), 8.04 (d, J = 8.3 Hz, 1H), 7.82 (dd, J = 8.0, 1.0 Hz, 1H), 7.65 
(ddd, J = 8.4, 7.1, 1.4 Hz, 1H), 7.49 (ddd, J = 8.1, 7.1, 1.1 Hz, 1H), 3.21 – 3.04 (m, 4H), 2.01 – 
1.92 (m, 2H), 1.92 – 1.82 (m, 2H), 1.10 (td, J = 7.4, 6.1 Hz, 6H). 13C NMR (126 MHz, CDCl3)  
172.1, 144.5, 143.5, 140.8, 138.6, 129.2, 129.2, 125.7, 124.6, 121.4, 39.9, 36.2, 23.2, 18.6, 
14.1, 13.8. MS (ESI) calculated for C17H19N3OS, m/z 313.12, found 314.13 [M+H]
+. 
 
15g: N-(2-propylthiazolo[4,5-c]quinolin-4-yl)octanamide. White solid (25 mg, 83%).  1H NMR 
(400 MHz, CDCl3)  8.95 (s, 1H), 8.04 (d, J = 8.3 Hz, 1H), 7.82 (dd, J = 8.0, 0.9 Hz, 1H), 7.65 
(ddd, J = 8.4, 7.1, 1.4 Hz, 1H), 7.52 – 7.44 (m, 1H), 3.15 (t, J = 7.5 Hz, 4H), 1.96 (dd, J = 14.9, 
7.4 Hz, 2H), 1.83 (dd, J = 15.2, 7.7 Hz, 2H), 1.54 – 1.45 (m, 2H), 1.39 – 1.23 (m, 6H), 1.09 (t, J 
= 7.4 Hz, 3H), 0.89 (t, J = 6.9 Hz, 3H). 13C NMR (126 MHz, CDCl3)  172.1, 144.5, 143.5, 140.8, 
138.6, 129.3, 129.2, 125.7, 124.7, 121.4, 38.1, 36.2, 31.9, 29.8, 29.6, 29.3, 25.2, 23.2, 22.8, 
14.2, 13.8. MS (ESI) calculated for C21H27N3OS, m/z 369.19, found 370.22 [M+H]
+. 
 
15h: N-(2-propylthiazolo[4,5-c]quinolin-4-yl)palmitamide. Yellow solid (33 mg, 84%). 1H 
NMR (500 MHz, CDCl3)  8.95 (s, 1H), 8.04 (d, J = 8.3 Hz, 1H), 7.83 (dd, J = 8.0, 1.0 Hz, 1H), 
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7.65 (ddd, J = 8.4, 7.1, 1.4 Hz, 1H), 7.49 (ddd, J = 10.4, 5.8, 2.2 Hz, 1H), 3.20 – 3.10 (m, 4H), 
2.01 – 1.91 (m, 2H), 1.84 (dt, J = 15.2, 7.6 Hz, 2H), 1.53 – 1.44 (m, 2H), 1.43 – 1.34 (m, 2H), 
1.34 – 1.19 (m, 20H), 1.09 (t, J = 7.4 Hz, 3H), 0.88 (t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, 
CDCl3)  172.1, 144.5, 143.6, 140.8, 138.6, 129.3, 129.2, 125.7, 124.7, 121.5, 38.1, 36.2, 32.1, 
29.8, 29.8, 29.8, 29.7, 29.6, 29.6, 29.5, 25.2, 23.2, 22.8, 14.3, 13.8. MS (ESI) calculated for 
C29H43N3OS, m/z 481.31, found 482.33 [M+H]
+. 
 
15i: N-(2-propylthiazolo[4,5-c]quinolin-4-yl)benzamide. White solid (24 mg, 96%). 1H NMR 
(400 MHz, CDCl3)  9.70 (s, 1H), 8.24 (d, J = 8.5 Hz, 1H), 8.07 (d, J = 7.4 Hz, 2H), 7.86 (d, J = 
7.6 Hz, 1H), 7.69 (t, J = 7.5 Hz, 1H), 7.62 – 7.51 (m, 4H), 3.19 (t, J = 7.6 Hz, 2H), 1.98 (dt, J = 
14.9, 7.5 Hz, 2H), 1.12 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3)  172.4, 164.7, 144.7, 
143.8, 140.9, 139.3, 135.0, 132.4, 130.1, 129.2, 129.0, 127.7, 126.1, 124.5, 121.8, 36.2, 23.4, 
13.9. MS (ESI) calculated for C20H17N3OS, m/z 347.11, found 348.12 [M+H]
+. 
 
Synthesis of compound 15j: 2-Azido-N-(2-propylthiazolo[4,5-c]quinolin-4-yl)acetamide. To 
a stirred solution of 2-azidoacetic acid (18.6 mg, 0.123 mmol) in DMF (1 mL) were added 
triethylamine (23 L, 0.164 mmol) and HBTU (46.6 mg, 0.123 mmol), and the resulting mixture 
was stirred at room temperature for 15 min. Compound 8c (20 mg, 0.082 mmol) was then 
added, and stirring was continued for 4 h. The reaction mixture was diluted with water and 
extracted with CH2Cl2 (3 × 10 mL). The organic layer was dried over Na2SO4, concentrated 
under reduced pressure, and the crude residue was purified by silica gel column 
chromatography (0-5% MeOH in CH2Cl2) to obtain compound 15j as a white solid (50 mg, 96%). 
1H NMR (500 MHz, CDCl3)  9.25 (d, J = 0.6 Hz, 1H), 8.03 (d, J = 8.1 Hz, 1H), 7.84 (dd, J = 8.0, 
1.0 Hz, 1H), 7.68 (ddd, J = 8.4, 7.1, 1.4 Hz, 1H), 7.52 (ddd, J = 8.1, 7.2, 1.1 Hz, 1H), 4.86 (s, 
2H), 3.17 (t, J = 7.5 Hz, 2H), 2.01 – 1.92 (m, 2H), 1.10 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, 
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CDCl3)  172.7, 143.6, 143.1, 141.4, 138.2, 129.5, 129.1, 126.2, 124.8, 121.6, 54.7, 36.2, 23.2, 
13.8. MS (ESI) calculated for C15H14N6OS, m/z 326.10, found 327.11 [M+H]
+. 
 
Compounds 15k-15l were synthesized similarly as compound 15j. 
 
15k: 3-Azido-N-(2-propylthiazolo[4,5-c]quinolin-4-yl)propan-amide. White solid (59 mg, 
85%). 1H NMR (500 MHz, CDCl3)  9.07 (s, 1H), 8.03 (d, J = 8.3 Hz, 1H), 7.84 (dd, J = 8.0, 0.9 
Hz, 1H), 7.67 (ddd, J = 8.4, 7.1, 1.4 Hz, 1H), 7.53 – 7.48 (m, 1H), 3.82 (t, J = 6.6 Hz, 2H), 3.59 
(s, 2H), 3.16 (t, J = 7.5 Hz, 2H), 2.01 – 1.91 (m, 2H), 1.09 (dd, J = 9.3, 5.4 Hz, 3H). 13C NMR 
(126 MHz, CDCl3)  172.4, 144.1, 143.3, 141.1, 138.3, 129.4, 129.1, 125.9, 124.7, 121.5, 46.9, 
37.6, 36.2, 23.2, 13.8. MS (ESI) calculated for C16H16N6OS, m/z 340.11, found 341.12 [M+H]
+. 
 
15l: N-(2-propylthiazolo[4,5-c]quinolin-4-yl)pent-4-ynamide. White solid (60 mg, 90%). 1H 
NMR (500 MHz, CDCl3)  9.02 (s, 1H), 8.05 (d, J = 8.3 Hz, 1H), 7.82 (dd, J = 8.0, 0.9 Hz, 1H), 
7.66 (ddd, J = 8.4, 7.1, 1.4 Hz, 1H), 7.49 (ddd, J = 8.1, 7.1, 1.1 Hz, 1H), 3.49 (s, 2H), 3.15 (dd, J 
= 8.6, 6.5 Hz, 2H), 2.75 (ddd, J = 9.0, 6.9, 2.7 Hz, 2H), 2.03 (t, J = 2.7 Hz, 1H), 2.00 – 1.90 (m, 
2H), 1.09 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3)  172.2, 144.2, 143.4, 141.0, 138.4, 
129.3, 129.2, 125.8, 124.7, 121.5, 83.6, 68.9, 37.2, 36.2, 23.2, 14.3, 13.8. MS (ESI) calculated 
for C18H17N3OS, m/z 323.11, found 324.13 [M+H]
+. 
 
Synthesis of compound 15m: Methyl (2-propylthiazolo[4,5-c]quinolin-4-yl)carbamate. To a 
stirred solution of 8c (50 mg, 0.205 mmol) in CH2Cl2 (2 mL) were added triethylamine (57 L, 
0.410 mmol) and methyl chloroformate (32 L, 0.3075 mmol), and the resulting mixture was 
stirred at room temperature for 5 h. The reaction mixture was diluted with water and extracted 
with CH2Cl2 (3 × 10 mL). The organic layer was dried over Na2SO4, concentrated under reduced 
 66  
pressure, and the crude residue was purified by silica gel column chromatography (0-5% MeOH 
in CH2Cl2) to obtain compound 15m as a white solid (58 mg, 94%). 
1H NMR (500 MHz, CDCl3)  
8.51 (s, 1H), 8.16 (d, J = 8.4 Hz, 1H), 7.82 (dd, J = 8.0, 0.9 Hz, 1H), 7.69 – 7.63 (m, 1H), 7.52 – 
7.46 (m, 1H), 3.91 (s, 3H), 3.17 – 3.11 (m, 2H), 1.95 (dt, J = 14.8, 7.4 Hz, 2H), 1.09 (t, J = 7.4 
Hz, 3H). 13C NMR (126 MHz, CDCl3)  172.2, 152.2, 144.3, 143.8, 140.8, 138.6, 129.7, 129.2, 
125.7, 124.5, 121.4, 52.9, 36.2, 23.3, 13.8. MS (ESI) calculated for C15H15N3O2S, m/z 301.09, 
found 302.17 [M+H]+. 
 
Compounds 15n-15p were synthesized similarly as compound 15m. 
 
15n: Ethyl (2-propylthiazolo[4,5-c]quinolin-4-yl)carbamate. Yellow solid (50 mg, 77%). 1H 
NMR (500 MHz, CDCl3)  8.48 (s, 1H), 8.17 (t, J = 8.3 Hz, 1H), 8.17 (t, J = 8.3 Hz, 1H), 7.81 
(dd, J = 8.0, 1.0 Hz, 1H), 7.81 (dd, J = 8.0, 1.0 Hz, 1H), 7.69 – 7.61 (m, 1H), 7.51 – 7.45 (m, 
1H), 4.36 (q, J = 7.1 Hz, 2H), 3.18 – 3.12 (m, 2H), 2.01 – 1.90 (m, 2H), 1.39 (t, J = 7.1 Hz, 3H), 
1.09 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3)  172.1, 151.6, 144.5, 143.8, 140.8, 138.6, 
129.8, 129.1, 125.7, 124.5, 121.3, 61.8, 36.2, 23.3, 14.7, 13.8. MS (ESI) calculated for 
C16H17N3O2S, m/z 315.10, found 316.19 [M+H]
+. 
 
15o: Butyl (2-propylthiazolo[4,5-c]quinolin-4-yl)carbamate. White solid (52 mg, 74%). 1H 
NMR (500 MHz, CDCl3)  8.47 (s, 1H), 8.18 – 8.13 (m, 1H), 7.81 (dd, J = 8.0, 0.9 Hz, 1H), 7.66 
(qd, J = 8.5, 2.6 Hz, 1H), 7.52 – 7.45 (m, 1H), 4.31 (t, J = 6.7 Hz, 2H), 3.19 – 3.11 (m, 2H), 2.02 
– 1.91 (m, 2H), 1.80 – 1.70 (m, 2H), 1.54 – 1.44 (m, 2H), 1.13 – 1.06 (m, 3H), 0.98 (t, J = 7.4 
Hz, 3H). 13C NMR (126 MHz, CDCl3)  172.1, 151.8, 144.5, 143.7, 140.8, 138.6, 129.8, 129.1, 
125.7, 124.5, 121.3, 65.7, 36.2, 31.0, 23.3, 19.2, 13.9, 13.8. MS (ESI) calculated for 
C18H21N3O2S, m/z 343.14, found 344.14 [M+H]
+. 
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15p: Octyl (2-propylthiazolo[4,5-c]quinolin-4-yl)carbamate. White solid (60 mg, 73%). 1H 
NMR (500 MHz, CDCl3)  8.47 (s, 1H), 8.17 – 8.13 (m, 1H), 7.81 (dd, J = 8.0, 1.0 Hz, 1H), 7.68 
– 7.61 (m, 1H), 7.47 (ddd, J = 8.1, 7.2, 1.1 Hz, 1H), 4.30 (t, J = 6.7 Hz, 2H), 3.15 (dd, J = 9.7, 
5.5 Hz, 2H), 2.02 – 1.90 (m, 3H), 1.80 – 1.71 (m, 2H), 1.51 – 1.39 (m, 3H), 1.38 – 1.22 (m, 
10H), 1.09 (dd, J = 9.0, 5.8 Hz, 5H), 0.88 (t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, CDCl3)  
172.1, 151.8, 144.5, 143.9, 140.8, 138.6, 129.7, 129.1, 125.6, 124.5, 121.3, 66.0, 36.2, 31.9, 
29.4, 29.4, 29.0, 26.0, 23.3, 22.8, 14.2, 13.8. MS (ESI) calculated for C22H29N3O2S, m/z 399.20, 
found 400.21 [M+H]+. 
 
Synthesis of compound 15q: 1-(2-Propylthiazolo[4,5-c]quinolin-4-yl)urea. To a stirred 
solution of 8c (50 mg, 0.205 mmol) in acetonitrile (2 mL) were added NaHCO3 (26 mg, 0.307 
mmol) and chlorosulfonyl isocyanate (27 L, 0.307 mmol), and the resulting mixture was stirred 
at room temperature for 1 h. Then, one more equivalent of chlorosulfonyl isocyanate (27 L, 
0.307 mmol) was added and the reaction mixture was stirred at room temperature for additional 
1h. The reaction mixture was diluted with water and extracted with EtOAc (3 × 10 mL). The 
organic layer was dried over Na2SO4, concentrated under reduced pressure, and the crude 
residue was purified by silica gel column chromatography (0-5% MeOH in CH2Cl2) to obtain 
compound 15q as a white solid (26 mg, 45% starting material was recovered). 1H NMR (500 
MHz, CDCl3)  9.84 (d, J = 10.8 Hz, 1H), 8.86 (d, J = 10.3 Hz, 1H), 8.03 – 7.94 (m, 1H), 7.84 
(ddd, J = 8.0, 1.4, 0.5 Hz, 1H), 7.67 (ddd, J = 8.5, 7.0, 1.4 Hz, 1H), 7.50 (ddd, J = 8.1, 7.1, 1.2 
Hz, 1H), 3.24 – 3.08 (m, 2H), 2.05 – 1.87 (m, 2H), 1.09 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, 
CDCl3)  172.7, 162.0, 143.8, 143.2, 141.7, 137.5, 129.5, 128.8, 125.8, 124.8, 121.9, 36.2, 23.1, 
13.8. MS (ESI) calculated for C14H14N4OS, m/z 286.09, found 287.09 [M+H]
+. 
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Synthesis of compound 15r: N-(2-propylthiazolo[4,5-c]quinolin-4-yl)methanesulfonamide. 
To a stirred solution of 8c (40 mg, 0.146 mmol) in dichloromethane (2 mL) was added methyl 
methanesulfonyl chloride (26 L, 0.292 mmol), and the resulting mixture was stirred at room 
temperature for 12 h. The reaction mixture was diluted with water and extracted with CH2Cl2 (3 
× 10 mL). The organic layer was dried over Na2SO4, concentrated under reduced pressure, and 
the crude residue was purified by silica gel column chromatography (0-5% MeOH in CH2Cl2) to 
obtain compound 15r as a white solid (34 mg, 65%). 1H NMR (500 MHz, CDCl3)  11.91 (s, 1H), 
7.73 (d, J = 7.8 Hz, 1H), 7.58 (t, J = 7.4 Hz, 1H), 7.40 (t, J = 7.6 Hz, 2H), 3.29 (s, 3H), 3.20 – 
3.15 (m, 2H), 1.97 – 1.87 (m, 2H), 1.07 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3)  173.0, 
148.8, 143.4, 141.6, 133.5, 130.6, 125.4, 125.2, 117.5, 116.9, 43.2, 36.3, 23.7, 13.8. MS (ESI) 
calculated for C14H15N3O2S2, m/z 321.06, found 322.06 [M+H]
+. 
 
Compounds 15s-15v were synthesized similarly as compound 15r. 
 
15s: N-(2-propylthiazolo[4,5-c]quinolin-4-yl)ethanesulfonamide. White solid (35 mg, 63%). 
1H NMR (500 MHz, CDCl3)  12.05 (s, 1H), 7.72 (d, J = 6.7 Hz, 1H), 7.58 (t, J = 7.1 Hz, 1H), 
7.40 (d, J = 7.3 Hz, 2H), 3.34 (d, J = 5.0 Hz, 2H), 3.18 (t, J = 7.7 Hz, 2H), 1.99 – 1.87 (m, 2H), 
1.46 (t, J = 7.4 Hz, 3H), 1.07 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3)  172.9, 149.9, 
143.3, 141.9, 133.5, 130.7, 125.5, 125.0, 117.7, 116.8, 49.4, 36.3, 23.8, 13.8, 8.3. MS (ESI) 
calculated for C15H17N3O2S2, m/z 335.08, found 336.08 [M+H]
+. 
 
15t: N-(2-propylthiazolo[4,5-c]quinolin-4-yl)propane-1-sulfonamide. White solid (35 mg, 
61%). 1H NMR (500 MHz, CDCl3)  12.05 (s, 1H), 7.72 (d, J = 6.7 Hz, 1H), 7.58 (t, J = 7.1 Hz, 
1H), 7.40 (d, J = 7.3 Hz, 2H), 3.34 (d, J = 5.0 Hz, 2H), 3.18 (t, J = 7.7 Hz, 2H), 1.99 – 1.87 (m, 
2H), 1.46 (t, J = 7.4 Hz, 3H), 1.07 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3)  172.9, 
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149.9, 143.3, 141.9, 133.5, 130.7, 125.5, 125.0, 117.7, 116.8, 49.4, 36.3, 23.8, 13.8, 8.3. MS 
(ESI) calculated for C16H19N3O2S2, m/z 349.09, found 350.09 [M+H]
+. 
 
15u: N-(2-propylthiazolo[4,5-c]quinolin-4-yl)butane-1-sulfonamide. White solid (37 mg, 
62%). 1H NMR (500 MHz, CDCl3)  12.04 (s, 1H), 7.71 (d, J = 6.7 Hz, 1H), 7.57 (t, J = 7.0 Hz, 
1H), 7.39 (d, J = 6.2 Hz, 2H), 3.32 (s, 2H), 3.18 (t, J = 7.7 Hz, 2H), 2.00 – 1.82 (m, 4H), 1.55 – 
1.40 (m, 2H), 1.07 (t, J = 7.4 Hz, 3H), 0.94 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3)  
172.8, 149.7, 143.3, 141.9, 133.5, 130.7, 125.5, 125.0, 117.6, 116.8, 54.8, 36.3, 25.5, 23.8, 
21.7, 13.8, 13.8. MS (ESI) calculated for C17H21N3O2S2, m/z 363.11, found 364.11 [M+H]
+. 
 
15v: 4-Methyl-N-(2-propylthiazolo[4,5-c]quinolin-4-yl)benzenesulfonamide. White solid (40 
mg, 61%). 1H NMR (500 MHz, CDCl3)  12.04 (s, 1H), 7.71 (d, J = 6.7 Hz, 1H), 7.57 (t, J = 7.0 
Hz, 1H), 7.39 (d, J = 6.2 Hz, 2H), 3.32 (s, 2H), 3.18 (t, J = 7.7 Hz, 2H), 2.00 – 1.82 (m, 4H), 1.55 
– 1.40 (m, 2H), 1.07 (t, J = 7.4 Hz, 3H), 0.94 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3)  
172.8, 149.0, 143.4, 143.0, 142.1, 139.9, 133.5, 130.7, 129.4, 126.7, 125.5, 125.1, 117.7, 117.0, 
36.2, 23.67, 21.7, 13.8. MS (ESI) calculated for C20H19N3O2S2, m/z 397.09, found 398.10 
[M+H]+. 
 
Synthesis of compound 15w: Diethyl (2-propylthiazolo[4,5-c]quinolin-4-yl) 
phosphoramidate. To a stirred solution of 8c (50 mg, 0.205 mmol) in CH2Cl2 (2 mL) was added 
diethyl chlorophosphate (60 L, 0.810 mmol), and the resulting mixture was stirred at room 
temperature for 12 h. The reaction mixture was diluted with water and extracted with CH2Cl2 (3 
× 10 mL). The organic layer was dried over Na2SO4, concentrated under reduced pressure, and 
the crude residue was purified by silica gel column chromatography (0-5% MeOH in CH2Cl2) to 
obtain compound 15w as a white solid (45 mg, 56%). 1H NMR (500 MHz, DMSO)  8.41 (d, J = 
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10.1 Hz, 1H), 7.96 (d, J = 7.8 Hz, 1H), 7.83 (d, J = 8.3 Hz, 1H), 7.68 (dd, J = 11.2, 4.0 Hz, 1H), 
7.49 (t, J = 7.4 Hz, 1H), 4.24 (p, J = 7.2 Hz, 4H), 3.20 (t, J = 7.5 Hz, 2H), 1.94 – 1.85 (m, 2H), 
1.27 (t, J = 7.0 Hz, 6H), 1.02 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, DMSO)  171.9, 147.0, 
143.0, 140.3, 138.0 (d, J = 10.4 Hz), 131.2, 129.2 (d, J = 207.2 Hz), 127.8 (d, J = 94.8 Hz), 
124.9 (d, J = 12.8 Hz),, 120.2, 63.1 (d, J = 5.6 Hz), 35.2, 63.1 (d, J = 5.6 Hz), 16.2 (d, J = 6.8 
Hz) 13.5. MS (ESI) calculated for C17H22N3O3PS, m/z 379.11, found 380.12 [M+H]
+. 
 
Synthesis of compound 17: 1-(2-Propylthiazolo[4,5-c]quinolin-4-yl)guanidine. Compound 
7c (100 mg, 0.411 mmol) was dissolved in POCl3 (3 mL) and stirred at 100 °C for 1 h. POCl3 
was evaporated under reduced pressure, ice cold water was added and the residue was 
extracted with CH2Cl2 (3 × 10 mL). The organic layer was dried over Na2SO4, concentrated 
under reduced pressure to give crude 16 (100 mg, 93%) which was used further without 
purification. To a stirred solution of guanidine (62 mg, 0.615 mmol) in 1,4-dioxane (2 mL) was 
added NaH (12 mg, 0.492 mmol), the reaction mixtures was stirred at 60 °C for 30 min. 
Compound 16 (30 mg, 0.123 mmol) in DMF (2 mL) was added and heating was continued at 90 
°C for 12 h. The reaction mixture was diluted with water and extracted with CH2Cl2 (3 × 10 mL). 
The organic layer was dried over Na2SO4, concentrated under reduced pressure, and the crude 
residue was purified by silica gel column chromatography (0-10% MeOH in CH2Cl2) to obtain 
compound 17 as a yellow solid (25 mg, 71%). 1H NMR (500 MHz, MeOD)  8.05 (dd, J = 8.4, 
0.5 Hz, 1H), 8.00 – 7.96 (m, 1H), 7.75 (ddd, J = 8.4, 7.1, 1.4 Hz, 1H), 7.62 (ddd, J = 8.2, 7.1, 1.2 
Hz, 1H), 3.25 (dd, J = 8.7, 6.4 Hz, 2H), 2.06 – 1.97 (m, 2H), 1.11 (t, J = 7.4 Hz, 3H). 13C NMR 
(126 MHz, MeOD)  175.2, 157.5, 146.0, 143.5, 142.7, 138.9, 131.0, 129.3, 128.0, 125.9, 122.5, 
36.9, 24.2, 14.0. MS (ESI) calculated for C14H15N5S, m/z 285.10, found 286.11 [M+H]
+. 
 
Compound 18a was synthesized similarly as compound 15c. 
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18a: N-(2-butylthiazolo[4,5-c]quinolin-4-yl)formamide. White solid (32 mg, 71%).1H NMR 
(500 MHz, CDCl3)  9.85 (d, J = 10.8 Hz, 1H), 8.86 (d, J = 10.3 Hz, 1H), 7.99 (d, J = 8.4 Hz, 
1H), 7.85 (dd, J = 8.0, 0.9 Hz, 1H), 7.67 (ddd, J = 8.4, 7.1, 1.4 Hz, 1H), 7.50 (ddd, J = 8.1, 7.1, 
1.1 Hz, 1H), 3.20 – 3.16 (m, 2H), 1.91 (dt, J = 15.2, 7.6 Hz, 2H), 1.55 – 1.45 (m, 2H), 1.01 (t, J = 
7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3)  172.8, 161.9, 143.7, 143.2, 141.6, 137.4, 129.4, 
128.7, 125.7, 124.7, 121.8, 33.8, 31.6, 22.2, 13.8. MS (ESI) calculated for C15H15N3OS, m/z 
285.09, found 286.10 [M+H]+. 
 
Compounds 18b and 18c were synthesized similarly as compound 15d. 
 
18b: N-(2-butylthiazolo[4,5-c]quinolin-4-yl)acetamide. White solid (50 mg, 85%). 1H NMR 
(500 MHz, CDCl3)  8.97 (s, 1H), 8.02 (d, J = 8.3 Hz, 1H), 7.82 (ddd, J = 8.0, 1.4, 0.5 Hz, 1H), 
7.65 (ddd, J = 8.4, 7.1, 1.4 Hz, 1H), 7.49 (ddd, J = 8.1, 7.1, 1.2 Hz, 1H), 3.21 – 3.13 (m, 2H), 
2.82 (s, 3H), 1.96 – 1.85 (m, 2H), 1.55 – 1.44 (m, 2H), 1.04 – 0.96 (m, 3H). 13C NMR (126 MHz, 
CDCl3)  172.4, 144.4, 143.4, 140.9, 138.5, 129.2, 129.1, 125.7, 124.7, 121.5,  34.0, 31.8, 25.9, 
22.3, 13.9. MS (ESI) calculated for C16H17N3OS, m/z 299.11, found 300.11 [M+H]
+. 
 
18c: N-(2-butylthiazolo[4,5-c]quinolin-4-yl)butyramide. White solid (55 mg, 87%). 1H NMR 
(500 MHz, CDCl3)  8.95 (s, 1H), 8.05 (d, J = 8.3 Hz, 1H), 7.82 (ddd, J = 8.0, 1.4, 0.4 Hz, 1H), 
7.65 (ddd, J = 8.4, 7.1, 1.4 Hz, 1H), 7.49 (ddd, J = 8.1, 7.1, 1.2 Hz, 1H), 3.22 – 3.06 (m, 4H), 
1.95 – 1.83 (m, 4H), 1.54 – 1.45 (m, 2H), 1.10 (t, J = 7.4 Hz, 3H), 1.00 (t, J = 7.4 Hz, 3H). 13C 
NMR (126 MHz, CDCl3)  172.2, 144.3, 143.4, 140.7, 138.4, 129.1, 129.0, 125.6, 124.5, 121.3, 
39.8, 33.8, 31.7, 22.2, 18.5, 14.0, 13.8. MS (ESI) calculated for C18H21N3OS, m/ 327.14, found 
328.14 [M+H]+. 
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Human TLR-7/-8 reporter gene assays (NF-B induction). The induction of NF-B was 
quantified using HEK-Blue-7 (hTLR7-specific) and HEK-Blue-8 (hTLR8-specific) cells as 
previously described by us.30, 55b, 69 HEK293 cells stably co-transfected with human TLR7 or 
human TLR8 and secreted alkaline phosphatase (sAP), were maintained in HEK-Blue™ 
Selection medium containing zeocin and normocin. Stable expression of secreted alkaline 
phosphatase (sAP) under control of NF-B/AP-1 promoters is inducible by appropriate TLR 
agonists, and extracellular sAP in the supernatant is proportional to NF-B induction. HEK-Blue 
cells were incubated at a density of ~105 cells/ml in a volume of 80 l/well, in 384-well, flat-
bottomed, cell culture-treated microtiter plates until confluency was achieved, and subsequently 
stimulated with graded concentrations of stimuli. sAP was assayed spectrophotometrically using 
an alkaline phosphatase-specific chromogen (present in HEK-detection medium as supplied by 
the vendor) at 620 nm.  
 
Immunoassays for Interferon (IFN)-, IFN-, Interleukin (IL)-12, IL-18, and cytokines. Fresh 
human peripheral blood mononuclear cells (hPBMCs) were isolated from human blood obtained 
by venipuncture with informed consent and as per institutional guidelines on Ficoll-Hypaque 
gradients as described elsewhere.73 Aliquots of PBMCs (105 cells in 100 L/well) were 
stimulated for 12 h with graded concentrations of test compounds. Supernatants were isolated 
by centrifugation, and were assayed in triplicates using either high-sensitivity analyte-specific 
ELISA kits (PBL Interferon Source, Piscataway, NJ and R&D Systems, Inc., Minneapolis, MN), 
or analyte-specific multiplexed cytokine/chemokine bead array assays as reported by us 
previously.69 PBMC supernatants were also analyzed for 41 chemokines and cytokines (EGF, 
Eotaxin, FGF-2, Flt-3 ligand, Fractalkine, G-CSF, GM-CSF, GRO, IFN-2, IFN-, IL-10, IL-12 
(p40), IL-12 (p70), IL-13, IL-15, IL-17, IL-1ra, IL-1, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, 
IL-9, IP-10, MCP-1, MCP-3, MDC (CCL22), MIP-1, MIP-1, PDGF-AA, PDGF-AB/BB, 
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RANTES, TGF, TNF-, TNF-, VEGF, and sCD40L) using a magnetic bead-based 
multiplexed assay kit (Milliplex MAP Human Cytokine/Chemokine kit). Data were acquired and 
processed on a MAGPIX instrument (EMD Millipore, Billerica, MA) with intra-assay coefficients 
of variation ranging from 4 to 8% for the 41 analytes. 
 
Rabbit immunization and antigen-specific ELISA. All experiments were performed at Harlan 
Laboratories (Indianapolis, IN) in accordance with institutional guidelines (University of Kansas 
IACUC permit # 119-06). Cohorts of adult female New Zealand White rabbits (n = 4 per cohort) 
were immunized intramuscularly in the flank region with (a) 100 g of bovine -lactalbumin in 
0.2 mL saline, or (b) 100 g of bovine -lactalbumin plus 100 g of either 8c or 8d in 0.2 mL 
saline. Pre-immune test-bleeds were first obtained on Day 1 via venipuncture of the marginal 
vein of the ear. Animals were immunized on Days 1 and 15. A final test-bleed was performed 
via the marginal vein of the ear on Day 28. Sera were stored at -80 °C until used. Bovine -
lactalbumin-specific ELISAs were performed in 384-well format using automated liquid handling 
methods as described by us.74 
 
 
     
  











Dual TLR7/TLR8 Antagonists  




As mentioned earlier, small molecule TLR7/8 activators constitute a small set of compounds 
occupying	 a very small chemical space. The identification of simpler molecules as TLR7/8 
agonists may pave the way for inexpensive vaccine constructs, and we are therefore keenly 
interested in exploring alternative chemotypes that are synthetically less complex. A detailed 
structural characterization of the mode of binding of TLR7 ligands is not yet available to guide 
scaffold-hopping approaches.75 We speculated that 3,8-diamino-imidazo[1,2-a]pyrazines 4 may 
bear sufficient structural similarities to the known TLR7/8 ligands (Fig. 1). These molecules are, 
in principle, readily accessible in two steps (one-pot synthetic process) via the Groebke-
Blackburn-Bienaymé multicomponent reaction,76 and we envisaged a rapid elaboration and 
screening of a library of compounds for TLR7/8 agonistic activities.  
 
Fig. 1. TLR7/8 agonistic scaffolds. R1 is typically alkyl or O-alkyl, R2 is alkyl or benzyl, and R3 is usually 
alkyl and OH in oxoadenines. 
 
 
We began with the syntheses of small test-libraries of 3,8-diamino-imidazo[1,2-a]pyrazines as 
well as 3-amino-imidazo[1,2-a]pyridine/pyrazines (Schemes 1 and 2). Most of these compounds 
(5a-d, 6-23) were inactive in NF-B reporter gene assays specific for human TLR-3, -7, -8, and -
9; however compounds 26-29 obtained with pyridoxal as the aldehyde component were found to 
specifically activate NF-B signaling in TLR8-transfected HEK293 cells. Detailed spectroscopic 
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analyses confirmed the formation of a hitherto unknown 2,3-diamino-furo[2,3-c]pyridine skeleton 
via a non-canonical pathway, which was unambiguously confirmed by single crystal X-ray 
analysis. The TLR8-specific agonistic properties of this novel and unexpected chemotype 
warranted a systematic SAR, which is presented herein. 
 
 
3.2. Results and Discussion 
 
We have previously described extensive SAR on the 1,2-disubstituted-(1H-imidazo[4,5-
c]quinoline-4-amines) class of compounds (1a, Fig. 1) as TLR7/8 agonists,55b, 58, 69, 77 and their 
application in designing self-adjuvanting vaccine constructs.56 In our ongoing search toward 
identifying novel and synthetically simpler candidate vaccine adjuvants, we hypothesized that 
the imidazo[1,2-a]pyrazines 4 would possess sufficient structural similarity with the known small 
molecule TLR7/8 ligands such as 1-3 (Fig. 1). These molecules are readily accessible in a one-
pot, two-step process using the Groebke-Blackburn-Bienaymé multicomponent reaction as a 
key step. An acid-catalyzed (HCl in dioxane), microwave-mediated (400 W, 110 ºC, 10 min) 
reaction using 2-amino-3-chloropyrazine (amidine component), isocyanocyclohexane (isonitrile 
component) and benzaldehyde (aldehyde component) resulted, as expected, in 8-chloro-N-
cyclohexyl-2-phenylimidazo[1,2-a]pyrazin-3-amine (Scheme 1). Subsequent microwave-
mediated ipso-chloro displacement using ammonium hydroxide was unsuccessful, but 
conventional heating in a sealed tube (110 ºC, 16 h) furnished the desired N3-cyclohexyl-2-
phenylimidazo[1,2-a]pyrazine-3,8-diamine 5a (Scheme 1) in 30% yield over two steps. Using 
this one-pot process, a small set of 8-amino-imidazo[1,2-a]pyrazines 5b-d was synthesized by 
varying the aldehyde and isonitrile components (Scheme 1).  
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Scheme 1. A two step one-pot synthetic process. 
 
 
Scheme 2. Twenty-four membered diverse test-library.  
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Simultaneously, a diverse test-library comprising of twenty-four compounds was also 
synthesized using two amidines (2-aminopyridine and 2-aminopyrazine), three isonitriles (2-
isocyano-2-methylpropane, isocyanocyclohexane, (isocyanomethyl)benzene), and four 
aldehydes (benzaldehyde, isonicotinaldehyde, salicylaldehyde, and pyridoxal) (Scheme 2). The 
syntheses of 6-23 proceeded smoothly. However, the typical Groebke reaction, carried out at 
110 ºC for 20 min in CH3CN, was found to be excessively harsh for reactions using pyridoxal 
(24-29), leading to low yields and charring of reaction mixtures. Reactions for this subset of 
compounds progressed rapidly in 2 min under microwave conditions at 80 ºC and 600 W power 
in CH3CN or MeOH. We noticed that only compounds 24-29 (synthesized using pyridoxal) were 
fluorescent on TLC under long-wave ultraviolet radiation.  
 
The compounds were screened in NF-B reporter gene assays specific for human TLR-3, -4, -5, 
-7, -8, and -9. The 3,8-diamino-imidazo[1,2-a]pyrazines 5a-d as well as 3-amino-imidazo[1,2-
a]pyridine/pyrazine library members 6-23 did not display any activity in these assays up to 
concentrations of 250 M. However, compounds 26-29 obtained with the use of pyridoxal as the 
aldehyde component, were found to specifically activate NF-B signaling in human TLR8-
transfected HEK293 cells (Table 1, Fig. 2), but not human TLR-3, -4, -5, -7, and -9. 
 
The NMR spectra of compounds 26-29 as well as their fluorescence properties alerted us to the 
possibility of the formation of a new chemical entity with a heterocyclic system other than the 
classical imidazo[1,2-a]pyridine/pyrazines during the Groebke-Blackburn-Bienaymé multi-
component reaction. In 1H NMR spectra, the aliphatic CH of the cyclohexyl group in compounds 
8/9, 14/15, and 20/21 (Scheme 2) appeared in the range of 3.0 to 3.1  ppm, whereas a 
pronounced downfield shift of this CH proton (up to 3.85  ppm) was observed in compounds 26 
and 27. Similar observations were noted in another set in which the aliphatic benzylic CH2 in 
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compounds 10/11, 16/17, and 22/23 appeared in the range of 4.2 to 4.3  ppm, whereas a 
pronounced downfield shift of this CH2 (up to 4.76  ppm) was observed in compounds 28 and 
29. 13C NMR spectra of compounds 24-29 showed an unusual upfield shift of one of the 
aromatic quaternary carbons in the region (90-96  ppm) (Fig. 3). These observations 
suggested a different heterocyclic system in 24-29. Initial efforts to crystallize these molecules 
were unsuccessful. Pending continuing crystallization efforts, we sought to elucidate the 
structures of these compounds via alternate routes.  
 
 Fig. 2. Dose-response profiles of TLR8 agonism by select 2,3-diamino-furo[2,3-c]pyridines. Top: TLR8 
agonism by compounds derived from Schemes 2 and 5. Bottom: TLR8 agonism by compounds derived 
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Fig. 3. 1H and 13C NMR spectra of the classic Groebke products (15 and 17) and non-Groebke, 




Three possible cyclization products appeared plausible in this acid-catalyzed multicomponent 
reaction (Panel A in Scheme 3). As mentioned earlier, NMR spectroscopic observations for 
compounds 24-29 were not congruent with the 4-(3-(cyclohexylamino)imidazo[1,2-a]pyridin-2-
yl)-5-(hydroxymethyl)-2-methylpyridin-3-ol 32, the expected product via the canonical Groebke 
mechanism (‘Path A’, Panel A in Scheme 3). In order to test whether the phenolic or benzylic 
hydroxyl groups of pyridoxal may be involved in an alternate pathway of cyclization, we carried 
out a reaction using a pyridoxal derivative 34 with its phenolic hydroxyl protected with a benzyl 
group (Scheme 4). This resulted in a product with a spectral signature entirely consistent with 
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the classical Groebke product (5-(benzyloxy)-4-(3-(cyclohexylamino)imidazo[1,2-a]pyridin-2-yl)-
6-methylpyridin-3-yl)methanol 35, indirectly also ruling out the possibility of cyclization involving 
the benzylic hydroxyl group (‘Path B’, Panel A in Scheme 3). We reasoned that annulation via 
‘Path C’ ought to lead to a furo[2,3-c]pyridine skeleton 26, and that if this were indeed the case, 
this cyclization could proceed even if the amidine were to be replaced with an aniline.  
 
Scheme 3. Possible cyclization pathways and proposed mechanism. 
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Scheme 4. Synthesis of compound 35 using a pyridoxal derivative 34 with its phenolic hydroxyl protected 
with a benzyl group.   
 
 
We were gratified that a multicomponent reaction involving aniline, benzyl isonitrile and 
pyridoxal (Scheme 5) yielded the fluorescent compound 36, which 1H and 13C NMR spectra 
resembled those of compounds 24-29. Interestingly, 36 was also found to be weakly active 
(EC50 = 1.68 M) in primary TLR8 screens (Table 1, Fig. 2). Our investigations suggested the 
formation of a hitherto unknown furo[2,3-c]pyridine structure, exclusively when pyridoxal was 
used as the aldehyde component in the Groebke-Blackburn-Bienaymé multicomponent 
reaction. 
 
Scheme 5. Synthesis of compound 36 using aniline. 
 
 
Although a definitive elucidation of the reaction mechanism leading to the unexpected furo[2,3-
c]pyridine was not an immediate goal, understanding plausible mechanisms was of interest, and 
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was probed in some detail.  Formation of the pyrano[3,4-c]pyridine 33 via nucleophilic attack of 
the benzylic hydroxyl group, and its subsequent rearrangement to the furo[2,3-c]pyridine 26 
(Path D, Panel A in Scheme 3) appeared improbable. Salicylaldehyde, which lacks the bulky 
hydroxymethylene group, yielded the classical imidazo[1,2-a]pyridine 20 (confirmed by single 
crystal X-ray analysis, see below), rather than the benzofuran derivative B.3 (Panel B in 
Scheme 3). We reasoned, therefore, that the benzylic hydroxyl in the transition state 31 could 
assist cyclization via Path C (Panel A in Scheme 3) due to steric reasons, apposing the phenolic 
hydroxyl with the electrophilic carbon. In addition to the direct formation of the furo[2,3-c]pyridine 
26 via path C, a plausible alternate mechanism for this unusual cyclization route, involving the 
pyridine ring system is proposed in Scheme 3 (Panel C). 
 
After many unsuccessful attempts, a hydrochloride salt of compound 28 was crystallized as 
multiply-twinned bundles in acetonitrile. A multi-domain specimen of 28 was cut from one 
bundle which gave a set of diffracted intensities, permitting a crystal structure solution (non-
centrosymmetric, triclinic P1-C1 space group with eight crystallographically-independent 
molecules in the asymmetric unit), but not a satisfactory refinement (Fig. 4). The structure of 28 
unambiguously confirmed the furo[2,3-c]pyridine chemotype. The structure of compound 20 
(obtained with salicylaldehyde, which also possesses a phenolic OH; Scheme 2) was also 
elucidated, which established the formation of a classic Groebke product 2-(3-(cyclohexylamino) 
imidazo[1,2-a]pyridin-2-yl)phenol (Fig. 4). These observations clearly emphasize the 
significance of the additional substituents of pyridoxal, directing the unique cyclization route 
leading to the furo[2,3-c]pyridine scaffold. 
 
Thus, our initial attempts toward the synthesis of twenty-four membered imidazo[1,2-a]pyrazine/ 
pyridine test-library unexpectedly resulted in the formation of densely substituted furo[2,3-
c]pyridines 24-29. Pyridoxal was found to be an indispensable component for this cyclization 
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reaction. Four of the six compounds obtained (26-29, Scheme 2) were found to be active in our 
primary screens using TLR8-transfected HEK293 cells, while compounds 24 and 25, 
synthesized using 2-isocyano-2-methylpropane as one of the components, were found to be 
inactive, warranting detailed structure based activity relationship investigations for this new 
chemotype. 
 
Fig. 4. Crystal structures of the salicylaldehyde-derived classic Groebke product (imidazo[1,2-





Among the active compounds 26-29, we observed that compounds 26 and 28 (derived from 2-
aminopyridine) were more active than 27 and 29 (from 2-aminopyrazine; Table 1, Fig. 2). We 
therefore selected 2-aminopyridine and pyridoxal as the invariant components and varied the 
isonitrile component. We explored thirteen different isonitriles (Scheme 6), including linear 
aliphatic (as in 37a and 37b), branched aliphatic (37c-e), linear aliphatic with silyl (37f), 
heteroaromatic ring (37g), ester (37h and 37i), and phosphate ester (37j) termini, as well as 
aromatic substituents (37k-m). Maximal activity was observed in 37b, with a pentylene 
substituent on the C2 amine (Scheme 6, Fig. 2). Diminishing the chain length by one methylene 
unit (37a) decreased activity, and potency was further attenuated in compounds with alpha-
20
28
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branched substituents (37d). Compound 37n, with a free NH2 at C2 obtained by N-dealkylation 
of the tert-octylamine group78 of 37e with trifluoroacetic acid, as well as compounds with 
aromatic substituents (37k-m) were devoid of TLR8-stimulatory activity (Table 1). Thus, a 
distinct dependence of the nature of the C2 amino substituent on the activity profiles was 
observed in the furo[2,3-c]pyridines, with the C2-N-pentyl (37b) and C2-N-(trimethylsilyl)methyl 
analogues (37f) displaying dominant TLR8 agonism. 
 
Scheme 6. Synthesis of C2 N-alkyl analogues exploring isonitriles. 
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As mentioned earlier, our earlier efforts at unambiguously confirming the structure of 28 did not 
allow for satisfactory crystal structure refinement because of the intrinsic properties of the 
crystal space group. Having synthesized thirteen additional furo[2,3-c]pyridines (37a-m) for 
purposes of delineating SAR, a parallel crystallization of these compounds was attempted using 
various solvents. Suitable crystals of compound 37e were obtained as pale yellow crystals by 
slow evaporation of a super-saturated solution of 37e in CH3CN/CH3OH mixtures at room 
temperature. A single-domain specimen was selected and the X-ray diffraction data was 
collected. The ORTEP diagram of 37e is shown in Fig. 5, confirming the non-Groebke furo[2,3-
c]pyridine.  
 
Fig. 5. Crystal structure (ORTEP view) of the non-Groebke furo[2,3-c]pyridine, 37e, obtained with the 
use of pyridoxal as the aldehyde component. 
 
 
Previous mention was made that 36 (Scheme 5) was found to be weakly active (EC50 = 1.68 
M, Table 1, Fig. 2) relative to the lead compound 28, suggesting that the 2-aminopyridine core 
could be substituted by anilines in this multicomponent reaction. Having optimized the C2 group 
as pentylamine (derived from 1-isocyanopentane, Scheme 6), three more furo[2,3-c]pyridines 
were synthesized using aniline 38a, 3-fluoroaniline 38b, and 3-nitroaniline 38c in combination 
with 1-isocyanopentane and pyridoxal (Scheme 7).  
37e
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Scheme 7. Synthesis of analogues using substituted anilines.  
 
 
The C2 N-pentyl analogue 38a was found to be more active than the C2 N-benzyl analogue 36 
(Fig. 2, Table 1). The nitro derivative 38c was found to be as potent as the parent compound 
38a, whereas substantial gain in TLR8 activity was noticed for the fluoro-substituted compound 
38b in TLR8-specific functional assays. However, these compounds exhibited a poorer dose-
response profile (lower area-under the-curve, Fig. 2). It is pertinent to note that no stable 
product could be obtained by the replacement of 2-aminopyridine with aliphatic amines. 
 
Several TLRs are thought to signal via ligand-induced dimerization, as evident in the crystal 
structures of TLRs. Therefore, the dimeric compound 39 was also synthesized using 1,6-
diisocyanohexane (Scheme 8); the activity of this analogue was comparable in its TLR8-
agonistic potency to the most active compounds, 28, 37a, 37b and 37f (Table 1).  
 
Scheme 8. Synthesis of dimeric compounds 39. 
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We examined the cytokine-inducing properties25a, 30 of a subset of compounds that were 
maximally active (28, 37a, 37b and 37f), all of which showed robust dose-response profiles in 
primary TLR8-agonistic screens (Fig. 2). We used 2-propylthiazolo[4,5-c]quinolin-4-amine 40 
(CL075) as a reference TLR8 agonist,45, 62 which exhibited an EC50 of 1.32 M (Fig. 2). In 
human PBMCs, only the reference thiazoloquinoline 40, but none of the furo[2,3-c]pyridines 
showed any proinflammatory cytokine induction (Fig. 6). 
 
 Fig. 6. Dose-response profiles of proinflammatory cytokine induction in hPBMCs by compounds 28, 37a, 
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We do not yet know if the dissociation between TLR8-specific NF-B induction on the one hand, 
and lack of cytokine induction on the other is ascribable to a non-myeloid differentiation primary 
response gene 88 (MyD88)-independent mechanism.33a, 79 However, mindful of recent 
observations that proinflammatory activity is not an absolute prerequisite for adjuvantic 
properties,80 and because we had previously observed potent NF-B transactivation in a bis-
quinoline, 7-chloro-N-(4-(7-chloroquinolin-4-ylamino)butyl)quinolin-4-amine 41 (RE-660)81 
unaccompanied by any proinflammatory cytokine induction, we decided to examine two 
representative compounds (37b and 37f) in transcriptomal profiling experiments. Consistent 
with the cytokine assays, there were no transcriptional signatures of inflammation; however, 
both compounds upregulated several chemokine ligand (both CXCL and CCL) genes. Although 
entirely bereft of any proinflammatory activity, the bis-quinoline compound 41 was found to be a 
potent adjuvant which appears to be related to its functional agonism at CCR1.81 Given some 
similarities in activity profiles between the furo[2,3-c]pyridines and 41, we decided to evaluate 
and compare the adjuvantic activity of 37b alongside the reference compounds, 40 and 41. 
Rabbits were immunized using bovine -lactalbumin as a model subunit antigen.56  
 
Anti--lactalbumin IgG titers in immune sera clearly showed an adjuvantic effect of 37b, with a 
rise-in-titer values of >1000, comparable to the adjuvantic activities of the reference 
compounds, 40 and 41 (Fig. 7). The complete lack of proinflammatory cytokine induction 
coupled with strong adjuvantic activity of the novel furo[2,3-c]pyridines render this hitherto 
unknown chemotype an exceedingly attractive class of compounds which are expected to be 
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Fig. 7. Anti-bovine -lactalbumin-specific IgG titers in rabbits adjuvanted with 37b, 40, and 41 (n=4, for 
each cohort). Box-plots of ratios of immune/pre-immune titers yielding absorbance values of 1.0 are 


















In our ongoing search toward identifying novel and synthetically simpler candidate vaccine 
adjuvants, we hypothesized that the imidazo[1,2-a]pyrazines, readily accessible via the 
Groebke−Blackburn−Bienaymé multicomponent reaction, would possess sufficient structural 
similarity with TLR7/8-agonistic imidazoquinolines. With pyridoxal as the aldehyde component, 
furo[2,3-c]pyridines, rather than the expected imidazo[1,2-a]pyridines, were obtained, which 
were characterized by NMR spectroscopy and crystallography. Several analogues were found 
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distinct SAR was observed with varying substituents at C2. In human PBMCs, none of the 
furo[2,3-c]pyridines showed any proinflammatory cytokine induction but upregulated several 
chemokine ligand genes. In immunization studies in rabbits, the most active compound showed 
prominent adjuvantic effects. The complete lack of proinflammatory cytokine induction coupled 
with strong adjuvantic activity of the novel furo[2,3-c]pyridines render this hitherto unknown 







Chemistry. All of the solvents and reagents used were obtained commercially and used as 
such unless noted otherwise. Moisture- or air-sensitive reactions were conducted under nitrogen 
atmosphere in oven-dried (120 °C) glass apparatus. The solvents were removed under reduced 
pressure using standard rotary evaporators. Flash column chromatography was carried out 
using RediSep Rf “Gold” high performance silica columns on a CombiFlash Rf instrument 
unless otherwise mentioned, while thin-layer chromatography was carried out on silica gel (200 
m) CCM precoated aluminum sheets. The purity of all final compounds was confirmed to be 
greater than 95% by HPLCMS using a Zorbax Eclipse Plus 4.6 mm × 150 mm, 5 m analytical 
reverse phase C18 column with either H2O−isopropanol or H2O−CH3CN gradients, a diode-
array detector operating in the 190−500 nm range (2 nm bandpass), and an Agilent ESI-TOF 
mass spectrometer (integration on total ion intensity counts, with a mass accuracy of 10 ppm) 
operating in the positive ion acquisition mode. 
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Synthesis of compound 5a: N3-cyclohexyl-2-phenylimidazo[1,2-a]pyrazine-3,8-diamine. 
To a solution of 2-amino-3-chloropyrazine (64 mg, 0.50 mmol) in anhydrous acetonitrile (1 mL), 
were added benzaldehyde (60L, 0.60 mmol), 4N HCl/dioxane (10L) and cyclohexylisonitrile 
(74 L, 0.60 mmol). The reaction mixture was then heated under microwave conditions (400 W, 
110 ºC) in a sealed vial for 20 min. The reaction mixture was cooled to room temperature; 
ammonium hydroxide (NH3 content 28-30%, 0.5 mL) was added and further heated at 110 ºC in 
a sealed vial for overnight. After cooling the reaction mixture to room temperature, the solvents 
were removed and the residue was purified using column chromatography to obtain compound 
5a (47 mg, 30%). 1H NMR (500 MHz, MeOD)  8.02 (dd, J = 8.2, 1.3 Hz, 2H), 7.64 (d, J = 4.8 
Hz, 1H), 7.46 (dd, J= 10.9, 4.6 Hz, 2H), 7.39 – 7.28 (m, 1H), 7.21 (d, J = 4.8 Hz, 1H), 2.96 – 
2.83 (m, 1H), 1.76 (d, J = 11.6 Hz, 2H), 1.71 – 1.62 (m, 2H), 1.57-1.51 (m, 1H), 1.31 – 1.19 (m, 
2H), 1.19 – 1.03 (m, 3H).13C NMR (126 MHz, MeOD)  151.14, 136.46, 135.17, 129.95, 129.55, 
129.44, 128.67, 128.24, 128.11, 109.02, 57.87, 35.05, 26.86, 25.99. MS (ESI) calcd for 
C18H21N5, m/z 307.1797, found 308.1923 [M+H]
+. 
 
Compounds 5b-5d were synthesized similarly as compound 5a. 
 
5b: 2-([1,1'-Biphenyl]-4-yl)-N3-cyclohexylimidazo[1,2-a]pyrazine-3,8-diamine. 44 mg, 23%. 
1H NMR (500 MHz, MeOD)  8.13 (d, J = 8.2 Hz, 2H), 7.72 (d, J = 8.3 Hz, 2H), 7.71 – 7.67 (m, 
2H), 7.64 (d, J = 4.8 Hz, 1H), 7.45 (t, J = 7.7 Hz, 2H), 7.38 – 7.31 (m, 1H), 7.22 (d, J = 4.8 Hz, 
1H), 3.02 – 2.84 (m, 1H), 1.80 (d, J = 12.2 Hz, 2H), 1.69 (dd, J = 8.2, 5.3 Hz, 2H), 1.55 (s, 1H), 
1.35 – 1.23 (m, 2H), 1.24 – 1.01 (m, 3H). 13C NMR (126 MHz, MeOD)  151.16, 141.92, 141.53, 
136.10, 134.18, 130.07, 129.93, 129.56, 128.57, 128.45, 128.13, 128.02, 127.86, 109.03, 57.99, 
35.12, 26.88, 26.03. MS (ESI) calcd for C24H25N5, m/z 383.2110, found 384.2382 [M+H]
+. 
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5c: N3-benzyl-2-butylimidazo[1,2-a]pyrazine-3,8-diamine. 10 mg, 7%. 1H NMR (500 MHz, 
MeOD)  7.44 (d, J = 4.8 Hz, 1H), 7.29 – 7.17 (m, 5H), 7.12 (d, J = 4.8 Hz, 1H), 4.13 (s, 2H), 
2.51 – 2.42 (m, 2H), 1.54 – 1.42 (m, 2H), 1.31 (dq, J = 14.8, 7.4 Hz, 2H), 0.91 (t, J = 7.4 Hz, 
3H). 13C NMR (126 MHz, MeOD)  150.52, 141.10, 138.98, 130.14, 129.57, 129.49, 128.81, 
128.40, 127.74, 108.93, 53.28, 32.76, 27.26, 23.73, 14.26. MS (ESI) calcd for C17H21N5, m/z 
295.1797, found 296.1952 [M+H]+. 
 
5d: 2-Butyl-N3-(4-methoxyphenyl)imidazo[1,2-a]pyrazine-3,8-diamine. 36 mg, 23%. 1H NMR 
(500 MHz, MeOD)  7.26 (d, J = 4.7 Hz, 1H), 7.16 (d, J = 4.7 Hz, 1H), 6.80 – 6.69 (m, 2H), 6.49 
– 6.38 (m, 2H), 3.70 (s, 3H), 2.67 (t, J = 7.6 Hz, 2H), 1.73 – 1.62 (m, 2H), 1.41 – 1.23 (m, 2H), 
0.88 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, MeOD)  154.65, 150.75, 142.09, 140.98, 129.90, 
128.28, 124.98, 115.97, 115.50, 109.10, 56.07, 32.40, 27.41, 23.46, 14.15. MS (ESI) calcd for 
C17H21N5O, m/z 311.1746, found 312.1905 [M+H]
+. 
 
Synthesis of compound 6: N-(tert-butyl)-2-phenylimidazo[1,2-a]pyridin-3-amine. To a 
solution of 2-aminopyridine (24 mg, 0.25 mmol) in anhydrous acetonitrile, were added 
benzaldehyde (28 L, 0.28 mmol), 4N HCl/dioxane (5 L) and tert-butyl isonitrile (27 L, 0.24 
mmol). The reaction mixture was then heated under microwave conditions (400 W, 110 ºC) in a 
sealed vial for 20 min. After cooling the reaction mixture to room temperature, the solvents were 
removed and the residue was purified using column chromatography to obtain compound 6 (44 
mg, 70%). 1H NMR (400 MHz, CDCl3)  8.23 (dt, J = 6.9, 1.2 Hz, 1H), 7.90 (dt, J = 8.1, 1.6 Hz, 
2H), 7.55 (dt, J = 9.0, 1.0 Hz, 1H), 7.43 (t, J = 7.6 Hz, 2H), 7.31 (t, J = 7.4 Hz, 1H), 7.13 (ddd, J 
= 9.0, 6.6, 1.3 Hz, 1H), 6.77 (td, J = 6.8, 1.1 Hz, 1H), 3.12 (s, 1H), 1.04 (s, 9H). 13C NMR (101 
MHz, CDCl3)  142.15, 135.42, 135.40, 128.43, 128.32, 127.52, 124.17, 123.64, 117.48, 
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111.46, 101.91, 56.59, 30.43. MS (ESI) calcd for C17H19N3, m/z 265.1579, found 266.1664 
[M+H]+. 
 
Compounds 7-29 were synthesized similarly as compound 6. 
 
7: N-(tert-butyl)-2-phenylimidazo[1,2-a]pyrazin-3-amine. 47 mg, 74%. 1H NMR (400 MHz, 
CDCl3)  9.00 (d, J = 1.4 Hz, 1H), 8.14 (dd, J = 4.6, 1.5 Hz, 1H), 7.91 (dd, J = 8.3, 1.3 Hz, 2H), 
7.86 (d, J = 4.6 Hz, 1H), 7.46 (t, J = 7.5 Hz, 2H), 7.37 (t, J = 7.4 Hz, 1H), 3.19 (s, 1H), 1.05 (s, 
9H). 13C NMR (101 MHz, CDCl3)  143.54, 142.40, 137.43, 134.38, 129.04, 128.66, 128.38, 
128.33, 125.17, 116.49, 57.11, 30.45. MS (ESI) calcd for C16H18N4, m/z 266.1531, found 
267.1588 [M+H]+. 
 
8: N-cyclohexyl-2-phenylimidazo[1,2-a]pyridin-3-amine. 64 mg, 86%. 1H NMR (500 MHz, 
CDCl3)  8.16 (d, J = 6.8 Hz, 1H), 8.05 (dd, J = 8.3, 1.2 Hz, 2H), 7.62 (d, J = 9.0 Hz, 1H), 7.45 (t, 
J = 7.8 Hz, 2H), 7.32 (t, J = 7.4 Hz, 1H), 7.17 (ddd, J = 8.9, 6.7, 1.2 Hz, 1H), 6.82 (td, J = 6.8, 
0.9 Hz, 1H), 3.32 (s, 1H), 3.07 – 2.85 (m, 1H), 1.81 (d, J = 13.1 Hz, 2H), 1.68 (dd, J = 9.1, 3.6 
Hz, 2H), 1.60 – 1.54 (m, 1H), 1.28 – 1.12 (m, 5H). 13C NMR (126 MHz, CDCl3)  141.02, 135.43, 
133.45, 128.74, 127.74, 127.20, 125.17, 125.04, 123.07, 116.94, 112.30, 57.02, 34.27, 25.81, 
24.94. MS (ESI) calcd for C19H21N3, m/z 291.1735, found 292.1832 [M+H]
+. 
 
9: N-cyclohexyl-2-phenylimidazo[1,2-a]pyrazin-3-amine. 25 mg, 36%. 1H NMR (500 MHz, 
CDCl3)  8.99 (d, J = 1.4 Hz, 1H), 8.01 (ddd, J = 4.6, 3.2, 1.8 Hz, 3H), 7.85 (d, J = 4.6 Hz, 1H), 
7.48 (t, J = 7.7 Hz, 2H), 7.38 (t, J = 7.4 Hz, 1H), 3.26 (s, 1H), 3.00 (m, 1H), 2.22 (s, 1H), 1.82 
(dd, J = 6.6, 5.4 Hz, 2H), 1.70 (dd, J = 9.3, 3.3 Hz, 2H), 1.62 – 1.55 (m, 1H), 1.34 – 1.07 (m, 
5H). 13C NMR (126 MHz, CDCl3) 143.37, 139.08, 136.82, 133.62, 129.01, 128.90, 128.30, 
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127.42, 126.70, 115.73, 57.02, 34.41, 25.69, 24.91. MS (ESI) calcd for C18H20N4, m/z 292.1688, 
found 293.1775 [M+H]+. 
 
10: N-benzyl-2-phenylimidazo[1,2-a]pyridin-3-amine. 62 mg, 86%. 1H NMR (500 MHz, 
CDCl3)  7.98 (ddt, J = 3.7, 3.0, 1.6 Hz, 3H), 7.57 (dt, J = 9.0, 1.0 Hz, 1H), 7.45 (t, J = 7.7 Hz, 
2H), 7.39 – 7.26 (m, 6H), 7.13 (ddd, J = 9.0, 6.7, 1.3 Hz, 1H), 6.74 (td, J = 6.8, 1.1 Hz, 1H), 4.20 
(d, J = 6.1 Hz, 2H), 3.52 (t, J = 6.0 Hz, 1H), 2.45 (s, 1H). 13C NMR (126 MHz, CDCl3)  141.57, 
139.06, 136.04, 134.13, 128.84, 128.30, 127.82, 127.65, 127.16, 125.77, 124.32, 122.50, 
117.52, 111.94, 52.57. MS (ESI) calcd for C20H17N3, m/z 299.1422, found 300.1490 [M+H]
+. 
 
11: N-benzyl-2-phenylimidazo[1,2-a]pyrazin-3-amine. 45 mg, 62%. 1H NMR (500 MHz, 
CDCl3)  8.98 (d, J = 1.3 Hz, 1H), 7.94 (dt, J = 8.1, 1.6 Hz, 2H), 7.82 (dd, J = 4.6, 1.4 Hz, 1H), 
7.77 (d, J = 4.6 Hz, 1H), 7.47 (t, J = 7.6 Hz, 2H), 7.39 (t, J = 7.4 Hz, 1H), 7.34 – 7.27 (m, 5H), 
4.23 (d, J = 2.4 Hz, 2H), 3.66 (s, 1H), 2.20 (s, 1H). 13C NMR (126 MHz, CDCl3)  143.46, 
138.76, 138.56, 136.79, 133.34, 129.06, 129.03, 128.99, 128.46, 128.24, 128.08, 127.42, 
127.18, 115.38, 52.39. MS (ESI) calcd for C19H16N4, m/z 300.1375, found 301.1494 [M+H]
+. 
 
12: N-(tert-butyl)-2-(pyridin-4-yl)imidazo[1,2-a]pyridin-3-amine. 50 mg, 78%. 1H NMR (500 
MHz, CDCl3)  8.65 (d, J = 5.9 Hz, 2H), 8.20 (dt, J = 6.9, 1.0 Hz, 1H), 7.96 (dd, J = 4.7, 1.4 Hz, 
2H), 7.56 (d, J = 9.1 Hz, 1H), 7.18 (ddd, J = 9.0, 6.6, 1.2 Hz, 1H), 6.81 (td, J = 6.8, 1.0 Hz, 1H), 
3.07 (s, 1H), 1.10 (s, 9H). 13C NMR (126 MHz, CDCl3)  149.69, 142.82, 142.39, 136.46, 
124.86, 124.77, 123.38, 122.17, 117.68, 111.82, 56.78, 30.38. MS (ESI) calcd for C16H18N4, m/z 
266.1531, found 267.1747 [M+H]+. 
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13: N-(tert-butyl)-2-(pyridin-4-yl)imidazo[1,2-a]pyrazin-3-amine. 49 mg, 76%. 1H NMR (500 
MHz, CDCl3)  9.02 (d, J = 1.4 Hz, 1H), 8.69 (dd, J = 4.5, 1.6 Hz, 2H), 8.11 (dd, J = 4.7, 1.5 Hz, 
1H), 7.94 (dd, J = 4.5, 1.6 Hz, 2H), 7.88 (d, J = 4.7 Hz, 1H), 3.12 (s, 1H), 1.10 (s, 9H). 13C NMR 
(126 MHz, CDCl3)  150.22, 144.25, 141.96, 139.25, 137.72, 129.39, 126.24, 122.42, 116.42, 
57.46, 30.61. MS (ESI) calcd for C15H17N5, m/z 267.1484, found 268.1705 [M+H]
+. 
 
14: N-cyclohexyl-2-(pyridin-4-yl)imidazo[1,2-a]pyridin-3-amine. 69 mg, 98%. 1H NMR (500 
MHz, CDCl3)  8.64 (dd, J = 4.6, 1.6 Hz, 2H), 8.07 (dt, J = 6.9, 1.2 Hz, 1H), 8.00 (dd, J = 4.6, 1.6 
Hz, 2H), 7.54 (dt, J = 9.1, 1.0 Hz, 1H), 7.17 (ddd, J = 9.1, 6.6, 1.3 Hz, 1H), 6.81 (td, J = 6.8, 1.1 
Hz, 1H), 3.11 (d, J = 3.9 Hz, 1H), 2.98 (td, J = 10.3, 4.1 Hz, 1H), 1.83 (d, J = 10.8 Hz, 2H), 1.71 
(dd, J = 9.4, 3.3 Hz, 2H), 1.59 (dd, J = 7.3, 1.4 Hz, 1H), 1.32 – 1.09 (m, 5H). 13C NMR (126 
MHz, CDCl3)  150.03, 142.26, 142.11, 133.78, 126.92, 124.92, 122.87, 121.21, 117.99, 
112.31, 57.26, 34.42, 25.75, 24.97. MS (ESI) calcd for C18H20N4, m/z 292.1688, found 293.1854 
[M+H]+. 
 
15: N-cyclohexyl-2-(pyridin-4-yl)imidazo[1,2-a]pyrazin-3-amine. 56 mg, 80%. 1H NMR (500 
MHz, CDCl3)  9.01 (d, J = 1.5 Hz, 1H), 8.70 (dd, J = 4.5, 1.6 Hz, 2H), 8.03 – 7.93 (m, 3H), 7.88 
(d, J = 4.6 Hz, 1H), 3.21 (d, J = 5.9 Hz, 1H), 3.06 – 2.97 (m, 1H), 1.84 (d, J = 10.5 Hz, 2H), 1.72 
(dd, J = 9.7, 2.6 Hz, 2H), 1.63 – 1.58 (m, 1H), 1.31 – 1.14 (m, 5H). 13C NMR (126 MHz, CDCl3)  
150.42, 144.32, 141.25, 137.17, 135.99, 129.45, 128.03, 121.37, 115.69, 57.35, 34.55, 25.62, 
24.93.MS (ESI) calcd for C17H19N5, m/z 293.1640, found 294.1894 [M+H]
+. 
 
16: N-benzyl-2-(pyridin-4-yl)imidazo[1,2-a]pyridin-3-amine. 54 mg, 75%. 1H NMR (500 MHz, 
CDCl3)  8.62 (dd, J = 4.6, 1.6 Hz, 2H), 7.94 (dt, J = 6.9, 1.1 Hz, 1H), 7.90 (dd, J = 4.6, 1.6 Hz, 
2H), 7.55 (dt, J = 9.1, 1.0 Hz, 1H), 7.34 – 7.27 (m, 5H), 7.17 (ddd, J = 9.1, 6.6, 1.3 Hz, 1H), 6.76 
 98  
(td, J = 6.8, 1.1 Hz, 1H), 4.22 (d, J = 6.1 Hz, 2H), 3.52 (t, J = 6.1 Hz, 1H). 13C NMR (126 MHz, 
CDCl3)  150.12, 142.11, 141.94, 138.64, 133.41, 128.98, 128.31, 128.06, 127.46, 125.05, 
122.50, 121.13, 118.06, 112.42, 52.64. MS (ESI) calcd for C19H16N4, m/z 300.1375, found 
301.1599 [M+H]+. 
 
17: N-benzyl-2-(pyridin-4-yl)imidazo[1,2-a]pyrazin-3-amine. 47 mg, 65%. 1H NMR (500 MHz, 
CDCl3)  9.01 (d, J = 1.4 Hz, 1H), 8.67 (dd, J = 4.5, 1.6 Hz, 2H), 7.87 (dd, J = 4.5, 1.6 Hz, 2H), 
7.78 (dt, J = 4.6, 3.0 Hz, 2H), 7.30 (dd, J = 5.1, 1.9 Hz, 3H), 7.24 (dd, J = 6.9, 2.6 Hz, 2H), 4.25 
(d, J = 6.2 Hz, 2H), 3.66 (t, J = 6.2 Hz, 1H). 13C NMR (126 MHz, CDCl3)  150.46, 144.33, 
140.94, 138.23, 137.12, 135.70, 129.45, 129.14, 128.45, 128.32, 128.25, 121.34, 115.35, 52.59. 
MS (ESI) calcd for C18H15N5, m/z 301.1327, found 302.1474 [M+H]
+. 
 
18: 2-(3-(tert-butylamino)imidazo[1,2-a]pyridin-2-yl)phenol. 20 mg, 30%. 1H NMR (500 MHz, 
CDCl3)  12.47 (bs, 1H), 8.19 (d, J = 6.9 Hz, 1H), 8.12 (dd, J = 7.8, 1.6 Hz, 1H), 7.51 (d, J = 9.0 
Hz, 1H), 7.24 – 7.17 (m, 2H), 7.07 – 6.97 (m, 1H), 6.95 – 6.87 (m, 1H), 6.83 (td, J = 6.8, 0.9 Hz, 
1H), 3.16 (bs, 1H), 1.16 (s, 9H). 13C NMR (126 MHz, CDCl3)  157.07, 148.51, 140.76, 138.42, 
134.51, 131.35, 129.43, 128.13, 124.82, 123.01, 118.69, 117.76, 116.96, 112.09, 109.94, 57.22, 
30.50. MS (ESI) calcd for C17H19N3O, m/z 281.1528, found 282.1770 [M+H]
+. 
 
19: 2-(3-(tert-butylamino)imidazo[1,2-a]pyrazin-2-yl)phenol. 40 mg, 59%. 1H NMR (500 
MHz, CDCl3)  11.87 (s, 1H), 8.98 (d, J = 1.4 Hz, 1H), 8.16 – 8.08 (m, 2H), 7.92 (d, J = 4.6 Hz, 
1H), 7.31 – 7.24 (m, 1H), 7.05 (dd, J = 8.2, 1.0 Hz, 1H), 6.93 (td, J = 7.9, 1.2 Hz, 1H), 3.22 (bs, 
1H), 1.17 (s, 9H). 13C NMR (126 MHz, CDCl3)  157.08, 142.79, 140.85, 135.93, 130.39, 
129.72, 128.31, 123.47, 119.03, 118.04, 117.65, 115.85, 57.73, 30.54. MS (ESI) calcd for 
C16H18N4O, m/z 282.1481, found 283.1690 [M+H]
+. 
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20: 2-(3-(Cyclohexylamino)imidazo[1,2-a]pyridin-2-yl)phenol. 30 mg, 41%. 1H NMR (500 
MHz, CDCl3)  13.16 (s, 1H), 8.17 (d, J = 6.8 Hz, 1H), 8.04 (dd, J = 7.8, 1.3 Hz, 1H), 7.50 (dt, J 
= 9.0, 0.9 Hz, 1H), 7.25 – 7.17 (m, 2H), 7.04 (dd, J = 8.2, 1.1 Hz, 1H), 6.95 – 6.89 (m, 1H), 6.87 
(td, J = 6.8, 1.0 Hz, 1H), 3.17 – 2.99 (m, 2H), 1.83 (d, J = 12.5 Hz, 2H), 1.72 (dd, J = 9.5, 3.1 
Hz, 2H), 1.64 – 1.57 (m, 1H), 1.32 (dd, J = 22.7, 11.7 Hz, 2H), 1.26 – 1.13 (m, 3H). 13C NMR 
(126 MHz, CDCl3)  157.67, 139.51, 136.00, 129.25, 126.41, 124.88, 123.55, 122.62, 118.82, 
117.84, 117.40, 116.64, 112.46, 57.08, 34.19, 25.83, 24.96. MS (ESI) calcd for C19H21N3O, m/z 
307.1685, found 308.1995 [M+H]+. 
  
21: 2-(3-(Cyclohexylamino)imidazo[1,2-a]pyrazin-2-yl)phenol. 54 mg, 73%. 1H NMR (500 
MHz, CDCl3)  12.52 (bs, 1H), 8.96 (d, J = 1.4 Hz, 1H), 8.05 (ddd, J = 9.5, 6.2, 1.5 Hz, 2H), 7.94 
(d, J = 4.6 Hz, 1H), 7.30 – 7.26 (m, 1H), 7.07 (dd, J = 8.2, 1.1 Hz, 1H), 6.94 (td, J = 8.0, 1.2 Hz, 
1H), 3.31 – 2.99 (m, 2H), 1.83 (d, J = 12.3 Hz, 2H), 1.77 – 1.70 (m, 2H), 1.62 (dd, J = 7.5, 2.3 
Hz, 1H), 1.33 (dd, J = 21.3, 10.5 Hz, 2H), 1.27 – 1.15 (m, 3H). 13C NMR (126 MHz, CDCl3)  
157.70, 142.41, 138.53, 134.72, 130.19, 129.97, 126.50, 125.10, 119.13, 118.09, 116.60, 
115.35, 57.17, 34.34, 25.69, 24.92.MS (ESI) calcd for C18H20N4O, m/z 308.1637, found 
309.1856 [M+H]+. 
 
22: 2-(3-(Benzylamino)imidazo[1,2-a]pyridin-2-yl)phenol. 10 mg, 13%. 1H NMR (500 MHz, 
CDCl3)  13.02 (s, 1H), 8.06 – 7.95 (m, 2H), 7.51 (d, J = 9.0 Hz, 1H), 7.42 – 7.29 (m, 5H), 7.25 – 
7.17 (m, 2H), 7.06 (dd, J = 8.2, 1.0 Hz, 1H), 6.95 – 6.89 (m, 1H), 6.80 (td, J = 6.8, 0.9 Hz, 1H), 
4.24 (bs, 2H), 3.41 (s, 1H).13C NMR (126 MHz, CDCl3)  157.75, 139.49, 138.91, 135.58, 
129.38, 128.96, 128.43, 127.97, 125.95, 124.95, 124.41, 122.19, 119.04, 117.88, 117.21, 
116.74, 112.51, 52.43. MS (ESI) calcd for C20H17N3O, m/z 315.1372, found 316.1611 [M+H]
+. 
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23: 2-(3-(Benzylamino)imidazo[1,2-a]pyrazin-2-yl)phenol. 43 mg, 57%. 1H NMR (500 MHz, 
CDCl3)  12.40 (bs, 1H), 8.95 (d, J = 1.4 Hz, 1H), 8.02 (dd, J = 7.9, 1.6 Hz, 1H), 7.82 (d, J = 4.6 
Hz, 1H), 7.78 (dd, J = 4.6, 1.4 Hz, 1H), 7.37 – 7.27 (m, 6H), 7.09 (dd, J = 8.3, 1.2 Hz, 1H), 6.94 
(ddd, J = 7.9, 7.3, 1.2 Hz, 1H), 4.26 (d, J = 5.1 Hz, 2H), 3.53 (s, 1H). 13C NMR (126 MHz, 
CDCl3)  157.70, 142.41, 138.44, 138.07, 134.64, 130.35, 129.95, 129.12, 128.39, 128.24, 
126.21, 125.76, 119.36, 118.13, 116.33, 114.97, 52.35. MS (ESI) calcd for C19H16N4O, m/z 
316.1324, found 317.1545 [M+H]+. 
 
24: (2-(tert-butylamino)-7-methyl-3-(pyridin-2-ylamino)furo[2,3-c]pyridin-4-yl)methanol. 13 
mg, 17%. 1H NMR (400 MHz, MeOD)  7.97 (d, J = 4.1 Hz, 1H), 7.87 (s, 1H), 7.59 (ddd, J = 8.7, 
7.2, 1.8 Hz, 1H), 6.75 (ddd, J = 7.0, 5.2, 0.7 Hz, 1H), 6.67 (d, J = 8.4 Hz, 1H), 4.61 (s, 2H), 2.72 
(s, 3H), 1.53 (s, 9H). 13C NMR (126 MHz, MeOD)  165.65, 159.92, 147.97, 143.43, 140.55, 
139.89, 132.15, 131.86, 125.53, 115.57, 110.65, 96.72, 59.04, 55.33, 30.04, 13.08. MS (ESI) 
calcd for C18H22N4O2, m/z 326.1743, found 327.1782 [M+H]
+. 
 
25: (2-(tert-butylamino)-7-methyl-3-(pyrazin-2-ylamino)furo[2,3-c]pyridin-4-yl)methanol. 14 
mg, 18%. 1H NMR (500 MHz, MeOD)  8.01 (d, J = 1.1 Hz, 1H), 7.88 (dd, J = 2.8, 1.4 Hz, 1H), 
7.80 (s, 1H), 7.77 (d, J = 2.8 Hz, 1H), 4.56 (s, 2H), 2.65 (s, 3H), 1.43 (s, 9H). 13C NMR (126 
MHz, MeOD)  165.60, 156.50, 143.30, 143.00, 140.79, 134.76, 134.39, 132.05, 131.74, 




19 mg, 22%. 1H NMR (500 MHz, MeOD)  8.07 (t, J = 7.4 Hz, 1H), 7.96 (s, 1H), 7.90 (d, J = 5.9 
Hz, 1H), 7.29 (d, J = 8.4 Hz, 1H), 7.07 (t, J = 6.7 Hz, 1H), 4.64 (s, 2H), 3.91 – 3.79 (m, 1H), 2.75 
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(s, 3H), 2.05 (d, J = 8.8 Hz, 2H), 1.87 – 1.77 (m, 2H), 1.68 (d, J = 13.1 Hz, 1H), 1.48 – 1.33 (m, 
4H), 1.21 (dd, J = 12.1, 9.2 Hz, 1H). 13C NMR (126 MHz, MeOD)  164.86, 155.98, 145.65, 
143.70, 142.10, 137.34, 133.72, 132.85, 124.81, 115.77, 115.45, 89.79, 59.50, 54.25, 34.33, 




24 mg, 28%. 1H NMR (500 MHz, MeOD)  8.10 (s, 1H), 7.97 (d, J = 1.4 Hz, 1H), 7.86 (s, 2H), 
4.64 (s, 2H), 3.86 – 3.78 (m, 1H), 2.71 (s, 3H), 2.03 – 1.96 (m, 2H), 1.80 (dd, J = 5.3, 3.1 Hz, 
2H), 1.66 (d, J = 13.0 Hz, 1H), 1.38 (t, J = 9.6 Hz, 4H), 1.23 – 1.15 (m, 1H). 13C NMR (126 MHz, 
MeOD)  165.01, 156.57, 143.09, 142.98, 141.82, 134.49, 132.10, 131.50, 125.12, 94.07, 
58.98, 53.94, 34.42, 26.31, 26.20, 12.80. MS (ESI) calcd for C19H23N5O2, m/z 353.1852, found 
354.1902 [M+H]+. 
 
28: (2-(Benzylamino)-7-methyl-3-(pyridin-2-ylamino)furo[2,3-c]pyridin-4-yl)methanol. 13 
mg, 15%. 1H NMR (500 MHz, MeOD)  8.06 – 8.01 (m, 1H), 8.00 (s, 1H), 7.89 (d, J = 5.9 Hz, 
1H), 7.44 – 7.39 (m, 2H), 7.34 (t, J = 7.5 Hz, 2H), 7.28 (t, J = 7.3 Hz, 1H), 7.23 (d, J = 8.6 Hz, 
1H), 7.05 (t, J = 6.7 Hz, 1H), 4.76 (s, 2H), 4.65 (s, 2H), 2.77 (s, 3H). 13C NMR (126 MHz, MeOD) 
 165.45, 156.13, 145.31, 143.75, 142.15, 138.61, 138.18, 133.67, 133.22, 130.23, 130.00, 
129.91, 128.97, 128.77, 125.32, 115.82, 115.01, 90.66, 59.42, 47.33, 12.98. MS (ESI) calcd for 
C21H20N4O2, m/z 360.1586, found 361.1830 [M+H]
+. 
 
29: (2-(Benzylamino)-7-methyl-3-(pyrazin-2-ylamino)furo[2,3-c]pyridin-4-yl)methanol. 15 
mg, 16%. 1H NMR (500 MHz, MeOD)  7.99 (s, 1H), 7.94 (dd, J = 2.8, 1.5 Hz, 1H), 7.87 (s, 1H), 
7.81 (d, J = 2.8 Hz, 1H), 7.37 – 7.32 (m, 2H), 7.29 (dd, J = 10.3, 5.0 Hz, 2H), 7.21 (t, J = 7.3 Hz, 
1H), 4.64 (s, 2H), 4.61 (s, 2H), 2.61 (s, 3H). 13C NMR (126 MHz, MeOD)  163.44, 156.59, 
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143.82, 143.17, 139.78, 139.64, 135.93, 134.61, 134.23, 134.16, 129.68, 128.54, 128.38, 
125.19, 93.30, 59.41, 47.06, 14.34. MS (ESI) calcd for C20H19N5O2, m/z 361.1539, found 
362.1805 [M+H]+. 
 
Synthesis of compound 34: (2-(Benzylamino)-7-methyl-3-(phenylamino)furo[2,3-c]pyridin-
4-yl)methanol. To a solution of aniline (45 L, 0.5 mmol) in anhydrous methanol, were added 
pyridoxal hydrochloride (112 mg, 0.55 mmol), 4N HCl/dioxane (10 L) and benzyl isonitrile (68 
L, 0.55 mmol). The reaction mixture was then heated under microwave conditions (600 W, 80 
ºC) in a sealed vial for 2 min. After cooling the reaction mixture to room temperature, the 
solvents were removed and the residue was purified using column chromatography to obtain 
compound 34 (84 mg, 47%). 1H NMR (500 MHz, MeOD)  7.88 (s, 1H), 7.34 (d, J = 7.8 Hz, 2H), 
7.29 (t, J = 7.6 Hz, 2H), 7.21 (t, J = 7.2 Hz, 1H), 7.09 (t, J = 7.9 Hz, 2H), 6.66 (td, J = 7.3, 0.9 
Hz, 1H), 6.58 – 6.51 (m, 2H), 4.57 (s, 2H), 4.52 (s, 2H), 2.54 (s, 3H). 13C NMR (126 MHz, 
MeOD)  160.73, 150.14, 141.35, 141.10, 138.40, 137.10, 130.29, 129.51, 128.35, 128.23, 
119.02, 114.15, 94.89, 60.27, 47.02, 16.66. MS (ESI) calcd for C22H21N3O2, m/z 359.1634, 
found 360.1832 [M+H]+. 
 
Synthesis of compound 35: 3-(Benzyloxy)-5-(hydroxymethyl)-2-methylisonicotin 
aldehyde. To a solution of pyridoxal hydrochloride (500 mg, 2.45 mmol) in anhydrous DMF, 
were added potassium carbonate (408 mg, 2.95 mmol), and benzyl bromide (0.35 mL, 2.95 
mmol). The reaction mixture was stirred at room temperature for overnight. After the completion 
of reaction, water (20 mL) was added and the crude product obtained was extracted in ethyl 
acetate. The organic layer was washed with water, dried over anhydrous sodium sulfate and 
evaporated. The residue was purified using column chromatography to obtain compound 35 
(100 mg, 15%). 1H NMR (500 MHz, CDCl3)  8.05 (s, 1H), 7.45 – 7.32 (m, 5H), 6.64 (d, J = 1.7 
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Hz, 1H), 5.34 (d, J = 11.2 Hz, 1H), 5.22 (d, J = 12.7 Hz, 1H), 5.19 (d, J = 11.2 Hz, 1H), 4.99 (d, 
J = 12.7 Hz, 1H), 2.50 (s, 3H). 13C NMR (126 MHz, CDCl3)  150.88, 148.63, 136.84, 136.17, 
135.53, 135.42, 128.80, 128.47, 127.74, 100.10, 74.13, 69.95, 19.38. MS (ESI) calcd for 
C15H15NO3, m/z 257.1052, found 258.1279 [M+H]
+. 
 
Synthesis of compound 36: (5-(Benzyloxy)-4-(3-(cyclohexylamino)imidazo[1,2-a]pyridin-
2-yl)-6-methylpyridin-3-yl)methanol. To a solution of 2-aminopyridine (24 mg, 0.25 mmol) in 
anhydrous acetonitrile, were added 3-(benzyloxy)-5-(hydroxymethyl)-2-methylisonicotin-
aldehyde 34 (68 mg, 0.28 mmol), 4N HCl/dioxane (5 L) and cyclohexylisonitrile (30 L, 0.24 
mmol). The reaction mixture was then heated under microwave conditions (400 W, 110 ºC) in a 
sealed vial for 20 min. After cooling the reaction mixture to room temperature, the solvents were 
removed and the residue was purified using column chromatography to obtain compound 36 (19 
mg, 17%). 1H NMR (500 MHz, CDCl3)  8.41 (s, 1H), 8.07 (d, J = 6.9 Hz, 1H), 7.54 (d, J = 9.1 
Hz, 1H), 7.26 – 7.15 (m, 4H), 7.02 – 6.97 (m, 2H), 6.90 (td, J = 6.8, 1.0 Hz, 1H), 4.59 (bs, 1H), 
4.43 (s, 2H), 4.36 (bs, 1H), 3.88 (d, J = 7.9 Hz, 1H), 2.61 (bs, 1H), 2.58 (s, 3H), 1.85-1.75 (m, 
1H), 1.70-1.65 (m, 1H), 1.50-1.40 (m, 2H), 1.37-1.28 (m, 1H), 1.22-1.05(s, 2H), 1.05-0.85 (m, 
2H), 0.60 (bs, 1H). 13C NMR (126 MHz, CDCl3)  152.95, 150.53, 145.20, 141.29, 135.58, 
129.62, 129.25, 128.76, 128.58, 128.57, 128.40, 126.28, 125.05, 123.16, 117.47, 112.53, 76.73, 
61.64, 56.36, 34.32, 33.74, 25.60, 25.03, 24.53, 19.58. MS (ESI) calcd for C27H30N4O2, m/z 
442.2369, found 443.2410 [M+H]+. 
 
Synthesis of compound 37a: (2-(Butylamino)-7-methyl-3-(pyridin-2-ylamino)furo[2,3-c] 
pyridin-4-yl)methanol. To a solution of 2-aminopyridine (24 mg, 0.25 mmol) in anhydrous 
acetonitrile, were added pyridoxal hydrochloride (56 mg, 0.28 mmol), 4N HCl/dioxane (5 L) and 
n-butyl isonitrile (25 L, 0.24 mmol). The reaction mixture was then heated under microwave 
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conditions (600 W, 80 ºC) in a sealed vial for 2 min. After cooling the reaction mixture to room 
temperature, solvents were removed and the residue was purified using column 
chromatography to obtain compound 37a (32 mg, 41%). 1H NMR (500 MHz, MeOD)  8.06 (t, J 
= 8.0 Hz, 1H), 7.96 (s, 1H), 7.90 (d, J = 5.8 Hz, 1H), 7.29 (d, J = 8.5 Hz, 1H), 7.07 (t, J = 6.6 Hz, 
1H), 4.65 (s, 2H), 3.56 (t, J = 7.1 Hz, 2H), 2.75 (s, 3H), 1.75 – 1.61 (m, 2H), 1.49 – 1.35 (m, 2H), 
0.96 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, MeOD)  165.68, 155.98, 145.61, 143.66, 142.08, 
137.58, 133.67, 132.87, 124.84, 115.82, 115.31, 90.01, 59.50, 43.64, 32.79, 20.93, 13.99, 
12.96. MS (ESI) calcd for C18H22N4O2, m/z 326.1743, found 327.1925 [M+H]
+. 
 
Compounds 37b-37m were synthesized similarly as compound 37a. 
 
37b: (7-Methyl-2-(pentylamino)-3-(pyridin-2-ylamino)furo[2,3-c]pyridin-4-yl)methanol. 27 
mg, 33%. 1H NMR (500 MHz, MeOD)  8.06 (t, J = 8.0 Hz, 1H), 7.96 (s, 1H), 7.91 (d, J = 5.9 Hz, 
1H), 7.28 (d, J = 8.5 Hz, 1H), 7.07 (t, J = 6.6 Hz, 1H), 4.65 (s, 2H), 3.56 (t, J = 7.1 Hz, 2H), 2.75 
(s, 3H), 1.75 – 1.64 (m, 2H), 1.38 (d, J = 3.6 Hz, 4H), 0.92 (t, J = 6.9 Hz, 3H). 13C NMR (126 
MHz, MeOD)  165.68, 156.04, 145.55, 143.66, 142.09, 137.74, 133.66, 132.85, 124.85, 
115.82, 115.25, 90.09, 59.49, 43.90, 30.42, 29.98, 23.31, 14.32, 12.95.MS (ESI) calcd for 




20 mg, 27%. 1H NMR (500 MHz, MeOD)  8.05 (t, J = 8.0 Hz, 1H), 7.95 (s, 1H), 7.90 (d, J = 5.9 
Hz, 1H), 7.26 (d, J = 8.6 Hz, 1H), 7.05 (t, J = 6.7 Hz, 1H), 4.63 (s, 2H), 4.25 (dt, J = 13.0, 6.5 Hz, 
1H), 2.74 (s, 3H), 1.33 (d, J = 6.5 Hz, 6H). 13C NMR (126 MHz, MeOD)  164.96, 156.16, 
145.41, 143.72, 142.06, 137.79, 133.63, 132.82, 124.86, 115.77, 115.24, 90.04, 59.48, 47.16, 
23.12, 12.94. MS (ESI) calcd for C17H20N4O2, m/z 312.1586, found 313.1740 [M+H]
+. 
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37d: (7-Methyl-2-(pentan-2-ylamino)-3-(pyridin-2-ylamino)furo[2,3-c]pyridin-4-yl)methanol. 
34 mg, 42%. 1H NMR (500 MHz, MeOD)  7.99 (t, J = 8.0 Hz, 1H), 7.88 (s, 1H), 7.83 (d, J = 5.2 
Hz, 1H), 7.20 (d, J = 7.3 Hz, 1H), 7.00 (t, J = 6.7 Hz, 1H), 4.56 (s, 2H), 4.03 (dq, J = 12.9, 6.5 
Hz, 1H), 2.66 (s, 3H), 1.60 – 1.41 (m, 2H), 1.38 – 1.26 (m, 2H), 1.23 (d, J = 6.6 Hz, 3H), 0.86 (t, 
J = 7.4 Hz, 3H). 13C NMR (126 MHz, MeOD)  165.14, 155.98, 145.72, 143.66, 142.17, 137.38, 
133.77, 132.84, 124.79, 115.82, 115.41, 89.73, 59.52, 51.18, 39.97, 21.53, 20.53, 14.15, 12.94. 




pyridin-4-yl)methanol. 33 mg, 36%. 1H NMR (500 MHz, MeOD)  8.08 (t, J = 8.0 Hz, 1H), 7.99 
(s, 1H), 7.90 (s, 1H), 7.27 (s, 1H), 7.08 (dd, J = 7.0, 6.4 Hz, 1H), 4.63 (s, 2H), 2.78 (s, 3H), 1.95 
(d, J = 12.9 Hz, 2H), 1.60 (s, 6H), 1.00 (s, 9H). 13C NMR (126 MHz, MeOD)  165.37, 156.14, 
145.64, 143.96, 141.40, 137.05, 133.87, 132.93, 124.92, 115.77, 115.62, 90.82, 59.88, 59.51, 




yl)methanol. 24 mg, 28%. 1H NMR (500 MHz, MeOD)  8.03 (t, J = 8.0 Hz, 1H), 7.91-7.90 (m, 
2H), 7.24 (d, J = 8.7 Hz, 1H), 7.04 (t, J = 6.6 Hz, 1H), 4.62 (s, 2H), 3.11 (s, 2H), 2.72 (s, 3H), 
0.12 (s, 9H). 13C NMR (126 MHz, MeOD)  165.66, 156.25, 145.27, 143.32, 142.02, 138.19, 
133.57, 132.16, 124.28, 115.77, 115.00, 90.25, 59.52, 34.64, 12.94, -2.60. MS (ESI) calcd for 




methanol. 9 mg, 10%. 1H NMR (500 MHz, MeOD)  8.03 (s, 2H), 7.93 (d, J = 5.8 Hz, 1H), 7.27 
 106  
(d, J = 7.3 Hz, 1H), 7.05 (t, J = 6.5 Hz, 1H), 4.66 (s, 2H), 4.06-3.95 (m, 6H), 3.54 (bs, 2H), 3.42 
(bs, 4H), 2.80 (s, 3H). 13C NMR (126 MHz, MeOD)  165.51, 156.26, 145.10, 143.92, 141.95, 
138.27, 134.09, 133.62, 126.01, 115.97, 115.07, 90.35, 64.80, 59.39, 57.37, 53.45, 37.84, 
13.21. MS (ESI) calcd for C20H25N5O3, m/z 383.1957, found 384.2132 [M+H]
+. 
 
37h: Ethyl 2-((4-(hydroxymethyl)-7-methyl-3-(pyridin-2-ylamino)furo[2,3-c]pyridin-2-yl) 
amino)acetate. 21 mg, 25%. 1H NMR (500 MHz, MeOD)  8.07 (t, J = 8.0 Hz, 1H), 8.03 (s, 1H), 
7.91 (d, J = 6.1 Hz, 1H), 7.29 (d, J = 8.9 Hz, 1H), 7.08 (t, J = 6.7 Hz, 1H), 4.66 (s, 2H), 4.36 (s, 
2H), 4.18 (q, J = 7.1 Hz, 2H), 2.74 (s, 3H), 1.25 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, MeOD) 
 170.68, 165.42, 155.75, 145.81, 143.87, 142.15, 137.71, 133.94, 133.89, 125.93, 115.98, 
115.25, 91.02, 62.95, 59.42, 44.55, 14.48, 13.03. MS (ESI) calcd for C18H20N4O4, m/z 356.1485, 
found 357.1738 [M+H]+. 
 
37i: tert-Butyl 3-((4-(hydroxymethyl)-7-methyl-3-(pyridin-2-ylamino)furo[2,3-c]pyridin-2-yl) 
amino)propanoate. 20 mg, 21%. 1H NMR (500 MHz, MeOD)  8.08 (t, J = 8.0 Hz, 1H), 8.00 (s, 
1H), 7.91 (d, J = 5.8 Hz, 1H), 7.29 (d, J = 7.8 Hz, 1H), 7.08 (t, J = 6.7 Hz, 1H), 4.66 (s, 2H), 3.80 
(t, J = 6.4 Hz, 2H), 2.78 (s, 3H), 2.67 (t, J = 6.7 Hz, 2H), 1.42 (s, 9H). 13C NMR (126 MHz, 
MeOD)  171.99, 165.49, 155.86, 145.77, 143.76, 142.08, 137.49, 133.79, 133.30, 125.17, 
115.86, 115.36, 90.25, 82.28, 59.49, 39.67, 36.03, 28.31, 13.02. MS (ESI) calcd for C21H26N4O4, 
m/z 398.1954, found 399.2128 [M+H]+. 
 
37j: Diethyl (((4-(hydroxymethyl)-7-methyl-3-(pyridin-2-ylamino)furo[2,3-c]pyridin-2-yl) 
amino)methyl)phosphonate. 13 mg, 13%. 1H NMR (500 MHz, MeOD)  8.08 – 8.00 (m, 2H), 
7.95 (d, J = 5.7 Hz, 1H), 7.23 (d, J = 4.9 Hz, 1H), 7.06 (t, J = 6.5 Hz, 1H), 4.69 (s, 2H), 4.24 – 
4.16 (m, 4H), 4.09 (d, J = 10.6 Hz, 2H), 2.81 (s, 3H), 1.33 (t, J = 7.0 Hz, 6H). 13C NMR (126 
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MHz, MeOD)  164.98, 156.41, 145.04, 143.68, 142.06, 139.12, 133.83, 133.71, 125.96, 
115.97, 114.67, 91.93, 64.56 (d, J = 6.9 Hz), 59.37, 39.02 (d, J = 158.9 Hz), 16.78 (d, J = 5.6 




methanol. 13 mg, 14%. 1H NMR (500 MHz, MeOD)  7.99 – 7.87 (m, 2H), 7.62 (t, J = 7.8 Hz, 
1H), 7.33 (d, J = 8.8 Hz, 2H), 6.90 (d, J = 8.8 Hz, 2H), 6.77 (t, J = 6.3 Hz, 2H), 4.66 (s, 2H), 3.77 
(s, 3H), 2.71 (s, 3H). 13C NMR (126 MHz, MeOD)  162.79, 159.21, 158.92, 146.57, 143.34, 
141.31, 140.61, 132.84, 132.22, 130.80, 126.51, 124.33, 115.64, 115.43, 111.46, 96.53, 62.30, 




4-yl) methanol. 27 mg, 28%. 1H NMR (500 MHz, MeOD)  8.10 (s, 1H), 7.90 (dd, J = 20.4, 6.6 
Hz, 2H), 7.28 – 7.15 (m, 3H), 7.03 (t, J = 6.6 Hz, 1H), 6.95 (s, 1H), 4.70 (s, 2H), 2.75 (s, 3H), 
2.32 (s, 3H). 13C NMR (126 MHz, MeOD)  162.57, 155.17, 145.80, 144.21, 142.68, 139.93, 
136.98, 134.45, 133.96, 133.78, 132.14, 130.74, 128.65, 126.80, 115.93, 114.82, 91.45, 59.30, 




methanol. 28 mg, 31%. 1H NMR (500 MHz, MeOD)  7.92 (s, 1H), 7.89 (t, J = 8.0 Hz, 1H), 7.90 
– 7.81 (m, 1H), 7.38 (d, J = 7.6 Hz, 2H), 7.29 (t, J = 7.4 Hz, 2H), 7.21 (t, J = 7.2 Hz, 1H), 7.05 
(d,J = 6.1 Hz, 1H), 6.94 (t, J = 6.4 Hz, 1H), 5.20 (q, J = 6.8 Hz, 1H), 4.58 (s, 2H), 2.68 (s, 3H), 
1.60 (d, J = 6.9 Hz, 3H). 13C NMR (126 MHz, MeOD)  164.81, 157.13, 144.72, 143.97, 143.61, 
142.11, 140.61, 133.20, 132.80, 129.92, 128.71, 126.98, 125.52, 115.70, 113.93, 91.91, 59.24, 
54.49, 23.31, 12.88. MS (ESI) calcd for C22H22N4O2, m/z 374.1743, found 375.1931 [M+H]
+. 
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Synthesis of compound 37n: ((2-Amino-7-methyl-3-(pyridin-2-ylamino)furo[2,3-c]pyridin-
4-yl)methanol. The solution of compound 37e (95 mg, 0.25 mmol) in TFA/CH2Cl2 (50%, 4 mL) 
was stirred at room temperature for 6 h. The solvents were removed and the residue obtained 
was column purified to afford compound 37n (56 mg, 84%). 1H NMR (500 MHz, MeOD)  7.91 – 
7.86 (m, 2H), 7.81 (t, J = 7.9 Hz, 1H), 6.96 (d, J = 8.6 Hz, 1H), 6.87 (t, J = 6.5 Hz, 1H), 4.61 (s, 
2H), 2.66 (s, 3H). 13C NMR (126 MHz, MeOD)  167.39, 157.68, 143.36, 143.14, 142.12, 
132.82, 132.44, 125.47, 115.59, 113.10, 92.54, 59.18, 12.80. MS (ESI) calcd for C14H14N4O2, 
m/z 270.1117, found 271.1310 [M+H]+. 
 
Compounds 38a-38c were synthesized similarly as compound 34. 
 
38a: (7-Methyl-2-(pentylamino)-3-(phenylamino)furo[2,3-c]pyridin-4-yl)methanol. 117 mg, 
70%. 1H NMR (500 MHz, MeOD)  7.85 (s, 1H), 7.14 (dd, J = 8.6, 7.4 Hz, 2H), 6.71 (tt, J = 7.4, 
1.0 Hz, 1H), 6.60 (dd, J = 8.6, 1.0 Hz, 2H), 4.65 – 4.59 (m, 2H), 3.51 (t, J = 7.1 Hz, 2H), 2.68 (s, 
3H), 1.72 – 1.57 (m, 2H), 1.41 – 1.28 (m, 4H), 0.95 – 0.84 (m, 3H). 13C NMR (126 MHz, MeOD) 
 165.54, 149.56, 143.22, 141.35, 133.46, 132.44, 130.44, 125.33, 119.45, 114.08, 96.74, 
59.31, 43.42, 31.00, 29.94, 23.33, 14.34, 13.48. MS (ESI) calcd for C20H25N3O2, m/z 339.1947, 
found 340.2087 [M+H]+. 
 
38b: (3-((3-Fluorophenyl)amino)-7-methyl-2-(pentylamino)furo[2,3-c]pyridin-4-yl) 
methanol. 70 mg, 82%. 1H NMR (500 MHz, MeOD)  7.81 (s, 1H), 7.06 (td, J = 8.2, 6.7 Hz, 
1H), 6.42 – 6.32 (m, 2H), 6.23 (d, J = 11.5 Hz, 1H), 4.60 (s, 2H), 3.46 (t, J = 7.1 Hz, 2H), 2.65 
(s, 3H), 1.59 (p, J = 7.1 Hz, 2H), 1.31 – 1.23 (m, 4H), 0.83 (t, J = 7.0 Hz, 3H). 13C NMR (126 
MHz, MeOD) 166.34, 165.62 (d, J = 242.1 Hz), 151.55 (d, J = 10.4 Hz), 142.79, 142.04, 131.84 
(d, J = 10.1 Hz), 131.65, 131.28, 125.42, 110.01,105.58 (d, J = 21.8 Hz), 100.74 (d, J = 25.8 
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Hz), 96.47, 58.95, 43.43, 30.83, 29.93, 23.33, 14.35, 12.79. MS (ESI) calcd for C20H24FN3O2, 
m/z 357.1853, found 358.2013 [M+H]+. 
 
38c: (7-Methyl-3-((3-nitrophenyl)amino)-2-(pentylamino)furo[2,3-c]pyridin-4-yl)methanol. 
34 mg, 37%. 1H NMR (500 MHz, MeOD)  7.90 (s, 1H), 7.49 (dd, J = 8.1, 2.2 Hz, 1H), 7.34 (s, 
1H), 7.31 (t, J = 8.1 Hz, 1H), 6.95 (d, J = 8.0 Hz, 1H), 4.54 (s, 2H), 3.41 (t, J = 7.0 Hz, 2H), 2.56 
(s, 3H), 1.65 – 1.52 (m, 2H), 1.30 (dd, J = 8.5, 4.8 Hz, 4H), 0.86 (t, J = 6.5 Hz, 3H). 13C NMR 
(126 MHz, MeOD) 160.86, 151.59, 150.89, 144.93, 141.84, 138.47, 136.71, 131.12, 124.51, 
120.06, 113.05, 107.81, 92.23, 60.13, 43.34, 31.50, 30.02, 23.40, 16.73, 14.35. MS (ESI) calcd 
for C20H24N4O4, m/z 384.1798, found 385.1950 [M+H]
+. 
 
Synthesis of compound 39: 2,2'-(Hexane-1,6-diylbis(azanediyl))bis(7-methyl-3-(pyridin-2-
ylamino)furo[2,3-c]pyridine-4,2-diyl))dimethanol. To a solution of 2-aminopyridine (48 mg, 
0.50 mmol) in anhydrous acetonitrile, were added pyridoxal hydrochloride (112 mg, 0.56 mmol), 
4N HCl/dioxane (10 L) and 1,6-diisocyanohexane (36 L, 0.24 mmol). The reaction mixture 
was then heated under microwave conditions (600 W, 80 ºC) in a sealed vial for 2 min. After 
cooling the reaction mixture to room temperature, solvent was removed and the residue was 
purified using column chromatography to obtain compound 39 (21 mg, 7%). 1H NMR (500 MHz, 
MeOD)  8.07 (t, J = 8.0 Hz, 2H), 7.97 (s, 2H), 7.90 (d, J = 5.6 Hz, 2H), 7.31 (d, J = 5.6 Hz, 2H), 
7.07 (t, J = 6.7 Hz, 2H), 4.64 (s, 4H), 3.57 (t, J = 7.0 Hz, 4H), 2.75 (s, 6H), 1.78 – 1.65 (m, 4H), 
1.46 (s, 4H). 13C NMR (126 MHz, MeOD)  165.67, 155.95, 145.66, 143.71, 142.10, 137.48, 
133.70, 132.91, 124.87, 115.83, 115.43, 90.05, 59.50, 43.86, 30.65, 27.48, 13.02. MS (ESI) 
calcd for C34H38N8O4, m/z 622.3016, found 623.3187 [M+H]
+. 
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X-ray crystallographic structural studies of 20, 28, and 37e. Crystals for compound 28 utilize 
the non-centrosymmetric triclinic space group P1-C1 with eight crystallographically-independent 
molecules in the asymmetric unit. They also invariably form multiply-twinned bundles. After 
many unsuccessful attempts, a multi-domain specimen of 28 was cut from one of these bundles 
that gave a set of diffracted intensities that permitted a crystal structure solution but not a 
satisfactory refinement. Full sets of unique diffracted intensities were measured for single-
domain specimens of compounds 20 and 37e using monochromated CuK radiation (= 
1.54178 Å) on a Bruker Proteum Single Crystal Diffraction System equipped with Helios 
multilayer optics, an APEX II CCD detector and a Bruker MicroStar microfocus rotating anode x-
ray source operating at 45kV and 60mA. Diffracted intensities were obtained with the Bruker 
program SAINT and the structures were solved using “direct methods” techniques incorporated 
into the Bruker SHELXTL Version 2010.3-0 software package. All stages of weighted full-matrix 
least-squares refinement were performed using the SHELXTL software with Fo
2 data. The final 
structural model for compounds 20 and 37e incorporated anisotropic thermal parameters for all 
non-hydrogen atoms and isotropic thermal parameters for all hydrogen atoms. The respective 
asymmetric units consist of four molecules of 20; one molecule of 37e. All hydrogen atoms for 
37e and hydrogen atoms of 20 that are bonded to amine nitrogens (one in each molecule) were 
located in a difference Fourier map and included in the structural model as independent 
isotropic atoms whose parameters were allowed to vary in least-squares refinement cycles. All 
hydroxyl hydrogens for 20 were placed at idealized sp3-hybridized positions with an O-H bond 
length of 0.84 Å; the hydroxyl group was then allowed to rotate about its O-C bond during least 
squares refinement cycles. The remaining hydrogen atoms for 20 were included in the structural 
model as idealized atoms (assuming sp2- or sp3-hybridization of the carbon or nitrogen atoms 
and C-H bond lengths of 0.95 to 1.00 Å or N-H bond lengths of 0.88 Å). The isotropic thermal 
parameters of all idealized hydrogen atoms for 20 were fixed at values 1.2 (nonmethyl) or 1.5 
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(methyl) times the equivalent isotropic thermal parameter of the carbon, nitrogen or oxygen 
atom to which they are covalently bonded.  
 
Human TLR-3/-4/-5/-7/-8/-9 reporter gene assays (NF-B induction). As described in 
Chapter 2. 
Immunoassays for cytokines. As described in Chapter 2. 
Rabbit immunization and antigen-specific ELISA. As described in Chapter 2. 
 
Transcriptomal profiling in human PBMCs. Detailed procedures for transcriptomal profiling 
have been described by us previously.30 Briefly, fresh human PBMC samples were stimulated 
with 10 g/mL of 37b and 37f for two hours, and total RNA was extracted from treated and 
negative control blood samples with QIAamp RNA Blood Mini Kit (Qiagen). Subsequently, 160 
ng of each of the RNA samples was used. The Human Genome GeneChip U133 plus 2.0 
oligonucleotide array (Affymetrix, Santa Clara, CA) was employed. Established standard 
protocols at the KU Genomics Facility were performed on cRNA target preparation, array 
hybridization, washing, staining and image scanning. The microarray data was first subjected to 
quality assessment using the Affymetrix GeneChip Operating Software (GCOS). QC criteria 
included low background, low noise, detection of positive controls, and a 5’/3’ ratio of < 3.0. To 
facilitate direct comparison of gene expression data between different samples, the GeneChip 
data were first subjected to preprocessing. This step involved scaling (in GCOS) data from all 
chips to a target intensity value of 500, and further normalizations steps in GeneSpring GX 
(Agilent Technologies, Santa Clara, CA). Prior to identifying target genes, genes that were 
detected as non-expressed in all samples, i.e., those with absence calls, were filtered out. To 
identify genes whose expression was changed by our compounds, a fold change threshold of 
2.0 between the compound treatment and the negative control was used.  






























MIC: 3.91 g/mL (MRSA)
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4.1. Introduction 
 
The introduction of antibiotics into the therapeutic armamentarium in the early 20th century 
revolutionized the management of microbial infections. Once considered ‘wonder drugs’, 
antibiotics have perhaps become victims of their own success, and resistance to these drugs 
has almost invariably followed on the heels of their widespread use (and misuse). The incidence 
of methicillin-resistant Staphylococcus aureus (MRSA) infections continues to increase 
alarmingly not only in hospital-associated settings (nosocomial infections), but in recent times, 
also in community settings in the United States, and throughout the globe. The increase in 
morbidity and mortality due to S. aureus infections82 is a reflection of increased invasive 
procedures, indwelling devices, older age, and comorbidities, as well as the acquisition of 
resistance to commonly-used antimicrobial agents. Of particular concern is the emergence of 
multidrug-resistant strains of Gram-positive bacteria, with the loss of susceptibility to a wide 
range of reserve antibiotics such as vancomycin.83 The need for the development of effective 
antibiotics is urgent, especially in the face of a diminishing pipeline of drugs for antimicrobial 
chemotherapy. 
 
As mentioned in Chapter 3, some of the initial compounds that were synthesized using the one-
pot multicomponent Groebke-Blackburn-Bienaymé reaction with the aim to explore new TLR7/8-
modulatory chemotype were proved to be neither agonistic nor antagonistic at TLR7/8 but found 
to have antibacterial activity against S. aureus with a clear indication of possible SARs. 
Subsequent focused libraries of compounds were synthesized and these latter compounds, too, 
were not active in TLR7 and TLR8 screens, but displayed prominent bacteriostatic activity 
against several Gram-positive bacteria, including MRSA. To investigate the mechanism of 
antibacterial activity of this new chemotype, a resistant strain of S. aureus was generated by 
serially passaging the organism in escalating doses of the most active analogue. A comparison 
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of minimum inhibitory concentrations (MICs) of known bacteriostatic agents in wild-type and 
resistant strains indicates a novel mechanism of action. These findings served as a point of 




4.2. Results and Discussion 
 
Our initial test-library comprising of twenty-four compounds was synthesized (Scheme 1) using 
two amidines (2-aminopyridine and 2-aminopyrazine), three isonitriles (2-isocyano-2-
methylpropane, isocyanocyclohexane, (isocyanomethyl)benzene), and four aldehydes 
(benzaldehyde, 2-phenylacetaldehyde, 1-naphthaldehyde, anthracene-9-carbaldehyde). The 
syntheses of 1a-3h (Scheme 1) proceeded smoothly.  All compounds were tested in TLR7 and 
TLR8 agonism and antagonism assays using specific reporter gene-based cellular assays as 
described earlier;58, 77 to our disappointment, none of the compounds displayed any activity in 
these assays up to concentrations of 250 M (data not shown). The assay plates were stored in 
the autoclave room at room temperature prior to disposal, and, quite by accident, we observed a 
dose-dependent inhibition of a bacterial contaminant in such plates. We therefore decided to 
examine the antibacterial activities of these compounds in antibacterial screens (E. coli ATCC 
9637 and S. aureus ATCC 13709) routinely employed in our laboratory.84 Four compounds were 
identified to be inhibitory to S. aureus ATCC 13709 but not E. coli ATCC 9637. Maximal 
antibacterial activity resided in compounds derived from 2-aminopyridine, bearing either a bulky 
N-tert-butyl, or cyclohexyl groups at C3, and a large aromatic pendant group (naphthyl or 
anthracenyl) at C2 (1e, 1g, 2e, 2g). The MICs of both 1g and 2g for S. aureus ATCC 13709 and 
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MRSA ATCC 33591 were 3.91 g/mL (Table 1), and 7.81 g/mL for coagulase-negative S. 
epidermidis ATCC 35983 (data not shown).  
 
 
Scheme 1. Synthesis of a library of compounds using Groebke multicomponent reaction. 
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 Fig. 1. Comparison of antimicrobial susceptibility of wild-type S. aureus ATCC 13709 (hatched bars) 


































































Concentration of compound 1g (g/mL)
 1g + 6.66 g/mL of PMBN
 1g + 0.832 g/mL of PMBN
 1g + 0.104 g/mL of PMBN
 1g + 0.013 g/mL of PMBN
 1g + 0.001g/mL of PMBN
 1g
PMBN = Polymyxin B nonapeptide
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The active compounds listed above were all determined to be bacteriostatic rather than 
bactericidal by conventional microplate MBC assays.85 The outer membrane of Gram-negative 
bacteria serves as a permeability barrier for hydrophobic antimicrobials,86 and we wondered if 
the lack of activity of these compounds against Gram-negative bacteria could be attributable to 
its bulky, nonpolar nature. We therefore performed additional assays using polymyxin B 
nonapeptide,87 which is commonly used to permeabilize the outer-membranes of Gram-negative 
bacteria, rendering the organisms susceptible to otherwise impermeable antimicrobials;88 
however, the imidazopyridines did not exert any significant antibacterial effect even at high 
concentrations of polymyxin B nonapeptide (Fig. 1), confirming that the antibacterial spectrum of 
these compounds is specific to Gram-positive organisms. 
 
Given that 1g and 2g demonstrated identical potencies, we arbitrarily selected 
isocyanocyclohexane and anthracene-9-carbaldehyde as the invariant components, and varied 
the amidine component; we chose 2-aminopyrimidine, 2,3-diaminopyridine, and 2-amino-3-
chloropyrazine (Scheme 2). The 2-amino-3-chloropyrazine-derived compound 4c was inactive, 
while 4a and 4b exhibited lower activities than 1g (Table 1).  
 
Scheme 2. Groebke reaction using different amidines. 
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Next, we varied the isonitrile component. We explored nine different isonitriles (Scheme 3) 
chosen to include linear aliphatic (as in 5a and 5b), branched aliphatic (5c-e), silyl-containing 
(5f), adamantyl (5g), and aromatic substituents (5h and 5i). We observed that the N-2,4,4-
trimethylpentan-2-yl group of 5e, could be dealkylated under strongly acidic conditions as has 
been reported recently,78 affording the possibility of introducing alkyl or acyl substituents 
(represented by 7a-c, Scheme 4) that were not accessible through commercially available 
isonitriles. Optimal activity profiles appeared to correspond to compounds with branched-chain 
substituents (5d and 5e), while compounds with aromatic substituents (5h and 5i) were bereft of 
antibacterial activity (Table 1).  
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Scheme 4. Derivatization of the C3-amine. 
 
 
Noting that bulky, aldehyde-derived aromatic substituents at C2 corresponded to maximal 
activity (exemplified by the anthracenyl group in 1g, 2g, and 5a-g), it was of interest to explore 
other similar functional groups. Compounds with biphenyl (8a), phenanthrenyl (8b), and pyrenyl 
(8c) substituents were therefore synthesized and evaluated (Scheme 5). Compounds 8b and 8c 
exhibited lower activity than the anthracenyl-bearing compound, while the biphenyl compound 
8a was inactive, pointing to the necessity of a large polycyclic, aromatic group at C2. 
 
Scheme 5. Groebke reaction using various aldehydes. 
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The compound that showed maximal activity thus far was the very lipophilic 5e, and it was 
desirable to explore more polar analogues for future evaluation in vivo models. We therefore 
attempted to introduce N,N-dimethylaminopropylamino groups on both the amidine- and 
aldehyde-derived portions of 5e. This was achieved in a straightforward manner using 
appropriate halo-substituted components, followed by Buchwald-Hartwig coupling as depicted in 
Scheme 6. The antibacterial activities of 10 and 12 were found to be identical to that of 5e 
(Table 1).  
 
Scheme 6. Synthesis of polar derivatives of 5e. 
 
 
Although the lead compounds of this chemotype exhibit narrow-spectrum bacteriostatic activity 
against Gram-positive organisms, the substantial potency against MRSA warranted an attempt 
at understanding the mechanism of action. Our preliminary studies have been to examine the 
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antibiograms of wild-type and 5e-resistant S. aureus organisms, comparing a variety of 
antimicrobials with known mechanisms of action. 5e-resistant S. aureus organisms were 
generated by exposing the bacterium to escalating doses of the compound. Within about 10 
serial passages, organisms that withstood 5e up to concentrations of 100 g/mL emerged.  The 
MICs of various classes of bacteriostatic and bactericidal antibiotics were found to be identical 
within experimental error for both the wild-type and 5e-resistant S. aureus, suggesting that the 
molecular target of 5e and related compounds were distinct and unique (Fig. 2). 
 
 Fig. 2. Comparison of antimicrobial susceptibility of wild-type S. aureus ATCC 13709 (hatched bars) 
and 5e-resistant organism (solid bars) to a range of bacteriostatic antibiotics with known mechanisms of 
action, and 5e. Bacteriostatics include trimethoprim and sulfamethoxazole (dihydrofolate reductase 
pathway), doxycycline and amikacin (30S ribosomal subunit), chloramphenicol (23S ribosomal subunit), 
erythromycin and tylosin (50S ribosomal subunit), nisin (lipid II), nitrofurantoin (bacterial DNA); also 





























































































Hatched bars: Wild-type S. aureus
Solid bars: 5e-resistant S. aureus
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We noticed, however, that upon prolonged storage (~ 2 weeks), aqueous solutions of 
hydrochloride salts of both 10 and 12 were degrading gradually, giving rise to N-dealkylated 
products as was discussed earlier. Furthermore, we were desirous of introducing a functional 
group that would permit facile coupling of probes such as fluorophores or biotin in order to 
identify the possible molecular target(s) of 5e. We elected to replace the N-2,4,4-trimethyl 
pentan-2-yl group with the more stable tert-butyl group, and the N,N-dimethylaminopropylamino 
group with a 1,8-diaminooctane, using the Buchwald-Hartwig coupling strategy employed earlier 
(Scheme 7). The introduction of the primary amine-bearing 1,8-diaminooctanyl group on either 
the anthracenyl or pyridinyl portions of the molecule did not result in significant attenuation of 
antibacterial activity relative to 1g (Table 1), allowing the possibility of exploring the binding 
partners for these compounds.  
 
Scheme 7. Synthesis of 1g derivatives bearing terminal primary amines. 
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S. aureus MRSA S. aureus MRSA 
 
1a ND NT 
 
2c ND NT 
 
1b ND NT 
 
2d ND NT 
 
1c ND NT 2e 7.81 15.62 
 
1d ND NT 2f ND NT 
 
1e 62.5 31.25 2g 3.91 3.91 
 
1f ND NT 2h 7.81 NT 
 
1g 3.91 3.91 3a ND NT 
 
1h ND NT 3b ND NT 
 
2a ND NT 
 
3c ND NT 
 
2b ND NT 
 
3d ND NT 
 
(continued on next page) 
 
 124  












S. aureus MRSA S. aureus MRSA 
 
3e 15.62 NT 5c 15.62 15.62 
 
3f ND NT 5d 7.81 3.91 
 
3g ND NT 5e 3.91 3.91 
 
3h ND NT 5f 15.62 NT 
 
4a 15.62 NT 5g 15.62 NT 
 
4b 15.62 NT 
 
5h ND NT 
 
4c ND NT 
 
5i ND NT 
 
5a 3.91 7.81 6 ND NT 
 
5b 3.91 7.81 7a 7.81 NT 
 
(continued on next page) 
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S. aureus MRSA S. aureus MRSA
 
7b 31.25 NT 11 15.62 NT 
 
7c 62.5 NT 12 3.91 NT 
 
8a ND NT 
 
13 7.81 NT 
 
8b 7.81 NT 14 7.81 15.62 
 
8c 15.62 NT 15 15.62 NT 
 
9 7.81 NT 16 3.91 7.81 
 
 
10 3.91 NT 
 
    
 
 
aND denotes no activity detected at 100 g/mL and NT denotes not tested. 
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4.3. Conclusions 
 
Our attempts at exploring imidazo[1,2-a]pyridin-3-amines for TLR7 (or 8)-modulatory activities 
have unexpectedly led to the identification of a novel chemotype with substantial bacteriostatic 
activity against Gram-positive bacteria, including methicillin-resistant S. aureus (MRSA). Our 
preliminary results suggest that the mechanism of action may be distinct from known 
bacteriostatics. Structure-activity relationship studies have led to the identification of positions 
on the scaffold for additional structural modifications that should allow for the introduction of 
probes designed to examine cognate binding partners and molecular targets, while not 





Chemistry. All of the solvents and reagents used were obtained commercially and used as 
such unless noted otherwise. Moisture- or airsensitive reactions were conducted under nitrogen 
atmosphere in oven-dried (120 °C) glass apparatus. The solvents were removed under reduced 
pressure using standard rotary evaporators. Flash column chromatography was carried out 
using RediSep Rf ‘Gold’ high performance silica columns on CombiFlash Rf instrument unless 
otherwise mentioned, while thin-layer chromatography was carried out on silica gel CCM pre-
coated aluminum sheets. Microwave reactions were done in Synthos 3000 instrument (Anton 
Paar). IR spectra were recorded on Shimadzu 8400 series FTIR instrument and values are 
reported in cm-1. Purity for all final compounds was confirmed to be greater than 95% by LC–MS 
using a Zorbax Eclipse Plus 4.6 × 150 mm, 5 m analytical reverse phase C18 column with 
H2O–isopropanol or H2O–CH3CN gradients and an Agilent ESI-TOF mass spectrometer (mass 
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accuracy of 3 ppm) operating in the positive ion acquisition mode. Unless otherwise mentioned, 
the compounds synthesized were obtained as yellow solids. 
 
Synthesis of compound 1a: N-(tert-butyl)-2-phenylimidazo[1,2-a]pyridin-3-amine. To the 
solution of 2-aminopyridine (24 mg, 0.25 mmol) in anhydrous acetonitrile, were added 
benzaldehyde (28 L, 0.28 mmol), a catalytic amount of 4N HCl/dioxane (10 L) and tert-butyl 
isonitrile (27 L, 0.24 mmol). The reaction mixture was then heated under microwave conditions 
(400 W, 110 °C, 20 min). After the reaction mixture was cooled to room temperature, solvent 
was removed and the residue was purified using column chromatography to obtain compound 
1a (44 mg, 69%). 1H NMR (400 MHz, CDCl3)  8.23 (dt, J = 6.9, 1.2 Hz, 1H), 7.90 (dt, J = 8.1, 
1.6 Hz, 2H), 7.55 (dt, J = 9.0, 1.0 Hz, 1H), 7.43 (t, J = 7.6 Hz, 2H), 7.31 (t, J = 7.4 Hz, 1H), 7.13 
(ddd, J = 9.0, 6.6, 1.3 Hz, 1H), 6.77 (td, J = 6.8, 1.1 Hz, 1H), 3.12 (s, 1H), 1.04 (s, 9H). 13C NMR 
(101 MHz, CDCl3)  135.42, 128.43, 128.32, 127.52, 124.17, 123.64, 117.48, 111.46, 101.91, 
56.59, 30.43. MS (ESI) calculated for C17H19N3, m/z 265.16, found 266.17 [M+H]
+.  
Compounds 1b-f, 2a-f, and 3a-f were synthesized similarly as compound 1a. 
 
1b: N-(tert-butyl)-2-phenylimidazo[1,2-a]pyrazin-3-amine. 45 mg, 62%. 1H NMR (400 MHz, 
CDCl3)  9.00 (d, J = 1.4 Hz, 1H), 8.14 (dd, J = 4.6, 1.5 Hz, 1H), 7.91 (dd, J = 8.3, 1.3 Hz, 2H), 
7.86 (d, J = 4.6 Hz, 1H), 7.46 (t, J = 7.5 Hz, 2H), 7.37 (t, J = 7.4 Hz, 1H), 3.19 (s, 1H), 1.05 (s, 
9H). 13C NMR (101 MHz, CDCl3)  143.54, 142.40, 137.43, 134.38, 129.04, 128.66, 128.38, 
128.33, 125.17, 116.49, 100.13, 57.11, 30.45. MS (ESI) calculated for C16H18N4, m/z 266.15, 
found 267.16 [M+H]+. 
 
1c: 2-Benzyl-N-(tert-butyl)imidazo[1,2-a]pyridin-3-amine. 41 mg, 61%. 1H NMR (400 MHz, 
CDCl3)  8.16 (dt, J = 6.9, 1.1 Hz, 1H), 7.47 (dt, J = 9.0, 1.0 Hz, 1H), 7.28 – 7.23 (m, 4H), 7.21 – 
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7.14 (m, 1H), 7.08 (ddd, J = 9.0, 6.7, 1.3 Hz, 1H), 6.72 (td, J = 6.8, 1.1 Hz, 1H), 4.20 (s, 2H), 
2.57 (s, 1H), 1.18 (s, 9H). 13C NMR (101 MHz, CDCl3)  139.83, 139.62, 128.68, 128.48, 
126.06, 123.41, 123.35, 117.06, 110.93, 101.78, 98.20, 55.71, 34.36, 30.45. MS (ESI) 
calculated for C18H21N3, m/z 279.17, found 280.19 [M+H]
+. 
 
1d: 2-Benzyl-N-(tert-butyl)imidazo[1,2-a]pyrazin-3-amine. 31 mg, 43%. 1H NMR (400 MHz, 
CDCl3)  8.92 (d, J = 1.4 Hz, 1H), 8.06 (dd, J = 4.6, 1.5 Hz, 1H), 7.81 (d, J = 4.6 Hz, 1H), 7.32 – 
7.27 (m, 2H), 7.25 – 7.18 (m, 3H), 4.24 (s, 2H), 2.62 (s, 1H), 1.20 (s, 9H). 13C NMR (101 MHz, 
CDCl3)  142.95, 142.78, 138.88, 137.32, 128.72, 128.67, 126.45, 116.28, 56.29, 34.39, 30.48. 
MS (ESI) calculated for C17H20N4, m/z 280.17, found 281.18 [M+H]
+. 
 
1e: N-(tert-butyl)-2-(naphthalen-1-yl)imidazo[1,2-a]pyridin-3-amine. 56 mg, 74%. 1H NMR 
(400 MHz, CDCl3)  8.34 (dt, J = 6.9, 1.1 Hz, 1H), 8.02 – 7.85 (m, 3H), 7.68 – 7.44 (m, 5H), 7.19 
(ddd, J = 9.0, 6.7, 1.3 Hz, 1H), 6.83 (td, J = 6.8, 1.1 Hz, 1H), 3.00 (s, 1H), 0.78 (s, 9H). 13C NMR 
(101 MHz, CDCl3)  133.83, 132.94, 131.98, 128.48, 128.25, 128.15, 126.57, 125.73, 125.70, 
125.34, 123.97, 123.64, 117.45, 111.37, 101.79, 100.00, 55.95, 29.76. MS (ESI) calculated for 
C21H21N3, m/z 315.17, found 316.19 [M+H]
+. 
 
1f: N-(tert-butyl)-2-(naphthalen-1-yl)imidazo[1,2-a]pyrazin-3-amine. 29 mg, 38%. 1H NMR 
(400 MHz, CDCl3)  9.07 (d, J = 1.4 Hz, 1H), 8.24 (dd, J = 4.6, 1.5 Hz, 1H), 7.97 – 7.87 (m, 4H), 
7.67 – 7.42 (m, 4H), 3.08 (s, 1H), 0.80 (s, 9H). 13C NMR (101 MHz, CDCl3)  143.57, 141.83, 
133.85, 131.76, 131.71, 128.98, 128.95, 128.67, 128.27, 126.94, 126.02, 125.31, 125.19, 
116.54, 105.36, 98.21, 56.51, 29.81. MS (ESI) calculated for C20H20N4, m/z 316.17, found 
317.17 [M+H]+. 
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1g: 2-(Anthracen-9-yl)-N-(tert-butyl)imidazo[1,2-a]pyridin-3-amine. 55 mg, 63%. IR (CHCl3) 
max (cm-1): 2970, 1500, 1473, 1342, 1311. 1H NMR (400 MHz, CDCl3)  8.52 (s, 1H), 8.40 (dt, J 
= 6.9, 1.2 Hz, 1H), 8.09 – 8.02 (m, 2H), 7.93 – 7.86 (m, 2H), 7.66 (dt, J = 9.0, 1.1 Hz, 1H), 7.51 
– 7.38 (m, 4H), 7.29 – 7.20 (m, 1H), 6.89 (td, J = 6.8, 1.1 Hz, 1H), 2.69 (s, 1H), 0.64 (s, 9H). 13C 
NMR (101 MHz, CDCl3)  142.71, 131.45, 130.94, 128.75, 127.60, 126.80, 126.34, 126.19, 
125.06, 124.00, 123.62, 117.57, 111.40, 101.78, 97.01, 55.59, 29.72. MS (ESI) calculated for 
C25H23N3, m/z 365.19, found 366.20 [M+H]
+. 
 
1h: 2-(Anthracen-9-yl)-N-(tert-butyl)imidazo[1,2-a]pyrazin-3-amine. 50 mg, 57%. 1H NMR 
(400 MHz, CDCl3)  9.14 (d, J = 1.5 Hz, 1H), 8.57 (s, 1H), 8.31 (dd, J = 4.6, 1.5 Hz, 1H), 8.12 – 
8.05 (m, 2H), 7.98 (d, J = 4.6 Hz, 1H), 7.83 – 7.75 (m, 2H), 7.53 – 7.42 (m, 4H), 2.75 (s, 1H), 
0.65 (s, 9H). 13C NMR (101 MHz, CDCl3)  143.65, 139.88, 138.08, 131.37, 130.86, 129.05, 
128.96, 128.35, 127.48, 126.81, 125.52, 125.24, 116.55, 101.78, 56.14, 29.77. MS (ESI) 
calculated for C24H22N4, m/z 366.18, found 367.19 [M+H]
+ and 389.18 [M+Na]+. 
 
2a: N-cyclohexyl-2-phenylimidazo[1,2-a]pyridin-3-amine. 51 mg, 73%. 1H NMR (500 MHz, 
CDCl3)  8.16 (d, J = 6.8 Hz, 1H), 8.05 (dd, J = 8.3, 1.2 Hz, 2H), 7.62 (d, J = 9.0 Hz, 1H), 7.45 (t, 
J = 7.8 Hz, 2H), 7.32 (t, J = 7.4 Hz, 1H), 7.17 (ddd, J = 8.9, 6.7, 1.2 Hz, 1H), 6.82 (td, J = 6.8, 
0.9 Hz, 1H), 3.32 (s, 1H), 3.07 – 2.85 (m, 1H), 1.81 (d, J = 13.1 Hz, 2H), 1.68 (dd, J = 9.1, 3.6 
Hz, 2H), 1.60 – 1.54 (m, 1H), 1.28 – 1.12 (m, 5H). 13C NMR (126 MHz, CDCl3)  141.02, 135.43, 
133.45, 128.74, 127.74, 127.20, 125.17, 125.04, 123.07, 116.94, 112.30, 57.02, 34.27, 25.81, 
24.94. MS (ESI) calculated for C19H21N3, m/z 291.17, found 292.18 [M+H]
+. 
 
2b: N-cyclohexyl-2-phenylimidazo[1,2-a]pyrazin-3-amine. 25 mg, 36%. 1H NMR (500 MHz, 
CDCl3)  8.99 (d, J = 1.4 Hz, 1H), 8.01 (ddd, J = 4.6, 3.2, 1.8 Hz, 3H), 7.85 (d, J = 4.6 Hz, 1H), 
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7.48 (t, J = 7.7 Hz, 2H), 7.38 (t, J = 7.4 Hz, 1H), 3.26 (s, 1H), 3.00 (s, 1H), 1.82 (dd, J = 6.6, 5.4 
Hz, 2H), 1.70 (dd, J = 9.3, 3.3 Hz, 2H), 1.62 – 1.55 (m, 1H), 1.34 – 1.07 (m, 5H). 13C NMR (126 
MHz, CDCl3)  143.37, 139.08, 136.82, 133.62, 129.01, 128.90, 128.30, 127.42, 126.70, 
115.73, 57.02, 34.41, 25.69, 24.91. MS (ESI) calculated for C18H20N4, m/z 292.17, found 293.18 
[M+H]+. 
 
2c: 2-Benzyl-N-cyclohexylimidazo[1,2-a]pyridin-3-amine. 51 mg, 70%. 1H NMR (500 MHz, 
CDCl3)  8.04 (dt, J = 6.8, 1.1 Hz, 1H), 7.52 – 7.46 (m, 1H), 7.31 – 7.26 (m, 4H), 7.19 (qd, J = 
5.3, 2.7 Hz, 1H), 7.10 (ddd, J = 9.0, 6.7, 1.3 Hz, 1H), 6.76 (td, J = 6.8, 1.1 Hz, 1H), 4.16 (s, 2H), 
2.77 (s, 1H), 2.60 (s, 1H), 1.79 – 1.67 (m, 4H), 1.59 (s, 1H), 1.32 – 1.04 (m, 5H). 13C NMR (126 
MHz, CDCl3)  141.11, 139.62, 137.49, 128.68, 128.53, 126.20, 125.44, 123.43, 122.59, 
116.93, 111.41, 57.32, 34.17, 34.11, 25.74, 24.85. MS (ESI) calculated for C20H23N3, m/z 
305.19, found 306.20 [M+H]+. 
 
2d: 2-Benzyl-N-cyclohexylimidazo[1,2-a]pyrazin-3-amine. 37 mg, 50%. 1H NMR (500 MHz, 
CDCl3)  8.92 (d, J = 1.4 Hz, 1H), 7.93 (dd, J = 4.6, 1.5 Hz, 1H), 7.81 (d, J = 4.6 Hz, 1H), 7.33 – 
7.25 (m, 4H), 7.22 (ddd, J = 6.2, 3.3, 1.6 Hz, 1H), 4.20 (s, 2H), 2.81 (s, 1H), 2.68 (s, 1H), 1.84 – 
1.65 (m, 4H), 1.60 (d, J = 6.1 Hz, 1H), 1.24 – 0.95 (m, 5H). 13C NMR (126 MHz, CDCl3)  
141.19, 139.22, 137.30, 135.01, 127.27, 127.20, 127.17, 125.71, 125.04, 114.00, 55.65, 32.84, 
32.76, 24.09, 23.31. MS (ESI) calculated for C19H22N4, m/z 306.18, found 307.20 [M+H]
+. 
 
2e: N-cyclohexyl-2-(naphthalen-1-yl)imidazo[1,2-a]pyridin-3-amine. 24 mg, 29%. 1H NMR 
(500 MHz, CDCl3)  8.20 (d, J = 6.8 Hz, 1H), 7.95 – 7.88 (m, 3H), 7.72 – 7.64 (m, 2H), 7.59 – 
7.54 (m, 1H), 7.53 – 7.45 (m, 2H), 7.25 – 7.20 (m, 1H), 6.90 (t, J = 6.8 Hz, 1H), 3.15 (s, 1H), 
2.63 (t, J = 9.6 Hz, 1H), 1.58 (d, J = 12.6 Hz, 2H), 1.50 – 1.36 (m, 3H), 1.04 – 0.77 (m, 5H). 13C 
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NMR (126 MHz, CDCl3)  141.06, 133.76, 131.95, 128.57, 128.49, 128.15, 126.76, 126.65, 
125.86, 125.50, 125.36, 124.30, 122.89, 117.21, 112.14, 56.32, 33.70, 25.47, 24.51. MS (ESI) 
calculated for C23H23N3, m/z 341.19, found 342.20 [M+H]
+. 
 
2f: N-cyclohexyl-2-(naphthalen-1-yl)imidazo[1,2-a]pyrazin-3-amine. 50 mg, 61%. 1H NMR 
(500 MHz, CDCl3)  9.05 (d, J = 1.5 Hz, 1H), 8.05 (dd, J = 4.6, 1.5 Hz, 1H), 7.96 – 7.93 (m, 2H), 
7.92 – 7.89 (m, 2H), 7.61 (ddd, J = 15.2, 7.5, 4.2 Hz, 4H), 7.55 – 7.48 (m, 1H), 3.27 (s, 1H), 
2.73 (s, 1H), 1.61 (dd, J = 9.5, 3.2 Hz, 2H), 1.44 (ddd, J = 14.5, 11.6, 4.6 Hz, 3H), 1.07 – 0.82 
(m, 5H). 13C NMR (126 MHz, CDCl3)  143.40, 138.38, 136.73, 133.80, 131.90, 130.80, 129.03, 
128.84, 128.58, 128.53, 128.07, 126.87, 126.08, 125.30, 125.27, 115.67, 56.12, 33.85, 25.35, 
24.50. MS (ESI) calculated for C22H22N4, m/z 342.18, found 343.19 [M+H]
+ and 365.17 [M+Na]+. 
 
2g: 2-(Anthracen-9-yl)-N-cyclohexylimidazo[1,2-a]pyridin-3-amine. 83 mg, 88%. 1H NMR 
(500 MHz, CDCl3)  8.54 (s, 1H), 8.23 (dt, J = 6.8, 1.2 Hz, 1H), 8.06 (d, J = 8.4 Hz, 2H), 7.83 
(dd, J = 8.7, 0.8 Hz, 2H), 7.66 (dt, J = 9.0, 1.0 Hz, 1H), 7.49 – 7.44 (m, 2H), 7.40 (ddd, J = 8.6, 
6.5, 1.3 Hz, 2H), 7.23 (ddd, J = 9.0, 6.7, 1.3 Hz, 1H), 6.90 (td, J = 6.8, 1.1 Hz, 1H), 2.80 (d, J = 
7.4 Hz, 1H), 2.62 – 2.49 (m, 1H), 1.47 (d, J = 12.6 Hz, 2H), 1.35 – 1.24 (m, 3H), 0.89 – 0.77 (m, 
3H), 0.68 (dt, J = 12.8, 6.6 Hz, 2H). 13C NMR (126 MHz, CDCl3)  142.02, 134.01, 131.38, 
131.20, 128.59, 128.34, 128.10, 127.64, 126.25, 126.12, 125.10, 123.40, 122.81, 117.72, 
111.60, 56.18, 33.62, 25.39, 24.38. MS (ESI) calculated for C27H25N3, m/z 391.20, found 392.22 
[M+H]+. 
 
2h: 2-(Anthracen-9-yl)-N-cyclohexylimidazo[1,2-a]pyrazin-3-amine. 17 mg, 18%. 1H NMR 
(500 MHz, CDCl3)  9.12 (d, J = 1.4 Hz, 1H), 8.59 (s, 1H), 8.13 – 8.06 (m, 3H), 7.97 (d, J = 4.6 
Hz, 1H), 7.72 (dd, J = 8.7, 0.6 Hz, 2H), 7.46 (dddd, J = 10.0, 7.8, 6.5, 1.1 Hz, 4H), 2.91 (d, J = 
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6.2 Hz, 1H), 2.62 (s, 1H), 1.48 (d, J = 12.6 Hz, 2H), 1.29 (dd, J = 24.7, 8.3 Hz, 3H), 0.91 – 0.76 
(m, 3H), 0.76 – 0.63 (m, 2H). 13C NMR (126 MHz, CDCl3)  142.63, 136.28, 135.36, 130.29, 
130.12, 128.74, 128.01, 127.76, 127.36, 125.75, 125.54, 124.62, 124.25, 114.68, 54.95, 32.71, 
24.20, 23.32. MS (ESI) calculated for C26H24N4, m/z 392.20, found 393.20 [M+H]
+. 
 
3a: N-benzyl-2-phenylimidazo[1,2-a]pyridin-3-amine. 62 mg, 86%. 1H NMR (500 MHz, 
CDCl3)  7.98 (ddt, J = 3.7, 3.0, 1.6 Hz, 3H), 7.57 (dt, J = 9.0, 1.0 Hz, 1H), 7.45 (t, J = 7.7 Hz, 
2H), 7.39 – 7.26 (m, 6H), 7.13 (ddd, J = 9.0, 6.7, 1.3 Hz, 1H), 6.74 (td, J = 6.8, 1.1 Hz, 1H), 4.20 
(d, J = 6.1 Hz, 2H), 3.52 (t, J = 6.0 Hz, 1H). 13C NMR (126 MHz, CDCl3)  141.57, 139.06, 
136.04, 134.13, 128.84, 128.30, 127.82, 127.65, 127.16, 125.77, 124.32, 122.50, 117.52, 
111.94, 52.57. MS (ESI) calculated for C20H17N3, m/z 299.14, found 300.15 [M+H]
+. 
 
3b: N-benzyl-2-phenylimidazo[1,2-a]pyrazin-3-amine. 45 mg, 62%. 1H NMR (500 MHz, 
CDCl3)  8.98 (d, J = 1.3 Hz, 1H), 7.94 (dt, J = 8.1, 1.6 Hz, 2H), 7.82 (dd, J = 4.6, 1.4 Hz, 1H), 
7.77 (d, J = 4.6 Hz, 1H), 7.47 (t, J = 7.6 Hz, 2H), 7.39 (t, J = 7.4 Hz, 1H), 7.34 – 7.27 (m, 5H), 
4.23 (d, J = 2.4 Hz, 2H), 3.66 (s, 1H). 13C NMR (126 MHz, CDCl3)  143.46, 138.76, 138.56, 
136.79, 133.34, 129.06, 129.03, 128.99, 128.46, 128.24, 128.08, 127.42, 127.18, 115.38, 52.39. 
MS (ESI) calculated for C19H16N4, m/z 300.14, found 301.15 [M+H]
+. 
 
3c: N,2-dibenzylimidazo[1,2-a]pyridin-3-amine. 33 mg, 44%. 1H NMR (500 MHz, CDCl3)  
7.95 (dt, J = 6.8, 1.1 Hz, 1H), 7.49 (dt, J = 9.1, 0.9 Hz, 1H), 7.38 – 7.15 (m, 10H), 7.09 (ddd, J = 
9.0, 6.7, 1.3 Hz, 1H), 6.72 (td, J = 6.7, 1.1 Hz, 1H), 4.01 (s, 2H), 3.94 (d, J = 5.5 Hz, 2H), 2.99 
(s, 1H). 13C NMR (126 MHz, CDCl3)  141.18, 139.68, 139.24, 137.57, 128.69, 128.62, 128.57, 
128.28, 127.59, 126.25, 125.93, 123.36, 122.14, 117.15, 111.44, 52.83, 34.13. MS (ESI) 
calculated for C21H19N3, m/z 313.16, found 314.18 [M+H]
+. 
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3d: N,2-dibenzylimidazo[1,2-a]pyrazin-3-amine. 19 mg, 25%. 1H NMR (500 MHz, CDCl3)  
7.83 – 7.72 (m, 2H), 7.35 – 7.25 (m, 5H), 7.25 – 7.18 (m, 4H), 7.16 (dd, J = 7.0, 2.2 Hz, 2H), 
4.03 (s, 2H), 3.96 (d, J = 3.9 Hz, 2H), 3.15 – 3.05 (m, 1H). 13C NMR (126 MHz, CDCl3)  141.87, 
139.52, 137.76, 137.68, 135.44, 128.01, 127.89, 127.75, 127.71, 127.66, 127.63, 127.59, 
127.56, 127.26, 127.19, 126.97, 126.84, 126.75, 125.57, 114.09, 51.49, 51.46, 33.19. MS (ESI) 
calculated for C20H18N4, m/z 314.15, found 315.17 [M+H]
+. 
 
3e: N-benzyl-2-(naphthalen-1-yl)imidazo[1,2-a]pyridin-3-amine. 42 mg, 50%. 1H NMR (500 
MHz, CDCl3)  8.15 – 8.10 (m, 1H), 8.01 (d, J = 8.3 Hz, 1H), 7.94 – 7.86 (m, 2H), 7.61 (d, J = 
9.0 Hz, 1H), 7.55 – 7.44 (m, 4H), 7.18 (ddd, J = 9.0, 6.7, 1.3 Hz, 1H), 7.15 – 7.11 (m, 3H), 7.02 
(dd, J = 6.5, 3.0 Hz, 2H), 6.83 (td, J = 6.8, 1.0 Hz, 1H), 3.92 (d, J = 4.9 Hz, 2H), 3.53 (s, 1H). 13C 
NMR (126 MHz, CDCl3)  141.35, 138.75, 135.57, 133.79, 132.14, 131.50, 128.45, 128.37, 
128.33, 127.88, 127.34, 127.31, 126.49, 125.88, 125.82, 125.27, 123.69, 122.50, 117.60, 
111.80, 52.42. MS (ESI) calculated for C24H19N3, m/z 349.16, found 350.18 [M+H]
+. 
 
3f: N-benzyl-2-(naphthalen-1-yl)imidazo[1,2-a]pyrazin-3-amine. 12 mg, 14%. 1H NMR (500 
MHz, CDCl3)  9.01 (d, J = 1.5 Hz, 1H), 7.97 – 7.89 (m, 4H), 7.83 (d, J = 4.6 Hz, 1H), 7.49 (tddd, 
J = 10.0, 6.8, 3.6, 1.4 Hz, 4H), 7.17 – 7.08 (m, 3H), 7.01 – 6.94 (m, 2H), 3.96 (d, J = 5.8 Hz, 
2H), 3.78 (t, J = 5.8 Hz, 1H). 13C NMR (126 MHz, CDCl3)  143.50, 138.21, 137.83, 136.53, 
133.78, 131.90, 130.44, 129.08, 128.95, 128.89, 128.49, 128.46, 128.02, 127.77, 127.73, 
127.58, 126.78, 126.06, 125.45, 125.21, 115.35, 51.83. MS (ESI) calculated for C23H18N4, m/z 
350.15, found 351.18 [M+H]+. 
 
3g: 2-(Anthracen-9-yl)-N-benzylimidazo[1,2-a]pyridin-3-amine. 47 mg, 49%. 1H NMR (500 
MHz, CDCl3)  8.55 (s, 1H), 8.18 (dt, J = 6.9, 1.2 Hz, 1H), 8.07 (d, J = 8.5 Hz, 2H), 7.82 (dd, J = 
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8.8, 0.9 Hz, 2H), 7.66 (dt, J = 9.0, 1.1 Hz, 1H), 7.50 – 7.43 (m, 2H), 7.39 (ddd, J = 8.7, 6.5, 1.3 
Hz, 2H), 7.22 (ddd, J = 9.0, 6.7, 1.3 Hz, 1H), 7.05 – 6.95 (m, 3H), 6.90 – 6.82 (m, 3H), 3.74 (d, J 
= 6.3 Hz, 2H), 3.25 (t, J = 6.3 Hz, 1H). 13C NMR (126 MHz, CDCl3)  140.88, 137.71, 132.57, 
130.36, 130.23, 127.77, 127.54, 127.15, 127.02, 126.76, 126.63, 126.10, 125.31, 125.10, 
124.09, 122.54, 121.46, 116.74, 110.71, 51.19. MS (ESI) calculated for C28H21N3, m/z 399.17, 
found 400.20 [M+H]+. 
 
3h: 2-(Anthracen-9-yl)-N-benzylimidazo[1,2-a]pyrazin-3-amine. 8 mg, 8%. 1H NMR (500 
MHz, CDCl3)  9.09 (d, J = 1.4 Hz, 1H), 8.59 (s, 1H), 8.08 (d, J = 8.5 Hz, 2H), 8.01 (dd, J = 4.6, 
1.5 Hz, 1H), 7.91 (d, J = 4.6 Hz, 1H), 7.69 (dd, J = 8.8, 0.7 Hz, 2H), 7.52 – 7.45 (m, 2H), 7.41 
(ddd, J = 8.6, 6.5, 1.2 Hz, 2H), 7.06 – 6.94 (m, 3H), 6.83 – 6.77 (m, 2H), 3.78 (d, J = 5.3 Hz, 
2H), 3.44 (s, 1H). 13C NMR (126 MHz, CDCl3)  143.66, 138.12, 137.10, 135.78, 131.32, 
131.19, 130.28, 129.06, 128.75, 128.50, 128.33, 127.55, 127.41, 126.56, 126.53, 125.74, 
125.28, 115.37, 51.61. MS (ESI) calculated for C27H20N4, m/z 400.17, found 401.19 [M+H]
+. 
 
Compounds 4a-4c were synthesized similarly as compound 1a. 
 
4a: 2-(Anthracen-9-yl)-N-cyclohexylimidazo[1,2-a]pyrimidin-3-amine. 40 mg, 43%. 1H NMR 
(500 MHz, CDCl3)  8.61 (dd, J = 4.1, 2.1 Hz, 1H), 8.56 (s, 1H), 8.54 (dd, J = 6.8, 2.1 Hz, 1H), 
8.07 (d, J = 8.4 Hz, 2H), 7.83 (dd, J = 8.7, 0.8 Hz, 2H), 7.49 – 7.44 (m, 2H), 7.41 (ddd, J = 8.6, 
6.5, 1.3 Hz, 2H), 6.97 (dd, J = 6.8, 4.1 Hz, 1H), 2.83 (s, 1H), 2.47 (s, 1H), 1.43 (d, J = 12.9 Hz, 
2H), 1.29 (d, J = 7.4 Hz, 3H), 0.82 (t, J = 6.6 Hz, 3H), 0.75 – 0.62 (m, 2H). 13C NMR (126 MHz, 
CDCl3)  148.91, 144.93, 135.89, 131.34, 131.05, 130.37, 128.66, 128.12, 127.26, 126.67, 
126.29, 126.07, 125.18, 108.17, 56.46, 33.55, 25.28, 24.28. MS (ESI) calculated for C26H24N4, 
m/z 392.20, found 393.22 [M+H]+. 
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4b: 2-(Anthracen-9-yl)-N3-cyclohexylimidazo[1,2-a]pyridine-3,8-diamine. 15 mg, 15%. 1H 
NMR (500 MHz, CDCl3)  8.54 (s, 1H), 8.06 (d, J = 8.4 Hz, 2H), 7.86 (dd, J = 8.7, 0.7 Hz, 2H), 
7.70 (dd, J = 6.7, 0.9 Hz, 1H), 7.49 – 7.44 (m, 2H), 7.43 – 7.37 (m, 2H), 6.74 (t, J = 7.0 Hz, 1H), 
6.40 (dd, J = 7.3, 0.9 Hz, 1H), 4.57 (s, 2H), 2.77 (s, 1H), 2.56 (s, 1H), 1.49 (d, J = 12.4 Hz, 2H), 
1.29 (d, J = 5.7 Hz, 3H), 0.94 – 0.75 (m, 3H), 0.75 – 0.61 (m, 2H). 13C NMR (126 MHz, CDCl3)  
135.97, 135.69, 132.06, 131.45, 131.37, 129.03, 128.57, 128.36, 127.62, 126.37, 126.06, 
125.12, 113.22, 112.69, 101.65, 56.09, 33.63, 25.41, 24.41. MS (ESI) calculated for C27H26N4, 
m/z 406.22, found 407.23 [M+H]+. 
 
4c: 2-(Anthracen-9-yl)-8-chloro-N-cyclohexylimidazo[1,2-a]pyrazin-3-amine. 20 mg, 20%. 
1H NMR (500 MHz, CDCl3)  8.59 (s, 1H), 8.10 – 8.06 (m, 3H), 7.77 (d, J = 4.5 Hz, 1H), 7.70 
(dd, J = 8.7, 0.7 Hz, 2H), 7.52 – 7.47 (m, 2H), 7.46 – 7.41 (m, 2H), 2.93 (d, J = 6.8 Hz, 1H), 2.66 
– 2.58 (m, 1H), 1.48 (d, J = 12.4 Hz, 2H), 1.32 (d, J = 6.9 Hz, 3H), 0.92 – 0.79 (m, 3H), 0.69 (dd, 
J = 22.4, 11.8 Hz, 2H). 13C NMR (126 MHz, CDCl3)  143.61, 136.76, 134.02, 131.59, 131.27, 
131.26, 128.77, 128.58, 127.43, 126.61, 126.17, 125.63, 125.29, 115.63, 56.13, 33.74, 25.16, 
24.33. MS (ESI) calculated for C26H23ClN4, m/z 426.16, found 427.17 [M+H]
+. 
 
Compounds 5a-5i were synthesized similarly as compound 1a. 
 
5a: 2-(Anthracen-9-yl)-N-butylimidazo[1,2-a]pyridin-3-amine. 22 mg, 25%. 1H NMR (500 
MHz, CDCl3)  8.55 (s, 1H), 8.19 (dt, J = 6.8, 1.2 Hz, 1H), 8.06 (d, J = 8.4 Hz, 2H), 7.84 (dd, J = 
8.7, 0.8 Hz, 2H), 7.67 (dt, J = 9.1, 1.0 Hz, 1H), 7.48 – 7.44 (m, 2H), 7.40 (ddd, J = 8.6, 6.5, 1.3 
Hz, 2H), 7.22 (ddd, J = 9.0, 6.7, 1.3 Hz, 1H), 6.90 (td, J = 6.8, 1.1 Hz, 1H), 2.89 (t, J = 6.1 Hz, 
1H), 2.64 (q, J = 6.6 Hz, 2H), 1.09 – 0.97 (m, 2H), 0.86 – 0.72 (m, 2H), 0.43 (t, J = 7.4 Hz, 3H). 
13C NMR (126 MHz, CDCl3) 141.97, 133.07, 131.52, 131.47, 129.40, 128.68, 128.39, 127.80, 
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126.46, 126.21, 125.25, 123.46, 122.61, 117.92, 111.80, 47.92, 32.18, 19.67, 13.53. MS (ESI) 
calculated for C25H23N3, m/z 365.19, found 366.20 [M+H]
+. 
 
5b: 2-(Anthracen-9-yl)-N-pentylimidazo[1,2-a]pyridin-3-amine. 35 mg, 38%. 1H NMR (500 
MHz, CDCl3)  8.55 (s, 1H), 8.19 (dt, J = 6.8, 1.2 Hz, 1H), 8.06 (d, J = 8.4 Hz, 2H), 7.84 (dd, J = 
8.7, 0.8 Hz, 2H), 7.67 (dt, J = 9.0, 1.1 Hz, 1H), 7.49 – 7.44 (m, 2H), 7.40 (ddd, J = 8.6, 6.5, 1.3 
Hz, 2H), 7.22 (ddd, J = 9.0, 6.7, 1.3 Hz, 1H), 6.90 (td, J = 6.8, 1.1 Hz, 1H), 2.91 (t, J = 6.4 Hz, 
1H), 2.65 (q, J = 6.7 Hz, 2H), 1.02 (dt, J = 14.3, 7.0 Hz, 2H), 0.82 – 0.65 (m, 4H), 0.52 (t, J = 7.1 
Hz, 3H). 13C NMR (126 MHz, CDCl3)  141.85, 132.95, 131.40, 131.34, 129.24, 128.56, 128.26, 
127.67, 126.32, 126.10, 125.13, 123.31, 122.48, 117.81, 111.67, 48.05, 29.68, 28.58, 22.07, 
13.70. MS (ESI) calculated for C26H25N3, m/z 379.20, found 380.22 [M+H]
+. 
 
5c: 2-(Anthracen-9-yl)-N-isopropylimidazo[1,2-a]pyridin-3-amine. 15 mg, 18%. 1H NMR 
(500 MHz, CDCl3)  8.54 (s, 1H), 8.25 (dt, J = 6.8, 1.2 Hz, 1H), 8.08 – 8.04 (m, 2H), 7.84 (dd, J 
= 8.7, 0.9 Hz, 2H), 7.66 (dt, J = 9.0, 1.1 Hz, 1H), 7.49 – 7.44 (m, 2H), 7.41 (ddd, J = 8.6, 6.5, 1.3 
Hz, 2H), 7.23 (ddd, J = 9.0, 6.7, 1.3 Hz, 1H), 6.90 (td, J = 6.8, 1.1 Hz, 1H), 2.86 (dq, J = 12.5, 
6.3 Hz, 1H), 2.71 (d, J = 6.4 Hz, 1H), 0.69 (d, J = 6.3 Hz, 6H). 13C NMR (126 MHz, CDCl3)  
142.10, 134.36, 131.39, 131.13, 128.63, 128.31, 128.29, 127.69, 126.23, 126.17, 125.11, 
123.56, 122.78, 117.69, 111.64, 49.20, 23.15. MS (ESI) calculated for C24H21N3, m/z 351.17, 
found 352.19 [M+H]+. 
 
5d: 2-(Anthracen-9-yl)-N-isopropylimidazo[1,2-a]pyridin-3-amine. 37 mg, 41%. 1H NMR 
(500 MHz, CDCl3)  8.54 (s, 1H), 8.23 (dd, J = 6.8, 1.0 Hz, 1H), 8.06 (d, J = 8.3 Hz, 2H), 7.89 – 
7.83 (m, 2H), 7.67 (dt, J = 9.0, 1.0 Hz, 1H), 7.50 – 7.37 (m, 4H), 7.23 (ddd, J = 9.0, 6.7, 1.3 Hz, 
1H), 6.90 (td, J = 6.8, 1.1 Hz, 1H), 2.79 – 2.61 (m, 2H), 1.12 – 0.95 (m, 2H), 0.92 – 0.82 (m, 
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2H), 0.79 – 0.67 (m, 1H), 0.63 (d, J = 6.2 Hz, 2H), 0.39 (t, J = 7.1 Hz, 2H), 0.29 (t, J = 7.4 Hz, 
1H). 13C NMR (126 MHz, CDCl3)  142.03, 134.21, 131.41, 131.39, 131.36, 131.19, 131.13, 
128.62, 128.61, 128.59, 128.36, 128.34, 127.64, 127.61, 126.26, 126.15, 126.13, 125.09, 
123.45, 123.34, 122.68, 122.60, 117.74, 117.71, 111.62, 59.63, 53.06, 39.14, 26.01, 20.85, 
18.53, 13.58, 9.01. MS (ESI) calculated for C26H25N3, m/z 379.20, found 380.22 [M+H]
+. 
 
5e: 2-(Anthracen-9-yl)-N-(2,4,4-trimethylpentan-2-yl)imidazo[1,2-a]pyridin-3-amine. 51 mg, 
50%. IR (CHCl3) max (cm-1): 2956, 1519, 1481, 1365, 1340. 1H NMR (500 MHz, CDCl3)  8.53 
(s, 1H), 8.41 (d, J = 6.9 Hz, 1H), 8.05 (d, J = 7.7 Hz, 2H), 7.88 (d, J = 8.5 Hz, 2H), 7.66 (d, J = 
9.0 Hz, 1H), 7.50 – 7.38 (m, 4H), 7.24 (ddd, J = 8.9, 6.7, 1.2 Hz, 1H), 6.88 (td, J = 6.8, 1.0 Hz, 
1H), 2.89 (s, 1H), 0.97 (s, 2H), 0.68 (s, 6H), 0.52 (s, 9H). 13C NMR (126 MHz, CDCl3)  142.71, 
137.08, 131.44, 131.01, 129.27, 128.71, 127.53, 126.78, 126.32, 126.24, 125.05, 123.94, 
123.70, 117.51, 111.35, 59.61, 55.82, 31.20, 30.95, 28.61. MS (ESI) calculated for C29H31N3, 
m/z 421.25, found 422.27 [M+H]+. 
 
5f: 2-(Anthracen-9-yl)-N-((trimethylsilyl)methyl)imidazo[1,2-a]pyridin-3-amine. 33 mg, 35%. 
1H NMR (500 MHz, CDCl3)  8.55 (s, 1H), 8.15 (dt, J = 6.8, 1.1 Hz, 1H), 8.06 (d, J = 8.4 Hz, 2H), 
7.89 (dd, J = 8.7, 0.7 Hz, 2H), 7.69 – 7.65 (m, 1H), 7.49 – 7.44 (m, 2H), 7.43 – 7.38 (m, 2H), 
7.22 (ddd, J = 9.0, 6.7, 1.3 Hz, 1H), 6.91 (td, J = 6.8, 1.0 Hz, 1H), 2.60 (s, 1H), 2.15 (s, 2H), -
0.31 (s, 9H). 13C NMR (126 MHz, CDCl3)  141.55, 132.06, 131.73, 131.42, 131.23, 128.58, 
128.10, 127.65, 126.45, 126.02, 125.11, 123.20, 122.44, 117.79, 111.61, 38.69, -3.37. MS (ESI) 
calculated for C25H25N3Si, m/z 395.18, found 396.20 [M+H]
+. 
 
5g: N-(adamantan-1-yl)-2-(anthracen-9-yl)imidazo[1,2-a]pyridin-3-amine. 46 mg, 43%. 1H 
NMR (500 MHz, CDCl3)  8.52 (s, 1H), 8.45 (dt, J = 6.9, 1.1 Hz, 1H), 8.08 – 8.03 (m, 2H), 7.87 
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(d, J = 8.8 Hz, 2H), 7.65 (dt, J = 9.0, 1.0 Hz, 1H), 7.44 (dddd, J = 10.0, 7.9, 6.5, 1.3 Hz, 4H), 
7.23 (ddd, J = 9.0, 6.7, 1.3 Hz, 1H), 6.88 (td, J = 6.8, 1.1 Hz, 1H), 2.66 (s, 1H), 1.65 (s, 3H), 
1.34 (d, J = 12.1 Hz, 3H), 1.19 (d, J = 11.4 Hz, 3H), 1.13 (d, J = 2.5 Hz, 6H). 13C NMR (126 
MHz, CDCl3)  142.80, 137.17, 131.51, 131.15, 129.27, 128.82, 127.68, 126.39, 126.35, 
125.99, 125.17, 123.99, 123.87, 117.61, 111.43,  55.78, 43.30, 36.03, 29.50. MS (ESI) 
calculated for C31H29N3, m/z 443.24, found 444.26 [M+H]
+. 
 
5h: 2-(Anthracen-9-yl)-N-(4-methoxyphenyl)imidazo[1,2-a]pyridin-3-amine. 36 mg, 36%. 1H 
NMR (500 MHz, CDCl3)  8.50 (s, 1H), 8.01 (d, J = 8.5 Hz, 2H), 7.90 – 7.83 (m, 3H), 7.74 (d, J = 
9.1 Hz, 1H), 7.46 – 7.39 (m, 2H), 7.38 – 7.28 (m, 3H), 6.87 (td, J = 6.8, 1.0 Hz, 1H), 6.61 – 6.56 
(m, 2H), 6.37 – 6.29 (m, 2H), 5.29 (s, 1H), 3.63 (s, 3H). 13C NMR (126 MHz, CDCl3)  153.58, 
142.85, 137.63, 136.25, 131.45, 131.34, 128.69, 128.04, 127.61, 126.28, 126.18, 125.19, 
124.47, 123.39, 123.21, 118.11, 115.45, 114.84, 112.22, 55.69. MS (ESI) calculated for 
C28H21N3O, m/z 415.17, found 416.19 [M+H]
+. 
 
5i: 2-(Anthracen-9-yl)-N-(2-chloro-6-methylphenyl)imidazo[1,2-a]pyridin-3-amine. 11 mg, 
11%. 1H NMR (500 MHz, CDCl3)  8.38 (s, 1H), 8.21 (dt, J = 6.8, 1.1 Hz, 1H), 7.94 (d, J = 8.4 
Hz, 2H), 7.75 (ddd, J = 15.6, 8.3, 4.8 Hz, 3H), 7.41 – 7.35 (m, 2H), 7.34 – 7.28 (m, 3H), 6.97 (td, 
J = 6.8, 1.1 Hz, 1H), 6.61 (dd, J = 7.9, 1.0 Hz, 1H), 6.41 – 6.35 (m, 1H), 6.29 (t, J = 7.7 Hz, 1H), 
5.43 (s, 1H), 1.48 (s, 3H). 13C NMR (126 MHz, CDCl3)  142.20, 139.32, 137.26, 131.22, 
129.58, 128.96, 128.51, 127.69, 127.36, 126.96, 126.32, 125.86, 124.98, 124.43, 124.33, 
122.77, 121.59, 118.07, 112.53, 18.14. MS (ESI) calculated for C28H20ClN3, m/z 433.13, found 
434.15 [M+H]+. 
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Synthesis of compound 6: 2-(Anthracen-9-yl)imidazo[1,2-a]pyridin-3-amine. Compound 5e 
(50 mg, 0.12 mmol) was stirred in a solution of 4M HCl/dioxane for 3 h, followed by removing 
the solvent under vacuum. The residue was then purified using column chromatography to 
obtain compound 6 in quantitative yield. 1H NMR (500 MHz, CDCl3)  8.55 (s, 1H), 8.12 (d, J = 
6.8 Hz, 1H), 8.07 (d, J = 8.4 Hz, 2H), 7.87 (d, J = 8.8 Hz, 2H), 7.66 (d, J = 9.1 Hz, 1H), 7.49 – 
7.45 (m, 2H), 7.44 – 7.38 (m, 2H), 7.23 – 7.17 (m, 1H), 6.91 (td, J = 6.8, 0.9 Hz, 1H), 3.07 (s, 
2H). 13C NMR (126 MHz, CDCl3)  141.49, 131.62, 131.32, 130.44, 128.77, 127.97, 127.79, 
126.54, 126.32, 125.88, 125.33, 123.00, 122.10, 117.82, 111.89. MS (ESI) calculated for 
C21H15N3, m/z 309.13, found 310.14 [M+H]
+. 
 
Syntheses of compounds 7a and 7b: To a solution of compound 6 (20 mg, 0.065 mmol) in 
anhydrous methanol, were added octyl aldehyde (15 L, 0.098 mmol), 4 drops of acetic acid 
and sodium cyanoborohydride (6 mg, 0.098 mmol). The reaction mixture was stirred for 18h and 
the solvent was then removed under vacuum. The residue was purified using column 
chromatography to obtain compounds 7a (0-3% MeOH in CH2Cl2) and 7b (0-2% MeOH in 
CH2Cl2). 
 
7a: 2-(Anthracen-9-yl)-N-octylimidazo[1,2-a]pyridin-3-amine. 10 mg, 36%. 1H NMR (500 
MHz, CDCl3)  8.54 (s, 1H), 8.20 (dt, J = 6.8, 1.1 Hz, 1H), 8.06 (d, J = 8.4 Hz, 2H), 7.84 (dd, J = 
8.7, 0.7 Hz, 2H), 7.67 (d, J = 9.0 Hz, 1H), 7.50 – 7.43 (m, 2H), 7.42 – 7.37 (m, 2H), 7.23 (ddd, J 
= 9.0, 6.7, 1.3 Hz, 1H), 6.91 (td, J = 6.8, 1.1 Hz, 1H), 2.92 (s, 1H), 2.70 – 2.61 (m, 2H), 1.21 – 
1.11 (m, 2H), 0.99 (ddd, J = 15.6, 8.8, 7.1 Hz, 4H), 0.90 – 0.84 (m, 2H), 0.82 (t, J = 7.3 Hz, 3H), 
0.73 – 0.66 (m, 4H). 13C NMR (126 MHz, CDCl3)  141.95, 132.96, 131.54, 131.48, 129.37, 
128.73, 128.28, 127.86, 126.44, 126.28, 125.28, 123.54, 122.65, 117.92, 111.86, 48.16, 31.79, 
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30.06, 29.11, 29.10, 26.56, 22.70, 14.22. MS (ESI) calculated for C29H31N3, m/z 421.25, found 
422.27 [M+H]+. 
 
7b: 2-(Anthracen-9-yl)-N,N-dioctylimidazo[1,2-a]pyridin-3-amine. 7 mg, 20%. 1H NMR (500 
MHz, CDCl3)  8.54 (s, 1H), 8.30 (d, J = 6.8 Hz, 1H), 8.04 (d, J = 8.5 Hz, 2H), 7.63 (d, J = 8.7 
Hz, 3H), 7.46 – 7.40 (m, 2H), 7.31 (ddd, J = 8.6, 6.5, 1.1 Hz, 2H), 7.26 – 7.21 (m, 1H), 6.90 (td, 
J = 6.8, 1.0 Hz, 1H), 2.51 – 2.45 (m, 4H), 1.32 – 1.19 (m, 8H), 1.19 – 1.08 (m, 8H), 1.08 – 0.93 
(m, 8H), 0.85 (t, J = 7.2 Hz, 6H). 13C NMR (126 MHz, CDCl3)  142.02, 135.49, 132.12, 131.84, 
131.45, 129.90, 128.41, 127.72, 127.10, 125.49, 125.20, 123.93, 123.19, 117.77, 111.74, 54.71, 
31.92, 29.51, 29.38, 29.16, 27.09, 22.75, 14.25. MS (ESI) calculated for C37H47N3, m/z 533.38, 
found 534.38 [M+H]+. 
 
Synthesis of compound 7c: N-(2-(anthracen-9-yl)imidazo[1,2-a]pyridin-3-yl)-2,2,2-trifluoro 
acetamide. To a solution of compound 6 (10 mg, 0.024 mmol) in anhydrous CH2Cl2, was added 
trifluoroacetic anhydride (4 L, 0.03 mmol) and the reaction mixture was stirred for 12 h. The 
solvent was then removed under vacuum and the residue was purified using column 
chromatography (0-3% MeOH in CH2Cl2) to obtain compound 7c (10 mg, 73%). IR (CHCl3) max 
(cm-1): 1730, 1494, 1355, 1315, 1240, 1195, 1157. 1H NMR (500 MHz, MeOD)  8.89 (s, 1H), 
8.76 (d, J = 6.8 Hz, 1H), 8.28 – 8.14 (m, 3H), 8.10 (d, J = 9.0 Hz, 1H), 7.77 (d, J = 8.5 Hz, 2H), 
7.72 (dd, J = 10.0, 4.0 Hz, 1H), 7.59 (ddt, J = 9.9, 6.6, 3.9 Hz, 4H). 13C NMR (126 MHz, MeOD) 
 161.71, 161.41, 161.11, 160.82, 159.55, 159.23, 158.92, 158.61, 140.74, 135.66, 132.62, 
132.61, 132.47, 130.22, 129.81, 129.06, 127.34, 127.00, 125.58, 118.91, 118.54, 113.88. MS 
(ESI) calculated for C23H14F3N3O, m/z 405.11, found 406.12 [M+H]
+. 
 
Compound 8a-8c were synthesized similarly as compound 1a. 
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8a: 2-([1,1'-Biphenyl]-4-yl)-N-(2,4,4-trimethylpentan-2-yl)imidazo[1,2-a]pyridin-3-amine. 60 
mg, 63%. 1H NMR (500 MHz, CDCl3)  8.27 (d, J = 6.9 Hz, 1H), 7.99 – 7.95 (m, 2H), 7.71 – 7.65 
(m, 4H), 7.61 (d, J = 9.0 Hz, 1H), 7.46 (dd, J = 10.5, 4.8 Hz, 2H), 7.38 – 7.33 (m, 1H), 7.21 – 
7.15 (m, 1H), 6.82 (dd, J = 6.6, 6.2 Hz, 1H), 3.29 (s, 1H), 1.61 (s, 2H), 1.05 (s, 9H), 0.99 (s, 6H). 
13C NMR (126 MHz, CDCl3)  140.75, 140.14, 128.92, 128.78, 128.70, 127.31, 127.27, 127.26, 
127.00, 126.96, 124.63, 123.66, 123.48, 117.04, 111.69, 60.86, 57.09, 31.86, 31.76, 29.02. MS 
(ESI) calculated for C27H31N3, m/z 397.25, found 398.25 [M+H]
+. 
 
8b: 2-(Phenanthren-9-yl)-N-(2,4,4-trimethylpentan-2-yl)imidazo[1,2-a]pyridin-3-amine. 79 
mg, 78%. 1H NMR (500 MHz, CDCl3)  8.78 (d, J = 8.2 Hz, 1H), 8.74 (d, J = 8.1 Hz, 1H), 8.37 
(dt, J = 6.9, 1.1 Hz, 1H), 8.04 (dd, J = 8.2, 1.0 Hz, 1H), 7.92 (dd, J = 7.9, 1.2 Hz, 1H), 7.90 (s, 
1H), 7.68 (dddd, J = 8.3, 6.9, 4.2, 1.4 Hz, 2H), 7.65 – 7.56 (m, 3H), 7.21 (ddd, J = 9.0, 6.7, 1.3 
Hz, 1H), 6.86 (td, J = 6.8, 1.1 Hz, 1H), 3.21 (s, 1H), 1.26 (s, 2H), 0.78 (s, 6H), 0.73 (s, 9H). 13C 
NMR (126 MHz, CDCl3)  142.35, 139.07, 131.88, 131.67, 131.27, 130.82, 130.44, 129.27, 
128.91, 127.17, 126.89, 126.83, 126.72, 126.63, 125.55, 124.24, 123.90, 123.18, 122.72, 
117.53, 111.59, 60.24, 56.39, 31.63, 31.45, 28.78. MS (ESI) calculated for C29H31N3, m/z 
421.25, found 422.26 [M+H]+ and 444.25 [M+Na]+. 
 
8c: 2-(Pyren-4-yl)-N-(2,4,4-trimethylpentan-2-yl)imidazo[1,2-a]pyridin-3-amine. 47 mg, 
44%. 1H NMR (500 MHz, CDCl3)  8.40 (dt, J = 6.9, 1.1 Hz, 1H), 8.28 (d, J = 7.8 Hz, 1H), 8.23 – 
8.16 (m, 4H), 8.11 (dd, J = 12.1, 5.0 Hz, 3H), 8.02 (t, J = 7.6 Hz, 1H), 7.67 (dt, J = 9.0, 0.9 Hz, 
1H), 7.23 (ddd, J = 9.0, 6.7, 1.3 Hz, 1H), 6.87 (td, J = 6.8, 1.1 Hz, 1H), 3.24 (s, 1H), 1.20 (s, 2H), 
0.73 (s, 9H), 0.67 (s, 6H). 13C NMR (126 MHz, CDCl3)  142.45, 139.49, 131.39, 131.00, 
130.94, 130.62, 129.17, 128.39, 128.17, 127.55, 127.46, 125.92, 125.48, 125.20, 125.05, 
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125.01, 124.95, 124.79, 124.06, 123.77, 117.46, 111.40, 60.22, 56.27, 31.54, 31.32, 28.53. MS 
(ESI) calculated for C31H31N3, m/z 445.25, found 446.26 [M+H]
+ and 468.25 [M+Na]+. 
 
Compound 9 was synthesized similarly as compound 1a. 
 
9: 2-(10-Chloroanthracen-9-yl)-N-(2,4,4-trimethylpentan-2-yl)imidazo[1,2-a]pyridin-3-
amine. 128 mg, 59%. 1H NMR (500 MHz, CDCl3)  8.60 (d, J = 8.8 Hz, 2H), 8.41 (d, J = 6.9 Hz, 
1H), 7.90 (d, J = 8.8 Hz, 2H), 7.67 (d, J = 9.0 Hz, 1H), 7.62 – 7.57 (m, 2H), 7.50 – 7.45 (m, 2H), 
7.28 – 7.25 (m, 1H), 6.90 (t, J = 6.8 Hz, 1H), 2.83 (s, 1H), 0.96 (s, 2H), 0.68 (s, 6H), 0.52 (s, 
9H). 13C NMR (126 MHz, CDCl3)  142.73, 136.53, 131.45, 129.61, 129.14, 128.64, 127.24, 
127.01, 126.69, 126.58, 126.55, 125.21, 124.28, 123.73, 117.53, 111.57, 59.62, 55.90, 31.20, 
31.00, 28.67. MS (ESI) calculated for C29H30ClN3, m/z 455.21, found 456.23 [M+H]
+. 
 
Synthesis of compound 10: N1,N1-dimethyl-N3-(10-(3-((2,4,4-trimethylpentan-2-yl)amino) 
imidazo[1,2-a]pyridin-2-yl)anthracen-9-yl)propane-1,3-diamine. To a solution of compound 9 
(50 mg, 0.11 mmol) in anhydrous dioxane, were added potassium tert-butoxide (38 mg, 0.34 
mmol), N1,N1-dimethylpropane-1,3-diamine (69 L, 0.55 mmol) and catalytic amounts of 
tris(dibenzylideneacetone)dipalladium [Pd2(dba)3]  and 2-dicyclohexylphosphino-2′-(N,N-
dimethylamino)biphenyl [DavePhos]. The reaction was heated in a sealed tube at 80 °C for 4 h. 
The solvent was then removed under vacuum and the residue was purified using column 
chromatography to obtain compound 10 (15 mg, 26%). 1H NMR (500 MHz, MeOD)  8.53 (dt, J 
= 6.9, 1.0 Hz, 1H), 8.47 (d, J = 8.7 Hz, 2H), 7.74 (d, J = 8.5 Hz, 2H), 7.60 – 7.56 (m, 1H), 7.51 – 
7.45 (m, 2H), 7.44 – 7.35 (m, 3H), 7.04 (td, J = 6.8, 1.1 Hz, 1H), 3.45 (t, J = 7.1 Hz, 2H), 2.57 – 
2.52 (m, 2H), 2.30 (s, 6H), 2.02 – 1.91 (m, 2H), 0.95 (s, 2H), 0.74 (s, 6H), 0.45 (s, 9H). 13C NMR 
(126 MHz, MeOD)  144.90, 143.81, 137.83, 133.18, 128.54, 127.84, 127.32, 126.52, 126.46, 
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125.51, 125.31, 125.08, 124.09, 117.18, 113.25, 60.30, 58.65, 56.77, 51.56, 45.43, 44.86, 
32.49, 31.81, 31.76, 29.47, 29.44. MS (ESI) calculated for C34H43N5, m/z 521.35, found 522.37 
[M+H]+. 
 
Compound 11 was synthesized similarly as compound 1a. 
 
11: 2-(Anthracen-9-yl)-6-bromo-N-(2,4,4-trimethylpentan-2-yl)imidazo[1,2-a]pyridin-3-
amine. 150 mg, 63%. 1H NMR (500 MHz, CDCl3)  8.54 – 8.51 (m, 2H), 8.08 – 8.04 (m, 2H), 
7.82 (dd, J = 8.6, 0.9 Hz, 2H), 7.56 (dd, J = 9.4, 0.7 Hz, 1H), 7.49 – 7.41 (m, 4H), 7.30 (dd, J = 
9.4, 1.9 Hz, 1H), 2.91 (s, 1H), 0.96 (s, 2H), 0.68 (s, 6H), 0.50 (s, 9H). 13C NMR (126 MHz, 
CDCl3)  141.22, 138.24, 131.56, 131.08, 128.94, 128.70, 127.97, 127.51, 127.30, 126.66, 
126.08, 125.26, 124.04, 118.41, 106.62, 59.88, 55.93, 31.31, 31.07, 28.78. MS (ESI) calculated 
for C29H30BrN3, m/z 499.16, found 500.18 [M+H]
+. 
Compound 12 was synthesized similarly as compound 10. 
 
12: 2-(Anthracen-9-yl)-N6-(3-(dimethylamino)propyl)-N3-(2,4,4-trimethylpentan-2-yl) 
imidazo[1,2-a]pyridine-3,6-diamine. 21 mg, 40%. 1H NMR (500 MHz, MeOD)  8.61 (s, 1H), 
8.11 (d, J = 8.2 Hz, 2H), 7.83 (d, J = 8.6 Hz, 2H), 7.65 (d, J = 1.9 Hz, 1H), 7.52 – 7.42 (m, 4H), 
7.39 (d, J = 9.5 Hz, 1H), 7.04 (dd, J = 9.5, 2.1 Hz, 1H), 3.18 (t, J = 6.8 Hz, 2H), 2.60 – 2.54 (m, 
2H), 2.34 (s, 6H), 1.98 – 1.90 (m, 2H), 0.93 (s, 2H), 0.73 (s, 6H), 0.46 (s, 9H). 13C NMR (126 
MHz, MeOD)  140.23, 138.50, 136.47, 133.04, 132.49, 130.41, 129.86, 128.71, 128.35, 
127.41, 127.33, 126.29, 121.96, 117.07, 103.72, 60.35, 58.54, 56.85, 45.44, 43.56, 31.78, 
31.70, 29.50, 27.45. MS (ESI) calculated for C34H43N5, m/z 521.35, found 522.36 [M+H]
+. 
 
Compound 13 was synthesized similarly as compound 1a. 
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13: N-(tert-butyl)-2-(10-chloroanthracen-9-yl)imidazo[1,2-a]pyridin-3-amine. 242 mg, 84%. 
1H NMR (500 MHz, CDCl3)  8.60 (d, J = 8.8 Hz, 2H), 8.40 (dt, J = 6.9, 1.1 Hz, 1H), 7.91 (d, J = 
8.8 Hz, 2H), 7.66 (d, J = 9.0 Hz, 1H), 7.60 (ddd, J = 8.8, 6.5, 1.1 Hz, 2H), 7.48 (ddd, J = 8.7, 6.5, 
1.1 Hz, 2H), 7.28 – 7.23 (m, 1H), 6.90 (td, J = 6.8, 1.1 Hz, 1H), 2.63 (s, 1H), 0.65 (s, 9H). 13C 
NMR (126 MHz, CDCl3)  142.88, 136.60, 131.47, 129.77, 129.12, 128.75, 127.13, 126.76, 
126.72, 126.67, 125.36, 124.42, 123.78, 117.69, 111.71, 55.76, 29.90. MS (ESI) calculated for 
C25H22ClN3, m/z 399.15, found 400.17 [M+H]
+. 
 
Compound 14 was synthesized similarly as compound 10. 
 
14: N1-(10-(3-(tert-butylamino)imidazo[1,2-a]pyridin-2-yl)anthracen-9-yl)octane-1,8-
diamine. 20 mg, 32%. 1H NMR (500 MHz, MeOD)  9.01 (d, J = 6.8 Hz, 1H), 8.55 (d, J = 8.8 
Hz, 2H), 8.15 – 8.08 (m, 1H), 7.99 (dd, J = 13.0, 4.8 Hz, 3H), 7.85 (dd, J = 8.4, 7.0 Hz, 2H), 7.80 
– 7.71 (m, 2H), 7.67 (dd, J = 10.0, 4.0 Hz, 1H), 3.79 (dd, J = 16.7, 8.6 Hz, 2H), 2.94 (dd, J = 
14.0, 6.6 Hz, 2H), 2.00 – 1.91 (m, 2H), 1.72 – 1.63 (m, 2H), 1.46 – 1.38 (m, 6H), 0.81 (s, 9H). 
13C NMR (126 MHz, MeOD)  139.74, 135.47, 135.36, 132.83, 130.52, 129.36, 129.01, 128.07, 
127.63, 127.26, 127.03, 125.59, 123.03, 118.21, 113.15, 56.34, 54.29, 40.75, 30.28, 30.13, 
29.99, 28.55, 27.62, 27.38, 27.35. MS (ESI) calculated for C33H41N5, m/z 507.34, found 508.35 
[M+H]+. 
 
Compound 15 was synthesized similarly as compound 1a. 
 
15: 2-(Anthracen-9-yl)-6-bromo-N-(tert-butyl)imidazo[1,2-a]pyridin-3-amine. 260 mg, 81%. 
1H NMR (500 MHz, CDCl3)  8.54 – 8.52 (m, 2H), 8.08 – 8.04 (m, 2H), 7.83 (d, J = 8.6 Hz, 2H), 
7.56 (dd, J = 9.4, 0.6 Hz, 1H), 7.49 – 7.42 (m, 4H), 7.30 (dd, J = 9.4, 1.9 Hz, 1H), 2.68 (s, 1H), 
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0.64 (s, 9H).  13C NMR (126 MHz, CDCl3)  141.20, 138.13, 131.52, 130.96, 128.97, 128.47, 
128.04, 127.60, 127.27, 126.67, 125.99, 125.25, 123.94, 118.41, 106.67, 55.85, 29.83. MS 
(ESI) calculated for C25H22BrN3, m/z 443.10, found 444.10 [M+H]
+. 
 
Compound 16 was synthesized similarly as compound 10. 
 
16: N6-(8-aminooctyl)-2-(anthracen-9-yl)-N3-(tert-butyl)imidazo[1,2-a]pyridine-3,6-diamine. 
55 mg, 47%. 1H NMR (500 MHz, MeOD)  8.81 (s, 1H), 8.20 (dd, J = 6.5, 2.3 Hz, 2H), 7.85 – 
7.80 (m, 2H), 7.72 – 7.56 (m, 7H), 3.23 (t, J = 7.0 Hz, 2H), 2.97 – 2.90 (m, 2H), 1.80 (dt, J = 
14.5, 7.1 Hz, 2H), 1.72 – 1.64 (m, 2H), 1.59 – 1.51 (m, 2H), 1.45 (s, 6H), 0.78 (s, 9H). 13C NMR 
(126 MHz, MeOD)  141.50, 141.40, 134.23, 132.75, 132.52, 131.64, 130.29, 128.91, 128.20, 
127.68, 126.85, 126.05, 121.64, 112.69, 104.55, 56.28, 45.40, 40.78, 30.46, 30.35, 30.30, 




Microbiological methods. MICs of the compounds were determined by broth microdilution 
method per CLSI (formerly NCCLS) guidelines as described earlier.89 Mid-log phase Mueller-
Hinton broth (MHB; noncation supplemented) cultures of organisms (40 L; optical density at 
600 nm adjusted to 0.5 AU, and diluted 10-fold) were added to equal volumes of 2-fold serially 
diluted compounds in a 384-well microtiter plate with the help of a Biotek Precision 2000 
automated microplate pipetting system. The MICs of known antibiotics were included as 
reference compounds for comparison of activity. The microtiter plates were sealed and 
incubated overnight at 37°C. The plates were read at an absorbance of 600 nm. The lowest 
concentration of an agent inhibiting growth of the organisms was recorded as the MIC. For MBC 
determinations, conventional microdilution techniques were employed wherein 0.5 L of each of 
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the 384 wells in the parent MIC plate was diluted into 80 L of fresh MHB using the Biotek 
Precision 2000 automated liquid handling device. The microtiter plates were incubated overnight 
at 37°C. The plates were read at an absorbance of 600 nm. 5e-resistant S. aureus organisms 
were generated by exposing S. aureus ATCC 13709 to escalating doses of the compound. 
Within about 10 serial passages, organisms that withstood 5e up to concentrations of 100 
g/mL emerged. 
  




































Potent TLR7-specific agonist (EC50 = 0.26 M)
High IFN- / Low Proinflammatory Cytokine Induction
H2N
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5.1. Introduction 
 
Occupancy of TLR731b, 51a, 90 or TLR991 in professional antigen-presenting cells (APCs), 
particularly plasmacytoid dendritic cells (pDCs), leads to the induction of IFN-/. Although the 
Type I IFNs are best known historically for their antiviral activities,92 recent studies show that 
they have many essential functions in the control of adaptive immunity.93 First, Type I IFNs 
promote cross-priming through direct stimulation of DCs, leading to specific CD8+ lymphocytic 
responses to soluble antigens.94 Second, Type I IFNs potently enhance the primary antibody 
responses to soluble antigens, inducing sustained and durable humoral responses with 
appropriate isotype switching, as well as the induction of immunological memory.95 B 
lymphocytes can differentiate into two distinct types of functionally polarized effectors: B-
effector-1-cells (Be-1), producing a Th1-like cytokine pattern, or Be-2, characterized by a Th2-
like profile.96 It is of particular interest that recent reports suggest that IFN- may serve as an 
initial trigger for Be-1-biased differentiation pattern.97 Third, Type I IFNs secondarily induce Type 
II IFN (IFN-) secretion, also driving Th1-biased adaptive immune responses.98 Type I IFN-
inducing TLR ligands may therefore hold promise as vaccine adjuvants. 
 
In an effort to identify optimal immunostimulatory chemotypes, we have screened representative 
members of virtually the entire compendium of known TLR agonists in a series of hierarchical 
assays including primary TLR-reporter assays, secondary indices of immune activation such as 
IFN-and cytokine induction, activation of lymphocytic subsets in whole human blood, and 
tertiary screens characterizing transcriptomal activation patterns.30 In these assays, small-
molecule agonists of TLR7 were uniquely immunostimulatory; they were potent inducers of 
Type I IFN and, unlike TLR-4, -5, or -8 agonists,30 did not evoke dominant proinflammatory 
cytokine responses, suggesting that they may be effective, yet safe vaccine adjuvants, a 
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premise that we have been actively exploring.56 Small molecule TLR7 agonists are also being 
investigated as orally bioavailable, endogenous Type I IFN inducers for the management of 
chronic viral diseases,99 especially hepatitis C and hepatitis B. Current therapeutic regimens for 
the therapy of hepatitis C and hepatitis B include parenteral IFN-.100 Clinical trials of TLR7 
agonists for hematological malignancies are also currently underway.101 
 
As mentioned earlier, the currently known small molecule agonists of TLR7 occupy a very small 
chemical space, and are represented by the 1H-imidazo[4,5-c]quinolines,37 8-hydroxy-76, 102 or 8-
oxoadenines,103 and guanine nucleoside analogues.31a, 104 We had previously reported structure-
activity relationships (SAR) in the imidazoquinolines with a focus on substituents at the N1, C2, 
N3 and N4 positions,55b, 69 and we had observed that relatively minor structural modifications at 
these positions yielded compounds with widely differing immunomodulatory properties.55a, 56, 58, 77 
It was of interest, therefore, to extend our SAR studies to the quinoline ring system. We asked if 
a part-structure (imidazopyridine) or a benzologue (benzoimidazoquinoline) would alter the 
biological properties of the parent imidazoquinoline compound. Examination of the structures of 
3M-003105 and the 8-hydroxy- and 8-oxoadenines (Fig. 1) suggested that the quinoline system 
may be dispensable, and activity would be retained in imidazopyridines. Indeed, imidazopyridine 
derivatives with alkyl groups at C6 and C7 positions,106 hydroxyalkyl,107 oxime and 
hydroxylamine-bearing substituents at C2,108 and alkylsulfonamide substituents at the N1 
position109 have been reported in the patent literature. Detailed activity profiles of these 
compounds, however, are not available, perhaps owing to the fact that the investigations of 
such compounds precede the discovery of the TLRs. 
 
Incorporating substituents that we had previously determined to be optimal in the 
imidazoquinolines (N1-benzyl and C2-butyl; IMDQ, Fig. 1), we embarked on the syntheses and 
biological evaluation of novel 1H-imidazo[4,5-c]pyridine analogues with modifications at the N4- 
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and C6 positions. The parent imidazopyridine compound, 1-benzyl-2-butyl-1H-imidazo[4,5-
c]pyridin-4-amine, exhibited moderate TLR7-agonistic activity. N4-acyl or -alkyl substitutions 
abrogated activity. The majority of C6 derivatives bearing aryl groups were also inactive, but 
analogues with N6-benzyl substituents gained TLR7-specific activity. Particular N6 substituents 
were found to augment TLR7-specific agonistic potency without compromising specificity at 
TLR7; consistent with their pure TLR7 activity (and undetectable TLR8 agonism), these 
compounds potently induced IFN- in human peripheral blood mononuclear cells (PBMCs), 
upregulated CD69 in lymphocytic subsets, and yet showed very weak proinflammatory cytokine-
inducing activities. Strong Type I IFN inducers, especially in conjunction with attenuated 
proinflammatory profiles are expected to be potently adjuvantic without inducing prominent local 
or systemic inflammation.  
 
Fig. 1. Structures of small molecule agonists of TLR7 represented by the 8-oxoadenine (SM360320), 8-
hydroxyadenines (CL264), 1H-imidazo[4,5-c]quinolines 3M-003, 1-isobutyl-1H-imidazo[4,5-c]quinolin-
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5.2. Results and Discussion 
 
Our interest in exploring TLR7 agonists as vaccine adjuvants has been greatly reinforced by our 
observations that pure TLR7 agonists, unlike other TLR ligands, are potently immunostimulatory 
without prominently activating inflammatory programs in human whole blood model systems.30 
As mentioned earlier, the structures of 3M-003105 and the 8-hydroxy- and 8-oxoadenines (Fig. 
1), as well as patent literature suggested that the quinoline system may be dispensable, and 
activity would be retained in imidazopyridines. Our previous SAR studies on the 
imidazoquinolines had established that N1-benzyl and C2-butyl substituents were optimal;69 our 
point of departure in examining structure-activity relationships in the imidazopyridines 
consequently began with the evaluation of 1-benzyl-2-butyl-1H-imidazo[4,5-c]pyridin-4-amine 
(5), following the synthetic strategy described earlier (Scheme 1).37, 69 Compound 5, itself a 
novel and unprecedented structure, was found to possess TLR7-specific agonistic activity 
(EC50: 1.57 M, Fig. 2, Table 1), with negligible TLR8 activity. The potency of the lead TLR7-
specific imidazoquinoline (1-benzyl-2-butyl-1H-imidazo[4,5-c]quinolin-4-amine, structure in Fig. 
1) was 0.06 M (Fig. 2).69   
 
Scheme 1. Synthesis of 1-benzyl-2-butyl-1H-imidazo[4,5-c]pyridin-4-amine 5. 
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Acylation (6a and 6b, Scheme 2) of the C4-NH2 resulted in complete abrogation of activity 
(Table 1).  
 
Scheme 2. Synthesis of C4-N-acylated analogues. 
 
 
C6-modified analogues were synthesized via an alternate route. Nitration of 4-amino-2-
chloropyridine resulted, as expected, in a mixture of the 3-and 5-nitro intermediates 7a and 7b, 
which were taken forward to obtain the 4- and 6-chloroimidazopyridines 10a and 10b (Scheme 
3). Excellent chromatographic separation of these advanced intermediates was possible. Pd-
catalyzed C-N cross-coupling reactions using n-butylamine and benzylamine from intermediate 
10a furnished the C4-N-alkylated analogues 11a and 11b, respectively (Scheme 3). A 4-butoxy 
analogue 11c was also obtained by ipso-chloro displacement with 1-butanol. Compounds 11a-c 
were, however, inactive (Table 1). We had envisaged utilizing the 6-chloroimidazopyridine 
intermediate 10b for synthesizing C6-functionalized analogues. However, this intermediate 
exhibited unexpectedly low reactivity to displacement with nucleophiles or to Buchwald-Hartwig 
coupling reactions. As outlined in Scheme 4, we utilized 4-amino-2,6-dichloropyridine as the 
starting material and obtained 13 as a key intermediate which, upon reaction with tert-
octylamine78 provided exclusively the N2-alkylated intermediate 14. The 6-chloro-N-(2,4,4- 
trimethylpentan-2-yl)-1H-imidazopyridin-4-amine intermediate 16 was obtained without difficulty, 
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and we were able to synthesize the N6-substituted analogues 19a-o under conventional 
Buchwald-Hartwig conditions (Scheme 4).  
Scheme 3. Synthesis of C4-N- and O-alkylated analogues. 
 
Scheme 4. Synthesis of N6-substituted analogues. 
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TLRs signal via ligand-induced dimerization, but since that the crystal structure of human TLR7 
and of its ligand binding modes are as yet unknown, we utilized intermediate 16 in constructing 
‘dimeric’ imidazopyridines (using p- and m-xylylenediamine, Scheme 5) to ascertain if such pre-
organized dimeric ligands could yield high-potency agonists.  
 
Scheme 5. Synthesis of dimeric compounds. 
 
 
The 6-chloroimidazopyridine 17 (Scheme 4) was inactive (Table 1). Buchwald-Hartwig-derived 
N6-substituted analogues 19a-q, however, showed a distinctive SAR. Compound 19a with a free 
NH2 at C6, obtained by coupling the tert-octylamine and subsequent N-dealkylation with HCl 
(Scheme 4, Table 1) displayed TLR7-specific agonism with a potency comparable to that of the 
parent C6-unsubstituted compound 5. Modest gains in potency were obtained in analogues with 
short aliphatic substituents with N6-butyl (19b) and N6-cyclohexylmethyl (19d), but potency 
diminished in the N6-heptyl analogue (19c). The N6-phenyl-substituted compound 19e was 
marginally weaker than 5; however, the potency of the N6-benzyl analogue 19f was ~7.6 times 
that of 5 (Table 1, Fig. 2), triggering a detailed SAR investigation on various aryl substituents at 
N6. Both steric and electronic effects appear to play a role in governing TLR7-agonistic potency, 
since the biphenylmethyl-substituted compound 19o was active, whereas the naphthylmethyl 
analogue 19n was quiescent; to a first approximation, electron-rich N6 substituents appear to be 
preferred, with the methoxybenzyl derivatives (19g and 19h) and the pyridinylmethyl 
compounds (19l and 19m) being marginally more active than the trifluoromethyl- (19i) or chloro- 
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(19j) substituted analogues. Compounds 19p and 19q were also active in primary screens, with 
EC50 values of 0.26 and 0.37 M, respectively (Table 1).  
 
For the C6-substituted compounds 23a-j (Scheme 6), we observed mediocre yields in pilot 
Suzuki coupling reactions with the advanced intermediate 16. We therefore exploited the 
electron-withdrawing resonance effect of the 3-nitro group in 14. As expected, the classical 
Suzuki reaction on intermediate 14 using various aliphatic and aromatic boronic acids/boronate 
esters resulted in the intermediates 20a-j (Scheme 6), which were further derivatized to obtain 
the desired C6 alkyl/aryl substituted imidazopyridines 23a-j. 
 
Scheme 6. Synthesis of C6-substituted analogues. 
 
  
In the C6-alkyl or -aryl analogues (Scheme 6), the SAR appeared more stringent. Whereas the 
C6-butyl compound 23a was more active than 5, direct aryl-aryl connections at C6 (23b-f) 
abrogated activity, but TLR7 agonistic properties were restored in the 6-benzyl (23g) and 6-
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phenethyl analogues (23j). Taken together with activity data of compounds of the 19 series, we 
surmised that rotational constraints about the C6-aryl groups may hinder TLR7 occupancy. 
Unlike TLR2, TLR3, TLR4,110 and TLR5111 for which crystal structures are available as 
complexes with their cognate ligands, a detailed structural characterization of the mode of 
binding of TLR7 ligands is not yet available to guide structure-based design of small molecule 
agonists of TLR7, necessitating classical SAR approaches to refine successive iterations of 
ligand design. 
 
Fig. 2. TLR7 agonistic activities of imidazopyridine compounds. Data points represent means and 
standard deviations on quadruplicates. 
 
 




































Compound Concentration (M)  
 
 
The benzologue 30 was also synthesized as shown in Scheme 7. It showed substantial 
improvements in potency over the parent imidazopyridine 5 (Fig. 3, Table 1), but the two most 
potent compounds in the entire series as adjudged by primary screens were the N6-(4-
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methoxybenzyl) and N6-(furan-2-ylmethyl) analogues (19g and 19k, respectively), both of which 
were approximately twenty-fold more potent than 5 (Fig. 2, Table 1). 
 
Scheme 7. Synthesis of benzologue 30. 
 
 
Fig. 3. Dose-response profiles of TLR7 agonistic activity of compounds 5 and 30. Data points represent 
means and standard deviations on quadruplicates. 
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Table1. EC50 values of compounds in human TLR7/8-specific reporter gene assay. 
 
 
aInactive: no activity was detected up to a concentration of 500 g/mL. 
No. R1 R2 
hTLR7-agonistic 
Activity (M) 
5 H H 1.57 
6a COCH3 H Inactive
a 
6b COC3H7 H Inactive 
11a C4H9 H Inactive 
11b CH2C6H5 H Inactive 
17 H Cl Inactive 
19a H NH2 1.25 
19b H NHC4H9 0.34 




19e H NHC6H5 1.72 











































23a H C4H9 0.28 

























30 Benzologue (Scheme 7) 0.22 
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We chose the nine most active compounds (19b, 19d, 19f-g, 19k-m, 19p, and 23a) for 
evaluation in secondary screens using IFN- and cytokine release in human PBMCs. We used, 
as reference compounds, imiquimod, a known TLR7 agonist,112 as well as CL075,45, 62 a 
predominantly TLR8-active agonist with an EC50 of 1.32 M in hTLR8 assays.113 
 
 Fig. 4. Dose-response profiles of Type I interferon (IFN-) and proinflammatory cytokine (IL-8, IL-1, 
and TNF-) induction by selected imidazopyridine (and reference) compounds. Representative data from 


























Given that the imidazopyridine compounds are pure TLR7 agonists, we expected to find 
prominent IFN- induction,30 and this was indeed the case, with 19p, 19m, and 19k being the 
most potent (EC50: 0.3 M, 0.4 M and 0.7 M, respectively; Fig. 4). CL075 was among the 
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least potent in IFN- induction (EC50: 2.6 M; Fig. 4), and as expected for a TLR8 agonist, 
CL075 was dramatically more active in inducing proinflammatory cytokines such as TNF-, IL-
1, and IL-8 (Fig. 4). We do not yet understand the basis for the slight discrepancy between 
rank-order potency in primary screens (19k≈19g>19f>19p; Fig. 2, Table 1) vis-à-vis IFN--
inducing potency in human PBMCs (19p≈19m>19k; Fig. 4), and we surmise that analogues with 
more basic C6 substituents may allow for higher endolysosomal partitioning. The dose-
response profiles show characteristic biphasic responses (dose-dependent activation, followed 
by apparent suppression) as we had previously observed in several chemotypes. We verified 
that the apparent suppression was not due to cytotoxicity using LDH release and mitochondrial 
redox-based assays.  
 
We had previously shown that of all the various classes of innate immune stimuli, TLR7 
agonists were extraordinarily immunostimulatory, stimulating virtually all subsets of lymphocytes 
(assessed by quantifying CD69 expression), and yet without inducing dominant proinflammatory 
cytokine responses,30 and we wished to confirm the rank-order potency observed in IFN- 
induction assays described above.  
 
We observed considerable dissociation between Type I IFN induction on the one hand (Fig. 4), 
and CD69 upregulation in lymphocytic subsets on the other (Fig. 5). Whereas the subset of 
active compounds induced IFN- with similar potencies (EC50 values between 0.3-2 M; Fig. 4), 
pronounced differences were observed in CD69 expression in natural killer, cytokine-induced 
killer and B lymphocytic subsets with 19p being as active as the reference TLR7 agonist IMDQ, 
and 19d showing virtually no activity (Fig. 5). Possible mechanisms underlying the differential 
activity in these two compounds are being investigated. 
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Fig. 5. CD69 upregulation in human natural killer (NK), cytokine-induced killer (CIK) and nominal B 
lymphocytes by select imidazopyridine (and reference) compounds. 
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5.3. Conclusions 
 
These findings raise the possibility of utilizing these compounds in selectively targeting Type I 
IFN induction versus lymphocytic activation, and are being explored in greater detail. The 
potential advantages of strong Type I IFN inducers as candidate vaccine adjuvants have been 
discussed earlier. Such compounds, especially in conjunction with attenuated proinflammatory 
cytokines, are expected to be potently adjuvantic without inducing prominent local or systemic 
inflammation. As mentioned earlier, the prominent Type I IFN-inducing abilities of the 
imidazopyridines may also find utility as an alternative therapeutic strategy to address disease 
states wherein systemic IFN- is of proven benefit. A clear delineation of structural features that 
confer TLR specificity not only charts a rational course for the development of effective, yet safe 






Chemistry. All of the solvents and reagents used were obtained commercially and used as 
such unless noted otherwise. Moisture- or air-sensitive reactions were conducted under nitrogen 
atmosphere in oven-dried (120 °C) glass apparatus. The solvents were removed under reduced 
pressure using standard rotary evaporators. Flash column chromatography was carried out 
using RediSep Rf ‘Gold’ high performance silica columns on CombiFlash Rf instrument unless 
otherwise mentioned, while thin-layer chromatography was carried out on silica gel (200 m) 
CCM pre-coated aluminum sheets. Purity for all final compounds was confirmed to be greater 
than 97% by LC-MS using a Zorbax Eclipse Plus 4.6 mm × 150 mm, 5 m analytical reverse 
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phase C18 column with H2O-isopropanol or H2O–CH3CN gradients and an Agilent 6520 ESI-
QTOF Accurate Mass spectrometer (mass accuracy of 5 ppm) operating in the positive ion (or 
negative ion, as appropriate) acquisition mode. 
 
Synthesis of compound 1: N-Benzyl-3-nitropyridin-4-amine. To a solution of 4-chloro-3-
nitropyridine (1.0 g, 6.31 mmol) in 25 mL of CH2Cl2 were added triethylamine (1.32 mL, 9.47 
mmol) and benzyl amine (0.83 mL, 7.57 mmol). The reaction mixture was refluxed for 18 h. The 
solvent was then evaporated under vacuum and H2O was added to the residue. The solution 
was extracted with CH2Cl2 (3 × 20 mL), washed with water and dried over sodium sulfate. The 
solvent was evaporated and the residue was purified using silica gel column chromatography 
(0-5% MeOH in CH2Cl2) to obtain compound 1 as a yellow solid (1.4 g, 94%). 
1H NMR (500 
MHz, CDCl3)  9.22 (s, 1H), 8.53 (s, 1H), 8.25 (dd, J = 6.1, 0.6 Hz, 1H), 7.41 – 7.35 (m, 2H), 
7.32 (dd, J = 7.2, 5.3 Hz, 3H), 6.69 (d, J = 6.2 Hz, 1H), 4.56 (d, J = 5.7 Hz, 2H). 13C NMR (126 
MHz, CDCl3)  153.38, 149.06, 148.68, 135.96, 130.04, 129.21, 128.22, 127.10, 108.25, 46.85. 
MS (ESI) calculated for C12H12N3O2, m/z 230.0924, found 230.0949 [M+H]
+.  
 
Synthesis of compound 2: N4-Benzylpyridine-3,4-diamine. To a solution of compound 1 (1.0 
g, 4.36 mmol) in 40 mL of MeOH were added zinc dust (1.4 g, 21.8 mmol) and ammonium 
formate (1.4 g, 21.8 mmol). The reaction mixture was stirred at room temperature for 10 min 
and filtered through celite. Then the solvent was evaporated and the residue was dissolved in 
water. This was extracted with EtOAc (3 × 20 mL), washed with water and dried over sodium 
sulfate. The solvent was evaporated under vacuum to obtain the compound 2 (0.8 g, 92%).1H 
NMR (500 MHz, CDCl3)  7.81 (d, J = 5.4 Hz, 1H), 7.77 (s, 1H), 7.29 – 7.19 (m, 5H), 6.36 (d, J = 
5.4 Hz, 1H), 4.87 (s, 1H), 4.28 (d, J = 5.4 Hz, 2H), 3.28 (s, 2H). 13C NMR (126 MHz, CDCl3)  
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144.52, 143.51, 138.22, 137.53, 128.96, 128.79, 127.55, 127.48, 105.29, 47.22. MS (ESI) 
calculated for C12H14N3, m/z 200.1182, found 200.1242 [M+H]
+.  
 
Synthesis of compound 3: 1-Benzyl-2-butyl-1H-imidazo[4,5-c]pyridine. To a solution of 
compound 2 (400 mg, 2.00 mmol) in 20 mL of anhydrous THF were added triethylamine (0.29 
mL, 2.10 mmol) and valeryl chloride (0.27 mL, 2.20 mmol). The reaction mixture was refluxed 
for 2 h. The solvent was then removed under vacuum, and the residue was dissolved in EtOAc 
and washed with water. The EtOAc fraction was dried using sodium sulfate and evaporated 
under vacuum to obtain the intermediate amide compound. This was dissolved in 20 mL of 
EtOH and NaOH (160 mg, 4.00 mmol) in 2 mL of H2O was added. The reaction mixture was 
refluxed for 4 h. The solvent was then removed under vacuum, and the residue was dissolved in 
EtOAc and washed with water. The organic layer was dried using sodium sulfate and 
evaporated and purified using column chromatography (0-5% MeOH in CH2Cl2) to obtain the 
compound 3 (210 mg, 40%).  1H NMR (500 MHz, CDCl3)  9.04 (d, J = 0.6 Hz, 1H), 8.34 (d, J = 
5.6 Hz, 1H), 7.34 – 7.28 (m, 3H), 7.14 (dd, J = 5.6, 1.0 Hz, 1H), 7.01 (dd, J = 7.7, 1.8 Hz, 2H), 
5.33 (s, 2H), 2.86 – 2.81 (m, 2H), 1.82 (dt, J = 15.5, 7.7 Hz, 2H), 1.46 – 1.36 (m, 2H), 0.91 (t, J 
= 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3)  157.30, 142.14, 142.00, 140.48, 140.01, 135.26, 
129.28, 128.37, 126.27, 105.12, 47.25, 29.44, 27.38, 22.61, 13.85. MS (ESI) calculated for 
C17H20N3, m/z 266.1652, found 266.1715 [M+H]
+. 
 
Synthesis of compound 4: 1-Benzyl-2-butyl-1H-imidazo[4,5-c]pyridine 5-oxide.  To a 
solution of compound 3 (210 mg, 0.79 mmol) in 15 mL of was added m-chloroperoxybenzoic 
acid (443 mg, 1.98 mmol), and the solution was refluxed at 45-50 ºC for 1 h. The solvent was 
then removed and the residue was purified using column chromatography (0-10% MeOH in 
CH2Cl2) to obtain the N-oxide derivative (188 mg, 85%). 
1H NMR (500 MHz, CDCl3)  8.71 (d, J 
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= 1.3 Hz, 1H), 8.05 (dd, J = 7.0, 1.6 Hz, 1H), 7.36 – 7.30 (m, 3H), 7.01 (dd, J = 10.4, 4.3 Hz, 
3H), 5.31 (s, 2H), 2.85 – 2.80 (m, 2H), 1.79 (dt, J = 15.4, 7.6 Hz, 2H), 1.44 – 1.34 (m, 2H), 0.90 
(t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3)  160.72, 140.89, 134.42, 134.32, 133.94, 
131.52, 129.48, 128.75, 126.24, 106.63, 47.75, 29.25, 27.49, 22.52, 13.78. MS (ESI) calculated 
for C17H20N3O, m/z 282.1601, found 282.1612 [M+H]
+. 
 
Synthesis of compound 5: 1-Benzyl-2-butyl-1H-imidazo[4,5-c]pyridin-4-amine. To a 
solution of compound 4 (188 mg, 0.67 mol) in 15 mL of CH2Cl2 was added benzoyl isocyanate 
(197 mg, 1.34 mmol) and heated at 45 ºC for 2 h. The solvent was then removed under 
vacuum, and the residue was dissolved in 15 mL of anhydrous MeOH, followed by the addition 
of excess sodium methoxide. The reaction mixture was then heated at 80 ºC for 1 h. The 
solvent was removed under vacuum and the residue was purified using column chromatography 
(0-7% MeOH in CH2Cl2) to obtain the compound 5 (56 mg, 30%). 
1H NMR (500 MHz, CDCl3)  
7.78 (d, J = 5.8 Hz, 1H), 7.34 – 7.28 (m, 3H), 7.03 (d, J = 6.4 Hz, 2H), 6.59 (d, J = 5.8 Hz, 1H), 
5.27 (s, 2H), 5.15 (s, 2H), 2.83 – 2.75 (m, 2H), 1.72 (ddd, J = 13.0, 9.0, 7.7 Hz, 2H), 1.44 – 1.34 
(m, 2H), 0.90 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3)  154.06, 151.00, 140.61, 140.41, 
135.76, 129.21, 128.23, 126.33, 97.74, 47.52, 30.10, 27.42, 22.68, 13.89. HRMS (ESI) 
calculated for C17H21N4, m/z 281.1761, found 281.1795 [M+H]
+. 
 
Synthesis of compound 6a: N-(1-Benzyl-2-butyl-1H-imidazo[4,5-c]pyridin-4-yl)acetamide. 
To a solution of compound 5 (30 mg, 0.11 mmol) in 2 mL of CH2Cl2 were added triethylamine 
(17 L, 0.12 mmol) and acetyl chloride (8 L, 0.11 mmol). The reaction mixture was stirred at 
room temperature for 3 h and purified using column chromatography (5% MeOH/CH2Cl2) to 
obtain the compound 6a as white solid (6 mg, 16%). 1H NMR (500 MHz, CDCl3)  11.60 (s, 1H), 
8.20 (s, 1H), 7.37 (dd, J = 7.7, 5.5 Hz, 3H), 7.20 (d, J = 5.6 Hz, 1H), 7.05 (dd, J = 6.3, 2.5 Hz, 
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2H), 5.46 (s, 2H), 3.03 – 2.94 (m, 2H), 2.55 (s, 3H), 1.85 (dt, J = 15.0, 7.6 Hz, 2H), 1.43 (dq, J = 
14.6, 7.3 Hz, 2H), 0.92 (t, J = 7.3 Hz, 3H). 13C NMR (126 MHz, CDCl3)  141.48, 129.64, 
129.40, 129.17, 126.30, 126.25, 48.47, 29.06, 24.87, 22.44, 13.60.  HRMS (ESI) calculated for 
C19H23N4O, m/z 323.1866, found 323.1911 [M+H]
+. 
 
Compound 6b was synthesized similarly as compound 6a. 
 
6b: N-(1-Benzyl-2-butyl-1H-imidazo[4,5-c]pyridin-4-yl)butyramide. Butyryl chloride was used 
as a reagent. 4 mg, 14 %. 1H NMR (500 MHz, CDCl3)  11.31 (s, 1H), 8.30 (d, J = 4.8 Hz, 1H), 
7.38 – 7.34 (m, 3H), 7.27 (s, 1H), 7.04 (dd, J = 6.4, 2.6 Hz, 2H), 5.50 (s, 2H), 2.94 (t, J = 7.5 Hz, 
2H), 2.78 (t, J = 7.4 Hz, 2H), 1.80 (dp, J = 22.1, 7.5 Hz, 4H), 1.41 (dt, J = 14.7, 7.4 Hz, 2H), 1.01 
(t, J = 7.4 Hz, 3H), 0.91 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3)  174.32, 141.35, 
133.50, 129.69, 129.16, 126.46, 103.38, 48.58, 39.27, 29.16, 27.45, 22.55, 18.38, 13.75. HRMS 
(ESI) calculated for C21H27N4O, m/z 351.2179, found 351.2240 [M+H]
+. 
 
Synthesis of compound 10a: 1-Benzyl-2-butyl-4-chloro-1H-imidazo[4,5-c]pyridine. 4-
Amino-2-chloropyridine (2.0 g, 15.6 mmol) was taken in 20 mL of conc. H2SO4 in an ice-bath to 
which was added 10 mL of conc. HNO3 slowly. The reaction mixture was gradually brought to 
room temperature and stirred for 1 h. The reaction was quenched by pouring the reaction 
mixture on ice. Ammonium hydroxide solution was slowly added until a pH of 3 was reached. A 
white solid was obtained which was filtered, washed with water, and dried. This (N-
nitro)aminopyridine intermediate was taken up in 10 mL of conc. H2SO4 and the reaction 
solution was heated at 90 ºC for 30 min. It was cooled to room temperature and poured into ice. 
It was slowly neutralized with ammonium hydroxide solution until a pH of 7 and the formed 
yellow solid was filtered, washed with water and dried to obtain compound 7 as a mixture of 2-
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chloro-3-nitropyridin-4-amine and 2-chloro-5-nitropyridin-4-amine intermediates. Sodium hydride 
(275 mg, 6.90 mmol) was carefully added to 20 mL of THF under N2 and compound 7 (1.0 g, 
5.76 mmol) was slowly added to the solution at 0 ºC. The reaction mixture was stirred for 1 h, 
followed by the addition of benzyl bromide (0.75 mL, 6.34 mmol). The reaction mixture was 
stirred at room temperature for 2 h and poured into ice water. Then it was extracted with EtOAc 
(3 × 20 mL), washed with water, dried over sodium sulfate. The solvent was removed and the 
crude residue was purified using column chromatography (0-20% EtOAc in hexane) to obtain 
the compound 8 as a mixture of regioisomeric N-benzyl-2-chloro-3-nitropyridin-4-amine and N-
benzyl-2-chloro-5-nitropyridin-4-amine intermediates. To this regioisomeric mixture (1.0 g, 4.2 
mmol) in 20 mL of MeOH were added zinc dust (1.4 g, 21.0 mmol) and ammonium formate (1.4 
g, 21.0 mmol). The reaction mixture was stirred at room temperature for 10 min and filtered 
through celite. Then the solvent was evaporated and the residue was dissolved in water. This 
was extracted with EtOAc (3 × 20 mL), washed with water and dried over sodium sulfate. The 
filtrate evaporated under vacuum, and chromatographed (0-20% EtOAc in hexane) to obtain the 
required N4-benzyl-2-chloropyridine-3,4-diamine compound 9a. Also obtained was N4-benzyl-6-
chloropyridine-3,4-diamine as a side-product. To a solution of compound 9a (495 mg, 2.12 
mmol) in 20 mL of anhydrous THF were added triethylamine (0.31 mL, 2.23 mmol) and valeryl 
chloride (0.28 mL, 2.33 mmol). The reaction mixture was refluxed for 1 h. The solvent was then 
removed under vacuum, and the residue was dissolved in 20 mL of EtOH and NaOH (170 mg, 
4.24 mmol) in 2 mL of H2O was added. The reaction mixture was refluxed for 2 h. The solvent 
was then removed under vacuum, and the residue was dissolved in EtOAc and washed with 
water. The EtOAc fraction was dried using sodium sulfate and evaporated and purified using 
column chromatography (0-5% MeOH in CH2Cl2) to obtain the compound 10a (203 mg, 32%). 
1H NMR (500 MHz, CDCl3)  8.10 (d, J = 5.6 Hz, 1H), 7.35 – 7.30 (m, 3H), 7.08 (d, J = 5.6 Hz, 
1H), 7.01 (dd, J = 7.4, 2.0 Hz, 2H), 5.34 (s, 2H), 2.91 – 2.86 (m, 2H), 1.78 (dt, J = 15.7, 7.7 Hz, 
2H), 1.45 – 1.36 (m, 2H), 0.90 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3)  158.03, 141.88, 
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141.75, 141.12, 137.03, 134.84, 129.39, 128.58, 126.25, 105.18, 47.90, 30.04, 27.63, 22.73, 
13.82. MS (ESI) calculated for C17H19ClN3, m/z 300.1262, found 300.1159 [M+H]
+. 
 
Synthesis of compound 11a: 1-Benzyl-N,2-dibutyl-1H-imidazo[4,5-c]pyridin-4-amine. To a 
solution of compound 10 (50 mg, 0.17 mmol) in 1 mL of dioxane were added potassium tert-
butoxide (57 mg, 0.51 mmol), catalytic amount of 2-dicyclohexylphosphino-2′-(N,N-dimethyl 
amino)biphenyl (DavePhos) and tris(dibenzylideneacetone)dipalladium(0) (Pd2(dba)3) and butyl 
amine (83 L, 0.83 mmol). The reaction mixture was then heated under microwave conditions 
(500 W, 100 ºC) in a sealed vial for 1 h. It was cooled to room temperature and filtered through 
celite and washed with MeOH. The solvent was removed and the crude residue was purified 
using column chromatography (0-5% MeOH in CH2Cl2) to obtain the compound 11a (21 mg, 
36%). 1H NMR (500 MHz, CDCl3)  7.84 (d, J = 5.9 Hz, 1H), 7.33 – 7.27 (m, 3H), 7.03 (dd, J = 
4.5, 3.6 Hz, 2H), 6.48 (d, J = 5.9 Hz, 1H), 5.41 (s, 1H), 5.25 (s, 2H), 3.60 (dt, J = 12.9, 6.5 Hz, 
2H), 2.80 – 2.74 (m, 2H), 1.73 – 1.67 (m, 4H), 1.49 (dt, J = 15.0, 7.4 Hz, 3H), 1.38 (dd, J = 15.0, 
7.5 Hz, 2H), 0.96 (t, J = 7.4 Hz, 3H), 0.89 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3)  
153.15, 151.39, 135.95, 129.24, 129.15, 128.15, 127.25, 126.34, 126.18, 96.16, 47.43, 41.09, 
32.22, 30.27, 27.41, 22.69, 20.47, 14.11, 13.89. HRMS (ESI) calculated for C21H29N4, m/z 
337.2387, found 337.2451 [M+H]+. 
 
Compound 11b was synthesized similarly as compound 11a. 
 
11b: N,1-Dibenzyl-2-butyl-1H-imidazo[4,5-c]pyridin-4-amine. Benzyl amine was used as a 
reagent. 33 mg, 52%. 1H NMR (500 MHz, CDCl3)  7.86 (d, J = 5.9 Hz, 1H), 7.45 (dd, J = 7.9, 
0.9 Hz, 2H), 7.35 – 7.27 (m, 6H), 7.03 (d, J = 6.4 Hz, 2H), 6.54 (d, J = 5.9 Hz, 1H), 5.76 (s, 1H), 
5.26 (s, 2H), 4.83 (d, J = 5.6 Hz, 2H), 2.79 – 2.74 (m, 2H), 1.72 – 1.67 (m, 2H), 1.37 (dq, J = 
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14.8, 7.4 Hz, 2H), 0.88 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3)  153.39, 150.92, 
140.51, 139.81, 139.78, 135.88, 129.18, 128.62, 128.23, 128.19, 127.24, 126.36, 126.24, 96.73, 
47.46, 45.40, 30.14, 27.38, 22.67, 13.88. HRMS (ESI) calculated for C24H27N4, m/z 371.2230, 
found 371.2303 [M+H]+. 
 
Synthesis of compound 11c: 1-Benzyl-4-butoxy-2-butyl-1H-imidazo[4,5-c]pyridine. To a 
suspension of sodium hydride (48 mg, 2.00 mmol) in 2 mL of anhydrous THF was added 1-
butanol (0.18 mL, 2.00 mmol). It was stirred at room temperature for 1 h, followed by the 
addition of compound 10 (100 mg, 0.33 mmol). The reaction mixture was heated at 60 ºC for 18 
h and then solvent was evaporated under vacuum. The residue was extracted with EtOAc (3 × 
10 mL), washed with water and dried over sodium sulfate. The solvent was removed and the 
crude residue was purified using column chromatography (0-5% MeOH in CH2Cl2) to obtain the 
compound 11c (61 mg, 55%). 1H NMR (500 MHz, CDCl3)  7.85 (d, J = 5.8 Hz, 1H), 7.33 – 7.28 
(m, 3H), 7.01 (dd, J = 7.7, 1.7 Hz, 2H), 6.77 (d, J = 5.8 Hz, 1H), 5.30 (s, 2H), 4.52 (t, J = 7.0 Hz, 
2H), 2.87 – 2.82 (m, 2H), 1.90 (dd, J = 15.0, 7.1 Hz, 2H), 1.75 (dt, J = 15.7, 7.7 Hz, 2H), 1.58 – 
1.48 (m, 2H), 1.38 (dq, J = 14.7, 7.4 Hz, 2H), 0.97 (t, J = 7.4 Hz, 3H), 0.88 (t, J = 7.4 Hz, 3H). 
13C NMR (126 MHz, CDCl3)  156.04, 155.18, 142.02, 138.95, 135.59, 129.21, 128.27, 127.41, 
126.27, 100.47, 66.25, 47.61, 31.34, 30.21, 27.44, 22.75, 19.45, 14.09, 13.85. HRMS (ESI) 
calculated for C21H28N3O, m/z 338.2227, found 338.2307 [M+H]
+. 
 
Synthesis of compound 12: 2,6-Dichloro-3-nitropyridin-4-amine. 4-Amino-2,6-dichloro 
pyridine (2.0 g, 12.27 mmol) was added to 20 mL of conc. H2SO4. The mixture was cooled to 0 
ºC and 10 mL of conc. HNO3 was dropwise at 0 ºC. The reaction mixture was stirred at room 
temperature for 1 h and then poured into crushed ice. The white solid was filtered, washed with 
water and dried. This intermediate was dissolved in 10 mL of conc. H2SO4 and the reaction 
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solution was heated at 90 ºC for 30 min. It was cooled to room temperature and poured into ice. 
It was slowly neutralized with ammonium hydroxide solution until a pH of 9 and the formed 
yellow solid was filtered, washed with water and dried to obtain compound 12 as light yellow 
solid. 1H NMR (500 MHz, MeOD)  6.84 (s, 1H). 13C NMR (126 MHz, MeOD)  152.53, 151.18, 
144.57, 111.12. 
 
Synthesis of compound 13: N-Benzyl-2,6-dichloro-3-nitropyridin-4-amine. Sodium hydride 
(138 mg, 5.77 mmol) was carefully suspended in 10 mL of dry THF under N2. The grey 
suspension was cooled to 0 ºC and compound 12 (1.0 g, 4.81 mmol) was slowly added to the 
suspension at 0 ºC. The reaction mixture was stirred for 1 h, followed by the addition of benzyl 
bromide (0.5 mL, 5.29 mmol). The reaction mixture was stirred at room temperature for 2 h and 
poured into ice water. Then it was extracted with EtOAc (3 × 20 mL), washed with water, dried 
over sodium sulfate. The solvent was removed and the crude residue was purified using column 
chromatography (0-20% EtOAc in hexane) to obtain the compound 13 as yellow solid.  1H NMR 
(500 MHz, CDCl3)  7.44 – 7.34 (m, 3H), 7.32 – 7.27 (m, 2H), 6.99 (s, 1H), 6.67 (s, 1H), 4.47 (d, 
J = 5.4 Hz, 2H). 13C NMR (126 MHz, CDCl3)  152.07, 149.97, 145.68, 135.01, 129.48, 128.71, 
127.32, 106.62, 47.74.  
 
Synthesis of compound 14: N4-Benzyl-6-chloro-3-nitro-N2-(2,4,4-trimethylpentan-2-yl) 
pyridine-2,4-diamine. To a solution of compound 13 (300 mg, 1.02 mmol) in 20 mL of CH2Cl2 
were added triethylamine (0.21 mL, 1.53 mmol) and tert-octylamine (0.5 mL, 3.06 mmol). The 
reaction mixture was refluxed for 48 h and the solvent was removed under vacuum. The crude 
residue was purified using column chromatography (0-20% EtOAc in hexane) to obtain the 
compound 14 as yellow solid (360 mg, 91%). 1H NMR (500 MHz, CDCl3)  9.57 (s, 1H), 9.51 (s, 
1H), 7.39 (ddd, J = 7.5, 4.4, 1.3 Hz, 2H), 7.36 – 7.30 (m, 3H), 5.92 (s, 1H), 4.44 (d, J = 5.4 Hz, 
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2H), 1.95 (s, 2H), 1.56 (s, 6H), 0.98 (s, 9H). 13C NMR (126 MHz, CDCl3)  155.05, 154.25, 
153.44, 136.10, 129.24, 128.24, 127.43, 115.80, 94.21, 57.32, 51.54, 47.64, 31.94, 31.66, 
29.84. MS (ESI) calculated for C20H28ClN4O2, m/z 391.1895, found 391.1901 [M+H]
+.  
 
Synthesis of compound 16: 1-Benzyl-2-butyl-6-chloro-N-(2,4,4-trimethylpentan-2-yl)-1H-
imidazo[4,5-c]pyridin-4-amine. To a solution of compound 14 (260 mg, 0.66 mmol) in 20 mL 
of MeOH were added zinc dust (434 mg, 6.60 mmol) and ammonium formate (416 mg, 6.60 
mmol). The reaction mixture was stirred at room temperature for 10 min and filtered through 
celite. Then the solvent was evaporated and the residue was dissolved in water. This was 
extracted with EtOAc (3 × 20 mL), washed with water and dried over sodium sulfate. The 
solvent was removed under vacuum to obtain compound 15, brown oil (184 mg, 77%). To a 
solution of compound 15 (184 mg, 0.50 mmol) in 10 mL of anhydrous THF were added 
triethylamine (74 L, 0.52 mmol) and valeryl chloride (62 L, 0.50 mmol). The reaction mixture 
was refluxed for 1 h. The solvent was then removed under vacuum, and the residue was 
dissolved in 10 mL of EtOH and NaOH (40 mg, 1.00 mmol) in 1 mL of H2O was added. The 
reaction mixture was refluxed for 5 h. The solvent was then removed under vacuum, and the 
residue was dissolved in EtOAc and washed with water. The EtOAc fraction was dried using 
sodium sulfate and evaporated and purified using column chromatography (0-20% EtOAc in 
hexane) to obtain the compound 16 as yellow solid (120 mg, 56%). 1H NMR (500 MHz, CDCl3)  
7.34 – 7.28 (m, 3H), 7.02 (d, J = 6.5 Hz, 2H), 6.42 (s, 1H), 5.38 (s, 1H), 5.16 (s, 2H), 2.76 – 2.69 
(m, 2H), 2.02 (s, 2H), 1.71 – 1.65 (m, 4H), 1.60 (s, 6H), 1.37 (dd, J = 15.0, 7.5 Hz, 2H), 1.01 (s, 
9H), 0.89 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3)  153.37, 149.45, 141.67, 140.77, 
135.64, 129.21, 128.22, 126.31, 125.50, 93.95, 55.74, 51.42, 47.42, 31.91, 31.73, 30.12, 29.96, 
27.37, 22.66, 13.87. MS (ESI) calculated for C25H36ClN4, m/z 427.2623, found 427.2635 [M+H]
+. 
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Synthesis of compound 17: 1-Benzyl-2-butyl-6-chloro-1H-imidazo[4,5-c]pyridin-4-amine. 
Compound 16 (34 mg, 0.082 mmol) was dissolved in 1 mL of HCl (4M in dioxane) and stirred at 
room temperature for 30 min. Then the solvent was removed under vacuum to obtain compound 
17 (11 mg, 42%). 1H NMR (500 MHz, CDCl3)  7.36 – 7.30 (m, 3H), 7.01 (d, J = 6.4 Hz, 2H), 
6.58 (s, 1H), 5.23 (s, 2H), 5.21 (s, 2H), 2.80 – 2.73 (m, 2H), 1.72 (dt, J = 15.5, 7.7 Hz, 2H), 1.39 
(dq, J = 14.8, 7.4 Hz, 2H), 0.90 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3)  154.83, 
149.94, 142.31, 141.73, 135.26, 129.32, 128.57, 128.41, 126.26, 96.29, 47.59, 29.92, 27.36, 
22.63, 13.87. HRMS (ESI) calculated for C17H20ClN4, m/z 315.1371, found 315.1422 [M+H]
+. 
 
Synthesis of compound 19a: 1-Benzyl-2-butyl-1H-imidazo[4,5-c]pyridine-4,6-diamine. To a 
solution of compound 16 (70 mg, 0.16 mmol) in 1 mL of dioxane were added potassium tert-
butoxide (92 mg, 0.82 mmol), catalytic amount of DavePhos and Pd2(dba)3 and tert-octylamine 
(83 L, 0.83 mmol). The reaction mixture was then heated under microwave conditions (500 W, 
100 ºC) in a sealed vial for 1 h. It was cooled to room temperature and filtered through celite 
and washed with MeOH. The solvent was removed and the crude residue was purified using 
column chromatography (0-20% EtOAc in hexane) to obtain the compound 18a, brown solid (41 
mg, 49%). Compound 18a (33 mg, 0.063 mmol) was dissolved in 1 mL of HCl (4M in dioxane) 
and stirred at room temperature for 30 min. Then the solvent was removed under vacuum to 
obtain compound 19a as brown solid (11 mg, 58%). 1H NMR (500 MHz, DMSO)  7.37 – 7.31 
(m, 2H), 7.30 – 7.25 (m, 1H), 7.09 – 7.04 (m, 2H), 6.41 (s, 2H), 5.65 (s, 1H), 5.24 (s, 2H), 2.73 – 
2.67 (m, 2H), 1.59 (dt, J = 15.3, 7.5 Hz, 2H), 1.31 (dq, J = 14.7, 7.4 Hz, 2H), 0.83 (t, J = 7.4 Hz, 
3H). 13C NMR (126 MHz, DMSO)  151.81, 147.80, 144.08, 136.91, 128.81, 128.77, 127.47, 
126.29, 117.96, 76.19, 46.11, 29.27, 26.17, 21.80, 13.68. HRMS (ESI) calculated for C17H22N5, 
m/z 296.1870, found 296.1906 [M+H]+.  
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Compounds 19b-19o were synthesized similarly as compound 19a. 
 
19b: 1-Benzyl-N6,2-dibutyl-1H-imidazo[4,5-c]pyridine-4,6-diamine. Butyl amine was used as 
a reagent. Brown solid. 23 mg, 79%. 1H NMR (500 MHz, CDCl3)  7.31 (ddd, J = 8.6, 6.4, 3.4 
Hz, 3H), 7.05 (d, J = 6.7 Hz, 2H), 5.46 (s, 1H), 5.26 (s, 1H), 5.16 (s, 2H), 3.03 (t, J = 7.1 Hz, 
2H), 2.72 – 2.66 (m, 2H), 1.68 (dd, J = 15.5, 7.6 Hz, 2H), 1.55 (dd, J = 14.8, 7.2 Hz, 2H), 1.43 – 
1.33 (m, 4H), 0.90 (dt, J = 16.4, 7.4 Hz, 6H). 13C NMR (126 MHz, CDCl3)  152.42, 148.50, 
144.42, 135.99, 129.14, 128.06, 126.33, 74.80, 47.20, 43.09, 31.41, 30.03, 27.37, 22.66, 20.40, 




4,6-diamine. Heptylamine was used as a reagent. Brown oil. 43 mg, 65%. 1H NMR (500 MHz, 
CDCl3)  7.32 – 7.26 (m, 3H), 7.05 (d, J = 6.7 Hz, 2H), 5.39 (s, 1H), 5.13 (s, 1H), 5.11 (s, 2H), 
3.13 (t, J = 7.2 Hz, 2H), 2.68 – 2.64 (m, 2H), 2.04 (s, 2H), 1.65 – 1.55 (m, 11H), 1.41 – 1.22 (m, 
12H), 1.01 (s, 9H), 0.89 – 0.84 (m, 6H). 13C NMR (126 MHz, CDCl3)  154.28, 150.38, 149.22, 
142.39, 136.63, 128.97, 128.05, 127.76, 126.40, 120.44, 95.52, 73.57, 55.27, 51.72, 47.00, 
43.63, 31.97, 31.94, 31.90, 31.79, 30.47, 30.29, 29.97, 29.32, 27.44, 27.39, 22.77, 22.71, 14.25, 
13.90. MS (ESI) calculated for C32H52N5, m/z 506.4217, found 506.4209 [M+H]
+.  
 
19c: 1-Benzyl-2-butyl-N6-heptyl-1H-imidazo[4,5-c]pyridine-4,6-diamine. Light brown solid. 
24 mg, 80%. 1H NMR (500 MHz, DMSO)  8.03 (s, 2H), 7.38 – 7.33 (m, 2H), 7.32 – 7.28 (m, 
1H), 7.12 (d, J = 7.2 Hz, 2H), 6.84 (s, 1H), 5.98 (s, 1H), 5.39 (s, 2H), 3.08 (t, J = 7.0 Hz, 2H), 
2.73 – 2.68 (m, 2H), 1.59 (dt, J = 15.3, 8.2 Hz, 2H), 1.50 (dd, J = 14.3, 7.2 Hz, 2H), 1.33 – 1.21 
(m, 12H), 0.85 (t, J = 7.0 Hz, 3H), 0.81 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, DMSO)  
154.62, 145.66, 145.15, 136.32, 128.96, 128.86, 127.73, 126.64, 126.55, 74.21, 46.34, 42.24, 
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31.25, 28.78, 28.42, 28.09, 26.34, 26.18, 22.07, 21.71, 13.98, 13.62. HRMS (ESI) calculated for 




c]pyridine-4,6-diamine. N-Cyclohexylmethylamine was used as a reagent. Yellow solid. 50 mg, 
62%. 1H NMR (500 MHz, CDCl3)  7.32 – 7.27 (m, 3H), 7.06 (d, J = 6.7 Hz, 2H), 5.37 (s, 1H), 
5.10 (s, 2H), 2.99 (d, J = 6.7 Hz, 2H), 2.69 – 2.64 (m, 2H), 2.04 (s, 2H), 1.79 (d, J = 13.2 Hz, 
2H), 1.73 – 1.60 (m, 9H), 1.58 (s, 6H), 1.35 (dd, J = 15.0, 7.5 Hz, 2H), 1.27 – 1.13 (m, 4H), 1.01 
(s, 9H), 0.98 – 0.91 (m, 2H), 0.86 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3)  154.37, 
150.36, 149.19, 142.41, 136.65, 128.97, 127.76, 126.44, 120.35, 73.62, 55.26, 51.67, 50.18, 
47.02, 37.88, 31.91, 31.80, 31.48, 30.51, 30.31, 27.46, 26.80, 26.17, 22.72, 13.91. MS (ESI) 
calculated for C32H50N5, m/z 504.4061, found 504.41 [M+H]
+. 
 
19d: 1-Benzyl-2-butyl-N6-(cyclohexylmethyl)-1H-imidazo[4,5-c]pyridine-4,6-diamine. Light 
brown. 28 mg, 80%. 1H NMR (500 MHz, DMSO)  7.35 (t, J = 7.3 Hz, 2H), 7.31 – 7.27 (m, 1H), 
7.10 (d, J = 7.2 Hz, 2H), 6.34 (d, J = 3.1 Hz, 1H), 5.85 (s, 1H), 5.33 (s, 2H), 2.92 (t, J = 6.1 Hz, 
2H), 2.71 – 2.66 (m, 2H), 1.75 – 1.64 (m, 4H), 1.57 (dt, J = 15.3, 7.6 Hz, 3H), 1.49 (dtd, J = 
11.2, 7.4, 3.7 Hz, 1H), 1.30 (dt, J = 14.8, 7.4 Hz, 2H), 1.21 – 1.09 (m, 4H), 0.91 (dd, J = 22.3, 
10.5 Hz, 2H), 0.81 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, DMSO)  153.32, 146.28, 145.05, 
136.69, 128.79, 127.61, 126.53, 116.94, 74.21, 48.49, 46.22, 36.76, 30.47, 29.02, 26.21, 26.05, 




4,6-diamine. Aniline was used as a reagent. Yellow solid. 51 mg, 55%. 1H NMR (500 MHz, 
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CDCl3)  7.31 (dt, J = 16.5, 5.5 Hz, 3H), 7.22 (t, J = 7.8 Hz, 2H), 7.16 (d, J = 7.6 Hz, 2H), 7.05 
(d, J = 6.7 Hz, 2H), 6.90 (t, J = 6.9 Hz, 1H), 6.16 (s, 1H), 6.02 (s, 1H), 5.23 (s, 1H), 5.12 (s, 2H), 
2.74 – 2.67 (m, 2H), 2.03 (s, 2H), 1.66 (dd, J = 15.8, 8.2 Hz, 4H), 1.60 (s, 6H), 1.38 (dd, J = 
15.0, 7.5 Hz, 2H), 1.02 (s, 9H), 0.89 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3)  151.49, 
149.42, 149.11, 142.46, 141.51, 136.32, 129.16, 129.06, 127.93, 126.53, 121.98, 120.91, 
118.83, 55.42, 51.80, 47.26, 31.93, 31.80, 30.44, 30.19, 27.46, 22.71, 13.91. MS (ESI) 
calculated for C31H42N5, m/z 484.3435, found 484.3459 [M+H]
+. 
 
19e: 1-Benzyl-2-butyl-N6-phenyl-1H-imidazo[4,5-c]pyridine-4,6-diamine. Light yellow solid. 
28 mg, 76%. 1H NMR (500 MHz, DMSO)  9.10 (s, 1H), 8.08 (s, 1H), 7.39 – 7.35 (m, 2H), 7.33 
– 7.28 (m, 3H), 7.11 (t, J = 7.3 Hz, 4H), 7.01 (t, J = 7.3 Hz, 1H), 6.41 (s, 1H), 5.44 (s, 2H), 2.82 
(t, J = 7.5 Hz, 2H), 1.63 (dt, J = 15.3, 7.6 Hz, 2H), 1.33 (dd, J = 14.9, 7.4 Hz, 2H), 0.84 (t, J = 7.4 
Hz, 3H). 13C NMR (126 MHz, DMSO)  146.34, 140.41, 136.06, 129.52, 128.92, 127.84, 126.69, 
122.44, 118.87, 46.68, 28.89, 26.15, 21.72, 13.63. HRMS (ESI) calculated for C23H26N5, m/z 
372.2183, found 372.2219 [M+H]+.  
 
18f: N6,1-Dibenzyl-2-butyl-N4-(2,4,4-trimethylpentan-2-yl)-1H-imidazo[4,5-c]pyridine-4,6-
diamine. Benzyl amine was used as a reagent. Light brown solid. 30 mg, 46%. 1H NMR (500 
MHz, CDCl3)  7.35 (d, J = 7.4 Hz, 2H), 7.26 (dddd, J = 9.4, 7.2, 6.1, 1.6 Hz, 6H), 7.03 (d, J = 
6.8 Hz, 2H), 5.44 (s, 1H), 5.17 (s, 1H), 5.07 (s, 2H), 4.42 (s, 2H), 2.70 – 2.64 (m, 2H), 1.67 – 
1.60 (m, 2H), 1.55 (s, 6H), 1.35 (dq, J = 14.7, 7.4 Hz, 2H), 1.02 – 0.94 (m, 9H), 0.87 (t, J = 7.4 
Hz, 3H). 13C NMR (126 MHz, CDCl3)  153.83, 150.58, 149.20, 142.27, 140.52, 136.49, 128.98, 
128.56, 127.80, 127.68, 126.97, 126.46, 126.39, 74.17, 55.29, 51.62, 47.59, 47.07, 31.87, 
31.76, 30.45, 30.28, 30.20, 27.42, 22.70, 13.90. MS (ESI) calculated for C32H44N5, m/z 
498.3591, found 498.3599 [M+H]+.  
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19f: N6,1-Dibenzyl-2-butyl-1H-imidazo[4,5-c]pyridine-4,6-diamine. White solid. 22 mg, 85%. 
1H NMR (500 MHz, DMSO)  8.07 (s, 2H), 7.38 – 7.35 (m, 2H), 7.34 – 7.29 (m, 5H), 7.29 – 7.25 
(m, 1H), 7.07 (d, J = 6.3 Hz, 2H), 6.06 (s, 1H), 5.33 (s, 2H), 4.38 (s, 2H), 2.75 – 2.69 (m, 2H), 
1.58 (dt, J = 15.3, 7.6 Hz, 2H), 1.30 (dt, J = 14.8, 7.4 Hz, 2H), 0.81 (t, J = 7.4 Hz, 3H). 13C NMR 
(126 MHz, DMSO)  154.68, 145.29, 137.99, 136.12, 128.85, 128.45, 127.78, 127.51, 127.23, 
126.74, 75.08, 46.43, 45.67, 28.76, 26.16, 21.70, 13.62. HRMS (ESI) calculated for C24H28N5, 
m/z 386.2339, found 386.2389 [M+H]+.  
 
19g: 1-Benzyl-2-butyl-N6-(4-methoxybenzyl)-1H-imidazo[4,5-c]pyridine-4,6-diamine. 4-
Methoxy-benzylamine was used as a reagent. Light yellow solid. 22 mg, 69%. 1H NMR (500 
MHz, DMSO)  8.07 (s, 2H), 7.34 – 7.28 (m, 5H), 7.08 (d, J = 6.4 Hz, 2H), 6.87 (d, J = 8.7 Hz, 
2H), 6.04 (s, 1H), 5.34 (s, 2H), 4.29 (s, 2H), 3.72 (s, 3H), 2.75 – 2.70 (m, 2H), 1.58 (dt, J = 15.3, 
7.6 Hz, 2H), 1.29 (dd, J = 14.9, 7.4 Hz, 2H), 0.81 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, 
DMSO)  158.48, 154.67, 145.28, 145.27, 136.13, 129.73, 128.92, 128.84, 127.78, 126.74, 
113.82, 75.11, 55.08, 46.43, 45.18, 28.76, 26.16, 21.71, 13.62. HRMS (ESI) calculated for 




Methoxy-benzylamine was used as a reagent. Brown solid. 27 mg, 69%. 1H NMR (500 MHz, 
DMSO)  7.32 – 7.27 (m, 3H), 7.23 (t, J = 7.9 Hz, 1H), 7.06 (d, J = 6.1 Hz, 2H), 6.94 (dd, J = 
12.3, 4.8 Hz, 2H), 6.83 (dd, J = 8.1, 2.2 Hz, 1H), 6.03 (s, 1H), 5.31 (s, 2H), 4.33 (d, J = 5.8 Hz, 
2H), 3.71 (s, 3H), 2.70 (t, J = 7.6 Hz, 2H), 1.57 (dt, J = 15.3, 7.6 Hz, 2H), 1.29 (dd, J = 14.9, 7.4 
Hz, 2H), 0.81 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, DMSO)  159.37, 136.32, 129.52, 128.80, 
127.72, 126.70, 119.55, 113.13, 112.50, 75.05, 55.00, 46.33, 45.63, 40.11, 40.02, 39.94, 28.89, 
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4-(Trifluoromethyl)benzylamine was used as a reagent. Brown solid. 17 mg, 77%. 1H NMR (500 
MHz, DMSO)  7.60 (d, J = 8.2 Hz, 2H), 7.51 (d, J = 8.1 Hz, 2H), 7.29 – 7.21 (m, 3H), 7.02 (d, J 
= 6.7 Hz, 2H), 6.23 (s, 1H), 5.70 (s, 2H), 5.57 (s, 1H), 5.15 (s, 2H), 4.41 (d, J = 6.3 Hz, 2H), 2.69 
– 2.63 (m, 2H), 1.56 (dt, J = 15.3, 7.5 Hz, 2H), 1.29 (dd, J = 14.9, 7.4 Hz, 2H), 0.82 (t, J = 7.4 
Hz, 3H). 13C NMR (126 MHz, DMSO)  153.45, 150.32, 149.41, 146.48, 143.12, 137.24, 128.58, 
127.82, 127.31, 126.51, 124.88, 124.85, 118.91, 75.32, 46.04, 44.94, 29.43, 26.19, 21.82, 
13.69. HRMS (ESI) calculated for C25H27F3N5, m/z 454.2213, found 454.2284 [M+H]
+. 
 
19j: 1-Benzyl-2-butyl-N6-(4-chlorobenzyl)-1H-imidazo[4,5-c]pyridine-4,6-diamine. 4-Chloro 
benzylamine was used as a reagent. Yellow solid. 15 mg, 63%. 1H NMR (500 MHz, DMSO)  
7.33 – 7.25 (m, 8H), 7.02 (d, J = 6.6 Hz, 2H), 6.18 (s, 1H), 5.83 (s, 2H), 5.59 (s, 1H), 5.16 (s, 
2H), 4.30 (d, J = 6.0 Hz, 2H), 2.68 – 2.64 (m, 2H), 1.56 (dt, J = 15.3, 7.5 Hz, 2H), 1.29 (dd, J = 
14.9, 7.4 Hz, 2H), 0.82 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, DMSO)  150.57, 149.14, 
143.25, 140.18, 137.18, 130.77, 129.08, 128.63, 127.96, 127.37, 126.56, 118.72, 75.34, 46.06, 
44.71, 40.11, 40.02, 39.94, 29.40, 26.20, 21.82, 13.69. HRMS (ESI) calculated for C24H27ClN5, 
m/z 420.1950, found 420.1976 [M+H]+. 
 
18k: 1-Benzyl-2-butyl-N6-(furan-2-ylmethyl)-N4-(2,4,4-trimethylpentan-2-yl)-1H-imidazo[4,5-
c]pyridine-4,6-diamine. Furfurylamine was used as a reagent. Yellow oil. 53 mg, 54%. 1H NMR 
(500 MHz, CDCl3)  7.30 (ddd, J = 10.9, 4.6, 1.1 Hz, 4H), 7.04 (d, J = 6.6 Hz, 2H), 6.28 (dd, J = 
3.2, 1.9 Hz, 1H), 6.15 (dd, J = 3.2, 0.6 Hz, 1H), 5.50 (s, 1H), 5.10 (s, 2H), 4.43 (s, 2H), 2.72 – 
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2.64 (m, 2H), 2.03 (s, 2H), 1.68 – 1.59 (m, 4H), 1.58 (s, 6H), 1.35 (dt, J = 14.7, 7.4 Hz, 2H), 1.00 
(s, 9H), 0.87 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3)  153.92, 153.28, 150.77, 149.15, 
142.19, 141.69, 136.47, 129.00, 127.83, 126.42, 110.36, 106.53, 74.85, 55.32, 51.68, 47.09, 
40.78, 31.89, 31.77, 30.47, 30.31, 27.43, 22.71, 13.90. MS (ESI) calculated for C30H42N5O, m/z 
488.3384, found 488.3446 [M+H]+. 
 
19k: 1-Benzyl-2-butyl-N6-(furan-2-ylmethyl)-1H-imidazo[4,5-c]pyridine-4,6-diamine. Brown 
solid. 21 mg, 55%. 1H NMR (500 MHz, DMSO)  7.55 (s, 1H), 7.34 (t, J = 7.3 Hz, 2H), 7.31 – 
7.27 (m, 1H), 7.10 (d, J = 7.3 Hz, 2H), 6.36 (dd, J = 3.0, 1.9 Hz, 1H), 6.29 (d, J = 2.6 Hz, 1H), 
5.99 (s, 1H), 5.31 (s, 2H), 4.35 (d, J = 5.8 Hz, 2H), 2.73 – 2.67 (m, 2H), 1.58 (dt, J = 15.2, 7.6 
Hz, 2H), 1.30 (dd, J = 14.9, 7.4 Hz, 2H), 0.82 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, DMSO)  
142.17, 136.66, 128.79, 127.62, 126.61, 110.39, 107.43, 75.34, 60.19, 46.26, 38.71, 29.07, 




[4,5-c]pyridine-4,6-diamine. 4-Picolylamine was used as a reagent. Yellow solid. 25 mg, 31%. 
1H NMR (500 MHz, CDCl3)  8.48 (dd, J = 4.5, 1.6 Hz, 2H), 7.29 – 7.25 (m, 3H), 7.24 (dd, J = 
4.5, 1.5 Hz, 2H), 7.01 (d, J = 6.1 Hz, 2H), 5.40 (s, 1H), 5.06 (s, 2H), 4.49 (s, 2H), 2.70 – 2.64 (m, 
2H), 1.92 (s, 2H), 1.63 (dt, J = 15.5, 7.7 Hz, 2H), 1.48 (s, 6H), 1.36 (dt, J = 14.9, 7.4 Hz, 2H), 
0.95 (s, 9H), 0.87 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3)  149.83, 136.31, 129.01, 
127.89, 126.40, 122.20, 74.67, 55.25, 51.56, 47.13, 46.09, 31.81, 31.75, 31.71, 30.44, 30.23, 
27.41, 22.69, 13.89. MS (ESI) calculated for C31H43N6, m/z 499.3544, found 499.3475 [M+H]
+. 
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19l: 1-Benzyl-2-butyl-N6-(pyridin-4-ylmethyl)-1H-imidazo[4,5-c]pyridine-4,6-diamine. Brown 
solid. 7 mg, 47%. 1H NMR (500 MHz, DMSO)  8.43 (dd, J = 4.5, 1.5 Hz, 2H), 7.27 (ddd, J = 
9.7, 6.8, 4.4 Hz, 5H), 7.03 (d, J = 6.7 Hz, 2H), 6.50 – 6.28 (m, 2H), 5.65 (s, 1H), 5.18 (s, 2H), 
4.37 (d, J = 6.3 Hz, 2H), 2.69 – 2.65 (m, 2H), 1.57 (dt, J = 15.3, 7.5 Hz, 2H), 1.30 (dd, J = 14.9, 
7.4 Hz, 2H), 0.81 (d, J = 7.4 Hz, 3H). 13C NMR (126 MHz, DMSO)  149.28, 137.09, 130.51, 
128.65, 127.43, 126.53, 122.35, 113.97, 75.37, 46.09, 44.38, 29.34, 26.19, 21.80, 13.68. HRMS 




Picolylamine was used as a reagent. Light brown solid. 33 mg, 63%. 1H NMR (500 MHz, 
DMSO)  8.92 (s, 1H), 8.80 (d, J = 5.3 Hz, 1H), 8.46 (d, J = 8.0 Hz, 1H), 8.12 (s, 2H), 7.94 (dd, J 
= 7.9, 5.7 Hz, 1H), 7.69 (s, 1H), 7.33 – 7.25 (m, 3H), 7.04 (d, J = 6.9 Hz, 2H), 6.03 (s, 1H), 5.32 
(s, 2H), 4.64 (s, 2H), 2.72 (t, J = 7.6 Hz, 2H), 1.56 (dt, J = 15.2, 7.6 Hz, 2H), 1.28 (dd, J = 14.9, 
7.4 Hz, 2H), 0.80 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, DMSO)  154.65, 145.80, 145.01, 
143.55, 141.29, 141.12, 138.17, 136.10, 128.83, 127.76, 126.68, 126.52, 75.49, 46.45, 42.51, 




1-Naphthylmethylamine was used as a reagent. Light brown solid. 28 mg, 70%. 1H NMR (500 
MHz, DMSO)  12.12 (s, 1H), 8.10 (d, J = 8.0 Hz, 1H), 8.04 (s, 2H), 7.99 – 7.96 (m, 1H), 7.88 
(d, J = 8.2 Hz, 1H), 7.61 – 7.53 (m, 3H), 7.45 (dd, J = 8.1, 7.1 Hz, 1H), 7.33 – 7.28 (m, 3H), 7.08 
(d, J = 6.4 Hz, 2H), 6.22 (s, 1H), 5.35 (s, 2H), 4.83 (s, 2H), 2.74 – 2.68 (m, 2H), 1.58 (dt, J = 
15.3, 7.6 Hz, 2H), 1.29 (dd, J = 14.9, 7.4 Hz, 2H), 0.81 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, 
DMSO)  154.69, 145.51, 145.31, 136.23, 133.44, 132.90, 130.92, 128.83, 128.63, 127.99, 
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127.76, 126.67, 126.39, 125.97, 125.49, 125.43, 123.63, 74.91, 46.39, 43.99, 28.80, 26.20, 




diamine. [1,1'-biphenyl]-4-yl methane amine was used as a reagent. Light brown solid. 21 mg, 
51%. 1H NMR (500 MHz, DMSO)  12.36 (s, 1H), 8.04 (s, 2H), 7.63 (dd, J = 12.4, 7.8 Hz, 4H), 
7.50 – 7.42 (m, 4H), 7.40 – 7.33 (m, 1H), 7.28 (t, J = 7.3 Hz, 2H), 7.23 (t, J = 7.2 Hz, 1H), 7.07 
(d, J = 7.3 Hz, 2H), 6.07 (s, 1H), 5.33 (s, 2H), 4.42 (s, 2H), 2.71 (t, J = 7.6 Hz, 2H), 1.57 (dt, J = 
15.2, 7.7 Hz, 2H), 1.29 (dq, J = 14.6, 7.3 Hz, 2H), 0.81 (t, J = 7.3 Hz, 3H). 13C NMR (126 MHz, 
DMSO)  154.65, 145.40, 145.35, 139.80, 139.07, 137.24, 136.17, 128.95, 128.80, 128.06, 
127.67, 127.43, 126.71, 126.69, 126.57, 75.11, 46.38, 45.31, 28.81, 26.18, 21.69, 13.61. HRMS 
(ESI) calculated for C30H32N5, m/z 462.2652, found 462.2698 [M+H]
+. 
 
Synthesis of compound 19p and 19r: N6-(4-(aminomethyl)benzyl)-1-benzyl-2-butyl-1H-
imidazo[4,5-c]pyridine-4,6-diamine. To a solution of compound 16 (70 mg, 0.16 mmol) in 1 
mL of dioxane were added potassium tert-butoxide (90 mg, 0.80 mmol), catalytic amount of 
DavePhos and Pd2(dba)3 and p-xylylenediamine (109 mg, 0.80 mmol). The reaction mixture was 
then heated under microwave conditions (500 W, 100 ºC) in a sealed vial for 1 h. It was cooled 
to room temperature and filtered through celite and washed with MeOH. The solvent was 
removed and the crude residue was purified using column chromatography (0-20% EtOAc in 
hexane) to obtain the compounds 18p and 18r. Compound 18p (33 mg, 0.063 mmol) was 
dissolved in 1 mL of HCl (4M in dioxane) and stirred at room temperature for 30 min. Then the 
solvent was removed under vacuum to obtain compound 19p as light yellow solid (5 mg, 63%). 
1H NMR (500 MHz, DMSO)  8.37 (s, 2H), 8.06 (s, 2H), 7.42 (q, J = 8.5 Hz, 4H), 7.36 – 7.30 (m, 
3H), 7.08 (d, J = 6.8 Hz, 2H), 6.08 (s, 1H), 5.34 (s, 2H), 4.40 (s, 2H), 3.98 (q, J = 5.8 Hz, 2H), 
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2.75 – 2.67 (m, 2H), 1.57 (dt, J = 15.3, 7.6 Hz, 2H), 1.28 (dd, J = 14.9, 7.4 Hz, 2H), 0.80 (t, J = 
7.4 Hz, 3H). 13C NMR (126 MHz, DMSO)  154.71, 145.41, 145.34, 138.43, 136.19, 132.98, 
129.02, 128.89, 127.79, 127.75, 126.65, 46.40, 45.31, 41.89, 28.78, 26.18, 21.70, 13.62. HRMS 




4,6-diamine). Compound 18r (35 mg, 0.038 mmol) was dissolved in 1 mL of HCl (4M in 
dioxane) and stirred at room temperature for 30 min. Then the solvent was removed under 
vacuum to obtain compound 19r as light yellow solid (12 mg, 45%).1H NMR (500 MHz, MeOD)  
7.27 (s, 4H), 7.21 – 7.17 (m, 6H), 7.02 – 6.98 (m, 4H), 5.20 (s, 4H), 4.33 (s, 4H), 2.78 – 2.73 (m, 
4H), 1.67 (dt, J = 15.3, 7.6 Hz, 4H), 1.37 (dd, J = 15.0, 7.5 Hz, 4H), 0.89 (t, J = 7.4 Hz, 6H). 13C 
NMR (126 MHz, MeOD)  155.94, 150.96, 148.16, 146.47, 138.77, 137.12, 130.00, 129.03, 
128.70, 127.70, 118.63, 48.01, 47.26, 30.28, 27.76, 23.29, 14.05. HRMS (ESI) calculated for 
C42H49N10, m/z 693.4136, found 693.4331 [M+H]
+. 
 
Compounds 19q and 19s were synthesized similarly as compounds 19p and 19r. 
 
19q: N6-(3-(aminomethyl)benzyl)-1-benzyl-2-butyl-1H-imidazo[4,5-c]pyridine-4,6-diamine. 
m-Xylylenediamine was used as a reagent. Light yellow solid. 1H NMR (500 MHz, MeOD)  7.49 
(s, 1H), 7.41 (dd, J = 3.9, 1.5 Hz, 2H), 7.39 – 7.35 (m, 1H), 7.32 – 7.28 (m, 3H), 7.05 – 7.02 (m, 
2H), 5.31 (s, 2H), 4.44 (s, 2H), 4.07 (s, 2H), 2.79 – 2.75 (m, 2H), 1.70 (dt, J = 15.3, 7.6 Hz, 2H), 
1.38 (dq, J = 14.8, 7.4 Hz, 2H), 0.89 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, MeOD)  157.36, 
147.23, 146.79, 140.00, 136.86, 134.96, 130.63, 130.12, 129.26, 129.19, 129.14, 129.00, 
127.62, 48.10, 47.15, 44.18, 30.00, 27.75, 23.24, 14.03. HRMS (ESI) calculated for C25H31N6, 
m/z 415.2605, found 415.2610 [M+H]+. 
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19s: N6,N6'-(1,3-phenylenebis(methylene))bis(1-benzyl-2-butyl-1H-imidazo[4,5-c]pyridine-
4,6-diamine). Light yellow solid. 1H NMR (500 MHz, DMSO)  12.38 (s, 2H), 8.04 (s, 4H), 7.38 
(s, 1H), 7.30 – 7.22 (m, 9H), 7.04 (d, J = 6.8 Hz, 4H), 6.01 (s, 2H), 5.28 (s, 4H), 4.34 (s, 4H), 
2.73 – 2.68 (m, 4H), 1.56 (dd, J = 15.3, 7.7 Hz, 4H), 1.29 (dd, J = 14.9, 7.4 Hz, 4H), 0.81 (t, J = 
7.4 Hz, 6H). 13C NMR (126 MHz, DMSO)  154.62, 145.36, 145.31, 138.22, 136.15, 128.80, 
128.61, 127.72, 126.66, 126.56, 126.38, 46.36, 45.73, 28.80, 26.19, 21.71, 13.62. HRMS (ESI) 
calculated for C42H49N10, m/z 693.4136, found 693.4131 [M+H]
+. 
 
Synthesis of compound 23a: To a solution of compound 14 (120 mg, 0.31 mmol) in 1 mL of 
dioxane were added cesium carbonate (303 mg, 0.93 mmol) in H2O (0.5 mL), [1,1′-
bis(diphenylphosphino)ferrocene]dichloropalladium(II) (Pd(dppf)Cl2) (15 mg, 0.019 mmol) and n-
butylboronic acid (98 L, 0.46 mmol) under N2. The reaction mixture was then heated at 90 ºC 
in a sealed vial for 18 h. It was cooled to room temperature and filtered through celite and 
washed with MeOH. The solvent was removed and the crude residue was purified using column 
chromatography (0-15% EtOAc in hexane) to obtain the compound 20a (97mg, 76%).  To a 
solution of compound 20a (94 mg, 0.23 mmol) in 10 mL of MeOH were added zinc dust (149 
mg, 2.30 mmol) and ammonium formate (145 mg, 2.30 mmol). The reaction mixture was stirred 
at room temperature for 10 min and filtered through celite. Then the solvent was evaporated and 
the residue was dissolved in water. This was extracted with EtOAc (3 × 20 mL), washed with 
water and dried over sodium sulfate. The solvent was removed under vacuum to obtain 
compound 21a (45 mg, 51%). To a solution of compound 21a (42 mg, 0.11 mmol) in 7 mL of 
anhydrous THF were added triethylamine (16 L, 0.12 mmol) and valeryl chloride (13 L, 0.11 
mmol). The reaction mixture was refluxed for 1 h. The solvent was then removed under vacuum, 
and the residue was dissolved in 5 mL of EtOH and NaOH (10 mg, 0.22 mmol) in 1 mL of H2O 
was added. The reaction mixture was refluxed for 18 h. The solvent was then removed under 
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vacuum, and the residue was dissolved in EtOAc and washed with water. The EtOAc fraction 
was dried using sodium sulfate and evaporated and purified using column chromatography (0-
20% EtOAc in hexane) to obtain the compound 22a (25 mg, 51%). Compound 22a (22 mg, 
0.049 mmol) was dissolved in 1 mL of HCl (4M in dioxane) and stirred at room temperature for 
30 min. Then the solvent was removed under vacuum to obtain compound 23a (11 mg, 69%). 
 
20a: N4-Benzyl-6-butyl-3-nitro-N2-(2,4,4-trimethylpentan-2-yl)pyridine-2,4-diamine. Yellow 
oil. 97 mg, 76%. 1H NMR (500 MHz, CDCl3)  9.51 (t, J = 4.4 Hz, 1H), 9.40 (s, 1H), 7.37 (ddd, J 
= 7.1, 4.4, 1.6 Hz, 2H), 7.34 – 7.30 (m, 3H), 5.74 (s, 1H), 4.45 (d, J = 5.4 Hz, 2H), 2.44 (t, J = 
7.5 Hz, 2H), 2.01 (s, 2H), 1.67 – 1.61 (m, 2H), 1.30 (dd, J = 15.0, 7.4 Hz, 2H), 0.96 (s, 9H), 0.89 
(t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3)  166.49, 154.69, 152.58, 136.94, 129.07, 
127.92, 127.42, 115.70, 94.41, 56.59, 51.17, 47.44, 38.87, 31.95, 31.64, 30.61, 30.19, 22.43, 
14.11. MS (ESI) calculated for C24H37N4O2, m/z 413.2911, found 413.3267 [M+H]
+. 
 
23a: 1-Benzyl-2,6-dibutyl-1H-imidazo[4,5-c]pyridin-4-amine. White solid. 11 mg, 69%. 1H 
NMR (500 MHz, CDCl3)  7.37 – 7.31 (m, 3H), 7.10 (d, J = 6.9 Hz, 2H), 6.81 (s, 1H), 5.47 (s, 
2H), 2.85 (t, 2H), 2.72 (t, 2H), 1.74 (dd, J = 15.3, 7.6 Hz, 2H), 1.67 (ddd, J = 15.3, 10.4, 7.0 Hz, 
2H), 1.38 (ddq, J = 14.8, 10.2, 7.4 Hz, 4H), 0.94 (t, J = 7.4 Hz, 3H), 0.90 (t, J = 7.4 Hz, 3H). 13C 
NMR (126 MHz, CDCl3)  157.75, 150.13, 143.74, 137.10, 130.16, 129.22, 127.59, 124.62, 
97.63, 35.61, 32.84, 30.27, 27.85, 23.31, 23.22, 14.12, 14.04. HRMS (ESI) calculated for 
C21H29N4, m/z 337.2387, found 337.2476 [M+H]
+.  
 
Compounds 23b-23j were synthesized similarly as compound 23a. 
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20b: N4-Benzyl-3-nitro-6-phenyl-N2-(2,4,4-trimethylpentan-2-yl)pyridine-2,4-diamine. 
Phenylboronic acid was used as a reagent. Yellow solid. 28 mg, 57%. 1H NMR (500 MHz, 
CDCl3) 9.68 (s, 1H), 9.54 (s, 1H), 7.92 (ddd, J = 4.4, 2.5, 1.4 Hz, 2H), 7.45 – 7.42 (m, 3H), 7.40 
– 7.38 (m, 3H), 7.34 – 7.31 (m, 1H), 7.26 (s, 1H), 6.39 (s, 1H), 4.58 (d, J = 5.4 Hz, 2H), 2.09 (s, 
2H), 1.64 (s, 6H), 0.99 (s, 9H). 13C NMR (126 MHz, CDCl3)  159.01, 154.74, 153.13, 138.88, 
136.87, 130.20, 129.19, 128.66, 128.06, 127.50, 127.44, 92.16, 56.72, 51.69, 47.62, 32.02, 




amine. Yellow solid. 31 mg, 47%. 1H NMR (500 MHz, CDCl3)  8.02 (dd, J = 8.3, 1.2 Hz, 2H), 
7.39 (t, J = 7.7 Hz, 2H), 7.34 – 7.27 (m, 4H), 7.07 (d, J = 6.7 Hz, 2H), 6.94 (s, 1H), 5.34 (s, 1H), 
5.28 (s, 2H), 2.79 – 2.73 (m, 2H), 2.18 (s, 2H), 1.73 – 1.66 (m, 8H), 1.39 (dd, J = 15.0, 7.5 Hz, 
2H), 1.03 (s, 9H), 0.89 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3)  153.22, 150.01, 148.43, 
141.28, 140.32, 136.16, 129.61, 129.42, 129.15, 128.41, 128.07, 127.67, 127.54, 126.72, 
126.36, 126.28, 126.22, 91.77, 55.45, 51.63, 47.28, 31.98, 31.81, 30.33, 30.25, 27.50, 22.72, 
13.90. MS (ESI) calculated for C31H41N4, m/z 469.3326, found 469.3350 [M+H]
+.  
 
23b: 1-Benzyl-2-butyl-6-phenyl-1H-imidazo[4,5-c]pyridin-4-amine. White solid. 13 mg, 73%. 
1H NMR (500 MHz, CDCl3)  7.91 (d, J = 7.2 Hz, 2H), 7.54 – 7.44 (m, 3H), 7.42 – 7.34 (m, 3H), 
7.05 (dd, J = 6.4, 1.1 Hz, 2H), 6.83 (s, 1H), 5.37 (s, 2H), 2.88 – 2.78 (m, 2H), 1.78 (dd, J = 15.2, 
7.8 Hz, 2H), 1.42 (dq, J = 14.7, 7.4 Hz, 2H), 0.93 (t, J = 7.3 Hz, 3H). 13C NMR (126 MHz, CDCl3) 
 157.54, 149.18, 142.11, 141.93, 134.08, 132.07, 130.82, 129.68, 129.66, 129.01, 127.38, 
126.25, 95.25, 48.13, 29.31, 27.40, 22.52, 13.84. HRMS (ESI) calculated for C23H25N4, m/z 
357.2074, found 357.2155 [M+H]+. 
 
 185  
20c: 4-(4-(Benzylamino)-5-nitro-6-((2,4,4-trimethylpentan-2-yl)amino)pyridin-2-yl) 
benzonitrile. 4-Cyanophenylboronic acid was used as a reagent. Yellow solid. 30 mg, 55%. 1H 
NMR (500 MHz, CDCl3)  9.72 (s, 1H), 9.51 (s, 1H), 7.97 (d, J = 8.6 Hz, 2H), 7.72 (d, J = 8.6 Hz, 
2H), 7.44 – 7.31 (m, 5H), 6.38 (s, 1H), 4.59 (d, J = 5.4 Hz, 2H), 2.06 (s, 2H), 1.63 (s, 6H), 0.99 
(s, 9H). 13C NMR (126 MHz, CDCl3)  156.75, 154.69, 153.26, 143.14, 136.53, 132.50, 129.28, 
128.23, 127.93, 127.35, 118.79, 113.38, 93.05, 56.87, 51.72, 47.68, 32.01, 31.72, 30.10. MS 




yl)benzamide. Cyano group was converted into amide in the basic condition. Yellow solid. 22 
mg, 41%. 1H NMR (500 MHz, CDCl3)  8.10 (d, J = 8.5 Hz, 2H), 7.84 (d, J = 8.5 Hz, 2H), 7.34 – 
7.28 (m, 3H), 7.08 – 7.04 (m, 2H), 6.99 (s, 1H), 6.14 (s, 1H), 5.79 (s, 1H), 5.41 (s, 1H), 5.29 (s, 
2H), 2.81 – 2.74 (m, 2H), 2.17 (s, 2H), 1.72 – 1.66 (m, 8H), 1.43 – 1.33 (m, 2H), 1.03 (s, 9H), 
0.89 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3)  169.46, 153.74, 150.08, 147.00, 144.87, 
140.11, 135.97, 131.83, 129.20, 128.15, 127.62, 126.76, 126.74, 126.31, 92.63, 55.50, 51.55, 
47.31, 31.95, 31.79, 30.25, 30.17, 27.46, 22.69, 13.89. MS (ESI) calculated for C32H42N5O, m/z 
512.3384, found 512.3408 [M+H]+.  
 
23c: 4-(4-Amino-1-benzyl-2-butyl-1H-imidazo[4,5-c]pyridin-6-yl)benzamide. White solid. 11 
mg, 79%. 1H NMR (500 MHz, MeOD)  8.09 – 8.05 (m, 2H), 7.89 – 7.85 (m, 2H), 7.51 (s, 1H), 
7.41 – 7.32 (m, 3H), 7.17 (d, J = 7.0 Hz, 2H), 5.62 (s, 2H), 3.76 – 3.72 (m, 1H), 3.68 – 3.64 (m, 
1H), 3.58 (dd, J = 7.0, 2.7 Hz, 1H), 2.94 – 2.89 (m, 2H), 1.78 (dt, J = 15.3, 7.6 Hz, 2H), 1.42 (dd, 
J = 15.0, 7.5 Hz, 2H), 0.92 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, MeOD)  171.03, 159.91, 
149.79, 143.90, 141.45, 137.23, 136.75, 136.73, 130.29, 129.74, 129.43, 128.43, 127.76, 
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125.80, 98.94, 73.57, 72.45, 62.18, 43.73, 30.01, 27.99, 23.28, 14.04. HRMS (ESI) calculated 




Pyridinylboronic acid was used as a reagent. Orange solid. 135 mg, 82%. 1H NMR (500 MHz, 
CDCl3)  9.74 (t, J = 5.1 Hz, 1H), 9.54 (s, 1H), 9.10 (dd, J = 2.2, 0.6 Hz, 1H), 8.65 (dd, J = 4.8, 
1.6 Hz, 1H), 8.21 – 8.16 (m, 1H), 7.42 – 7.36 (m, 5H), 7.35 – 7.31 (m, 1H), 6.38 (s, 1H), 4.59 (d, 
J = 5.5 Hz, 2H), 2.07 (s, 2H), 1.63 (s, 6H), 0.99 (s, 9H). 13C NMR (126 MHz, CDCl3)  156.52, 
154.78, 153.22, 150.86, 148.93, 136.60, 134.75, 134.36, 129.26, 128.17, 127.35, 123.54, 
116.37, 92.38, 56.86, 51.65, 47.65, 32.01, 31.72, 30.11. MS (ESI) calculated for C25H32N5O2, 
m/z 434.2551, found 434.2563 [M+H]+. 
 
23d: 1-Benzyl-2-butyl-6-(pyridin-3-yl)-1H-imidazo[4,5-c]pyridin-4-amine. Light yellow solid. 
10 mg, 72%. 1H NMR (500 MHz, MeOD)  9.28 (d, J = 1.9 Hz, 1H), 8.94 (dd, J = 5.5, 1.2 Hz, 
1H), 8.83 (d, J = 8.2 Hz, 1H), 8.11 (ddd, J = 8.2, 5.6, 0.5 Hz, 1H), 7.72 (s, 1H), 7.40 – 7.32 (m, 
3H), 7.18 (d, J = 6.9 Hz, 2H), 5.65 (s, 2H), 2.98 – 2.91 (m, 2H), 1.78 (dd, J = 15.3, 7.7 Hz, 2H), 
1.42 (dd, J = 15.0, 7.5 Hz, 2H), 0.92 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, MeOD)  150.19, 
143.97, 143.57, 143.11, 136.48, 130.41, 130.32, 129.52, 128.03, 127.74, 127.73, 100.47, 48.55, 




Furylboronic acid was used as a reagent. Yellow solid. 95 mg, 70%. 1H NMR (500 MHz, CDCl3) 
 9.68 (t, J = 4.8 Hz, 1H), 9.49 (s, 1H), 7.95 (dd, J = 1.5, 0.8 Hz, 1H), 7.45 (t, J = 1.7 Hz, 1H), 
7.41 – 7.34 (m, 4H), 7.34 – 7.30 (m, 1H), 6.69 (dd, J = 1.9, 0.8 Hz, 1H), 6.07 (s, 1H), 4.53 (d, J 
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= 5.4 Hz, 2H), 2.05 (s, 2H), 1.60 (s, 6H), 0.98 (s, 9H). 13C NMR (126 MHz, CDCl3)  154.88, 
153.66, 153.09, 143.99, 143.68, 136.85, 129.19, 128.06, 127.39, 127.36, 108.83, 91.66, 56.68, 




pyridin-4-amine. Brown oil. 30 mg, 41%. 1H NMR (500 MHz, CDCl3)  7.94 (dd, J = 1.6, 0.7 Hz, 
1H), 7.41 (t, J = 1.7 Hz, 1H), 7.34 – 7.27 (m, 3H), 7.05 (d, J = 6.6 Hz, 2H), 6.76 (dd, J = 1.8, 0.8 
Hz, 1H), 6.61 (s, 1H), 5.30 (s, 1H), 5.24 (s, 2H), 2.76 – 2.71 (m, 2H), 2.13 (s, 2H), 1.70 – 1.65 
(m, 2H), 1.64 (s, 6H), 1.36 (dt, J = 14.7, 7.4 Hz, 2H), 1.02 (s, 9H), 0.88 (t, J = 7.4 Hz, 3H). 13C 
NMR (126 MHz, CDCl3)  152.80, 150.15, 143.24, 142.70, 140.71, 140.01, 136.16, 129.15, 
128.83, 128.06, 126.33, 125.88, 108.87, 91.20, 55.44, 51.45, 47.25, 31.93, 31.79, 30.29, 30.16, 
27.45, 22.71, 13.90. MS (ESI) calculated for C29H39N4O, m/z 459.3118, found 459.3168 [M+H]
+.  
 
23e: 1-Benzyl-2-butyl-6-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-4-amine. Light yellow solid. 12 
mg, 64%. 1H NMR (500 MHz, MeOD)  8.23 – 8.19 (m, 1H), 7.73 – 7.70 (m, 1H), 7.42 (s, 1H), 
7.40 – 7.32 (m, 3H), 7.15 (d, J = 6.9 Hz, 2H), 6.97 (dd, J = 2.0, 0.9 Hz, 1H), 5.58 (s, 2H), 2.90 – 
2.85 (m, 2H), 1.75 (dt, J = 15.3, 7.6 Hz, 2H), 1.40 (dq, J = 14.8, 7.4 Hz, 2H), 0.91 (t, J = 7.4 Hz, 
3H). 13C NMR (126 MHz, MeOD)  159.50, 149.42, 146.46, 144.24, 142.92, 136.72, 135.38, 
130.27, 129.41, 127.69, 124.89, 121.45, 109.21, 96.82, 48.27, 29.95, 27.91, 23.26, 14.03. 




diamine. 3-Thienylboronic acid was used as a reagent. Yellow solid. 107 mg, 76%. 1H NMR 
(500 MHz, CDCl3)  9.69 (s, 1H), 9.52 (s, 1H), 7.89 (dd, J = 3.0, 1.2 Hz, 1H), 7.49 (dd, J = 5.1, 
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1.2 Hz, 1H), 7.42 – 7.30 (m, 6H), 6.26 (s, 1H), 4.56 (d, J = 5.4 Hz, 2H), 2.08 (s, 2H), 1.63 (s, 
6H), 0.99 (s, 9H). 13C NMR (126 MHz, CDCl3)  154.88, 154.61, 153.25, 142.21, 136.90, 
129.19, 128.05, 127.38, 126.59, 126.56, 126.28, 91.99, 56.68, 51.59, 47.61, 32.02, 31.72, 




pyridin-4-amine. Brown solid. 25 mg, 35%. 1H NMR (500 MHz, CDCl3)  7.79 (dd, J = 3.1, 1.2 
Hz, 1H), 7.58 (dd, J = 5.0, 1.2 Hz, 1H), 7.33 – 7.27 (m, 4H), 7.06 (d, J = 6.6 Hz, 2H), 6.79 (s, 
1H), 5.35 (s, 1H), 5.25 (s, 2H), 2.78 – 2.70 (m, 2H), 2.17 (s, 2H), 1.70 (dd, J = 8.7, 7.0 Hz, 3H), 
1.67 (s, 6H), 1.38 (dq, J = 14.7, 7.4 Hz, 2H), 1.26 (dd, J = 8.7, 5.6 Hz, 1H), 1.02 (s, 9H), 0.89 (t, 
J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3)  153.04, 150.02, 144.89, 144.32, 140.11, 136.13, 
129.14, 128.07, 126.45, 126.34, 125.94, 125.41, 121.55, 91.54, 55.43, 51.49, 50.96, 47.26, 
31.96, 31.80, 30.26, 30.21, 27.46, 22.71, 13.89. MS (ESI) calculated for C29H39N4S, m/z 
475.2890, found 475.2922 [M+H]+. 
 
23f: 1-Benzyl-2-butyl-6-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-4-amine. White solid. 9 mg, 
53%. 1H NMR (500 MHz, MeOD)  8.04 (dd, J = 2.9, 1.4 Hz, 1H), 7.66 (dd, J = 5.1, 2.9 Hz, 1H), 
7.58 (dd, J = 5.1, 1.4 Hz, 1H), 7.48 (s, 1H), 7.41 – 7.32 (m, 3H), 7.17 (d, J = 6.9 Hz, 2H), 5.59 
(s, 2H), 2.94 – 2.86 (m, 2H), 1.76 (dt, J = 15.3, 7.6 Hz, 2H), 1.41 (dq, J = 14.8, 7.4 Hz, 2H), 0.91 
(t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, MeOD)  159.63, 149.38, 144.24, 137.90, 136.73, 
135.24, 130.28, 129.42, 129.31, 127.74, 126.73, 126.03, 124.88, 97.21, 49.07, 29.96, 27.94, 
23.26, 14.03. HRMS (ESI) calculated for C21H23N4S, m/z 363.1638, found 363.1686 [M+H]
+. 
 
20g: N4,6-Dibenzyl-3-nitro-N2-(2,4,4-trimethylpentan-2-yl)pyridine-2,4-diamine. Benzyl 
boronic acid pinacol ester was used as a reagent. Orange oil. 135 mg, 91%. 1H NMR (500 MHz, 
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CDCl3)  9.54 (t, J = 5.0 Hz, 1H), 9.37 (s, 1H), 7.36 (ddd, J = 7.4, 4.5, 1.4 Hz, 2H), 7.31 (dt, J = 
9.8, 4.4 Hz, 1H), 7.27 (ddd, J = 6.7, 3.3, 1.4 Hz, 5H), 7.22 – 7.18 (m, 3H), 5.75 (s, 1H), 4.40 (d, 
J = 5.4 Hz, 2H), 3.75 (s, 2H), 1.89 (s, 2H), 1.49 (s, 6H), 0.90 (s, 9H). 13C NMR (126 MHz, 
CDCl3)  164.70, 154.68, 152.84, 138.77, 136.80, 129.45, 129.07, 128.54, 127.91, 127.46, 
126.50, 124.96, 115.72, 94.56, 56.63, 51.05, 47.44, 45.61, 31.87, 31.60, 30.09, 24.86. MS (ESI) 




Light brown solid. 55 mg, 60%. 1H NMR (500 MHz, CDCl3)  7.33 – 7.27 (m, 5H), 7.24 (t, J = 7.6 
Hz, 2H), 7.14 (t, J = 7.3 Hz, 1H), 7.01 (d, J = 6.4 Hz, 2H), 6.31 (s, 1H), 5.22 (s, 1H), 5.16 (s, 
2H), 3.96 (s, 2H), 2.74 – 2.67 (m, 2H), 2.02 (s, 2H), 1.66 – 1.61 (m, 2H), 1.56 (s, 6H), 1.35 (dd, 
J = 15.0, 7.5 Hz, 2H), 0.93 (s, 9H), 0.86 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3)  
152.37, 151.90, 150.06, 141.57, 140.10, 136.28, 129.31, 129.06, 128.21, 127.95, 126.38, 
125.78, 124.94, 93.59, 55.35, 50.98, 47.19, 45.39, 31.85, 31.68, 30.41, 30.27, 27.42, 22.67, 
13.87. MS (ESI) calculated for C32H43N4, m/z 483.3482, found 483.3526 [M+H]
+. 
 
23g: 1,6-Dibenzyl-2-butyl-1H-imidazo[4,5-c]pyridin-4-amine. White solid. 23 mg, 58%. 1H 
NMR (500 MHz, DMSO)  13.63 (s, 1H), 8.27 (s, 2H), 7.37 – 7.29 (m, 7H), 7.27 – 7.23 (m, 1H), 
7.15 (s, 1H), 7.11 (d, J = 6.9 Hz, 2H), 5.52 (s, 2H), 4.08 (s, 2H), 2.86 – 2.79 (m, 2H), 1.61 (dt, J 
= 15.3, 7.6 Hz, 2H), 1.31 (dt, J = 14.9, 7.4 Hz, 2H), 0.81 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, 
DMSO)  156.72, 148.03, 142.12, 141.72, 137.39, 135.93, 128.96, 128.72, 128.70, 127.92, 
126.98, 126.63, 123.29, 97.60, 46.84, 40.11, 38.20, 28.89, 26.28, 21.69, 13.61. HRMS (ESI) 
calculated for C24H27N4, m/z 371.2230, found 371.2285 [M+H]
+. 
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20h: N4-Benzyl-6-(4-methylbenzyl)-3-nitro-N2-(2,4,4-trimethylpentan-2-yl)pyridine-2,4-
diamine. 4-Methyl benzylboronic acid pinacol ester was used as a reagent. Yellow oil. 130 mg, 
91%. 1H NMR (500 MHz, CDCl3)  9.52 (t, J = 5.0 Hz, 1H), 9.37 (s, 1H), 7.37 – 7.30 (m, 3H), 
7.28 – 7.24 (m, 3H), 7.10 – 7.03 (m, 7H), 5.74 (s, 1H), 4.39 (d, J = 5.4 Hz, 2H), 3.70 (s, 2H), 
2.31 (s, 3H), 1.90 (s, 2H), 1.51 (s, 6H), 0.90 (s, 9H). 13C NMR (126 MHz, CDCl3)  165.00, 
154.68, 152.83, 136.82, 135.98, 135.70, 135.50, 134.26, 129.28, 129.23, 129.12, 129.05, 
128.98, 127.89, 127.47, 115.70, 94.47, 83.50, 56.63, 51.03, 47.44, 45.22, 31.87, 31.57, 30.12, 
24.87, 21.19, 21.11. MS (ESI) calculated for C28H37N4O2, m/z 461.2911, found 461.3003 [M+H]
+. 
 
23h: 1-Benzyl-2-butyl-6-(4-methylbenzyl)-1H-imidazo[4,5-c]pyridin-4-amine. White solid. 19 
mg, 66%. 1H NMR (500 MHz, MeOD)  7.38 – 7.32 (m, 3H), 7.16 (d, J = 7.9 Hz, 2H), 7.13 – 
7.08 (m, 4H), 6.89 (s, 1H), 5.49 (s, 2H), 4.08 (s, 2H), 2.92 – 2.87 (m, 2H), 2.32 (s, 3H), 1.76 (dt, 
J = 15.3, 7.6 Hz, 2H), 1.40 (dt, J = 14.8, 7.4 Hz, 2H), 0.91 (t, J = 7.4 Hz, 3H). 13C NMR (126 
MHz, MeOD)  159.11, 149.35, 144.27, 143.93, 138.37, 136.53, 134.52, 130.68, 130.25, 
129.85, 129.42, 127.74, 124.41, 99.41, 39.40, 30.01, 27.84, 23.26, 21.08, 14.03. HRMS (ESI) 




pyridine-2,4-diamine. 4-(Trifluoromethoxy)benzylboronic acid pinacol ester was used as a 
reagent. Yellow solid. 115 mg, 70%. 1H NMR (500 MHz, CDCl3)  9.57 (t, J = 5.0 Hz, 1H), 9.37 
(s, 1H), 7.38 – 7.29 (m, 3H), 7.28 (t, J = 1.8 Hz, 2H), 7.21 – 7.17 (m, 2H), 7.10 (d, J = 7.9 Hz, 
2H), 5.74 (s, 1H), 4.43 (d, J = 5.5 Hz, 2H), 1.83 (s, 2H), 1.45 (s, 6H), 0.88 (s, 9H). 13C NMR (126 
MHz, CDCl3)  163.87, 154.70, 152.91, 137.54, 136.71, 130.77, 129.10, 127.95, 127.33, 
121.09, 115.75, 94.57, 56.63, 50.96, 47.44, 44.69, 31.82, 31.55, 30.02. MS (ESI) calculated for 
C28H34F3N4O3, m/z 531.2578, found 531.2738 [M+H]
+.  
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23i: 1-Benzyl-2-butyl-6-(4-(trifluoromethoxy)benzyl)-1H-imidazo[4,5-c]pyridin-4-amine. 
White solid. 21 mg, 47%. 1H NMR (500 MHz, CDCl3)  7.37 – 7.29 (m, 5H), 7.21 (d, J = 8.0 Hz, 
2H), 7.08 (d, J = 6.5 Hz, 2H), 6.79 (s, 1H), 5.45 (s, 2H), 4.09 (s, 2H), 2.87 (dd, J = 9.3, 6.1 Hz, 
2H), 1.74 (dt, J = 15.3, 7.6 Hz, 2H), 1.41 (dt, J = 15.0, 7.4 Hz, 2H), 0.91 (t, J = 7.4 Hz, 3H). 13C 
NMR (126 MHz, MeOD)  157.96, 150.50, 149.43, 149.42, 143.48, 138.54, 136.96, 131.59, 
130.16, 129.25, 127.66, 124.97, 122.37, 99.02, 40.76, 30.29, 27.86, 23.31, 14.05. HRMS (ESI) 




Phenylethylboronic acid was used as a reagent. Yellow oil. 85 mg, 59%. 1H NMR (500 MHz, 
CDCl3)  9.52 (t, J = 4.9 Hz, 1H), 9.43 (s, 1H), 7.36 (t, J = 7.2 Hz, 2H), 7.33 – 7.28 (m, 4H), 7.27 
– 7.25 (m, 3H), 7.19 (d, J = 7.3 Hz, 1H), 7.17 (d, J = 7.0 Hz, 2H), 5.69 (s, 1H), 4.39 (d, J = 5.4 
Hz, 2H), 2.99 (dd, J = 9.1, 6.8 Hz, 2H), 2.75 (dd, J = 9.1, 6.8 Hz, 2H), 2.04 (s, 2H), 1.58 (s, 6H), 
0.98 (s, 9H). 13C NMR (126 MHz, CDCl3)  165.06, 154.74, 152.65, 141.77, 136.85, 129.09, 
128.52, 128.49, 127.95, 127.39, 126.10, 115.78, 94.52, 56.68, 51.35, 47.41, 40.87, 34.61, 
31.97, 31.69, 30.20. MS (ESI) calculated for C28H37N4O2, m/z 461.2911, found 461.3096 [M+H]
+. 
 
23j: 1-Benzyl-2-butyl-6-phenethyl-1H-imidazo[4,5-c]pyridin-4-amine. Yellow solid. 11 mg, 
42%. 1H NMR (500 MHz, CDCl3)  7.36 – 7.30 (m, 3H), 7.23 – 7.18 (m, 2H), 7.13 (ddd, J = 5.7, 
3.7, 1.5 Hz, 3H), 7.02 (d, J = 6.5 Hz, 2H), 6.68 (s, 1H), 5.38 (s, 2H), 2.99 (s, 4H), 2.85 – 2.79 (m, 
2H), 1.69 (ddd, J= 13.2, 8.5, 6.7 Hz, 2H), 1.37 (dq, J = 14.8, 7.4 Hz, 2H), 0.89 (t, J = 7.4 Hz, 
3H). 13C NMR (126 MHz, MeOD)  157.35, 150.48, 148.64, 143.39, 141.89, 137.14, 130.14, 
129.53, 129.43, 129.16, 127.59, 127.22, 124.68, 97.93, 48.17, 38.42, 36.84, 30.28, 27.83, 
23.31, 14.03. HRMS (ESI) calculated for C25H29N4, m/z 385.2387, found 385.2446 [M+H]
+. 
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Synthesis of compound 24: 3-Nitrobenzo[g]quinolin-4-ol. Nitromethane (0.96 mL, 18 mmol) 
was added dropwise to a solution of NaOH (2.2 g, 54 mmol) in water (5 mL), at 0 C. The 
mixture was then warmed to 40 ºC and nitromethane (0.96 mL, 18 mmol) was again added 
slowly at 40-45 ºC. The temperature was maintained until a clear solution was obtained. The 
reaction mixture was then heated to 55 ºC for 2-5 minutes, cooled to 30 ºC, poured onto 
crushed ice and acidified with conc. HCl (5 mL). The resultant solution of methazoic acid was 
added immediately to a filtered solution of 3-amino-2-naphtholic acid (3 g, 16 mmol) and conc. 
HCl (1 mL) in water (20 mL). The reaction mixture was allowed to stand at room temperature for 
12 h. After filtration, the residue obtained was washed with water, and dried (1.1 g, 90%). A 
solution of intermediate (2 g, 7.75 mmol) in acetic anhydride (10 mL) was placed in a 2-neck 
flask fitted with a reflux condenser. It was stirred and heated to 105 ºC until a clear solution was 
obtained. Heating was then discontinued and potassium acetate (0.77 g, 7.90 mmol) was 
added. The mixture was then refluxed for 15 min with vigorous stirring, until a solid started to 
precipitate. The reaction mixture was then slowly cooled to room temperature. The residue was 
filtered, washed with glacial acetic acid until the washings were colorless, then suspended in 
water, filtered, washed with water and dried at 110 ºC to get compound 24 (0.93 g, 50%). 1H 
NMR (500 MHz, DMSO)  13.12 (s, 1H), 9.28 (s, 1H), 8.95 (s, 1H), 8.27 – 8.21 (m, 2H), 8.11 (d, 
J = 8.4 Hz, 1H), 7.69 (t, J = 7.1 Hz, 1H), 7.61 (t, J = 7.1 Hz, 1H). 13C NMR (126 MHz, DMSO)  
168.61, 144.40, 135.05, 134.63, 130.14, 129.54, 128.94, 128.71, 127.46, 127.41, 126.65, 
126.48, 116.78. MS (ESI) calculated for C13H8N2O3, m/z 240.05, found 263.04 [M+Na]
+.  
 
Synthesis of compound 25: 4-Chloro-3-nitrobenzo[g]quinoline.  A suspension of compound 
24 (2.0 g, 8.30 mmol) in phosphorus(V) oxychloride was placed in a pressure vessel and it was 
heated at 150 ºC. After a clear solution was obtained, the reaction mixture was kept at 150 ºC 
for 1 h. Then it was slowly cooled to room temperature and the solvent was evaporated under 
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vacuum. The residue was poured over crushed ice while stirring and the formed solid was 
filtered, washed with water and dried to obtain compound 25 (1.95 g, 91%). 1H NMR (500 MHz, 
DMSO)  13.34 (d, J = 6.9 Hz, 1H), 9.26 (d, J = 7.3 Hz, 1H), 8.95 (s, 1H), 8.25 (d, J = 9.4 Hz, 
2H), 8.11 (d, J = 8.4 Hz, 1H), 7.72 – 7.67 (m, 1H), 7.61 (ddd, J = 8.1, 6.8, 1.1 Hz, 1H). 13C NMR 
(126 MHz, DMSO)  168.64, 144.23, 134.96, 134.64, 130.16, 129.56, 128.98, 128.70, 127.48, 
127.43, 126.69, 126.48, 116.74. 
 
Synthesis of compound 26: N-Benzyl-3-nitrobenzo[g]quinolin-4-amine. To a solution of 
compound 25 (1.0 g, 3.90 mol) in 20 mL of CH2Cl2 was added triethylamine (0.81 mL, 5.80 
mmol) and benzylamine (0.50 mL, 4.60 mmol). The reaction mixture was refluxed for 2 h. The 
solvent was then evaporated under vacuum and H2O was added to the residue. The solution 
was extracted with CH2Cl2 (3 × 20 mL), washed with water and dried over sodium sulfate. The 
solvent was evaporated and the residue was purified using silica gel column chromatography 
(0-5% MeOH in CH2Cl2) to obtain compound 26 as a yellow solid (1.1 g, 88%). 
1H NMR (500 
MHz, CDCl3)  10.57 (s, 1H), 9.41 (s, 1H), 8.87 (s, 1H), 8.50 (s, 1H), 8.02 (d, J = 8.4 Hz, 1H), 
7.83 (d, J = 8.4 Hz, 1H), 7.65 – 7.60 (m, 1H), 7.55 – 7.51 (m, 1H), 7.50 – 7.47 (m, 4H), 7.42 
(ddd, J = 11.0, 5.4, 3.0 Hz, 1H), 5.28 (d, J = 5.9 Hz, 2H). 13C NMR (126 MHz, CDCl3)  152.50, 
147.73, 145.88, 136.85, 135.48, 130.53, 129.64, 129.12, 129.03, 128.98, 128.83, 128.11, 
128.04, 127.29, 126.86, 124.21, 118.09, 53.19. MS (ESI) calculated for C20H16N3O2, m/z 
330.1237, found 330.1304 [M+H]+. 
 
Synthesis of compound 30: 1-Benzyl-2-butyl-1H-benzo[g]imidazo[4,5-c]quinolin-4-amine. 
To a solution of compound 26 (300 mg, 0.91 mmol) in 20 mL of MeOH were added zinc dust 
(594 mg, 9.10 mmol) and ammonium formate (574 mg, 9.10 mmol). The reaction mixture was 
stirred at room temperature for 30 min and filtered through celite. Then the solvent was 
 194  
evaporated and the residue was dissolved in water. This was extracted with EtOAc (3 × 20 mL), 
washed with water and dried over sodium sulfate. The solvent was removed under vacuum to 
obtain compound 27 (100 mg, 37%). To a solution of compound 27 (98 mg, 0.33 mmol) in 10 
mL of anhydrous THF were added triethylamine (48 L, 0.35 mmol) and valeryl chloride (40 L, 
0.33 mmol). The reaction mixture was refluxed for 2 h. The solvent was then removed under 
vacuum, and the residue was dissolved in 10 mL of EtOH and NaOH (26 mg, 0.66 mmol) in 1 
mL of H2O was added. The reaction mixture was refluxed for 2 h. The solvent was then 
removed under vacuum, and the residue was dissolved in EtOAc and washed with water. The 
EtOAc fraction was dried using sodium sulfate and evaporated and purified using column 
chromatography (0-10% MeOH in CH2Cl2) to obtain the compound 28 (76 mg, 63%). To a 
solution of compound 28 (76 mg, 0.21 mmol) in a solvent mixture of MeOH:CH2Cl2:CHCl3 
(1:10:10) was added 3-chloroperoxy benzoic acid (443 mg, 1.98 mmol), and the solution was 
refluxed at 45-50 ºC for 1 h. The solvent was then removed and the residue was purified using 
column chromatography (0-10% MeOH in CH2Cl2) to obtain the N-oxide derivative 29 (64 mg, 
80%). To a solution of compound 29 (64 mg, 0.17 mol) in 10 mL of CH2Cl2 was added benzoyl 
isocyanate (37 mg, 0.25 mmol) and heated at 45 ºC for 18 h. The solvent was then removed 
under vacuum, and the residue was dissolved in 15 mL of anhydrous MeOH, followed by the 
addition of excess sodium methoxide. The reaction mixture was then heated at 80 ºC for 2 h. 
The solvent was removed under vacuum and the residue was purified using column 
chromatography (0-10% MeOH in CH2Cl2) to obtain the compound 30 (20 mg, 30%). 
1H NMR 
(500 MHz, DMSO)  8.40 (s, 1H), 8.05 (s, 1H), 7.88 (d, J = 8.3 Hz, 1H), 7.77 (d, J = 8.3 Hz, 1H), 
7.38 (d, J = 7.2 Hz, 1H), 7.33 (dd, J = 12.9, 5.2 Hz, 3H), 7.24 (d, J = 7.4 Hz, 1H), 7.16 (d, J = 7.4 
Hz, 2H), 6.91 (s, 2H), 6.02 (s, 2H), 3.00 – 2.92 (m, 2H), 1.74 (dt, J = 15.4, 7.6 Hz, 2H), 1.40 (dd, 
J = 14.9, 7.4 Hz, 2H), 0.88 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, DMSO)  136.73, 131.80, 
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128.91, 127.99, 127.81, 127.46, 126.82, 125.81, 123.63, 118.72, 48.20, 29.71, 26.27, 21.85, 




Human TLR-7/-8 reporter gene assays (NF-B induction). As described in Chapter 2. 
 
Immunoassays for Interferon (IFN)-, and cytokines. As described in Chapter 2. 
 
Flow-cytometric immunostimulation experiments. CD69 upregulation was determined by 
flow cytometry using protocols published by us previously,30 and modified for rapid-throughput. 
Briefly, heparin-anticoagulated whole blood samples were obtained by venipuncture from 
healthy human volunteers with informed consent and as per guidelines approved by the 
University of Kansas Human Subjects Experimentation Committee. Serial dilutions of selected 
imidazopyridine compounds (and imiquimod, used as a reference compound) were performed 
using a Bio-Tek Precision 2000 XS liquid handler in sterile 96-well polypropylene plates, to 
which were added 100 L aliquots of anticoagulated whole human blood.  The plates were 
incubated at 37°C for 16.5 h. Negative (endotoxin free water) controls were included in each 
experiment.  Following incubation, fluorochrome-conjugated antibodies (CD3-PE, CD56-APC, 
CD69-PE-Cy7, 10 L of each antibody, Becton-Dickinson Biosciences, San Jose, CA) were 
added to each well with a liquid handler, and incubated at 37 °C in the dark for 30 min. 
Following staining, erythrocytes were lysed and leukocytes fixed by mixing 200 mL of the 
samples in 2 mL pre-warmed Whole Blood Lyse/Fix Buffer (Becton-Dickinson Biosciences, San 
Jose, CA) in 96 deep-well plates. After washing the cells twice at 200 g for 8 minutes in saline, 
the cells were transferred to a 96-well plate.  Flow cytometry was performed using a BD 
FACSArray instrument in the tri-color mode (tri-color flow experiment) and two-color mode (two-
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color flow experiment) for acquisition on 100,000 gated events. Compensation for spillover was 
computed for each experiment on singly-stained samples. CD69 activation in the major 
lymphocytic populations, viz., natural killer lymphocytes (NK cells: CD3-CD56+), cytokine-
induced killer phenotype (CIK cells: CD3+CD56+), B lymphocytes (B cells: CD3-CD19+). 
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6.1. Introduction 
 
Extensive SARs on several TLR7/8-agonistic scaffolds such as imidazo[4,5-c]quinolines,55b, 69 
thiazolo[4,5-c]quinolines (Chapter 2),113 furo[2,3-c]pyridines (Chapter 3),114 imidazo[4,5-
c]pyridines (Chapter 5),115 and furo[2,3-c]quinolines116 have been reported from our laboratory 
(Fig. 1). Recently, a C2-butyl furo[2,3-c]quinoline (5) having pure TLR8 agonistic activity was 
cocrystallized with the human TLR8 ectodomain.117 This served as the point of departure toward 
a focused structure-based ligand design study, leading to the identification of 3-pentylquinoline-
2-amine (6, Fig. 1) as a novel, structurally simple, and highly potent human TLR8-specific 
agonist.118  
 
Fig. 1. Structures of representative TLR7 and TLR8 agonists. 
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Our SAR investigations in several of these scaffolds, while continuing to incrementally improve 
our understanding of the structural features required for the TLR7/8 activity, pointed strongly 
also to the strict dependence of the selectivity for TLR7 vis-à-vis TLR8 on the electronic 
configurations of the heterocyclic systems, the nuances of which we desired to examine 
quantitatively with the goal of developing ‘heuristics’ to clearly define structural requisites 
governing activity at TLR7 and/or TLR8. In order to systematically examine the effect of 
electronic properties on the activity profiles, we undertook a scaffold hopping approach,119 which 
entailed the syntheses and biological evaluations of thirteen different chemotypes including 
oxazolo[4,5-c]quinoline, thiazolo/oxazolo[4,5-c]quinolin-2-amines, thiazolo/oxazolo[5,4-c] 
quinolines, imidazo[1,2-c]quinazoline, [1,2,4]triazolo[1,5-c]quinazoline, imidazo[1,2-a] 
quinoxaline, [1,2,4]triazolo[1,5-a]quinoxaline, [1,2,4]-triazolo[4,3-a]quinoxaline, and 
pyrazolo[3,4-c]quinoline. 
 
Crystal structures of TLR8 in complex with two most active compounds confirmed important 
binding interactions playing a key role in ligand occupancy and biological activity. Reasoning 
that stereo-electronic effects of heterocyclic ring systems could have a profound effect on the 
biological activity of TLR7/8 modulators, we undertook studies of three-dimensional molecular 
electrostatic potential (MESP) in an effort to obtain complementary and/or mechanistic 
information in characterizing active molecules.120 Density functional theory (DFT) based 
quantum chemical calculations and linear discriminant analyses were therefore performed. 
These studies allowed, for the first time, a clear delineation of inactive, TLR8-active and TLR7/8 
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6.2. Results and Discussion 
 
As mentioned earlier, a number of leads including pure TLR7 agonists (1 and 2), dual TLR7/8 
agonist (3), and pure TLR8 agonists (4, 5, and 6) are undergoing preclinical evaluation as 
vaccine adjuvants in our laboratory. Our earlier structure-activity relationship studies on the 
imidazo[4,5-c]quinolines,55b, 69 thiazolo[4,5-c]quinolines,113 furo[2,3-c]pyridines,114 as well as 
furo[2,3-c]quinolines116 had all converged on the optimal chain length for the C2 alkyl substituent 
being butyl. Our goal was therefore to examine the electronic effects of heterocyclic 
modifications, while holding the substituent at the C2 position invariant at 4 atoms.  
 
We envisioned that a reagent-based diversification approach121 could allow us to access to 
several different heterocyclic scaffolds (including the thiazolo[4,5-c]quinolines) with substantial 
variations in the electronic configurations (Scheme 1). Employing this diversification strategy, 
the previously described 2-butylthiazolo[4,5-c]quinoline was synthesized from aminoquinolin-4-
ol and valeroyl chloride via a one-pot, sequential reaction involving acylation and subsequent 
microwave-accelerated (120 °C, 600 W) cyclization using P2S5 (7, Scheme 1), while 
replacement of P2S5 with P2O5 in this reaction resulted in its congener 8 (2-butyloxazolo[4,5-
c]quinoline) in moderate yield. Microwave-assisted cyclization also yielded N-propylthiazolo[4,5-
c]quinolin-2-amine 10 using propyl isothiocyanate, whereas conventional heating was 
unsuccessful. The synthesis of N-propyloxazolo[4,5-c]quinolin-2-amine 12 using P2O5 led to the 
formation of a mixture of compounds with very poor yields; substituting N-(3-dimethylamino 
propyl)-N′-ethylcarbodiimide (EDC) for P2O5 in this reaction not only worked as a sulfur 
scavenger, but greatly enhanced yields of the desired oxazolo analog 12 (Scheme 1). The C4 
amine functionality was then installed using conventional methods69, 113 to furnish the 2-
butyloxazolo[4,5-c]quinolin-4-amine 9, the N-propylthiazolo[4,5-c]quinoline-2,4-diamine 11, and 
the N-propyloxazolo[4,5-c]quinoline-2,4-diamine 13. 
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The 2-butyloxazolo[4,5-c]quinolin-4-amine 9 displayed more potent dual TLR7/8-agonistic 
activity compared to the thiazolo[4,5-c]quinolin-4-amine 3, with EC50 values of 0.55 M and 0.18 
M in TLR7 and TLR8 assays, respectively (Fig. 2). The N-propylthiazolo[4,5-c]quinoline-2,4-
diamine 11, however, exhibited comparable TLR7-agonistic activity (EC50: 0.73 M), but a ten-
fold reduction in TLR8 potency (EC50: 3.94 M). Astonishingly, the N-propyloxazolo[4,5-
c]quinoline-2,4-diamines 13 was entirely devoid of any detectable TLR7- or TLR8-agonistic 
activity. The C2 N-acyl derivative,  N-(4-aminothiazolo[4,5-c]quinolin-2-yl)propionamide 16 and 
its des-acyl analog 17 were synthesized from commercially-available thiazolo[4,5-c]quinolin-2-
amine (Scheme 2). These compounds were also found to be inactive in cell based assays (Fig. 
2).  
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 Fig. 2. TLR7- and TLR8-agonistic potencies (EC50 values) of the compounds determined in TLR-specific 
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Scheme 2. Synthesis of C2 N-acyl derivative 16 and its des-acyl analog 17. 
  
 
The dramatic (and rather unexpected) differences in activity profiles of the closely-related 
congeners warranted a detailed investigation of analogues with variable electronic properties. 
We first synthesized and evaluated the regioisomeric 2-butylthiazolo[5,4-c]quinolin-4-amine 22a 
and 2-butyloxazolo[5,4-c]quinolin-4-amine 22b (Scheme 3). The thiazolo[5,4-c]quinoline 
derivative (22a) was completely inactive in both TLR7 and TLR8 agonism assays and the 
oxazolo[5,4-c]quinoline derivative (22b) was found to possess negligibly low TLR8-agonistic 
activity. This result, too, was unexpected, given that we had observed prominent and selective 
TLR8 agonism in the 2-butylfuro[2,3-c]quinolin-4-amine 5,116 but further strengthened the case 
for a systematic exploration of the role of electron densities in the heterocyclic core in 
determining TLR7/8 activity. 
 
Scheme 3. Synthesis of regioisomeric thiazolo/oxazolo[5,4-c]quinolin-4-amines. 
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Further scaffold modifications were therefore carried out based on the pure TLR7-agonistic lead 
molecule 1-benzyl-2-butyl-1H-imidazo[4,5-c]quinolin-4-amine 1 (Fig.1). ‘Repositioning’ of the 
nitrogen atoms in the imidazole ring as well as triazole analogues were designed and 
synthesized (Schemes 4-8).122 The novel analogues 2,3-dihydroimidazo[1,2-c]quinazoline 27 
and imidazo[1,2-c]quinazoline 29, with an altered imidazole fused ring (Scheme 4) were entirely 
inactive (Fig. 2). We sought to examine if activity could be restored by incorporating an 
additional nitrogen atom in ring system, but the triazole analogue 33 (2-butyl-[1,2,4]triazolo[1,5-
c]quinazolin-5-amine, Scheme 5) was also inactive. On the other hand, the 1,2-
dihydroimidazo[1,2-a]quinoxaline 37 and the imidazo[1,2-a]quinoxaline 39 shown in Scheme 6 
were found to be selective TLR8 agonists with EC50 values of 3.05 M and 7.99 M, 
respectively (Fig. 2). 
 
Scheme 4. Synthesis of imidazo[1,2-c]quinazolines. 
 
 
Scheme 5. Synthesis of [1,2,4]triazolo[1,5-c]quinazoline. 
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Scheme 6. Synthesis of imidazo[1,2-a]quinoxalines. 
 
 
Transitioning from the imidazo[1,2-a]quinoxaline scaffold to two other triazolo analogues (46 in 
Scheme 7 and 49 in Scheme 8) also resulted in complete loss of activity. 
 
Scheme 7. Synthesis of [1,2,4]triazolo[1,5-a]quinoxaline. 
 
 
Scheme 8. Synthesis of [1,2,4]triazolo[4,3-a]quinoxaline. 
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Our scaffold-hopping approach also led us to synthesize 2-butyl-2H-pyrazolo[3,4-c]quinolin-4-
amine 53 (Scheme 9). Compound 53 was found to be extraordinarily potent as a TLR7 agonist 
(EC50: 0.19 M), significantly greater than that of the thiazoloquinoline 3 (EC50: 0.86 M), the 
oxazoloquinoline 9 (EC50: 0.55 M), and the aminothiazoloquinoline 11 (EC50: 0.73 M), and 
approaching that of our best-in-class, pure TLR7 agonistic imidazoquinoline 1 (EC50: 0.059 M). 
Furthermore, the pyrazolo[3,4-c]quinoline 53 was also found to be the most potent in TLR8 
agonism assays (EC50: 0.056 M) among all TLR8-active compounds that we had hitherto 
characterized (Fig. 2).  
 




We confirmed TLR7/8 selectivity and potency of the active compounds in secondary screens 
including cytokine-inducing properties in human PBMCs, as well as cellular activation in ex vivo 
whole human blood. In IFN- induction assays, as expected and in accordance with our 
previous SAR, compounds with TLR7 agonistic activity (9, 11, and 53) showed IFN- inducing 
ability and the TLR8 selective compound 39 did not (Fig. 3).  
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 Fig. 3. Dose-response profiles of IFN- induction by the active compounds in human PBMCs. Means on 















We also found strong Type II IFN (IFN-), cytokine (IL-1, IL-1, IL-6, IL-10, TNF-), and 
chemokine (IP-10/CXCL-10, MCP-1, MIP-1) induction by the active compounds consistent with 
their TLR7/8 selectivity profiles (Fig. 4). The extraordinary potency of 53 was also manifested in 
CD69 expression in whole blood assays, showing dramatically enhanced expression in 
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Fig. 4. Cytokine and chemokine induction profiles in human PBMCs stimulated with 10 M of select 
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We were fortunate in also being able to obtain the crystal structures of TLR8 in complex with the 
two most active compounds: the oxazoloquinoline 9 and the pyrazoloquinoline 53. An 
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two compounds (Fig. 6). Major interactions include hydrogen bonding of the amidine group with 
Asp543 and the N atom of the oxazole/pyrazole ring with Thr574, -interactions of the 
quinoline ring with Phe405, and hydrophobic interactions of the alkyl chain in a pocket formed 
by Tyr348, Val378, and Phe405.  
 
 Fig. 6. Crystal structures of human TLR8 ectodomain complexed with compound 9 (Panel A) and 
compound 53 (Panel B), showing key interactions in the binding pocket. PDB codes for compounds 9 and 





















 211  
Whereas the steric properties of most of these analogues are very similar, their activity profiles 
are considerably different and the data, taken together, strongly pointed to electronic densities 
of ring system(s) being dominant determinants of occupancy and activation of TLR7 and TLR8 
by these analogues. We therefore undertook quantum chemical calculations of electron 
densities and of Mulliken atomic charges with the objective of obtaining insights into the 
properties of these molecules, which we hoped would lead to quantitative predictors of 
selectivity and potency at TLR7 and TLR8.  
 
As described earlier, the crystal structures of TLR8 complexed with active analogues showed 
key H-bonds between the amidine group of the quinoline moiety with the side chain of Asp543, 
and the N atoms of the oxazole or pyrazole moieties of compounds 9 and 53, respectively, with 
Thr574, providing major contributions to overall binding interactions (Fig. 6). Consistent with our 
expectation that the strength and geometry of the H-bonds are modulated by electron densities 
and Mulliken charges on appropriate heteroatoms, we observed clear differences in atoms 
known to be involved in H-bonding interactions. The active compounds 3, 9, 11, 39, and 53 (Fig. 
7) display pronounced negative charges (-0.24, -0.24, -0.29, -0.27, and -0.23 electron units, 
respectively) at position M1 of the five-membered ring. Compounds that do not have the 
electronegative atom at position M1 (22a and 29; +0.15, 0.0) were found to be inactive. We also 
noticed a higher partial positive charge at the M2 position in the oxazolo[4,5-c]quinoline-2,4-
diamine 13 (0.33 electron unit, Fig. 7c) compared to other compounds, attributable to adjacent 
electronegative heteroatoms (N and O), possibly explaining the lack of activity. The quinazoline 
analogues 29 and 33 were unique in that the presence of an additional electronegative nitrogen 
atom at position M5 (-0.25 and -0.22, respectively) resulted in strong positive charge at position 
M6 (+0.26 and +0.29 electron units, respectively), again correlating with absence of agonistic 
activities.  
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Fig. 7. Molecular electrostatic potential surfaces of selected compounds.  
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Given the importance of hydrogen bonding of the amidine group with Asp543, we examined 
electrostatic potentials at M7. Active compounds could be differentiated from inactive 
compounds (Fig. 8A) with three exceptions: compounds 13, 16 and 22a. The absence of 
TLR7/8-agonistic activity in 16 and 22a could be explained readily; the presence of a polar 
amide sidechain in 16 is expected to disfavor interactions in the hydrophobic pocket, while the 
regio-isomeric thiazoloquinoline 22a possesses a bulky sulfur atom at M1. The misclassification 
of 13 as an active compound may, as mentioned earlier, be related to the higher partial positive 
charge at the M2 position. 
 
The availability of electron density and charge parameters for all atoms in all of the analogues 
prompted us to examine if a formal classification of active vis-à-vis inactive compounds could be 
arrived at, with our goal of being able to utilize such methodology in prospectively designing 
‘bespoke’ compounds with predefined selectivity. Stepwise linear discriminant analyses were 
performed with the 13 compounds shown in Fig. 2 as a training set. A linear combination of the 
variables corresponding to M1-M6 explained 100% of the variance in two dimensions 
(Discriminant Functions 1 and 2, see Fig. 8B), allowing a clear-cut classification of inactive 
(coded ‘0’), TLR8-active (coded ‘1’), and TLR7/8 dual-active (coded ‘2’) compounds (Fig. 8B). 
The discriminant functions were utilized to examine a test set of compounds which included 5116 
(Fig. 1), CL097,43a as well as nine ‘hypothetical’ compounds (Fig. 8B). Compound 5 and CL097 
were correctly classified as being TLR8 (Group 1) and TLR7/8 dual-active (Group 2). All of the 
proposed analogues with the exception of H3 were predicted to be active. It is noteworthy that 
the isomeric compounds H8 and H9 (2-butyl-cyclopentaquinolin-4-amines) could be considered 
as conformationally-constrained analogues of 3-alkyl-quinoline-2-amines118 (Fig. 1) which we 
have recently designed and characterized as pure TLR8 agonists. The thienoquinolines H1 and 
H2 as well as the pyrroloquinolines H3 and H4 are of particular interest, and we are currently 
evaluating such analogues.   


































































Fig. 8. A: Classification of inactive and active compounds based on electrostatic potentials at M7. B: 
Linear discriminant analysis. Demarcation of Group 0 (inactive), Group 1 (TLR8-specific), and Group 
2 (TLR7/8-dual active) compounds obtained via linear discriminant analyses of Mulliken charges.  
B 
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6.3. Conclusion 
 
We undertook a scaffold-hopping approach, which entailed the syntheses and biological 
evaluations of 13 different chemotypes. Density functional theory based quantum chemical 
calculations on these compounds followed by linear discriminant analyses permitted the 
classification of inactive, TLR8-active, and TLR7/8 dual-active compounds, confirming the 
critical role of partial charges in determining biological activity. The question as to why the 
activity profiles of the oxazoloquinoline 9 and its 2-amino analogue 13 are completely divergent 
remains unclear, however, crystallographic observations of the complex of 9 with TLR8 even in 
conjunction with electronic structure calculations only allow us to speculate at the present time 
as to the role of the water molecule by virtue of its permanent dipole moment and polarizability 
on stabilizing (or destabilizing interactions) depending on electron densities around the five-
membered ring. We are gratified, nonetheless, that quantum chemical calculations in 
conjunction with rigorous multivariate analyses may afford an empirical, but accessible means 





Chemistry. All of the solvents and reagents used were obtained commercially and used as 
such unless noted otherwise. Moisture- or air-sensitive reactions were conducted under nitrogen 
atmosphere in oven-dried (120 °C) glass apparatus. The solvents were removed under reduced 
pressure using standard rotary evaporators. Flash column chromatography was carried out 
using RediSep Rf “Gold” high performance silica columns on CombiFlash Rf instrument unless 
otherwise mentioned, while thin-layer chromatography was carried out on silica gel CCM 
precoated aluminum sheets. Purity for all final compounds was confirmed to be greater than 
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97% by LC−MS using a Zorbax Eclipse Plus 4.6 mm × 150 mm, 5 m analytical reverse phase 
C18 column with H2O−CH3CN gradients and an Agilent 6520 ESIQTOF Accurate Mass 
spectrometer (mass accuracy of 5 ppm) operating in the positive ion acquisition mode. 
 
Synthesis of compound 7: 2-Butylthiazolo[4,5-c]quinoline. To a solution of 3-aminoquinolin-
4-ol (12 mg, 0.075 mmol) in pyridine (0.5 mL) was added valeroyl chloride (11 L, 0.09 mmol) 
and the resulting mixture was heated in a sealed vial at 50 °C for 1 h. P2S5 (33 mg) was added 
and the mixture was heated at 120 °C for 1 h under microwave irradiation. The solvents were 
removed and the crude residue was purified by flash chromatography (SiO2, 0-5% MeOH in 
CH2Cl2) to give compound 7 (13.4 mg, 79%) as reddish brown solid. [
1H NMR (500 MHz, CDCl3) 
 9.44 (s, 1H), 8.24 (d, J = 8.4 Hz, 1H), 7.96 (dd, J = 8.1, 0.9 Hz, 1H), 7.73 (ddd, J = 8.4, 5.4, 
1.4 Hz, 1H), 7.63 (ddd, J = 8.1, 7.1, 1.1 Hz, 1H), 3.25–3.19 (m, 2H), 1.97–1.89 (m, 2H), 1.55–
1.46 (m, 2H), 1.00 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3)  173.0, 147.9, 145.8, 144.2, 
140.6, 130.6, 128.8, 128.8, 127.6, 125.0, 123.6, 34.2, 32.0, 22.4, 13.9. MS (ESI-TOF, m/z): 
calculated for C14H14N2S 243.0950; found 243.0976 [M+H]
+ (Data from Org. Biomol. Chem. 
2013, 11, 1179]. 
 
Synthesis of compound 8: 2-Butyloxazolo[4,5-c]quinolone. To a solution of 3-
aminoquinolin-4-ol (12 mg, 0.075 mmol) in pyridine (0.5 mL) was added valeroyl chloride (11 L, 
0.09 mmol) and the resulting mixture was heated in a sealed vial at 50 °C for 1 h. P2O5 (22 mg) 
was added and the resulting mixture was heated at 120 °C for 1 h under microwave irradiation. 
The solvents were removed and the crude residue was purified by flash chromatography (SiO2, 
0-5% MeOH in CH2Cl2) to give compound 8 as pale yellow solid (11.5 mg, 63%). 
1H NMR (500 
MHz, CDCl3)  9.27 (s, 1H), 8.25 (d, J = 8.4 Hz, 1H), 8.20 (ddd, J = 8.1, 1.5, 0.6 Hz, 1H), 7.75 
(ddd, J = 8.5, 7.0, 1.5 Hz, 1H), 7.68 (ddd, J = 8.1, 7.0, 1.1 Hz, 1H), 3.08 (dd, J = 9.0, 6.3 Hz, 
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2H), 1.96 (ddd, J = 15.2, 7.6, 6.0 Hz, 2H), 1.51 (dt, J = 14.8, 7.4 Hz, 2H), 1.01 (t, J = 7.4 Hz, 
3H). 13C NMR (126 MHz, CDCl3)  167.5, 152.1, 145.9, 143.9, 134.9, 130.1, 128.7, 127.3, 
120.1, 116.3, 28.9, 28.4, 22.3, 13.7. MS (ESI-TOF, m/z): calculated for C14H14N2O 227.1179; 
found 227.1216 [M+H]+. 
 
Synthesis of 2-Butyloxazolo[4,5-c]quinoline 5-oxide. To a solution of compound 8 (68 mg, 
0.30 mmol) in CHCl3 (5 mL), was added m-CPBA ( 77%, 100 mg, 0.45 mmol) and the reaction 
mixture was stirred at room temperature for 4 h. The solvent was removed under reduced 
pressure and the crude residue was purified by flash chromatography (SiO2, 0-5% MeOH in 
CH2Cl2) to give 2-butyloxazolo[4,5-c]quinoline 5-oxide. 
1H NMR (500 MHz, CDCl3)  8.97 (s, 
1H), 8.92 – 8.87 (m, 1H), 8.18 (ddd, J = 6.4, 2.2, 0.6 Hz, 1H), 7.83 – 7.77 (m, 2H), 3.06 (dd, J = 
9.0, 6.3 Hz, 2H), 1.97 – 1.90 (m, 2H), 1.55 – 1.47 (m, 2H), 1.01 (t, J = 7.4 Hz, 3H). 13C NMR 
(126 MHz, CDCl3)  169.5, 144.3, 139.8, 134.6, 130.0, 129.7, 129.6, 121.5, 120.8, 116.6, 28.8, 
28.4, 22.3, 13.7. MS (ESI-TOF, m/z): calculated for C14H14N2O2 243.1128; found 243.1146 
[M+H]+. 
 
Synthesis of compound 9: 2-Butyloxazolo[4,5-c]quinolin-4-amine. 2-Butyloxazolo[4,5-c] 
quinoline 5-oxide (60 mg, 0.25 mmol) was dissolved in anhydrous CH2Cl2 (2 mL). Benzoyl 
isocyanate (74 mg, 0.50 mmol) was added and the resulting mixture was refluxed for 1.5 h. The 
solvent was removed and the residue was dissolved in anhydrous methanol (2 mL). Sodium 
methoxide (27 mg, 0.50 mmol) was added and the resulting mixture was refluxed for 30 min. 
The solvent was removed under reduced pressure and the crude residue was purified by flash 
chromatography (SiO2, 0-10% MeOH in CH2Cl2) to give compound 9 as white solid (37 mg, 
61%). 1H NMR (500 MHz, MeOD)  7.95 (ddd, J = 8.0, 1.5, 0.5 Hz, 1H), 7.70 – 7.65 (m, 1H), 
7.56 (ddd, J = 8.5, 7.0, 1.5 Hz, 1H), 7.35 (ddd, J = 8.1, 7.0, 1.1 Hz, 1H), 3.09 – 3.03 (m, 2H), 
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1.92 (ddd, J = 13.7, 8.2, 6.9 Hz, 2H), 1.55 – 1.46 (m, 2H), 1.02 (t, J = 7.4 Hz, 3H). 13C NMR 
(126 MHz, MeOD)  168.0, 154.0, 152.9, 146.4, 130.2, 126.3, 125.6, 124.0, 121.1, 114.3, 30.0, 
28.9, 23.3, 14.0. MS (ESI-TOF, m/z): calculated for C14H15N3O 242.1288; found 242.1313 
[M+H]+. 
 
Synthesis of compound 10: N-Propylthiazolo[4,5-c]quinolin-2-amine. To a solution of 3-
aminoquinolin-4-ol (32 mg, 0.20 mmol) in pyridine (1 mL) was added propyl isothiocyanate (31 
L, 0.30 mmol) and the resulting mixture was heated in a sealed vial at 50 °C for 30 min. P2S5 
(89 mg) was added and the resulting mixture was heated at 120 °C for 1 h under microwave 
irradiation. The solvent was removed and the crude residue was purified by flash 
chromatography (SiO2, 0-5% MeOH in CH2Cl2) to give compound 10 as pale brown solid (34 
mg, 70%). 1H NMR (400 MHz, CDCl3)  9.12 (s, 1H), 8.15 (dd, J = 8.3, 0.8 Hz, 1H), 7.78 – 7.71 
(m, 1H), 7.60 (ddd, J = 8.4, 7.0, 1.7 Hz, 1H), 7.55 (ddd, J = 8.2, 7.0, 1.4 Hz, 1H), 5.85 (s, 1H), 
3.47 (dd, J = 11.7, 7.0 Hz, 2H), 1.78 (dd, J = 14.4, 7.3 Hz, 2H), 1.06 (t, J = 7.4 Hz, 3H). 13C 
NMR (126 MHz, CDCl3)  168.3, 147.0, 143.1, 143.1, 134.0, 130.3, 127.1, 127.0, 123.7, 123.6, 
47.8, 22.7, 11.4. MS (ESI-TOF, m/z): calculated for C13H13N3S 244.0903; found 244.0946 
[M+H]+. 
 
11: N2-Propylthiazolo[4,5-c]quinoline-2,4-diamine. 1H NMR (500 MHz, MeOD)  7.57 (d, J = 
8.4 Hz, 1H), 7.50 (d, J = 8.0 Hz, 1H), 7.42 – 7.36 (m, 1H), 7.26 – 7.19 (m, 1H), 3.42 (t, J = 7.0 
Hz, 2H), 1.72 (h, J = 7.3 Hz, 2H), 1.02 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, MeOD)  169.3, 
152.0, 143.2, 137.6, 133.7, 128.3, 125.8, 124.4, 123.9, 121.0, 47.8, 23.5, 11.8. MS (ESI-TOF, 
m/z): calculated for C13H14N4S 259.1012; found 259.1054 [M+H]
+. 
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Synthesis of compound 12: N-Propyloxazolo[4,5-c]quinolin-2-amine. To a solution of 3-
aminoquinolin-4-ol (32 mg, 0.20 mmol) in pyridine (1 mL) was added propyl isothiocyanate (31 
L, 0.30 mmol) and the resulting mixture was heated in a sealed vial at 50 °C for 30 min. EDC 
(77 mg, 0.4 mmol) was added and the resulting mixture was heated at 120 °C for 30 min under 
microwave irradiation. The solvent was removed and the crude residue was purified by flash 
chromatography (SiO2, 0-5% MeOH in CH2Cl2) to give compound 12 as brown solid (25 mg, 
59%). 1H NMR (500 MHz, MeOD)  8.83 (s, 1H), 8.06 – 8.02 (m, 1H), 8.01 – 7.97 (m, 1H), 7.67 
– 7.58 (m, 2H), 3.42 (t, J = 7.1 Hz, 2H). 13C NMR (126 MHz, MeOD)  164.7, 150.1, 145.1, 
141.2, 137.8, 129.7, 128.7, 128.6, 120.2, 116.7, 45.9, 23.6, 11.6. MS (ESI-TOF, m/z): calculated 
for C13H13N3O 228.1131; found 228.1164 [M+H]
+. 
 
2-(Propylamino)oxazolo[4,5-c]quinoline 5-oxide. 1H NMR (500 MHz, DMSO-d6)  8.83 (s, 
1H), 8.58 (t, J = 5.8 Hz, 1H), 8.56 (d, J = 8.8 Hz, 1H), 7.97 (dd, J = 8.3, 0.6 Hz, 1H), 7.75 (ddd, J 
= 8.2, 6.9, 1.1 Hz, 1H), 7.69 – 7.64 (m, 1H), 3.36 – 3.30 (m, 10H), 1.69 – 1.59 (m, 2H), 0.94 (t, J 
= 7.4 Hz, 3H). 13C NMR (126 MHz, DMSO-d6)  163.8, 139.3, 137.2, 136.8, 129.4, 127.7, 127.3, 
120.5, 119.6, 115.3, 44.4, 22.0, 11.3. MS (ESI-TOF, m/z): calculated for C13H13N3O2 244.1081; 
found 244.0974 [M+H]+. 
 
13: N2-Propyloxazolo[4,5-c]quinoline-2,4-diamine. 1H NMR (500 MHz, DMSO-d6)  11.96 (s, 
1H), 8.16 (dd, J = 8.0, 1.2 Hz, 1H), 7.50 – 7.45 (m, 1H), 7.44 (dd, J = 8.2, 1.0 Hz, 1H), 7.16 
(ddd, J = 8.1, 6.6, 1.5 Hz, 1H), 7.06 (t, J = 5.9 Hz, 1H), 3.24 (dd, J = 14.1, 6.3 Hz, 2H), 1.63 – 
1.48 (m, 2H), 0.90 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, DMSO-d6)  161.7, 155.7, 150.2, 
137.4, 129.0, 124.9, 124.0, 120.2, 117.0, 112.8, 43.9, 22.6, 11.3. MS (ESI-TOF, m/z): calculated 
for C13H14N4O 243.1240; found 243.1141 [M+H]
+. 
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Synthesis of compound 15: 2-Propionamidothiazolo[4,5-c]quinoline 5-oxide. To a solution 
of thiazolo[4,5-c]quinolin-2-amine (100 mg, 0.497 mmol) in pyridine (2 mL) was added propionyl 
chloride (54 L, 0.62 mmol) and the resulting mixture was stirred at room temperature for 1 h. 
The solvent was removed and the crude residue was purified by flash chromatography (SiO2, 0-
5% MeOH in CH2Cl2) to give compound N-(thiazolo[4,5-c]quinolin-2-yl)propionamide 14 as 
impure solid, which was dissolved in CHCl3 (4 mL). m-CPBA (≤ 77%, 224 mg, 1.0 mmol) was 
added and the reaction mixture was stirred at room temperature for 4 h and then concentrated. 
The crude residue was purified by flash chromatography (SiO2, 0-5% MeOH in CH2Cl2) to give 
compound 15  as white solid (98 mg, 72%). 1H NMR (500 MHz, DMSO-d6)  12.75 (s, 1H), 9.11 
(s, 1H), 8.68 – 8.62 (m, 1H), 8.24 – 8.17 (m, 1H), 7.86 – 7.76 (m, 2H), 2.56 (q, J = 7.5 Hz, 2H), 
1.14 (t, J = 7.5 Hz, 3H). 13C NMR (126 MHz, DMSO-d6)  173.3, 160.0, 142.9, 137.8, 129.8, 
129.7, 128.7, 125.1, 124.6, 123.6, 120.3, 28.4, 8.8. MS (ESI-TOF, m/z): calculated for 
C13H11N3O2S 274.0645; found 274.0667 [M+H]
+. 
 
Synthesis of compound 16: N-(4-Aminothiazolo[4,5-c]quinolin-2-yl)propionamide. 
Compound 15 (55 mg, 0.20 mmol) was dissolved in anhydrous CH2Cl2 (2 mL). Benzoyl 
isocyanate (59 mg, 0.40 mmol) was added and the resulting mixture was refluxed for 1.5 h. The 
solvent was removed under reduced pressure and the residue was dissolved in anhydrous 
MeOH (2 mL). Sodium methoxide (22 mg, 0.40 mmol) was added and the reaction mixture was 
refluxed for 30 min. The solvent was removed and the crude residue was purified by flash 
chromatography (SiO2, 0-10% MeOH in CH2Cl2) to give compound 16 as white solid (41 mg, 
79%). 1H NMR (500 MHz, DMSO-d6)  12.53 (s, 1H), 7.80 (dd, J = 8.0, 1.0 Hz, 1H), 7.61 (dd, J 
= 8.3, 0.6 Hz, 1H), 7.48 (ddd, J = 8.4, 7.0, 1.4 Hz, 1H), 7.26 (ddd, J = 8.1, 7.0, 1.2 Hz, 1H), 2.55 
(q, J = 7.5 Hz, 2H), 1.14 (t, J = 7.5 Hz, 3H). 13C NMR (126 MHz, DMSO-d6)  173.1, 157.0, 
151.5, 144.2, 133.8, 133.1, 127.8, 125.9, 123.7, 122.2, 119.1, 28.3, 9.0. MS (ESI-TOF, m/z): 
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calculated for C13H12N4OS 273.0805; found 273.0832 [M+H]
+. The sodium methoxide solvolysis 
also resulted in small amount of thiazolo[4,5-c]quinoline-2,4-diamine 17 which was isolated from 
the crude mixture as white solid (4 mg, 9%). 1H NMR (500 MHz, MeOD)  7.58 (ddd, J = 8.4, 
1.0, 0.5 Hz, 1H), 7.52 (ddd, J = 8.0, 1.4, 0.5 Hz, 1H), 7.41 (ddd, J = 8.4, 7.0, 1.5 Hz, 1H), 7.24 
(ddd, J = 8.1, 7.1, 1.1 Hz, 1H). 13C NMR (126 MHz, MeOD)  169.6, 152.0, 143.6, 137.3, 134.7, 
128.4, 126.0, 124.4, 123.9, 121.1. MS (ESI-TOF, m/z): calculated for C10H8N4S 217.0542; found 
217.0569 [M+H]+. 
 
Synthesis of compound 18: N-(Quinolin-4-yl)valeramide. To a solution of 4-aminoquinoline 
(302 mg, 2.1 mmol) in pyridine (6 mL) was added valeroyl chloride (0.28 mL, 2.4 mmol). The 
mixture was heated at 65 °C for 90 min and then concentrated. The crude residue was purified 
by flash chromatography (SiO2, 0-10% MeOH in CH2Cl2) to give compound 18 as a dark brown 
solid (382 mg, 80%). 1H NMR (500 MHz, DMSO-d6)  11.11 (s, 1H), 9.07 (d, J = 6.5 Hz, 1H), 
8.95 (dd, J = 8.7, 1.1 Hz, 1H), 8.70 (d, J = 6.4 Hz, 1H), 8.32 (dd, J = 8.5, 1.1 Hz, 1H), 8.12 (ddd, 
J = 8.4, 6.9, 1.1 Hz, 1H), 7.93 (ddd, J = 8.4, 6.9, 1.1 Hz, 1H), 2.80 (t, J = 7.4 Hz, 2H), 1.66 (tt, J 
= 7.5 Hz, 2H), 1.39 (tq, J = 7.4 Hz, 2H), 0.94 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, DMSO-d6) 
 174.2, 149.6, 145.0, 139.0, 133.8, 128.1, 123.8, 121.2, 119.0, 108.9, 36.4, 26.6, 21.6, 13.7. 
MS (ESI-TOF, m/z): calculated for C14H16N2O 229.1341; found 229.1306 [M+H]
+. 
 
Synthesis of compound 19: N-(3-Bromoquinolin-4-yl)valeramide. To a suspension of 
compound 18 (151 mg, 0.66 mmol) in benzene (anhydrous, 10 mL) was added N-
bromosuccinimide (NBS, 143 mg, 0.81 mmol) and azobisisobutyronitrile (AIBN, 99 mg, 0.60 
mmol). The mixture was refluxed for 5 h and then concentrated. The crude residue was purified 
by flash chromatography (SiO2, 0-30% EtOAc in hexane) to give compound 19 as a light brown 
solid (86 mg, 42%). 1H NMR (500 MHz, DMSO-d6)  10.31 (s, 1H), 9.05 (s, 1H), 8.08 (dd, J= 
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8.5, 1.2 Hz, 1H), 7.95 (dd, J = 8.4, 1.4 Hz, 1H), 7.84 (ddd, J = 8.4, 6.9, 1.5 Hz, 1H), 7.70 (ddd, J 
= 8.2, 6.8, 1.3 Hz, 1H), 2.54-2.46 (m, 2H), 1.68 (quin, J = 7.5 Hz, 2H), 1.43 (sex, J = 7.4 Hz, 
2H), 0.95 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, DMSO-d6)  171.4, 152.1, 147.1, 141.5, 
130.2, 129.1, 127.8, 126.6, 123.8, 116.8, 35.2, 27.3, 21.9, 13.8. MS (ESI-TOF, m/z): calculated 
for C14H15BrN2O 307.0446; found 307.0254 [M+H]
+. 
 
Synthesis of compound 20a: 2-Butylthiazolo[5,4-c]quinoline. To a solution of compound 19 
(60.8 mg, 0.20 mmol) in pyridine (4 mL) was added Lawesson’s reagent (234 mg, 0.58 mmol). 
The resulting mixture was heated in a sealed vial under microwave irradiation (500 W, 140 °C) 
for 35 min and then concentrated. The crude residue was purified by flash chromatography 
(SiO2, 0-10% EtOAc in hexanes) to give compound 20a as brown oil (15 mg, 31%). 
1H NMR 
(500 MHz, CDCl3)  9.33 (s, 1H),  8.71 (dd, J = 8.1, 1.5 Hz, 1H), 8.22 (brd, J = 8.3 Hz, 1H), 7.76 
(ddd, J = 8.3, 7.0, 1.5 Hz, 1H), 7.70 (ddd, J = 8.1, 7.0, 1.2 Hz, 1H), 3.27 (t, J = 7.7 Hz, 2H), 1.95 
(tt, J = 7.6, 7.7 Hz, 2H), 1.52 (qt, J = 7.3, 7.4 Hz, 2H), 1.01 (t, J = 7.4 Hz, 3H). 13C NMR (126 
MHz, CDCl3)  177.3, 154.9, 145.9, 143.8, 129.4, 128.7, 127.8, 127.2, 123.6, 123.4, 34.3, 32.0, 
22.3, 13.8. MS (ESI-TOF, m/z): calculated for C14H14N2S 243.0956; found 243.1019 [M+H]
+. 
 
Synthesis of compound 21a: 2-Butylthiazolo[5,4-c]quinoline 5-oxide. To a solution of 
compound 20a (14.5 mg, 0.060 mmol) in CH2Cl2 (1 mL) was added m-CPBA (≤ 77%, 35.2 mg). 
The reaction mixture was stirred at room temperature for 2.5 h and then concentrated. The 
crude residue was purified by flash chromatography (SiO2, MeOH in CH2Cl2: 0 to 5%) to give 
compound 21a (13.5 mg, 87%) as brown oil. 1H NMR (500 MHz, CDCl3)  9.04 (s, 1H), 8.90-
8.76 (m, 1H), 8.78-8.58 (m, 1H), 7.95-7.72 (m, 2H), 3.25 (t, J = 7.7 Hz, 2H), 1.94 (tt, J = 7.6, 7.7 
Hz, 2H), 1.63-1.44 (m, 2H), 1.02 (t, 3H, J = 7.3 Hz). 13C NMR (126 MHz, CDCl3)  176.4, 147.8, 
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140.1, 134.3, 132.6, 130.0, 129.5, 128.0, 124.4, 120.3, 34.1, 31.9, 22.3, 13.8. MS (ESI-TOF, 
m/z): calculated for C14H14N2OS 259.0827; found 259.0755 [M+H]
+. 
 
Synthesis of compound 22a: 2-Butylthiazolo[5,4-c]quinolin-4-amine. To a solution of 
compound 21a (10.1 mg, 0.039 mmol) in CH2Cl2 (0.2 mL) was added benzoyl isocyanate (13.2 
mg, 0.090 mmol). The mixture was heated to reflux for 3 h and then concentrated. The crude 
residue was purified by flash chromatography (SiO2, 0-15% EtOAc in hexanes) to give 
intermediate as light brown oil (8.8 mg, 63%). Benzamide (8.8 mg, 0.024 mmol) was dissolved 
in NaOMe solution (0.5 mL, 0.5 M in MeOH). The mixture was heated to reflux overnight and 
then concentrated. The crude residue was purified by flash chromatography (SiO2, 0-5% MeOH 
in CH2Cl2) to give compound 22a as a yellow solid (5.6 mg, 89%). 
1H NMR (500 MHz, CDCl3)  
8.50 (dd, J = 8.1, 1.2 Hz, 1H), 7.82 (brd, J = 8.4 Hz, 1H), 7.62 (ddd, J = 8.4, 7.0, 1.5 Hz, 1H), 
7.44 (ddd, J = 8.0, 7.0, 1.1 Hz, 1H), 5.15 (brs, 2H), 3.25 (t, J = 7.7 Hz, 2H), 2.00-1.87 (m, 2H), 
1.61-1.43 (m, 2H), 1.02 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3)  175.7, 157.0, 150.9, 
145.8, 129.2, 125.7, 123.6, 123.5, 120.2, 116.7, 34.2, 32.0, 22.3, 13.8. MS (ESI-TOF, m/z): 
calculated for C14H15N3S 258.1065; found 258.0964 [M+H]
+. 
 
Synthesis of compound 20b: 2-Butyloxazolo[5,4-c]quinoline. To a solution of compound 19 
(50.4 mg, 0.16 mmol) in pyridine (2 mL) was added CuI (66 mg, 0.35 mmol) and K2CO3 (47 mg, 
0.34 mmol). The resulting mixture was heated in a sealed vial under microwave irradiation (500 
W, 140 °C) for 35 min and then concentrated. The crude residue was purified by flash 
chromatography (SiO2, 0-10% EtOAc in hexanes) to give compound 20b as a brown solid (28 
mg, 76%). 1H NMR (500 MHz, CDCl3)  9.20 (bs, 1H), 8.46 (bs, 1H), 8.25 (bs, 1H), 7.76 (bt, J = 
6.0 Hz, 1H), 7.72 – 7.64 (m, 1H), 3.09 (t, J = 7.6 Hz, 2H), 2.00 – 1.91 (m, 2H), 1.55 – 1.43 (m, 
2H), 1.00 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3)  169.8, 145.5, 143.7, 135.1, 129.9, 
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128.3, 127.4, 122.2, 29.0, 28.7, 22.3, 13.7. MS (ESI-TOF, m/z): calculated for C14H14N2O 
227.1184; found 227.1051 [M+H]+. 
 
Synthesis of compound 21b: 2-Butyloxazolo[5,4-c]quinoline 5-oxide. To a solution of 
compound 20b (28 mg, 0.124 mmol) in CH2Cl2 (2 mL) was added m-CPBA (≤ 77%, 83.5 mg). 
The reaction mixture was stirred at room temperature for 4 h and then concentrated. The crude 
residue was purified by flash chromatography (SiO2, 0-5% MeOH in CH2Cl2) to give compound 
21b as a red solid (22 mg, 73%). 1H NMR (500 MHz, CDCl3)  8.93 (s, 1H), 8.87-8.79 (m, 1H), 
8.46-8.41 (m, 1H), 7.84-7.75 (m, 2H), 3.06 (t, J = 7.6 Hz, 2H), 1.93 (tt, J = 7.7, 7.6 Hz, 2H), 1.50 
(qt, J = 7.4, 7.3 Hz, 2H), 1.01 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3)  169.9, 143.9, 
140.1, 135.7, 129.6, 129.3, 123.6, 122.8, 121.8, 120.8, 28.9, 28.5, 22.3, 13.7. MS (ESI-TOF, 
m/z): calculated for C14H14N2O2 243.1134; found 243.1032 [M+H]
+. 
 
Synthesis of compound 22b: 2-Butyloxazolo[5,4-c]quinolin-4-amine. To a solution of 
compound 21b (17.8 mg, 0.073 mmol) in CH2Cl2 (0.5 mL) was added benzoyl isocyanate (38.4 
mg, 0.26 mmol). The mixture was heated to reflux for 4 h and then concentrated. The crude 
residue was purified by flash chromatography (SiO2, 0-20% EtOAc in hexanes) to give 
intermediate as colorless oil (8.7 mg, 34%). Benzamide (6 mg, 0.017 mmol) was dissolved in 
NaOMe solution (0.5 mL, 0.5 M in MeOH). The mixture was heated to reflux for 8 h and then 
concentrated. The crude residue was purified by flash chromatography (SiO2, 0-5% MeOH in 
CH2Cl2) to give compound 22b as a yellow solid (3.3 mg, 79%). 
1H NMR (500 MHz, CDCl3)  
8.22 (dd, J = 8.2, 1.5 Hz, 1H), 7.80 (dd, J = 8.7, 1.5 Hz, 1H), 7.59 (ddd, J = 8.5, 7.0, 1.6 Hz, 1H), 
7.42 (ddd, J = 8.2, 7.0, 1.1 Hz, 1H), 5.15 (bs, 2H), 3.05 (t, J = 7.7 Hz, 2H), 2.01-1.85 (m, 2H), 
1.58-1.43 (m, 2H), 1.00 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3)  168.6, 144.9, 144.0, 
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135.2, 128.5, 127.3, 126.2, 123.5, 122.0, 119.0, 29.2, 28.6, 22.3, 13.7. MS (ESI-TOF, m/z): 
calculated for C14H15N3O 242.1293; found 242.1240 [M+H]
+. 
 
Synthesis of compound 23: Quinazoline-2,4(1H,3H)-dione. The mixture of anthranilic acid 
(500 mg, 3.65 mmol) and urea (2.2 g, mol) was heated at 150 ºC for 6 h. The reaction mixture 
was cooled to room temperature and then water (50 mL) was added to quench the reaction. The 
crude product was obtained by filtration, and then washed with water (20 mL × 3). The residue 
was dissolved in hot aq. NaOH and cooled to 0 ºC and pH was adjusted to 5-6 using dilute HCl 
and stirred for 30 min. The crude mixture was filtered and washed with water and dried under 
vacuum to yield compound 23 as white solid (500 mg, 85%). 1H NMR (500 MHz, DMSO-d6)  
11.28 (s, 1H), 11.14 (s, 1H), 7.88 (dd, J = 7.8, 1.1 Hz, 1H), 7.65 – 7.60 (m, 1H), 7.17 (ddd, J = 
8.2, 6.1, 1.8 Hz, 2H). 13C NMR (126 MHz, DMSO-d6)  162.9, 150.3, 140.9, 135.0, 127.0, 122.4, 
115.3, 114.4. MS (ESI-TOF, m/z): calculated for C8H6N2O2 163.0502; found 163.0491 [M+H]
+. 
 
Synthesis of compound 25: 2-((2-Chloroquinazolin-4-yl)amino)hexan-1-ol. POCl3 (5 mL) 
and DIPEA (430 L, 2.47 mmol) were added to compound 23 (200 mg, 1.23 mmol) and the 
reaction mixture was heated to reflux for 4 h. The excess POCl3 was removed by evaporation. 
The residue was dissolved in ice water, and then the suspension was filtered and washed with 
water to afford compound 24 as white solid (220 mg, 90%). To a solution of compound 24 (200 
mg, 1 mmol) in DMF (5 mL), was added DL-2-amino-1-hexanol (194 L, 1.5 mmol), the resulting 
mixture was heated at 100 ºC for 1 h, and allowed to cool, and concentrated. The residue was 
purified by flash chromatography (SiO2, 0-50% EtOAc in Hexane) to give compound 25 as a 
yellow solid (95 mg, 34 %). 1H NMR (500 MHz, DMSO-d6)  8.37 (dd, J = 8.4, 0.8 Hz, 1H), 8.24 
(d, J = 8.4 Hz, 1H), 7.78 (ddd, J = 8.3, 7.0, 1.3 Hz, 1H), 7.60 (dd, J = 8.3, 0.8 Hz, 1H), 7.52 
(ddd, J = 8.2, 7.0, 1.2 Hz, 1H), 4.80 (t, J = 5.7 Hz, 1H), 4.35 (qd, J = 5.7, 10.6 Hz, 1H), 3.56 – 
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3.46 (m, 2H), 1.74 – 1.65 (m, 1H), 1.62 – 1.52 (m, 1H), 1.29 (dddd, J = 14.8, 10.3, 8.2, 3.2 Hz, 
4H), 0.85 (t, J = 6.7 Hz, 3H). 13C NMR (126 MHz, DMSO-d6)  161.4, 157.1, 150.4, 133.6, 
126.6, 125.8, 123.5, 113.6, 62.8, 52.9, 30.1, 27.8, 22.1, 14.0. MS (ESI-TOF, m/z): calculated for 
C14H18ClN3O 280.1211; found 280.1279 [M+H]
+. 
 
Synthesis of compound 27: 2-Butyl-2,3-dihydroimidazo[1,2-c]quinazolin-5-amine. To a 
solution of compound 25 (50 mg, 0.18 mmol) in CH2Cl2 (2 mL) was added triethylamine (38 L, 
0.27 mmol) and methanesulfonyl chloride (17 L, 0.22 mmol) and the resulting mixture was 
stirred at room temperature overnight. CH2Cl2 (20 mL) was added and the organic layer was 
washed with water (10 mL x 2), dried over anhydrous sodium sulfate and evaporated to furnish 
the crude residue of compound 26 (45 mg, 96% crude yield). Ammonia in methanol (2M, 1 mL) 
was added to compound 26 (10 mg, 38 mol) and the reaction mixture was heated at 80 ºC for 
2 h and concentrated. The residue was purified by flash chromatography (SiO2, 0-10% MeOH in 
CH2Cl2) to give compound 27 as a yellow solid (6 mg, 66%). 
1H NMR (500 MHz, MeOD)  7.88 
(dd, J = 8.0, 1.2 Hz, 1H), 7.53 (ddd, J = 8.5, 7.2, 1.5 Hz, 1H), 7.20 (d, J = 8.0 Hz, 1H), 7.12 
(ddd, J = 8.1, 7.2, 1.0 Hz, 1H), 4.42 – 4.35 (m, 1H), 4.21 (t, J = 10.4 Hz, 1H), 3.77 (dd, J = 10.3, 
7.6 Hz, 1H), 1.87 – 1.78 (m, 1H), 1.66 (ddd, J = 11.0, 6.6, 3.7 Hz, 1H), 1.50 – 1.37 (m, 4H), 0.97 
(t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, MeOD)  156.9, 151.8, 150.6, 135.4, 126.5, 124.6, 
123.6, 113.2, 64.5, 51.9, 37.3, 28.6, 23.7, 14.4. MS (ESI-TOF, m/z): calculated for C14H18N4 
243.1604; found 243.1589 [M+H]+. 
 
Synthesis of compound 29: 2-Butylimidazo[1,2-c]quinazolin-5-amine. To a solution of 
compound 26 (28 mg, 0.11 mmol) in toluene (2 mL) was added MnO2 (47 mg, 0.54 mmol) and 
heated at reflux for 20 h. Additional MnO2 was added and the reaction mixture was refluxed for 
another 48 h. The mixture was allowed to cool, filtered and purified by column chromatography 
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(SiO2, 0-50% EtOAc in Hexane) to obtain compound 28 as a pale yellow solid (12 mg, 41%). 
Compound 28 (10 mg) in ammonia solution (2M in ammonia, 1 mL) was heated at 80 ºC for 2 h, 
concentrated and purified by column chromatography (SiO2, 0-10% MeOH in CH2Cl2) to obtain 
compound 29  as a pale yellow solid (4 mg, 36%). 1H NMR (500 MHz, MeOD)  8.28 (dd, J = 
8.0, 0.9 Hz, 1H), 7.70 (s, 1H), 7.58 – 7.51 (m, 2H), 7.35 (ddd, J = 8.1, 6.8, 1.5 Hz, 1H), 2.84 – 
2.78 (m, 2H), 1.79 (ddd, J = 13.1, 8.5, 6.6 Hz, 2H), 1.48 (dq, J = 14.8, 7.4 Hz, 2H), 1.01 (t, J = 
7.4 Hz, 3H). 13C NMR (126 MHz, MeOD)  131.5, 125.5, 124.7, 123.5, 108.3, 32.4, 29.1, 23.5, 
14.2. MS (ESI-TOF, m/z): calculated for C14H16N4 241.1448; found 241.1466 [M+H]
+. 
 
Synthesis of compound 30: Methyl (2-cyanophenyl)carbamate. 2-Aminobenzonitrile (200 
mg, 1.69 mmol) and sodium carbonate (359 mg, 3.39 mmol) was heated to reflux in methyl 
chloroformate (7 mL) for 4 h. The reaction mixture was concentrated and purified by column 
chromatography (SiO2, 0-20% EtOAc in Hexane) to obtain compound 30 as a white solid (276 
mg, 93%). 1H NMR (500 MHz, DMSO-d6)  9.77 (s, 1H), 7.79 (dd, J = 7.8, 1.3 Hz, 1H), 7.67 
(ddd, J = 8.2, 7.6, 1.6 Hz, 1H), 7.52 (d, J = 8.1 Hz, 1H), 7.33 (td, J = 7.6, 1.1 Hz, 1H), 3.69 (s, 
3H). 13C NMR (126 MHz, DMSO-d6)  154.5, 140.5, 133.9, 133.3, 125.5, 125.2, 116.8, 107.3, 
52.2. MS (ESI-TOF, m/z): calculated for C9H8N2O2 177.0659; found 177.0694 [M+H]
+. 
 
Synthesis of compound 31: 2-Butyl-[1,2,4]triazolo[1,5-c]quinazolin-5(6H)-one. To a 
solution of compound 30 (200 mg, 1.14 mmol) in N-methyl-2-pyrrolidone (NMP, 5 mL) was 
added valeric acid hydrazide (158 mg, 1.36 mmol) and the reaction mixture was heated at 180 
oC for 3 h. Crushed ice was added to the reaction mixture and the solid obtained was filtered 
and purified by column chromatography (SiO2, 0-50% EtOAc in hexanes) to obtain compound 
31 as white solid (270 mg, 98%). 1H NMR (500 MHz, DMSO-d6)  12.21 (s, 1H), 8.11 (dd, J = 
7.9, 1.1 Hz, 1H), 7.69 – 7.64 (m, 1H), 7.41 (d, J = 8.2 Hz, 1H), 7.39 – 7.33 (m, 1H), 2.82 (t, J = 
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7.6 Hz, 2H), 1.79 – 1.72 (m, 2H), 1.43 – 1.33 (m, 2H), 0.92 (t, J = 7.4 Hz, 3H). 13C NMR (126 
MHz, DMSO-d6)  166.5, 152.7, 143.8, 136.9, 132.6, 124.0, 123.5, 116.0, 110.3, 29.6, 27.7, 
21.8, 13.7. MS (ESI-TOF, m/z): calculated for C13H14N4O 243.1240; found 243.1350 [M+H]
+. 
 
Synthesis of compound 32: 2-Butyl-5-chloro-[1,2,4]triazolo[1,5-c]quinazoline. To a 
suspension of compound 31 (18 mg, 74 mol) in POCl3 (1 mL) was added DIPEA (29 L, 0.15 
mmol) and the resulting mixture was heated at 110 ºC for 18 h. The mixture was cooled to room 
temperature and concentrated. The residue was purified by flash chromatography (SiO2, 0-30% 
EtOAc in hexane) to give compound 32 as a pale yellow solid (15 mg, 79%). 1H NMR (500 MHz, 
DMSO-d6)  8.41 (d, J = 8.0 Hz, 1H), 7.99 (d, J = 8.3 Hz, 1H), 7.94 (t, J = 7.7 Hz, 1H), 7.82 (t, J 
= 7.5 Hz, 1H), 2.93 (t, J = 7.6 Hz, 2H), 1.84 – 1.76 (m, 2H), 1.47 – 1.37 (m, 2H), 0.94 (t, J = 7.4 
Hz, 3H). 13C NMR (126 MHz, DMSO-d6)  167.0, 152.0, 142.3, 135.3, 132.7, 129.1, 127.6, 
123.6, 116.8, 29.7, 27.8, 21.8, 13.7. MS (ESI-TOF, m/z): calculated for C13H13ClN4 261.0902; 
found 261.1021 [M+H]+. 
 
Synthesis of compound 33: 2-Butyl-[1,2,4]triazolo[1,5-c]quinazolin-5-amine. Compound 32 
(10 mg, 38 mol) was treated with 2M ammonia in methanol (1 mL), heated at 80 ºC for 20 h 
and concentrated. The residue was purified by flash chromatography (SiO2, 0-10% MeOH in 
CH2Cl2) to give compound 33 as a white solid (5 mg, 55%). 
1H NMR (500 MHz, MeOD)  8.21 
(ddd, J = 8.0, 1.5, 0.5 Hz, 1H), 7.65 (ddd, J = 8.5, 7.1, 1.5 Hz, 1H), 7.57 (dd, J = 8.4, 0.5 Hz, 
1H), 7.37 (ddd, J = 8.1, 7.1, 1.1 Hz, 1H), 2.97 – 2.89 (m, 2H), 1.86 (dt, J = 15.3, 7.6 Hz, 2H), 
1.50 – 1.38 (m, 2H), 0.98 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, MeOD)  167.9, 153.1, 146.3, 
146.1, 133.4, 126.0, 124.8, 124.5, 114.4, 31.4, 29.2, 23.4, 14.1. MS (ESI-TOF, m/z): calculated 
for C13H15N5 [242.1400; found 242.1399 M+H]
+. 
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Synthesis of compound 34: 2,3-Dichloroquinoxaline. Quinoxaline-2,3-diol (500 mg, 3.08 
mmol) and POCl3 (5 mL) in DMF (5 mL) were heated at 100 °C for 1.5 h, allowed to cool, and 
concentrated. The residue was treated with ice water and filtered to give compound 34 as off 
white solid (418 mg, 68%). 1H NMR (500 MHz, DMSO-d6)  8.10 – 8.06 (m, 2H), 7.96 – 7.91 (m, 
2H). 13C NMR (126 MHz, DMSO-d6)  144.7, 140.1, 131.8, 128.0. MS (ESI-TOF, m/z): 
calculated for C8H4Cl2N2 198.9824; found 198.9853 [M+H]
+. 
 
Synthesis of compound 35: 2-((3-Chloroquinoxalin-2-yl)amino)hexan-1-ol. To a solution of 
compound 34 (200 mg, 1 mmol) in EtOH (5 mL), was added DL-2-amino-1-hexanol (194 L, 1.5 
mmol) in EtOH (3 mL), heated at 90 ºC for 18 h, allowed to cool, and concentrated. The residue 
was purified by flash chromatography (SiO2, 0-20% EtOAc in Hexane) to give compound 35 as 
a yellow solid (160 mg, 57%). 1H NMR (500 MHz, CDCl3)  7.80 (dd, J = 8.2, 1.0 Hz, 1H), 7.66 
(dd, J = 8.3, 0.9 Hz, 1H), 7.58 (ddd, J = 8.4, 7.0, 1.4 Hz, 1H), 7.40 (ddd, J = 8.3, 7.0, 1.4 Hz, 
1H), 5.65 (d, J = 6.6 Hz, 1H), 4.30 – 4.22 (m, 1H), 3.90 (dd, J = 11.1, 2.8 Hz, 1H), 3.76 (dd, J = 
11.1, 6.3 Hz, 1H), 3.60 (s, 1H), 1.78 – 1.64 (m, 2H), 1.48 – 1.35 (m, 4H), 0.93 (t, J = 7.1 Hz, 
3H). 13C NMR (126 MHz, CDCl3)  148.5, 140.6, 138.1, 136.6, 130.5, 128.1, 125.7, 125.4, 66.8, 
54.6, 31.3, 28.5, 22.7, 14.1. MS (ESI-TOF, m/z): calculated for C14H18ClN3O 280.1211; found 
280.1296 [M+H]+. 
 
Synthesis of compound 36: 2-Butyl-4-chloro-1,2-dihydroimidazo[1,2-a]quinoxaline. To a 
solution of compound 35 (100 mg, 0.36 mmol) in CHCl3 (1 mL), was added thionyl chloride (1 
mL) at 0 ºC, and heated to reflux for 2 h. The mixture was cooled to room temperature and 
concentrated. The residue was purified by flash chromatography (SiO2, 0-10% MeOH in CH2Cl2) 
to give compound 36 as a yellow solid (75 mg, 80%). 1H NMR (500 MHz, DMSO-d6)  8.02 (dd, 
J = 8.1, 0.7 Hz, 1H), 7.94 – 7.89 (m, 1H), 7.67 (dd, J = 14.6, 7.6 Hz, 2H), 4.90 (m, 1H), 4.62 – 
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4.51 (m, 2H), 1.90 – 1.82 (m, 1H), 1.78 – 1.70 (m, 1H), 1.47 – 1.33 (m, 4H), 0.92 (t, J = 7.1 Hz, 
3H). 13C NMR (126 MHz, DMSO-d6)  147.5, 136.5, 134.3, 133.3, 129.0, 128.8, 126.8, 115.5, 
57.2, 53.4, 33.9, 26.3, 21.9, 13.9. MS (ESI-TOF, m/z): calculated for C14H16ClN3 262.1106; 
found 262.1173 [M+H]+. 
 
Synthesis of compound 37: 2-Butyl-1,2-dihydroimidazo[1,2-a]quinoxalin-4-amine. 
Compound 36 (29 mg, 0.11 mmol) was dissolved in 2 M ammonia in methanol (1 mL) and 
heated in a sealed vial at 90 ºC for 20 h and concentrated. The residue was purified by flash 
chromatography (SiO2, 0-10% MeOH in CH2Cl2) to give compound 37 as a yellow solid (18 mg, 
67%). 1H NMR (500 MHz, MeOD)  7.25 (dd, J = 7.9, 1.2 Hz, 1H), 7.13 (td, J = 7.9, 1.4 Hz, 1H), 
7.00 (td, J = 7.8, 1.3 Hz, 1H), 6.85 (dd, J = 8.0, 1.2 Hz, 1H), 4.38 – 4.30 (m, 1H), 4.26 – 4.20 (m, 
1H), 3.76 (dd, J = 10.3, 8.6 Hz, 1H), 1.79 – 1.71 (m, 1H), 1.68 – 1.57 (m, 1H), 1.53 – 1.37 (m, 
4H), 0.95 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, MeOD)  149.4, 147.7, 134.7, 130.9, 125.9, 
125.2, 123.0, 112.8, 65.8, 52.8, 37.8, 28.9, 23.8, 14.4. MS (ESI-TOF, m/z): calculated for 
C14H18N4 243.1604; found 243.1677 [M+H]
+. 
 
Synthesis of compound 38: 2-Butyl-4-chloroimidazo[1,2-a]quinoxaline. To a solution of 
compound 37 (357 mg, 1.36 mmol) in toluene (15 mL) was added MnO2 (593 mg, 6.82 mmol) 
and heated to reflux for 24 h. Additional MnO2 (593 mg, 6.82 mmol) was added and after 
another 48 h, the mixture was allowed to cool and filtered. The solvent was evaporated and the 
crude product was purified by flash chromatography (SiO2, 0-50% EtOAc in hexane) to give 
compound 38 as a yellow solid (99 mg, 28%). 1H NMR (500 MHz, DMSO-d6)  8.73 (s, 1H), 
8.33 (dd, J = 8.3, 0.9 Hz, 1H), 7.97 (dd, J = 8.2, 1.2 Hz, 1H), 7.78 – 7.73 (m, 1H), 7.67 – 7.62 
(m, 1H), 2.80 (t, J = 7.6 Hz, 2H), 1.72 (dd, J = 15.2, 7.6 Hz, 2H), 1.44 – 1.34 (m, 2H), 0.94 (t, J = 
7.4 Hz, 3H). 13C NMR (126 MHz, DMSO-d6)  158.1, 150.8, 144.0, 143.5, 138.8, 138.4, 136.3, 
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136.3, 125.5, 122.8, 40.3, 37.6, 31.4, 23.3. MS (ESI-TOF, m/z): calculated for C14H14ClN3 
260.0949; found 260.0900 [M+H]+. 
 
Synthesis of compound 39: 2-Butylimidazo[1,2-a]quinoxalin-4-amine. Compound 38 (70 
mg, 0.27 mmol) was dissolved in 2M ammonia in methanol (2 mL), heated in a sealed vial at 90 
ºC for 20 h and concentrated. The residue was purified by flash chromatography (SiO2, 0-100% 
EtOAc in hexane) to give compound 39 as a pale yellow solid (21 mg, 33%). 1H NMR (500 MHz, 
MeOD)  8.18 (s, 1H), 7.94 (dd, J = 8.1, 1.2 Hz, 1H), 7.60 (dd, J = 8.1, 1.2 Hz, 1H), 7.46 – 7.41 
(m, 1H), 7.36 (ddd, J = 8.5, 7.3, 1.4 Hz, 1H), 2.86 – 2.80 (m, 2H), 1.80 (ddd, J = 13.1, 8.4, 6.7 
Hz, 2H), 1.47 (dd, J = 15.0, 7.5 Hz, 2H), 1.00 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, MeOD)  
149.5, 148.1, 137.3, 132.9, 127.7, 126.7, 125.8, 125.0, 116.2, 112.2, 32.8, 29.2, 23.5, 14.2. MS 
(ESI-TOF, m/z): calculated for C14H16N4 241.1448; found 241.1462 [M+H]
+. 
 
Synthesis of compound 40: N'-(2-Nitrophenyl)pentanehydrazide. To a solution of (2-
nitrophenyl)hydrazine (500 mg, 3.26 mmol) in CH2Cl2 (10 mL) was added N-methylmorpholine 
(298 L, 4.24 mmol), followed by valeroyl chloride (415 L, 3.43 mmol). The reaction was stirred 
at room temperature for 1 h and concentrated. The residue was purified by flash 
chromatography (SiO2, 0-10% MeOH in CH2Cl2) to give compound 40 as a yellow solid (564 
mg, 73%). 1H NMR (500 MHz, DMSO-d6)  10.10 (s, 1H), 9.21 (s, 1H), 8.09 (dd, J = 8.5, 1.5 Hz, 
1H), 7.61 – 7.56 (m, 1H), 7.05 (dd, J = 8.6, 1.1 Hz, 1H), 6.85 (ddd, J = 8.4, 7.0, 1.3 Hz, 1H), 
2.23 (t, J = 7.5 Hz, 2H), 1.56 (dt, J = 15.0, 7.5 Hz, 2H), 1.33 (dq, J = 14.6, 7.4 Hz, 2H), 0.90 (t, J 
= 7.4 Hz, 3H). 13C NMR (126 MHz, DMSO-d6)  171.9, 145.5, 136.5, 131.6, 125.8, 117.7, 114.6, 
33.0, 27.0, 21.8, 13.7. MS (ESI-TOF, m/z): calculated for C11H15N3O3 238.1186; found 238.1189 
[M+H]+. 
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Synthesis of compound 41: N'-(2-Nitrophenyl)pentanehydrazonoyl chloride. Compound 40 
(82 mg, 0.35 mmol) in POCl3 (3 mL) was heated at 110 ºC for 2 h. The mixture was cooled to 
room temperature and concentrated. The residue was treated with ice water and extracted with 
CH2Cl2. The organic layer was washed with brine, dried over Na2SO4, concentrated and the 
crude product was purified by flash chromatography (SiO2, 0-10% EtOAc in hexane) to give 
compound 41 as yellow oil (68 mg, 76%). 1H NMR (500 MHz, DMSO-d6)  10.82 (s, 1H), 8.15 
(dt, J = 8.6, 0.9 Hz, 1H), 7.71 (dd, J = 4.5, 1.0 Hz, 2H), 7.03 – 6.99 (m, 1H), 2.76 – 2.71 (m, 2H), 
1.68 (dt, J = 20.6, 7.5 Hz, 2H), 1.42 – 1.32 (m, 2H), 0.92 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, 
DMSO-d6)  140.1, 137.0, 134.1, 131.4, 125.9, 119.5, 115.8, 37.9, 28.1, 21.1, 13.6. 
 
Synthesis of compound 42: N'-(2-Nitrophenyl)pentanehydrazonamide. Compound 41 (60 
mg, 0.23 mmol) was treated with 2 M ammonia in methanol (1 mL) and stirred at room 
temperature for 20 h. The residue was concentrated to give compound 42 as a red solid (38 mg, 
70%). 1H NMR (500 MHz, DMSO-d6)  9.73 (s, 1H), 8.11 (dd, J = 8.5, 1.4 Hz, 1H), 7.61 (ddd, J 
= 8.5, 7.2, 1.4 Hz, 1H), 7.22 (d, J = 8.5 Hz, 1H), 6.89 (t, J = 7.6 Hz, 1H), 2.44 (t, J = 7.6 Hz, 2H), 
1.71 – 1.62 (m, 2H), 1.38 (dt, J = 14.7, 7.4 Hz, 2H), 0.93 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, 
DMSO-d6)  142.5, 136.4, 125.9, 118.1, 114.5, 30.8, 28.6, 21.6, 13.6. MS (ESI-TOF, m/z): 
calculated for C11H16N4O2 237.1346; found 237.1344 [M+H]
+. 
 
Synthesis of compound 43: Ethyl 3-butyl-1-(2-nitrophenyl)-1H-1,2,4-triazole-5-
carboxylate. To a solution of compound 42 (78 mg, 0.33 mmol) in ether (3 mL) was added 
dropwise ethyl oxalyl chloride (110 L, 0.99 mmol) in ether (2 mL). Toluene (5 mL) was added, 
and the mixture was heated at 110 ºC for 3 h, and concentrated. The residue was purified by 
flash chromatography (SiO2, 0-50% EtOAc in hexane) to give compound 43 as yellow oil (60 
mg, 57%). 1H NMR (500 MHz, DMSO-d6)  8.26 (dd, J = 8.5, 1.4 Hz, 1H), 7.94 (ddd, J = 8.0, 
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7.4, 1.5 Hz, 1H), 7.87 – 7.83 (m, 2H), 4.20 (q, J = 7.1 Hz, 2H), 2.73 (t, J = 7.4 Hz, 2H), 1.71 – 
1.64 (m, 2H), 1.37 – 1.29 (m, 2H), 1.13 (t, J = 7.1 Hz, 3H), 0.90 (t, J = 7.4 Hz, 3H). 13C NMR 
(126 MHz, DMSO-d6)  164.6, 161.0, 156.5, 144.2, 134.6, 131.5, 131.2, 130.1, 125.3, 62.1, 
29.6, 27.1, 21.5, 13.8, 13.6. MS (ESI-TOF, m/z): calculated for C15H18N4O4 319.1401; found 
319.1410 [M+H]+. 
 
Synthesis of compound 44: 2-Butyl-[1,2,4]triazolo[1,5-a]quinoxalin-4(5H)-one. To a 
solution of compound 43 (58 mg, 0.18 mmol) in acetic acid (2 mL) was added iron powder (100 
mg). The mixture was heated at 90 ºC for 1 h, allowed to cool, filtered, and concentrated. The 
residue was purified by flash chromatography (SiO2, 0-10% MeOH in CH2Cl2) to give compound 
44 as a white solid (19 mg, 43%). 1H NMR (500 MHz, DMSO-d6)  12.31 (s, 1H), 8.04 (dd, J = 
8.2, 1.0 Hz, 1H), 7.50 – 7.43 (m, 2H), 7.36 (ddd, J = 8.5, 7.1, 1.6 Hz, 1H), 2.90 – 2.83 (m, 2H), 
1.76 (ddd, J = 13.3, 8.4, 6.7 Hz, 2H), 1.39 (dq, J = 14.7, 7.4 Hz, 2H), 0.93 (t, J = 7.4 Hz, 3H). 13C 
NMR (126 MHz, DMSO-d6)  166.0, 152.2, 144.3, 128.6, 127.8, 123.5, 122.4, 116.6, 115.4, 
29.9, 27.6, 21.7, 13.7. MS (ESI-TOF, m/z): calculated for C13H14N4O 243.1240; found 243.1227 
[M+H]+. 
 
Syntheses of compounds 45 and 46 were carried out as reported for 32 and 33, respectively. 
 
45: 2-Butyl-4-chloro-[1,2,4]triazolo[1,5-a]quinoxaline. 1H NMR (500 MHz, DMSO-d6)  8.35 
(dd, J = 8.3, 1.0 Hz, 1H), 8.13 (dd, J = 8.2, 1.0 Hz, 1H), 7.90 (ddd, J = 8.4, 7.3, 1.4 Hz, 1H), 7.79 
(ddd, J = 8.5, 7.3, 1.4 Hz, 1H), 3.00 – 2.93 (m, 2H), 1.81 (ddd, J = 13.3, 8.4, 6.7 Hz, 2H), 1.47 – 
1.36 (m, 2H), 0.94 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, DMSO-d6)  167.0, 142.7, 140.3, 
134.7, 130.9, 129.1, 128.0, 127.5, 115.3, 29.9, 27.8, 21.8, 13.7. MS (ESI-TOF, m/z): calculated 
for C13H13ClN4 261.0902; found 261.1890 [M+H]
+. 
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46: 2-Butyl-[1,2,4]triazolo[1,5-a]quinoxalin-4-amine. 1H NMR (500 MHz, MeOD)  8.17 (dd, J 
= 8.2, 1.0 Hz, 1H), 7.68 (dd, J = 8.2, 1.0 Hz, 1H), 7.54 – 7.50 (m, 1H), 7.44 (ddd, J = 8.5, 7.3, 
1.3 Hz, 1H), 3.00 – 2.97 (m, 2H), 1.88 (dt, J = 15.2, 7.6 Hz, 2H), 1.48 (dq, J = 14.8, 7.4 Hz, 2H), 
1.00 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, MeOD)  167.8, 149.1, 140.2, 137.9, 128.6, 126.8, 
126.5, 125.6, 116.0, 31.6, 29.2, 23.4, 14.1. MS (ESI-TOF, m/z): calculated for C13H15N5 
242.1400; found 242.1391 [M+H]+. 
 
Synthesis of compound 47: 2-Chloro-3-hydrazinylquinoxaline. To a solution of 2,3-
dichloroquinoxaline 34 (160 mg, 0.81 mmol) in MeOH (4 mL), hydrazine hydrate (100 L, 3.24 
mmol) was added and the reaction mixture was stirred at room temperature overnight. The 
solvent was evaporated to obtain compound 47 as a pale yellow solid (148 mg, 95%). 1H NMR 
(500 MHz, MeOD)  7.78 – 7.71 (m, 2H), 7.61 (ddd, J = 8.4, 7.1, 1.5 Hz, 1H), 7.42 (ddd, J = 8.4, 
7.1, 1.3 Hz, 1H). 13C NMR (126 MHz, MeOD)  150.9, 142.2, 138.3, 137.7, 131.4, 128.6, 126.7, 
126.3. MS (ESI-TOF, m/z): calculated for C8H7ClN4 195.0432; found 195.0344 [M+H]
+. 
 
Synthesis of compound 48: 1-Butyl-4-chloro-[1,2,4]triazolo[4,3-a]quinoxaline. Trimethyl 
orthovalerate (0.5 mL) was added to compound 47 (50 mg, 0.257 mmol) and the resulting 
mixture was heated at 100 ºC for 1 h. The solvent was removed and the product obtained was 
purified by flash chromatography to obtain compound 48 as a white solid (38 mg, 57%). 1H NMR 
(500 MHz, CDCl3)  8.12 (dd, J = 8.4, 1.1 Hz, 1H), 8.09 (dd, J = 8.0, 1.4 Hz, 1H), 7.74 (ddd, J = 
8.4, 7.4, 1.7 Hz, 1H), 7.68 (ddd, J = 7.9, 7.4, 1.3 Hz, 1H), 3.53 – 3.45 (m, 2H), 2.08 – 1.99 (m, 
2H), 1.67 – 1.54 (m, 2H), 1.04 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3)  152.8, 143.3, 
142.9, 135.8, 130.6, 130.0, 128.1, 126.4, 115.6, 28.8, 28.5, 22.6, 13.9. MS (ESI-TOF, m/z): 
calculated for C13H13ClN4 261.0902; found 261.1004 [M+H]
+. 
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Synthesis of compound 49: 1-Butyl-[1,2,4]triazolo[4,3-a]quinoxalin-4-amine. Compound 48 
(25 mg, 0.096 mmol) was dissolved in ammonia solution (2M in methanol, 1 mL) and heated in 
a sealed vial at 60 ºC for 4 h. Concentration and purification by column chromatography (SiO2, 
0-5% MeOH in CH2Cl2) to give compound 49 as a white solid (16 mg, 70%). 
1H NMR (500 MHz, 
CDCl3)  7.96 (dd, J = 8.4, 1.1 Hz, 1H), 7.71 (dd, J = 8.1, 1.4 Hz, 1H), 7.53 – 7.47 (m, 1H), 7.38 
(ddd, J = 8.7, 7.3, 1.5 Hz, 1H), 5.87 (bs, 2H), 3.48 – 3.39 (m, 2H), 2.07 – 1.98 (m, 2H), 1.60 (dq, 
J = 14.8, 7.4 Hz, 2H), 1.04 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3)  152.3, 147.1, 
139.9, 137.6, 127.7, 127.4, 124.6, 124.5, 115.4, 28.8, 28.4, 22.6, 13.9. MS (ESI-TOF, m/z): 
calculated for C13H15N5 242.1400; found 242.1426 [M+H]
+. 
 
Synthesis of compound 50: Ethyl 2-(1H-indol-3-yl)-2-oxoacetate. To a solution of indole 
(1.01 g, 8.66 mmol) in anhydrous Et2O (17 mL) and pyridine (0.95 mL, 11.7 mmol) was added a 
solution of ethyl chlorooxoacetate (1.2 mL, 10.7 mmol) in anhydrous Et2O (3 mL) at 0 °C over a 
period of 15 min. The reaction mixture was stirred at 0 °C for 2 h and filtered. The resulting solid 
was then wash with cold Et2O and water, dried over high vacuum to give compound 50 as a 
pale yellow powder (1.52 g, 81%). 1H NMR (500 MHz, DMSO-d6)  12.39 (bs, 1H), 8.42 (d, J = 
3.3 Hz, 1H), 8.18-8.13 (m, 1H), 7.57-7.53 (m, 1H), 7.32-7.24 (m, 2H), 4.36 (q, J = 7.1 Hz, 2H), 
1.34 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, DMSO-d6)  179.1, 163.6, 138.3, 136.7, 125.5, 
123.9, 122.9, 121.1, 112.8, 112.4, 61.6, 14.0. MS (ESI-TOF, m/z): calculated for C12H11NO3 
218.0812; found 218.0796 [M+H]+. 
 
Synthesis of compound 51: 2-Butyl-2H-pyrazolo[3,4-c]quinolin-4(5H)-one. To a solution of 
butylhydrazine hydrochloride salt (288 mg, 2.31 mmol) in absolute EtOH (20 mL) was added 
compound 50 (352 mg, 1.62 mmol) and acetic acid (0.4 mL). The reaction mixture was heated 
to reflux and stirred for 24 h, cooled to room temperature and concentrated. The crude product 
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was purified by flash chromatography (SiO2, 0-3% MeOH in CH2Cl2) to give compound 51 as a 
grey powder (243 mg, 62%). 1H NMR (500 MHz, DMSO-d6)  11.32 (s, 1H), 8.69 (s, 1H), 7.85 
(d, J = 7.8 Hz, 1H), 7.36-7.29 (m, 2H), 7.17 (m, 1H), 4.37 (t, J = 7.0 Hz, 2H), 1.94-1.80 (m, 2H), 
1.35-1.20 (m, 2H), 0.91 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, DMSO-d6)  157.0, 139.9, 
135.9, 127.2, 125.5, 123.5, 122.0, 121.2, 115.9, 115.3, 52.5, 31.8, 19.2, 13.4. MS (ESI-TOF, 
m/z): calculated for C14H15N3O 242.1288; found 242.1272 [M+H]
+. 
 
Synthesis of compound 52: 2-Butyl-4-chloro-2H-pyrazolo[3,4-c]quinoline. To a mixture of 
compound 51 (163 mg, 0.675 mmol) and PCl5 (33.3 mg, 0.160 mmol) was added POCl3 (3 mL). 
The reaction mixture was heated to reflux, stirred for 2 h and then concentrated. The residue 
was diluted with CH2Cl2 and washed with saturated NaHCO3, dried over Na2SO4, filtered and 
concentrated. The crude product was purified by flash chromatography (0-20% EtOAc in 
Hexanes) to give compound 52 as a yellow solid (152 mg, 86%). 1H NMR (500 MHz, CDCl3)  
8.31 (s, 1H), 8.08-8.04 (m, 1H), 8.02-7.98 (m, 1H), 7.63-7.55 (m, 2H), 4.53 (t, J = 7.3 Hz, 2H), 
2.12-2.00 (m, 2H), 1.46-1.37 (m, 2H), 0.99 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3)  
143.4, 142.1, 141.3, 129.4, 127.4, 127.4, 123.5, 123.1, 122.5, 121.9, 54.3, 32.7, 19.9, 13.6. MS 
(ESI-TOF, m/z): calculated for C14H14ClN3 260.0949; found 260.0989 [M+H]
+. 
 
Synthesis of compound 53: 2-Butyl-2H-pyrazolo[3,4-c]quinolin-4-amine. Ammonia solution 
(2M in MeOH, 1 mL) was added to compound 52 (60 mg, 0.23 mmol) and the reaction mixture 
was heated in a sealed vial at 100 oC for overnight and then concentrated. The crude product 
was purified by flash chromatography (0-10% MeOH in CH2Cl2) to give compound 53 as a pale 
yellow powder (27 mg, 48%). 1H NMR (500 MHz, DMSO-d6)  8.82 (s, 1H), 7.95 (dd, J = 7.8 Hz, 
J = 1.5 Hz, 1H), 7.53 (dd, J = 8.2, 1.2 Hz, 1H), 7.39 (ddd, J = 8.3, 7.1, 1.5 Hz, 1H), 7.29-7.22 
(m, 1H), 4.46 (t, J = 7.0 Hz, 2H), 3.42 (s, 2H), 2.00-1.84 (m, 2H), 1.37-1.24 (m, 2H), 0.92 (t, J = 
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7.4 Hz, 3H). 13C NMR (126 MHz, DMSO-d6)  150.1, 140.3, 135.5, 126.9, 125.3, 123.4, 123.3, 
122.5, 120.6, 118.1, 52.8, 32.0, 19.2, 13.5. MS (ESI-TOF, m/z): calculated for C14H16N4 
241.1448; found 241.1470 [M+H]+. 
 
 
Human TLR-7/-8 reporter gene assays (NF-B induction). As described in Chapter 2. 
 
Immunoassays for Interferon (IFN)- and cytokines. As described in Chapter 2. 
 
Flow-cytometric immunostimulation experiments. As described in Chapter 5. 
 
Protein expression, purification and crystallization. The extracellular domain of human 
TLR8 (hTLR8, residues27–827) was prepared as described previously,113 and was concentrated 
to 16 mg/mL in 10 mM MES (pH 5.5), 50 mM NaCl. The protein solutions for the crystallization 
of hTLR8/compound complexes contained hTLR8 (8.5 mg/mL) and compound (protein: 
compound molar ratio of 1:10) in a crystallization buffer containing 7 mM MES (pH 5.5), 35 mM 
NaCl. Crystallization experiments were performed with sitting-drop vapor-diffusion methods at 
293K. Crystals of hTLR8/compound were obtained with reservoir solutions containing 9-12% 
(w/v) PEG3350, 0.3 M potassium formate, and 0.1 M sodium citrate (pH 4.8-5.2).  
 
Data collection and structure determination. Diffraction datasets were collected on 
beamlines PF-AR NE3A (Ibaraki, Japan) and SPring-8 BL41XU under cryogenic conditions at 
100 K. Crystals of hTLR8/compound were soaked into a cryoprotectant solution containing 15% 
(w/v) PEG3350, 0.23 M potassium formate, 75 mM sodium citrate pH 4.8-5.2, 7.5 mM MES pH 
5.5, 38 mM NaCl, and 25% glycerol. Datasets were processed using the HKL2000 package119 
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or imosflm.120 HTLR8/compound structures were determined by the molecular replacement 
method using the Molrep program121 with the hTLR8/CL097 structure (PDB ID: 3W3J) as a 
search model. The model was further refined with stepwise cycles of manual model building 
using the COOT program122 and restrained refinement using REFMAC123 until the R factor was 
converged. Compound molecule, N-glycans, and water molecules were modeled into the 
electron density maps at the latter cycles of the refinement. The quality of the final structure was 
evaluated with PROCHECK.124 The figures representing structures were prepared with 
PyMOL.125 Coordinates have been deposited in the Protein Data Bank of the Research 
Collaboratory for Structural Bioinformatics; PDB codes for compounds 9 and 53 are, 
respectively, 4QBZ and 4QC0. 
 
Quantum chemical computations and linear discriminant analyses. Calculations were 
performed using the NWChem126 quantum chemical software for the electronic structure, 
electrostatic charge and property calculations. All the compounds were fully optimized at the 
density functional theory (DFT) level of theory using the M06-2X127 functional and correlation 
consistent cc-pVDZ basis set. The optimized structures were verified as minima by calculating 
the second-order Hessian matrices. The molecular electrostatic potentials were calculated on 
the DFT-optimized geometries and superimposed onto a constant electron density (0.002 e/Å3) 
to provide a measure of the electrostatic potential at roughly the van der Waals surface of the 
molecules using the Gauss View03 software. The color-coded surface provides a location of the 
positive (blue, positive) and negative (red, negative) electrostatic potentials. The regions of 
positive charge indicate relative electron deficiency, and regions of negative potential indicate 
areas of excess negative charge. Fisher’s linear discriminant analyses were performed using 
SPSS v22 (IBM, Armonk, NY); classification function coefficients. 
 
  






Hyaluronic acid conjugation of 
TLR7/8 agonists for 








 240  
7.1. Introduction 
 
The lymphatic system provides for unidirectional transport for interstitial fluid and proteins 
exiting microcirculation due to hydrostatic pressure, and returning then back to blood circulation. 
Lymphatic fluid drains from the initial lymphatics or lymphatic capillaries first into lymph nodes, 
which are highly organized secondary lymphoid tissues specialized in immune surveillance of 
the contents of afferent lymph.123 Immune cells located in specialized zones within lymph nodes 
not only respond to antigens arriving from distal sites of infection, but also receive and 
orchestrate appropriate immune responses to migrating antigen-presenting cells (APCs) bearing 
antigenic epitopes. This is of particular relevance in immunization, wherein, peripheral APCs, 
such as dendritic cells (DCs) and macrophages capture antigens from the injection site and then 
migrate into the lymphoid tissues to trigger downstream T- and B-lymphocyte activation as well 
as memory cell differentiation.124 The lymph nodes also contain a large number of resident 
APCs, which can actively process antigens and serve as major reservoir for long-lived memory 
B cells and central memory T cells, therefore playing a crucial role in generating long-term 
immunological memory.125  
 
The flow of interstitial fluid also brings fragments of extracellular matrix (ECM) macromolecules 
into lymph.126 Important among the constituents of ECM is hyaluronic acid (hyaluronan, HA), a 
linear glycosaminoglycan polymer with a molecular weight that can reach 107 Daltons, and 
composed of repeating polymeric disaccharides of D-glucuronic acid (GlcUA) and N-acetyl 
glucosamine (GlcNAc) linked by -1,4 and -1,3 glucosidic bonds (Fig. 1).127 HA serves to 
maintain a hydrated and stable extracellular space, not only by virtue of its ability to absorb a 
large amount of water expanding up to 1000 times its solid volume, but also due to its distinct 
hydrodynamic properties, such as very high viscosity. Depending on the molecular size, HA 
shows the capacity to interact with many different binding proteins and important group of 
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receptors.128 The two most abundant of these receptors are CD44, which is a single chain, 
transmembrane glycoprotein expressed on leukocytes that traffic through the lymphatics,129 and 
lymphatic vessel endothelial hyaluronan receptor-1 (LYVE-1), which is expressed almost 
exclusively on lymphatic endothelium.130 CD44–HA interaction is known to be involved in a 
variety of cellular functions, including cell–cell interactions, receptor-mediated internalization/ 
degradation of HA, and cell migration. LYVE-1 participates in HA-mediated leukocyte trafficking, 
adhesion, and transmigration.126b  
 
Fig. 1. Chemical structure of hyaluronic acid. 
 
 
The efficient delivery of antigen/adjuvant has been a major challenge in the development of 
subunit vaccines, and enhancing vaccine delivery to secondary lymphoid organs might be a 
promising approach for improving vaccine efficacy.124, 131 Several studies have addressed 
enhanced or targeted delivery of antigens to secondary lymphoid tissue, including the use of 
depot-forming adjuvants,132 nanoparticulate carriers that are preferentially internalized by 
APCs,133 or intralymphatic immunization,125a but strategies that could use well-defined molecular 
conjugates would be more attractive. We envisioned that we could take advantage of the 
characteristics of HA — biodegradability, biocompatibility, high potential loading, and most of all, 
selective interaction with receptors — for targeted delivery134 of small molecule Toll-like receptor 
(TLR) agonists to lymph nodes.  
 
A number of lead adjuvants including the pure TLR7 agonist (a, Chapter 5),115 the pure TLR8 
agonist (b) and the dual TLR7/8 agonists (c, d)56, 58 are undergoing preclinical evaluation as 
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vaccine adjuvants in our laboratory (Fig. 2). The approach of targeted delivery of these 
adjuvants may also serve to minimize systemic exposure of these small molecules with 
molecular properties that portend a large volume of distribution. For proof-of-concept studies, 
we selected these four compounds with an amine functional group (Fig. 2) that can be utilized in 
a straightforward manner for direct coupling with carboxylic acid group on HA. There are 
numerous methods that have been reported for HA conjugation;127 we eschewed methods 
entailing harsh reaction conditions such as strongly alkaline or acidic pH, prolonged heating, or 
conditions calling for ultra-sound or microwave irradiation which are all known to potentially 
induce significant HA degradation, and elected to use the recently-reported triazine-activated 
amidation strategy, since it allows for a highly controlled substitution under aqueous/mixed-
solvent conditions, at room temperature, and at neutral pH.135  
 





The conjugation reactions proceeded uneventfully, and spectroscopic and analytical 
characterization of the products suggested efficient hyaluronic acid conjugation with small 
molecules, as described below.  
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7.2. Results and Discussion 
 
The reaction of 2-chloro-4,6-dimethoxy-1,3,5-triazine (CDMT) with carboxylic acids of HA and 
amines of small molecule TLR agonists in the presence of N-methylmorpholine (NMM) 
proceeded smoothly as reported in the literature135 (Scheme 1).  
 
Scheme 1.  
 
 
All reactants were soluble in a mixture of water and acetonitrile (3:2) and the pH values of the 
reaction mixtures after addition of all reactants were about 7~8. After overnight stirring at room 
temperature, the reaction mixtures were treated with Dowex ion exchange resin before dialysis 
to remove the morpholinium species, as well as unreacted amines which could otherwise act as 
counter-ions in their protonated form toward non-modified carboxylic acid groups of HA. Dialysis 
against 0.1 N NaCl solutions also helped eliminate electrostatically bound amines from anionic 
 244  
polymers. As could be expected, the benzylic amine, and not the amidine amine participates in 
the formation of the amide bond, since the reaction with analogues that do not have the benzylic 
amine group did not yield detectable substitution (such as compound 6 in Chapter 6; data not 
shown). In addition to coupling the individual TLR7-, TLR8-, and TLR7/8-agonistic compounds 
on HA (HA–a, HA–b, HA–c, respectively), we also carried out the simultaneous coupling of HA 
with a mixture of three amine compounds — (HA–a+b+c) with the aim being to examine the 
relative adjuvanticity of a construct carrying multiple TLR agonists (conjugate 5). The product 
yields were calculated based on the average molecular weight of the disaccharide repeating 
units considering the degree of substitution and found similar between the products ranging 71–
75% (Table 1).  
 
All products were characterized using 1H NMR spectroscopy and the spectra for products 1-4, 
as well as that of native hyaluronic acid and of the small molecules a-d are presented in Fig. 3. 
The poorly-resolved broad multiplet between c.a. 3.2 – 4.0 ppm corresponds to the resonances 
of the protons in the sugar ring of HA; a broad peak at 4.5 ppm could be assigned to the two 
anomeric protons attached to the carbons adjacent to two oxygen atoms, and the CH3 protons 
of the N-acetyl group of HA could be readily identified at 1.95 ppm (Fig. 3). New peaks 
associated with aliphatic (butyl or pentyl chain) protons at 0.8 – 3.0 ppm and aromatic protons at 
7.0 – 8.5 ppm, both of which are diagnostic of the conjugated small molecules, were observed. 
The degrees of substitution (DS) were determined by comparing integrated signals of the -CH3 
resonance of the butyl/pentyl side chain of the small molecules (triplet, 0.86 ppm, shown as 
in Fig.  3); this resonance could be clearly resolved from that of the CH3 signal arising from 
the N-acetylglucosamine moiety (singlet, 1.95 ppm, shown as in Fig. 3) of native HA. As 
shown in Table 1, the DS ranged from 29 to 39%. The slight difference in the observed DS 
could be attributable to differential steric accessibility of the amines and/or solubility.  
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Fig. 3. 1H NMR spectra of hyaluronic acid, small molecules a-d, and conjugates 1-4.  
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While the ratios of peak integrals by 1H NMR spectroscopy showed high batch-to-batch 
repeatability and consistency, we were mindful of the broad signals due to highly viscous 
sample solutions, as well as sample microheterogeneity, we sought to quantify the ‘loading’ also 
using spectroscopic measurements at 260 nm. All the TLR7/8 agonistic small molecules used 
for conjugation exhibit a distinct and intense absorption profile in the UV spectral region, and it 
was therefore straightforward to measure small molecule loading. The highest loading amount 
was found in conjugate 3 and the lowest in conjugate 2 (31% and 10%, respectively, Table 1). 
 
Table 1. Properties of the conjugates. 
Conjugate 
No. 
TLR agonist (SM) Yield (%) DS (%) SM Content (w/w %) 
1 a  75 29 21 
2 b  75 35 10 
3 c  71 39 31 
4 d  74 36 21 
5 a + b + c N/A N/A N/A 
 
DS, degree of substitution; SM, small molecule 
 
 
Taking advantage of the UV absorptivity of compounds, the conjugates were also analyzed by 
gel electrophoresis. Samples were loaded on agarose gel and visualized by UV illumination. 
After a few minutes of running, we noticed that free small molecules (a and b) tend to travel 
toward the cathode due to its positive charges of the protonated amine (Figs. 4A and 4B; Lanes 
8 and 9), which was not observed from conjugate samples. The conjugates 1-5, on the other 
hand, clearly showed UV-absorbing bands (Fig. 4; Lanes 3-7), indicating covalent conjugation of 
the small molecules with hyaluronic acid, with an apparent molecular weight corresponding to 
500 kDa, as adjudged by comparing the electrophoretic mobility of rhodamine-labeled HA (Fig. 
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4C, Lane 2). This technique was particularly useful in characterizing conjugate 5 (HA–a+b+c; 
Lane 7 in Fig. 4), which was not amenable to quantification of the loading either by 1H NMR, or 
spectrophotometry owing to degeneracy of signals and spectral overlaps, respectively.  
 
Fig. 4. Agarose gel electrophoresis. Lane 1: HA; Lane 2: rhodamine-labeled HA; Lane 3: conjugate 1 
(HA–a); Lane 4: conjugate 2 (HA–b); Lane 5: conjugate 3 (HA–c); Lane 6: conjugate 4 (HA–d); Lane 7: 
conjugate 5 (HA–a+ b+ c); Lane 8: a; Lane 9: b; Lane 10: c; Lane 11: d. 
 
A. 5 min                                            B. 10 min                                     C. 40 min 
     
 
 
The conjugates were also confirmed by size exclusion chromatography (SEC) analysis as 
shown in Fig. 5A. HA has no significant absorption in the UV and the conjugates were clearly 
observed to elute with a retention time of 50 min. 
 
Reverse-phase HPLC analyses were also carried out to ensure the purity of conjugates. With a 
polymeric PRP-3 column, conjugate 3, for example, eluted at 32 min, while that of its 
corresponding small molecule c appeared at a retention time of 14 min. Again, the 
spectroscopic signatures of the small molecules enabled unambiguous identification of the 
conjugates and, importantly, verified that no unconjugated small molecules were detected in the 
conjugate samples (Fig. 5B).  
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Fig. 5. A: Size exclusion chromatography. B: Reverse-phase HPLC with polymeric PRP-3 column. 










Conjugate 1 (HA-a) Conjugate 2 (HA-b) 
Conjugate 3 (HA-c) Conjugate 5 (HA-a, b, c) 
A 
B 
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In vitro enzymatic degradation was performed using hyaluronidase (HAase) from bovine testes 
(400-1000 units/mg), and analyzed by LC-MS. After 45 h incubation of conjugates with 
hyaluronidase, oligosaccharides of HA covalently adducted with the small molecules were 
identified. Common major oligosaccharide species throughout the conjugates are tetra- and 
decasaccharides with one small molecule and dodecasaccharides with two small molecules on 
them (Table 2). From the HAase treated conjugate 5, these major oligosaccharides with each 
small molecule as well as with the combination of different small molecules were found.  
 
 
Table 2. Major oligosaccharide species found by LC-MS analysis after in vitro hyaluronidase enzymatic 












Conjugate 1 7.262 [GlcUA-GlcNAc]5–a Conjugate 3 6.234 [GlcUA-GlcNAc]2–c 
(HA–a) 7.927 [GlcUA-GlcNAc]2–a (HA–c) 6.965 [GlcUA-GlcNAc]6–[c]2 
8.885 [GlcUA-GlcNAc]6–[a]2 7.549 [GlcUA-GlcNAc]5–c 
Conjugate 2 6.966 [GlcUA-GlcNAc]2–b Conjugate 4 6.059 [GlcUA-GlcNAc]2–d 
(HA–b) 7.759 [GlcUA-GlcNAc]6–[b]2 (HA–d) 6.830 [GlcUA-GlcNAc]6–[d]2 
8.505 [GlcUA-GlcNAc]5–b 7.247 [GlcUA-GlcNAc]5–d 
 
Conjugate 5 6.243 [GlcUA-GlcNAc]2–c Conjugate 5 7.900 [GlcUA-GlcNAc]6–[a][c] 
(HA–a, b, c) 6.977 [GlcUA-GlcNAc]2–b (HA–a, b, c) 7.911 [GlcUA-GlcNAc]2–a 
 






7.376 [GlcUA-GlcNAc]6–[b][c] 8.293 [GlcUA-GlcNAc]6–[a][b] 
7.517 [GlcUA-GlcNAc]5–c 8.528 [GlcUA-GlcNAc]5–b 
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Next, the conjugates were screened in NF-B reporter gene assays specific for human TLR7 
and TLR8. Whereas all small molecule TLR-7 and/or -8 agonists (a-d) showed, as expected, 
agonistic activities, the HA conjugates did not display any detectable NF-B induction up to 
concentrations of 50 g/mL in both TLR7 and TLR8 agonism assays. Hyaluronic acid (used as 
control) was also verified to be quiescent in these assays (Fig. 7).  
 















We examined the cytokine/chemokine-inducing properties of these conjugates using human 
PBMCs and they did not show any proinflammatory cytokine induction (represented by IL-1, IL-
6, IL-8, and TNF- in Fig. 8). It is important to note that the hyaluronic acid conjugates become 
“silent”, presumably because the polyanionic character of the conjugates precludes significant 
internalization and access to the endolysosomal compartment. These results, importantly, augur 
very weak (if any) reactogenicity for the HA conjugates vis-à-vis the unconjugated agonists and, 
therefore, are predicted to have a very high safety profile in addition to their being highly 
adjuvantic.  




























 a: TLR7 agonist
 b: TLR8 agonist
 c: TLR7/8 agonist
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The adjuvantic activities of these conjugates were evaluated in New Zealand White rabbits and 
compared to a variety of candidate adjuvants under evaluation in our laboratory in a 
standardized manner. All candidate adjuvants were designed to be entirely water soluble, with a 
purity of at least 99.5% as judged by LC-MS profiles. The adjuvant dose was held constant at 
100 g/dose. The antigen used was Diphtheria toxoid (CRM197) at 10 g/dose. The vaccine 
construct was formulated under excipient-free conditions in sterile, pyrogen-free saline. Rabbits 
(n = 4 per cohort) were pre-bled on Day 0 for estimation of preimmune titers, and then primed 
with the first dose of vaccine. Animals were boosted on Days 15 and 28, and bled on Days 25 
(for Immune-1 sera) and 38 (for Immune-2 sera), respectively. All ELISA assays were carried 
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out in a 384-well plate format with automated liquid handling instrumentation as described in the 
Experimental Section. Reference hyperimmune sera were used in each plate for quality control 
purposes. 
 
As shown in Fig. 9, conjugates 3 and 4 were found to be highly adjuvantic in evoking high 
antigen-specific IgG titers even after a single boost; titers were higher than that obtained using 
the corresponding unconjugated small molecule TLR7/8 agonist c (Fig. 9B). Particularly, 
conjugate 4 was shown to be most adjuvantic among all TLR active compounds that we had 
characterized in our laboratory with a rise-in-titer values of >1000 (Fig. 10, overleaf). 
Considering very small dose of the TLR agonist in the conjugate, the strong adjuvantic activity 
of the conjugate after a single boost, coupled with the complete lack of proinflammatory cytokine 
induction in ex vivo models, as mentioned earlier, presages a highly effective and safe vaccine 
adjuvant. 
 
Fig. 9. Adjuvantic activities of HA conjugates after a single boost. Antigen: Diphtheria toxoid (CRM197), 
10 g/dose; Adjuvant: 100 g/dose in NZ rabbits; Formulation: excipient-free saline. A. Antigen-specific 
titers in HA conjugate-adjuvanted rabbits. Preimmune values are in open symbols. B. Box-and-whisker 
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Fig. 10. Induction of high anti-CRM197 IgG levels after a single boost (Immune-1 sera) by HA conjugate 
4 and Infanrix (left panel), compared to titers after two boosts (Immune-2 sera) for the HA conjugates, as 
well as a variety of experimental, candidate adjuvants. Also shown in red are titers obtained by 
immunization with a full human dose of Infanrix and unadjuvanted controls (right panel).   
 
 
Whilst measurements of serum antibody titers employing an immunoassay such as ELISA serve 
to quantify antigen-specific antibody concentrations, antibody ‘avidity’ (functional affinity; the 
sum of affinities of multiple antigen-binding sites in polyclonal antibodies simultaneously 































































































































































































































Immune-2 Titers (Prime+2 boosts)
n=4 rabbits/cohort
























































 255  
immune responses.136 In order to also assess the quality of antibody, the strength of the 
interaction between CRM197 and antigen-specific IgG antibodies obtained 10 days after a 
single boost (Immune-1) was determined using the chaotropic ELISA.137 Replicate wells 
containing antibody bound to antigens were exposed to increasing concentrations of the 
chaotropic thiocyanate ion that disrupts antibody-antigen complexes and the concentration of 
sodium thiocyanate (NaSCN) that decreases antibody binding by 50% was used as the 
measurement of avidity. As shown in Fig. 11B, the highest avidity was found in the conjugate 4-
adjuvanted sera with 50% attenuation of absorbance elicited at 1.0 M NaSCN. This result 
unambiguously indicates higher quality IgG elicited by the hyaluronic acid conjugates.  
 
Fig. 11. A. Chaotropic ELISA with increasing concentration of sodium thiocyanate (NaSCN) after a 
single boost (Immune-1 sera). B. Quantitation of antibody avidity in chaotropic ELISAs with NaSCN 




The observation of extraordinary adjuvantic potency completely dissociated with biomarkers of 
inflammation and reactogenicity is unprecedented in the field, and warranted confirmation. In an 
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independent experiment, cohorts of rabbits (n=4 per group) were immunized with either graded 
doses of antigen (human vaccine-grade formalin-inactivated Diphtheria toxoid, Statens Serum 
Institute, Denmark) with a fixed dose of conjugate 4 to examine dose-sparing effects, or graded 
doses of adjuvant with a fixed dose of Diphtheria toxoid. As shown in Fig. 12A, conjugate 4 
elicits very high titers even at an antigen concentration of 1 g/dose, confirming the excellent 
dose-sparing effect of the adjuvant. Although 100 g/dose of conjugate 4 is optimal, robust 
humoral responses are observed even with 10 g of conjugate 4, as depicted in Fig. 12B.  
 
Fig. 12. Dose-sparing effects of conjugate 4 as adjuvant in rabbits (n=4 per group) immunized with:   
Graded doses of formalin-inactivated Diphtheria toxoid with fixed dose (100 g/dose) of conjugate 4 (A); 
graded doses of conjugate 4 with fixed dose (10 g/dose) of antigen (B); unadjuvanted and compound d-
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7.3. Conclusion 
 
A potential drawback in using small molecule TLR agonists as vaccine adjuvants is their 
propensity to diffuse out of the vaccination site into systemic circulation, thereby not only limiting 
their adjuvantic properties, but perhaps also enhancing the risk of systemic reactogenicity. The 
administration of R-848 (Chapter 1) was poorly tolerated in human preclinical trials, with 
systemic side effects including fever, headache, malaise, and myalgia,42, 138 likely due to 
systemic immune activation. Indeed, intravenous injections of large doses of TLR7/8 agonists 
(described in earlier chapters; listed in Fig. 13) as a bolus in rabbits induce C-reactive protein, 
an acute-phase bio-marker of systemic inflammation (Fig. 13).139  
 
Fig. 13. Induction of C-reactive protein (CRP) in New Zealand White Rabbits (n=5 per cohort) by 
TLR7/8 agonists. Animals were bled two days before challenge to obtain baseline CRP levels, and were 
injected with either 1 mg of candidate adjuvant (or 100 μg of LPS, used as control) formulated in saline 
intravenously as a bolus, into the marginal vein of the ear, on Day 0. Successive bleeds were performed 
on Day 1, 2, 5 and 9 after injection. Rabbit CRP-specific ELISAs were performed to quantify CRP in the 
sera. 




TLR Agonists (1000 g dose):
 Hybrid-2 (dual TLR7/8 agonist)
 Compound 8c (Chapter 2)
 Compound 53 (Chapter 6)
 Compound c (Chapter 7)
Controls:
 Saline
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Limiting systemic exposure has recently been addressed by adsorbing small molecules 
incorporating phosphonate groups on ‘alum’ [Al(OH)3].
140 Whilst alum has been the mainstay of 
vaccines since the 1920s, aluminum exposure has been implicated in neurotoxicity,141 
especially in the preterm142 and infant populations and our understanding of innate immune 
signaling may have reached a threshold as to allow considering rational alternatives.  
 
Targeted delivery of the TLR agonists to secondary lymphoid organs using molecular 
conjugation to HA was therefore evaluated to simultaneously enhance selective delivery to 
draining lymph nodes while limiting systemic exposure. As mentioned earlier, both CD44 and 
LYVE-1 are known to interact with HA. Soluble antigens in the interstitial fluid are carried by bulk 
lymphatic via afferent lymphatic ducts into the subcapsular sinus of the draining lymph node.143 
Recent studies on the microanatomic architecture of the subcapsular sinus of the lymph node 
receiving afferent lymphatic fluid show that in the subcapsular sinus, plasmalemma vesicle-
associated protein (PLVAP; also known as PV-1, PAL-E or MECA-32 antigen) forms a physical 
sieve that limits the entry of molecules smaller than 70 kDa from accessing lymph node 
parenchyma, and confining such large molecules to the sinus (Fig. 14).144  
 
 
Fig. 14. The subcapsular sinus of the lymph node, lined by lymphatic endothelial cells, is directly 
connected to the afferent lymphatic vessels. The fibroblastic reticular cells (FRCs) constitute a network 
interconnecting the subcapsular sinus and vasculature, forming a conduit system for direct egress of fluid 
and small molecules arriving from the subcapsular sinus to the blood circulation. Molecules of size >70 
kDa are retained by a diaphragm made up of PLVAP, which forms a cartwheel structure. Adapted from: 
The lymph node filter revealed. M. Hons & M. Sixt, Nature Immunology 16, 338–340 (2015). 
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Sinus-lining macrophages are known to transfer antigens from the sinus lumen to the B cell 
follicles.145 Given that the size of HA that was used in these studies is approximately 500 kDa, 
we speculate that the retention of the HA conjugates in the subcapsular sinus may facilitate and 
enhance sampling by the sinus-resident macrophages, augment localized innate immune 
signaling, and marshal subsequent adaptive immune responses in a spatiotemporally far more 
efficient manner.  
 
As noted earlier, the hyaluronic acid conjugates entirely lose their TLR-agonistic activities, both 
in respect to TLR recognition as probed by the reporter gene assays, as well as in their ability to 
induce cytokines in secondary screens. One of these ‘silent’ conjugates has, however, yielded 
the best adjuvant, capable of evoking, with a single boost regimen, affinity-matured high-avidity 
immunoglobulins whose titers rival and surpass all of the best-in-class small molecule adjuvants 
that have been examined to date. As mentioned earlier, significant hyaluronidase activity is 
associated with macrophages,146 possibly rendering the conjugate into small oligosaccharide 
fragments bearing the TLR agonist(s). The high adjuvanticity observed with several of the 
conjugates tested perhaps additionally implies that amidases in the subcapsular macrophage 
may release the free agonist, which may act in the milieu where the antigen is also being 
sampled. These are questions yet to be formally addressed. Studies, for instance, have already 
begun on conjugates obtained with carboxymethylcellulose to probe the contribution of the 
receptor-mediated ‘uptake’ of hyaluronic acid vis-à-vis passive, but contemporaneous delivery 
of antigen and adjuvant via bulk lymphatic flow. Finally, the superior adjuvanticity observed with 
conjugate 4 suggests that HA conjugates bearing dual TLR7/8 agonists may be necessary for 
optimal innate immune signaling and subsequent adaptive immune recruitment, since neither 
conjugate 1 (bearing a pure TLR7 agonist), nor conjugate 2 (decorated with a pure TLR8 
agonist) were found to be as strongly adjuvantic as conjugate 4. These results, made possible 
by extensive SAR on a variety of chemotypes described in the preceding chapters, have laid the 
 260  
foundation and point the way forward for many other experimental approaches designed to 
probe the consequences of rational, targeted vaccine delivery that take into consideration not 
only the medicinal chemistry and immunology of small molecule innate immune stimuli, but also 
incorporate elements of the microanatomical organization and physiology of the immune 






Sodium hyaluronate (HA) from Streptococcus equi (bacterial glycosaminoglycan 
polysaccharide) was purchased from Sigma-Aldrich (USA) and used as received. All other 
reagents and solvents including 2-chloro-4,6-dimethoxy-1,3,5-triazine (CDMT, 97%), N-
methylmorpholine (NMM, 99%), as well as Dowex®50WX8 ion exchange resin (hydrogen form, 
50-100 mesh) were purchased from Sigma-Aldrich. Hyaluronate Rhodamine (500 kDa) was 
purchased from Creative PEGWorks (USA). Hyaluronidase from bovine testes (55 kDa, 400-
1000 units/mg) was purchased from Sigma-Aldrich and used for enzymatic degradation. For 
dialysis, Slide-A-Lyzer G2 Dialysis Cassettes, 3.5 K MWCO (Thermo Scientific) were used. 
 
Synthesis of hyaluronic acid conjugates 
General procedure for triazine-activated amidation of hyaluronic acid (HA). Sodium 
hyaluronate (1.0 eq., 100.0 mg, 0.25 mmol –COO−) was dissolved in 20 mL of water under 
gentle stirring. The solution was cooled in an ice bath and 14 mL of acetonitrile were added 
dropwise. 2-Chloro-4,6-dimethoxy-1,3,5-triazine (1.0 eq., 44 mg, 0.25 mmol) and N-
methylmorpholine (1.5 eq., 41 L, 0.38 mmol) were added to the solution and the mixture was 
subsequently allowed to come to room temperature and was stirred for 1 h. Thereafter the 
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amine compound (1.0 eq., 0.25 mmol) was added and the mixture was stirred at room 
temperature overnight. The crude mixture was stirred with Dowex®50WX8 ion exchange resin (1 
g) for 1 h, then filtered and dialyzed (3.5 kDa MW cutoff) against aq. NaCl (0.1 N) for 2 days and 
against dH2O for 3 days and lyophilized. The solids obtained were thoroughly washed with 
acetone. The product yields were calculated based on the average molecular weight of the 
disaccharide repeating units considering the degree of substitution. 
For the synthesis of conjugate 5, the mixture of small molecules a, b and c (each 0.4 eq., 0.1 
mmol) was used. 
 
Characterization of HA conjugates 
Proton nuclear magnetic resonance spectroscopy (1H NMR). 1H NMR spectra of the 
samples (5 mg/mL in D2O) were recorded on a Bruker Advance 400 MHz spectrometer. The 
chemical shifts are given in parts per million (ppm) and are calibrated relative to the residual 
solvent protons (HDO: 4.79 ppm). Degrees of substitution (DS) were calculated from comparing 
the integrals of the methyl protons (1.95 ppm) of the N-acetylglucosamine moiety of HA and 
distinctive peaks of the introduced methyl group of small molecules (0.86 ppm) and are given in 
% per 100 disaccharide units. 
 
Size exclusion chromatography (SEC). A Shimadzu analytical HPLC system was used with 
HiPrep 16/60 Sephacryl S-200 HR (GE Healthcare, PA, USA) size exclusion chromatography 
(SEC) column for analytical characterization. Samples of the conjugates (1 mg/mL, 50 L) were 
injected using PBS (pH 7.4) buffer containing 0.05% NaN3 as a mobile phase at a flow rate of 
1.5 mL/min. 
 
High performance liquid chromatography (HPLC). A Shimadzu analytical gradient reversed-
phase HPLC system was used with PRP-3 (cross-linked polystyrene/poly-divinylbenzene 
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polymeric stationary phase, Hamilton Laboratory Products, Reno, NV) column for analytical 
characterization. Gradient elution was carried out at constant flow of 1 mL/min, from 90% A to 
50% A (corresponding to 10% B to 50% B) for 50 min and from 50% A to 0% A (corresponding 
to 50% B to 100% B) for 5 min followed by an isocratic elution at 100% B for 5 min. Mobile 
phase compositions were (A) water with 0.1% TFA and (B) acetonitrile with 0.1% TFA.  
 
Quantification of small molecule loading in HA conjugates. The compound (TLR7/8 
agonist; a, b, c, d) stock solutions at a concentration of 1 mg/mL were used to prepare standard 
solutions with concentrations of 0.78, 1.56, 3.125, 6.25, 12.5, 25, 50, and 100 g/mL, 
respectively. The conjugate solutions were also prepared by dissolving 100g of each conjugate 
sample in 1 mL of water. Percentage of small molecule loading was determined by UV 
measurement at 260 nm by correlating with the standard curve. 
 
Gel electrophoresis. Samples were subjected to electrophoresis using 1.2% Clear E-Gel® 
agarose gel (Life Technologies). 20 l of prepared samples (1mg/mL) were loaded into each 
well and gel was run for 40 min. Bands were visualized in the gel by UV illumination. The size of 
the oligosaccharides was compared with rhodamine labeled, commercially available HA of 
defined size (500 kDa). 
 
In vitro enzymatic degradation. The reaction solutions were prepared by mixing 200 L of HA 
conjugates (1 mg/mL in H2O) with 200 L of hyaluronidase solution (HAase, 400-1000 U/mL in 
H2O). The solutions were incubated at 37 °C for 48 h then analyzed by LC-MS. 
 
 
Human TLR-7/-8 reporter gene assays (NF-B Induction). As described in Chapter 2. 
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Immunoassays for cytokines. As described in Chapter 2. 
 
Rabbit immunization and antigen-specific ELISA. All experiments were performed at Harlan 
Laboratories (Indianapolis, IN) in accordance with institutional guidelines (University of Kansas 
IACUC permit # 119-06). Adult New Zealand White rabbits are immunized intramuscularly in the 
flank region with (a) 10 g of antigen (CRM197) in 0.2 mL saline (n = 4 for unadjuvanted, 
antigen+saline control cohort), or (b) 10 g of antigen plus 100 g of adjuvant in 0.2 mL saline 
(n = 4 for antigen+adjuvant test cohorts). Pre-immune test-bleeds were first obtained via 
venipuncture of the marginal vein of the ear on Day 1. Animals are immunized on Days 1, 15 
and 28. A test-bleed is performed via the marginal vein of the ear on Days 25 and 38. Sera are 
banked at -80 °C for antigen-specific IgG quantitation by ELISA. 
 
C-reactive protein (CRP) measurements. Cohorts of New Zealand White Rabbits (n=5 per 
cohort) were bled two days before administration of the test compounds to obtain baseline CRP 
levels. Animals were injected with either 1 mg of candidate adjuvant (or 100 g of LPS, used as 
control) formulated in saline intravenously as a bolus, into the marginal vein of the ear, on Day 
0. Successive bleeds were performed on Day 1, 2, 5 and 9 after injection. Sera were stored at -
80 °C until used and rabbit CRP-specific ELISAs were performed to obtain the concentrations of 
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